NUTRITIONAL PEPTIDOMICS: DISCOVERY, QUANTIFICATION, AND FUNCTIONAL ANALYSIS OF PLANT PROTEIN DERIVED PEPTIDES by G. Aiello
 
 
 
 
DEPARTMENT OF PHARMACEUTICAL SCIENCES 
DOCTORAL SCHOOL IN PHARMACEUTICAL SCIENCES 
PhD Cycle the 30th  
 
 
NUTRITIONAL PEPTIDOMICS: DISCOVERY, QUANTIFICATION, 
AND FUNCTIONAL ANALYSIS OF PLANT PROTEIN DERIVED 
PEPTIDES 
Sector CHIM/10 - Food chemistry 
 
 
 
Dr. Aiello Gilda 
R10872 
 
 
Faculty advisor: Prof. Anna Arnoldi  
PhD coordinator: Prof. Giancarlo Aldini  
 
ACADEMIC YEAR 
2016/2017 
 
 
 
 
 
 
 
 
 
Dedicated to the persons I love 
 
 
“Everything and every event of the physical universe require, to justify its existence, the use 
of something else, outside of them. We must therefore resort to something non-physical and 
supernatural: God” 
 
Davies Paul 
Davies, God and the new physics, 1984 
i 
 
 
Table of Contents 
  
List of Tables i 
List of Figures iii 
Index v 
 
List of Tables         Page 
Table 1.1 Commercial products and ingredients with health or functional 
claims containing bioactive peptides 
8  
Table 3.1 LC-ESI-MS/MS based identification of tryptic and peptic peptides 
from transport experiments 
45 
Table 3.2 Docking scores for the simulated negatively charged BL peptides 48 
Table 4.1  Peptides identified in the basolateral compartment of Caco-2 cells 
grown in two compartment systems 
62 
Table 4.2 Analytical parameters of quantification 73 
Table 5.1 Calibration range, linearity (R2) and LOQ-LOD of the LC–ESI-
MS/MS method   
87 
Table 6.1 Identified proteins from hempseed raw, pH 2.2, and 7.2 samples 111 
Table 6.2 KEGG-Analysis achieved using STRING software: list of 
established pathways and number of genes in which they are 
involved 
119 
Table 7.1 Predicted bioactive peptides by PeptideRanker and BIOPEP  154 
Table 9.1 Identified proteins in P. armeniaca kernels: comparison of EEP 
and Raw compositions  
190 
Table 9.2 Predicted bioactive peptides generated from Prunin 1 (E3SH28) 
and Prunin 2 (E3SH29) by in silico digestion 
198 
 
List of Supplementary Tables  
Table 3.1S Calculated pI’s and net charges of BL peptides and their 
potential bioactivities according to BIOPEP database search 
54 
Table 5.1S Data of the standard curves 97 
Table 6.1S  A) List of 56 unique gene products identified by C. sativa 
database search 
124 
ii 
 
Table 6.1S  B) List of 125 proteins identified by the use of A. thaliana 
database search 
126 
Table 6.1S  C) List of identified peptides belonging to C. sativa proteins 129 
Table 7.1S LC-ESI-MS/MS based identification of hydrolysates of hempseed 
proteins  
160 
Table 9.1S STRING Interactions 201 
 
iii 
 
List of Figures         Page 
Figure 1.1 Stage of peptide drugs in discovery and development 7 
Figure 1.2 Hypocholesterolemic mechanism of action mediated by lupin 
peptides in human hepatic HepG2 cells 
13  
Figure 1.3 Diagram of a Caco-2 monolayer grown on a permeable filter 
support 
15 
Figure 2.1  Integrated analytical workflow for peptidomic investigation 19 
Figure 2.2  Comparison of conventional data-dependent analysis to targeted 
MRM-MS   
22 
Figure 2.3 Classification of known peptides based on their reported activities 
in the BioPep database (n=2594) 
26 
Figure 3.1 MS/MS total ion current of lupin BL samples: A) tryptic peptides, 
B) peptic peptides 
43  
Figure 3.2  Effect of absorbed peptides on the catalytic domain of HMGCoAR 47 
Figure 3.3 Comparison of computed poses for reference peptide 
YVVNPDNDEN (tube in red) with P5 (tube in mauve) and P7 
(tube in lime) 
48 
Figure 3.4 Schematic 2D representation of main contacts stabilizing the 
putative complex for T1 
49 
Figure 4.1 Effects of peptic and tryptic lupin peptides on the PCSK9-LDLR 
binding inhibition 
67 
Figure 4.2 Three-dimensional structure of lupin small-peptides at the end of 
MD simulations and subsequent energy minimization 
68 
Figure 4.3 Docking and MD simulations results for T9 (panel A) and P5 
(panel B) 
69 
Figure 4.4 Peptides T9 and P5 inhibit the PCSK9-LDLR binding 69 
Figure 4.5 Fluorescent LDL-uptake assay after lupin peptide treatments of 
HepG2 
70 
Figure 4.6  MS/MS spectra of P5, A) and T9, B) respectively 71 
Figure 5.1  Extract ion chromatograms (EICs) of three soy peptides 85 
Figure 5.2 Soy peptide fragment ion spectra 86 
Figure 5.3 Calibration curves 87 
Figure 5.4 Time-dependent increase of peptide concentrations at BL side 89 
Figure 5.5 In vitro permeability 89 
Figure 5.6 MS/MS spectra of metabolites 91 
Figure 5.7 AP and BL Extracted ion chromatogram (EIC) of precursor 
peptides and hydrolytic fragments after 120 min 
92 
Figure 5.8 Peptide relative abundance 93 
Figure 6.1 SDS-PAGE profiles of the untreated (raw) sample versus the 
eluates of CPLL 
109 
iv 
 
Figure 6.2 Venn diagrams of the total number of identified species in the raw 
extract of hempseed versus those detected in all eluates after CPLL 
treatment considering both database. 
110 
Figure 6.3 Protein-protein interactomic network of the hempseed obtained by 
clustering K-MEANS using STRING software.   
118 
Figure 6.4 Pie charts of (A) biological processes, (B) molecular functions, and 
(C) cellular components refer to the 181 unique gene products 
described in hempseeds. 
122 
Figure 7.1 Tricine-SDS-PAGE of hempseed protein hydrolysates. M (marker) 
26.6-3.5 kDa. Pep, Tryp, Panc, Cod represent the four 
hydrolysates.  
148 
Figure 7.2 A) Percent distribution of identified peptides according to their 
parent proteins. B) Venn diagrams of the total number of identified 
proteins in each hydrolysate.  
150 
Figure 7.3 A) MW distribution (in Da) of the identified peptides in each 
hydrolysate. B) Hierarchical clustering analysis (HCA) with 
dendrogram of amino acid data set composition of each 
hydrolysate.  
151 
Figure 7.4 Effect of the hydrolysates on the catalytic domain of HMGCoAR 152 
Figure 7.5 PeptideRanker score of potentially bioactive peptides vs. Total 
Protein Spectrum Intensity (TPSI) of parent proteins 
153 
Figure 8.1 Effects of hempseed peptides on SREBP-2-LDLR pathway 175 
Figure 8.2 Fluorescent LDL-uptake assay after treatment of HepG2 with 
hempseed peptides 
176 
Figure 9.1 A) SDS-PAGE profiles of Raw sample versus EEP sample. B) Venn 
diagrams of all identified species in Raw and EEP samples against 
Uniprot_Viridiplantae database. 
187 
Figure 9.2 Gene Ontology (GO) analysis of identified gene products. Pie 
graphs of (A) biological processes, (B) molecular functions, and (C) 
cellular components show the percentage of proteins in each 
functional category. 
194 
Figure 9.3 Molecular Function GO Term Annotation Comparison obtained 
plotting the unique ID entries for Raw and EEP, respectively.  
195 
Figure 9.4 Protein-Protein interaction network obtained by STRING software 
(p-value = 0.045). Different colored edges represent the existence of 
different types of evidence. A green line indicates neighborhood 
evidence; a blue line, gene-co-occurrence; a yellow line, text 
mining; a purple line, experimental evidence 
197 
 
 
List of Supplementary Figures  
Figure 6.1S The protein functional interactomic network of the hempseed 
proteins obtained by STRING software 
123 
Figure 7.1S Chromatograms of peptic, tryptic, pancreatic and codigested 
hydrolysates 
167 
v 
 
INDEX 
Aim of the thesis 
Motivations and outlines of the PhD thesis ......................................................................................... 2 
Part I. State of the art  
 
1 Introduction ........................................................................................................................................ 6 
1.1 Peptide therapeutics: current status and future directions ................................................. 6 
1.2 Peptide drug market between food and pharma .................................................................. 7 
1.3 Regulation and application of bioactive peptides in food .................................................... 9 
1.4 Bioactive Peptides: Definition and Sources ........................................................................ 10 
1.5 Beneficial biological functionalities of plant-derived peptides .......................................... 10 
1.6 Bioavailability of plant-derived peptides ............................................................................ 14 
2 Technological strategies in the discovery of bioactive peptides ................................................... 18 
2.1 Peptidomic-based approach for the analysis of hydrolysed proteins ............................... 18 
2.2 Classical downstream processing for discovering of bioactive peptides .......................... 18 
2.3 The role of MS in biopeptides discovery ............................................................................. 20 
2.4 Quantitative peptidomics ..................................................................................................... 23 
2.5 Technical issues in bioactive peptide discovery strategies ................................................. 23 
2.6 Bioinformatics-driven approaches and peptide function prediction ................................ 25 
 
Part II. Scientific contributions   
 
A MULTIDISCIPLINARY INVESTIGATION ON THE BIOAVAILABILITY AND 
ACTIVITY OF PEPTIDES FROM LUPIN PROTEIN 
3.0 Abstract .......................................................................................................................................... 35 
3.1 Introduction ................................................................................................................................... 35 
3.2 Materials and methods ................................................................................................................. 36 
3.2.1 Chemicals and reagents ..................................................................................................... 36 
3.2.2 Preparation of the pepsin and trypsin peptide mixtures ................................................ 37 
3.2.3 Cell culture and differentiation ........................................................................................ 38 
3.2.4 Trans-epithelial transport of peptic and tryptic lupin peptides .................................... 38 
3.2.5 Cell monolayer integrity evaluation ................................................................................. 39 
3.2.6 HPLC-Chip-MS/MS analysis ............................................................................................ 39 
3.2.7 Mass spectral data elaboration and database searching ................................................ 40 
3.2.8 Determination of the P-abs and T-abs peptidic concentration ...................................... 40 
3.2.9 HMGCoAR activity assay ................................................................................................. 40 
3.2.10 In silico docking simulations of BL peptides to the HMGCoAR catalytic site ........... 41 
3.2.11 Potential biological activities of available peptides ....................................................... 42 
3.3 Results ............................................................................................................................................ 42 
3.3.1 Trans-epithelial transport of lupin peptides .................................................................... 42 
3.3.2 Peptide sequencing by LC-MS/MS ................................................................................... 42 
3.3.3 Characterisation of bioavailable lupin peptides .............................................................. 43 
3.3.4 Absorbed peptic and tryptic lupin peptides are able to inhibit HMGCoAR activity .. 47 
3.3.5 In silico evaluation of the capacity of BL peptides to interact with the HMGCoAR 
catalytic site ................................................................................................................................. 47 
3.4 Discussions ..................................................................................................................................... 50 
3.4.1 Absorbed peptides features ....................................................................................................... 50 
3.4.2 Role of absorbed peptides in cholesterol metabolism ..................................................... 51 
3.4.3 Potential bioactivity according to bioinformatic prediction .......................................... 52 
 
vi 
 
LUPIN PEPTIDES MODULATE THE PROTEIN-PROTEIN INTERACTION OF PCSK9 
WITH THE LOW DENSITY LIPOPROTEIN RECEPTOR IN HEPG2 CELLS 
4.0 Abstract .......................................................................................................................................... 60 
4.1 Introduction ................................................................................................................................... 61 
4.2 Methods .......................................................................................................................................... 63 
4.2.1 Preparation of the pepsin and trypsin peptide mixtures ................................................ 63 
4.2.2 In vitro PCSK9-LDLR binding assay ............................................................................... 63 
4.2.3 In vitro PCSK9-LDLR binding assay of synthetic T9 and P5 ........................................ 64 
4.2.4 Cell line culture .................................................................................................................. 64 
4.2.5 Fluorescent LDL uptake cell based assay ........................................................................ 65 
4.2.6 Statistical analysis of biological assays ............................................................................. 65 
4.2.7 HPLC-Chip-MRM analysis of peptide T9 and P5 in T-abs and P-abs ......................... 65 
4.2.8 Quantification of T9 in T-abs and P5 in P-abs ................................................................ 66 
4.2.9 Analytical parameter evaluation ...................................................................................... 66 
4.3 Results ............................................................................................................................................ 67 
4.3.1 Absorbed peptic and tryptic lupin peptides maintain their capacity to interfere with 
the PCSK9/ LDLR PPI ............................................................................................................... 67 
4.3.2 In silico model of the human PCSK9 and lupin peptides ............................................... 68 
4.3.3 Isolated lupin peptides inhibit the PCSK9-LDLR binding ............................................ 69 
4.3.4 Through the inhibition of PCSK9-LDR PPI, T9 and P5 increase the ability of HepG2 
cells to uptake LDL from the extracellular environment ........................................................ 70 
4.3.5 LC-MRM assays for the T9 and P5 quantification ......................................................... 71 
4.4 Discussion....................................................................................................................................... 74 
 
ABSORPTION AND METABOLISM OF SOY PEPTIDES ACROSS CACO-2 CELL 
MONOLAYERS 
5.0 Abstract .......................................................................................................................................... 78 
5.1 Introduction ................................................................................................................................... 79 
5.2 Materials and Methods ................................................................................................................. 80 
5.2.1 Chemicals and reagents. .................................................................................................... 80 
5.2.2 Cell cultures. ....................................................................................................................... 81 
5.2.3 Cell monolayer integrity evaluation. ................................................................................ 81 
5.2.4 Trans-epithelial absorption of soy peptides. .................................................................... 81 
5.2.5 LC/ESI-MRM analysis ...................................................................................................... 82 
5.2.6 Calibration curves and quantification of soy peptides. .................................................. 83 
5.2.7 Accuracy and precision evaluation ................................................................................... 83 
5.2.8 Apparent permeability measurement. ............................................................................. 83 
5.2.9 Statistical analysis. ............................................................................................................. 84 
5.3 Results ............................................................................................................................................ 84 
5.3.2 Evaluation of the analytical parameters. ......................................................................... 86 
5.3.3 Permeation experiments and calculation of apparent permeability coefficients. ........ 88 
5.3.4 Degradation by brush border peptidases. ........................................................................ 89 
5.3.5 Comparative stability of breakdown fragments through Caco-2 monolayers. ............ 92 
5.4 Discussion....................................................................................................................................... 93 
 
PROTEOMIC CHARACTERIZATION OF HEMPSEED (CANNABIS SATIVA L.) 
6.0 Abstract ........................................................................................................................................ 102 
6.1 Introduction ................................................................................................................................. 103 
6.2 Materials and Methods ............................................................................................................... 105 
6.2.1 Chemicals .......................................................................................................................... 105 
6.2.2 Hempseed proteome extraction and CPLL treatment.................................................. 105 
6.2.3 SDS-PAGE Analysis ........................................................................................................ 106 
6.2.4 Mass spectrometry and Data Analysis ........................................................................... 107 
6.3 Results and Discussion ................................................................................................................ 108 
6.3.1 Protein identification ....................................................................................................... 108 
vii 
 
6.3.2 Protein-protein association network analysis ................................................................ 117 
6.3.3 Protein biology ................................................................................................................. 120 
6.4 Conclusion ................................................................................................................................... 122 
 
EXPLORATION OF POTENTIALLY BIOACTIVE PEPTIDES GENERATED FROM THE 
ENZYMATIC HYDROLYSIS OF HEMPSEED PROTEINS 
PART-I ............................................................................................................................................... 140 
7.0 Abstract ........................................................................................................................................ 140 
7.1 Introduction ................................................................................................................................. 141 
7.2 Materials and Methods ............................................................................................................... 142 
7.2.1 Reagents ............................................................................................................................ 142 
7.2.2 Protein concentrate preparation ..................................................................................... 143 
7.2.3 Preparation of the hempseed protein hydrolysates ....................................................... 143 
7.2.4 Evaluation of the percent peptide yield and DH of the hydrolysates .......................... 144 
7.2.5 Tricine SDS-PAGE Separation ....................................................................................... 144 
7.2.6 MS/MS peptide profiling ................................................................................................. 145 
7.2.7 Database searching, protein identification and validation ........................................... 145 
7.2.8 Amino acid composition .................................................................................................. 146 
7.2.9 HMGCoAR activity assay ............................................................................................... 146 
7.2.10 Profile of potential biological activities and peptide ranking ..................................... 147 
7.2.11 Statistical analysis in the HMGCoAR activity assay .................................................. 147 
7.3 Results .......................................................................................................................................... 147 
7.3.1 Hydrolysis trend, yield, and DH of hempseed hydrolysates ......................................... 147 
7.3.2 Chemical characterization of the protein hydrolysates ................................................ 148 
7.3.3 Inhibitory effects of the hydrolysates on the HMGCoAR activity .............................. 151 
7.3.4 Peptide ranking, protein abundance and bioactivity searching .................................. 152 
7.4 Discussion..................................................................................................................................... 157 
 
PART-II 
PEPTIC HEMPSEED HYDROLYSATE EXERTS HYPOCHOLESTEROLEMIC EFFETCTS 
WITH A STATIN-LIKE MECHANISM 
8.0 Abstract ........................................................................................................................................ 171 
8.1 Introduction ................................................................................................................................. 171 
8.2 Materials and Methods ............................................................................................................... 172 
8.2.1 Cell culture conditions. .................................................................................................... 172 
8.2.2 Western blot analysis. ...................................................................................................... 172 
8.2.3 Fluorescent LDL uptake cell based assay ...................................................................... 173 
8.2.4 Statistically Analysis. ....................................................................................................... 173 
8.3 Results .......................................................................................................................................... 173 
8.3.1 Preparation and analysis of the peptic hydrolysate from hempseed protein. ............ 173 
8.3.2 Effects on the LDLR pathway modulation. ................................................................... 174 
8.3.3 Effects on AMPK pathway activation. ........................................................................... 174 
8.3.4 Modulation of the LDL-uptake in HepG2 cells. ............................................................ 175 
8.4 Discussion..................................................................................................................................... 176 
8.4.1 Molecular and cellular investigation of the hypocholesterolemic properties of the 
peptic hempseed hydrolysate. .................................................................................................. 176 
 
PROTEOMIC ANALYSIS OF SWEET ALGERIAN APRICOT KERNELS (PRUNUS 
ARMENIACA L.) BY COMBINATORIAL PEPTIDE LIGAND LIBRARIES AND LC-MS/MS 
9.0 Abstract ........................................................................................................................................ 180 
9.1 Introduction ................................................................................................................................. 181 
9.2 Materials and Methods ............................................................................................................... 183 
9.2.1 Chemicals .......................................................................................................................... 183 
9.2.2 Treatment of apricot kernels .......................................................................................... 183 
9.2.3 SDS-PAGE analysis ......................................................................................................... 184 
viii 
 
9.2.4 Nano LC-MS/MS analysis ............................................................................................... 184 
9.2.5 Protein identification from MS data .............................................................................. 185 
9.2.6 Functional categorisation of identified proteins ............................................................ 185 
9.2.7 In silico simulated gastrointestinal digestion of major storage proteins and potential 
biological activities of generated peptides ............................................................................... 186 
9.2.8 Statistically Analysis ........................................................................................................ 186 
9.3. Results and Discussion ............................................................................................................... 187 
9.3.1 Characterisation of apricot kernel proteome ................................................................ 187 
9.3.2 Protein functional data analysis ...................................................................................... 194 
9.3.3 Protein biology ................................................................................................................. 195 
9.3.4 PPI network of apricot kernel ......................................................................................... 197 
9.3.5 Bioactivities of peptides from in silico digestion of prunins ......................................... 197 
9.4. Conclusions ................................................................................................................................. 201 
 
Part III. Concluding Remarks 
GENERAL CONCLUSIONS AND PERSPECTIVES .................................................................. 208 
 
Appendix 
Appendix ............................................................................................................................................ 210 
Evaluation of metabolic and systematic drug perturbation on human colon cancer cell model by 
targeted SRM and SWATH-MS analysis ....................................................................................... 215 
 
Scientific Publications & Communications 
Scientific Publications & Communications .................................................................................... 224 
 
 
 
 
 
1 
 
 
 
 
 
 
 
Aim of the thesis 
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Motivations and outlines  
of the PhD thesis 
 
Recently the increase in human diseases and side effects of drugs has promoted research in 
food components endowed with biologically active molecules. These bioactive components 
play a pivotal role in reducing and regulating the onset of such chronic diseases. The great 
interest seems to be focused on protein and peptides mostly derived from seeds of crop plants, 
which represent an excellent starting point for therapeutics. Actually, soy and lupin proteins 
have been largely investigated for their healthy properties in cardiovascular prevention for 
improving the clinical state of patients suffering of diabetes, hypertension, obesity and 
hypercolesterolemia. The interest into the consumption of food with potential bioactivities 
coincides with a clear shift in medicine and biosciences toward prevention of future diseases 
through adequate food intakes. In particular, the use of food-derived peptides, especially those 
derived from plants, could be appreciated, since they are recognised for being highly selective, 
efficacious and, at the same time, relatively safe and well tolerated by humans. The 
identification of biologically active peptides in food matrices and as well as the investigation 
of their pharmacological promise is, therefore, a challenging task in food technology.  
However, although numerous studies report several modulating activities attributable to natural 
peptides, the main issue concerns their ability to cross the cell membrane for being active.  The 
matter of bioabsorption has to be faced in order to explore their concrete potential.  
Based on these considerations, the main aims of my PhD thesis were focused on the discovery, 
quantification and functional analysis of plant protein-derived peptides. These objectives were 
reached by use of different tools, comprising advanced analytical techniques, such as mass 
spectrometry (MS) coupled to biochemical and bioinformatics tools, in order to improve the 
understanding of their mechanism of action at cellular level, their intestinal absorption profile 
as well as to forecast their potential bioactivities.  
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Briefly, the main aims of the present study were: 
 
 To investigate the bioavailability, the intestinal absorption and the bioactivity of lupin 
peptides using an in vitro epithelial model (Caco-2 cells). 
 To evaluate the absorption and the metabolic degradation of soy peptides at Caco-2 cell 
surface. 
 To develop qualitative (untargeted) and quantitative (targeted) LC-MS methods for the 
characterization of the pool of absorbed peptides (discovery phase) or quantify the most 
active ones obtaining simultaneously semi-quantitative information about their 
absorption.  
 To investigate the wide proteome of hempseeds including the identification of the 
minor protein components. 
 To produce hydrolysates of bioactive peptides with hypocholesterolemic properties 
from hempseed proteins using different enzymatic proteases.  
 To investigate the functional and descriptive proteome of apricot kernel, focusing the 
attention on the in silico prediction of the potential bioactive peptides released by 
simulated gastrointestinal digestions.  
 
The thesis contains three parts:  
Part I introduces the state of art of bioactive peptides.  
In Chapter 1 an introduction about bioactive peptides, peptidomics and as well as mass 
spectrometry techniques is provided. Specifically, the underlying biological question 
concerning the bioavailability and bioabsorption of plant protein-derived peptides, such as 
Lupinus and Glycine max, is introduced.  
Chapter 2 is dedicated prevalently to the strategies used in the peptidomic and on the technical 
issues in bioactive peptide discovery.  
Part II contains my own scientific contributions.  
The first original one is presented in Chapter 3 with a novel methodologic approach aimed at 
the investigation of the potentially absorbed peptides derived from lupin proteins through 
gastrointestinal system. By the use of untargeted MS assay, this contribution explores the pool 
of lupin-absorbed peptides across the Caco-2 systems and the investigation of their capacity to 
modulate the cholesterol metabolism through the inhibition of 3-hydroxy-3-methylglutaryl 
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coenzyme A reductase (HMGCoAR). A further in silico docking simulations was applied to 
hypothesise which peptides may bind more efficiently to the HMGCoAR.  
Moving the focus on a different molecular target, i.e. Proprotein convertase subtilisin/kexin 
type 9 (PCSK9), which it has been recently recognised as a new useful target for 
hypercholesterolemia treatment, a refined in silico model for the inhibition of the 
PCSK9/LDLR interaction mediated by absorbed-lupin peptides, was developed. Afterwards, a 
MS-quantitative evaluation of some selected absorbed peptide, identified as the best candidate 
inhibitors of PCSK9/LDLR binding was performed as reported in Chapter 4.  
Chapter 5 is dedicated to the investigation of the absorption and the metabolism of soy 
peptides across Caco-2 cell monolayers. This contribution provides: i) the development of fit-
for-purpose analytical methodology for quantifying three synthetic soy peptides with 
cholesterol-lowering activity through small intestine epithelium, ii) the evaluation of peptide 
degradation by epithelial peptidases.  
Finally, Chapter 6 and Chapter 7 are dedicated to proteome and peptidome exploration of 
hempseeds, respectively. Considering the recent interest in hemp food products and the missing 
information about the protein composition of this seed, the first objective was to provide a 
deeper characterization of its proteome. Combinatorial peptide ligand libraries (CPLLs), a 
well-established technique able to enhance the presence of low or very low abundant proteins, 
have been adopted for an extensive investigation of the proteome of hempseed flour.  
Chapter 7 and 8 present an exploration of potentially bioactive peptides generated from the 
enzymatic hydrolysis of hempseed proteins using different proteases in order to screen which 
were the most active ones on the modulation of cholesterol metabolism. The overall objectives 
of this last research were: i) to identify the peptide composition of hempseed protein 
hydrolysates by MS, ii) to determine the ability of hempseed protein hydrolysates to reduce the 
low-density lipoprotein (LDL) cholesterol level through the inhibition of HMGCoAR, focusing 
the attention mainly on peptic hydrolysate, iv) the prediction of additional biological activities 
using in silico bioinformatics tools. Chapter 9 presents the proteomic mapping of apricot and 
the in silico release of bioactive peptides derived from the most abundant proteins through a 
simulated gastrointestinal digestion.  
Finally, Part III presents the concluding remarks and the impact of this thesis on the field of 
biopeptides discovery. In addition, the appendix contains the skills acquired during the foreign 
study experience, with specific reference to very innovative proteomic approaches.  
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CHAPTER 1 
 
1 Introduction  
 
1.1 Peptide therapeutics: current status and future directions 
More than 7000 naturally occurring peptides, having crucial roles in human physiology, 
including actions as hormones, neurotransmitters, growth factors, ion channel ligands, or anti-
infective, have been recently identified.1-4 Within the organism, peptides may exert diverse 
biological roles, most prominently as signalling/regulatory molecules in a broad variety of 
physiological processes, including defence, immunity, stress, growth, homeostasis, and 
reproduction.5 Based on these features, peptides have been of great interest from the point of 
view of different disciplines, such as pharmaceutical, clinical, functional foods or nutriomics.6 
Given their attractive pharmacological profile and intrinsic properties, natural peptides 
represent an excellent starting point for the design of novel therapeutics and their specificity 
has been seen to translate into excellent safety, tolerability, and efficacy profiles in humans. In 
this scenario, new tendencies in the discovery of drug candidates involve the study of natural 
bioactive peptides since their accumulation in organs, such like kidney and liver, is very low, 
resulting in a minimal development of the most severe toxic side-effects.7 This aspect might 
also be the primary differentiating factor of peptides compared with traditional small 
molecules. In addition, therapeutic peptides are typically associated with lower production 
complexity compared with protein-based biopharmaceuticals and, therefore, the production 
costs could be lower, generally approaching those of small molecules.  
In the face of these positive aspects, however, in the past naturally occurring peptides were 
often considered not directly suitable for use as convenient therapeutics, because they show 
intrinsic weaknesses, including poor chemical and physical stability, and short circulating 
plasma-life. Despite such neglect, a number of recent technological breakthroughs and 
advances have sparked major interest in their usage as both diagnostic as well as therapeutics. 
Peptides have greater potential to meet the ever-increasing expectations of new drugs, as they 
are highly specific to individual protein targets, amenable to site-specific modification and 
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highly selective. In other words, some attributes originally considered troublesome in drug 
development may now turn out to be more convenient rather than unfavourable.  
 
1.2 Peptide drug market between food and pharma 
In the current pharmaceutical industry, peptides are considered mature compounds addressing 
unmet medical needs, and accelerating the personalised medicine model.8 In details, peptides 
promise to combine the lower production costs of conventional (small molecular chemical) 
drugs with the high specificity of (the larger) biological entities. The market contains already 
peptides used as drugs, i.e. LupronTM from Abbott Laboratories is used for the treatment of 
prostate cancer and more, which achieved global sales of more than 2.3 billion US$ in 2011.9 
In addition, LantusTM from Sanofi (which is really at the border between a peptide drug and a 
small biopharmaceutical) reached sales of 7.9 billion US$ in 2013. Currently, there are more 
than 70 US Food and Drug Administration (FDA)-approved peptide medicines on the market 
and this is expected to grow significantly, with approximately 200 peptide drugs at present in 
clinical trials and more than 600 therapeutic peptides in preclinical development10 (Figure 1.1). 
In terms of value, the global peptide drug market has been predicted to increase from 14.1 
billion US$ in 2011 to an estimated 25.4 billion US$ in 2018, with an underlying increase in 
novel innovative peptide drugs from 8.6 billion US$ in 2011 (60%) to 17.0 billion US$ (66%) 
in 2018.11  
The most recent example of a novel peptide drug class is the group of glucagon-like peptide-1 
(GLP-1) agonists for the treatment of type 2 diabetes mellitus, which reached total sales of over 
2.6 billion US$ in 2013, with VictozaTM, the most prominent member of the class, reaching 
blockbuster status.  
 
 
Figure 1.1 - Stage of peptide drugs in discovery and development.10 
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The main disease areas currently driving the therapeutic use of peptide drugs are metabolic 
disease and oncology. However, increasing attention is directed towards the use of peptide 
therapeutics in the treatment of diabetes and obesity. That is probably why North America 
currently represents the largest share of the peptide drug market, with the Asian market 
expected to have the largest growth. This commercial trend leads to pay attention, 
consequently, to occurring bioactive peptides mostly derived from plants for their potential 
pharmaceutical and/or nutraceutical applications.12 The interest for health-promoting 
functional food, dietary supplements and pharmaceutical preparations containing bioactive 
peptides is actually markedly increasing.13  
Table 1.1 describes commercial products that companies have launched on the market with 
antihypertensive, antimicrobial and mineral-binding peptides. These industrial-scale 
applications include from dairy food (Calpis®, Evolus®, Peptide Soup EX), ingredients 
(Capolac® MM0525, Lacprodan®, RecaldentTM, Ameal peptide®) to food supplements 
(Ameal bp®, PeptACE® Fish Peptide, Vasotensin®). At least, the two milk fermented 
products, Calpis® and Evolus®, have shown beneficial effects on blood pressure in several rat 
models and human studies.14-16 
 
Table 1.1 Commercial products and ingredients with health or functional claims 
containing bioactive peptides 
 
Brand name 
Type of 
product 
Bioactive peptides 
Health/function 
claims 
Manufacturers 
Alpha lactalbumin 
Whey protein 
isolate 
α-lactalbumin 
Helps sleep and 
memory 
Davisco Foods International Inc., USA 
http://www.daviscofoods.com/specialty/alpha 
Ameal bp ®, 
Ameal peptide ® 
Tablets, 
ingredient 
VPP, IPP derived from 
β-casein and κ-casein 
Reduction of blood 
pressure 
Calpis Co., Japan http://www.amealbp.com/ 
BioZate 1 
Hydrolyzed 
whey protein 
isolate 
β-lactoglobulin 
fragments 
 
Reduction in blood 
pressure 
Davisco Foods International Inc., USA 
http://www.daviscofoods.com/specialty/biozate 
BioZate 3 
Hydrolyzed 
whey protein 
isolate 
 
β-lactoglobulin 
fragments 
Peptides to extend 
shelf life by 
providing a softer 
texture over time 
 
Davisco Foods International Inc., USA 
http://www.daviscofoods.com/specialty/biozate 
Calpis/Calpico® Sour milk 
VPP, IPP derived from 
β-casein and κ-casein 
Reduction in blood 
pressure 
 
Calpis Co., Japan http://www.calpis.net/, 
http://www.calpico.com/ 
Capolac ® 
MM0525 
Ingredient Caseino phosphopeptides 
Helps mineral 
absorption 
Arla Foods Ingredients Group P/S, Denmark 
http://www.arlafoodsingredients.com/products/mi
lkprotein- 
minerals/milk-minerals/ 
Evolus ® 
Fermented 
milk drink 
VPP, IPP derived from 
β-casein and κ-casein 
Reduction in blood 
pressure 
 
Valio Ltd., Finland 
http://ammattilaiset.valio.fi/portal/page/portal/ 
valiocom/R_D/Nutritional_research/ 
evolus18082006094558 
HI-NUTE series Ingredient Soy protein oligopeptides 
Helps prevent obesity 
and muscle fatigue 
Fuji Oil Co. Ltd., Japan 
http://www.fujioil.co.jp/fujioil_e/product/ 
soy_index3.html 
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Kotsu Kotsu 
calcium 
Soft Drink Caseino phosphopeptides 
Helps mineral 
absorption 
Asahi Soft Drinks Co. Ltd., Japan 
https://www.asahiinryo.co.jp/products/tokuho/ 
special_ca/ 
Lacprodan ® 
ALPHA-20 
Ingredient α-lactoalbumin (60 %) 
Helps reduce peptic 
ulcers 
Arla Foods Ingredients Group P/S, Denmark 
http://www.arlafoodsingredients.com/news/ 
lacprodan-alpha-20-and-peptic-ulcers/ 
PeptACE ® fish 
peptides 
Capsules 
Bonito-derived peptide 
(85 %): LKPNM 
Hypotensive 
Natural Factors, USA 
http://naturalfactors.com/ca/en/products/detail/26
98/ 
peptace 
Peptide ACE 
tablet type 
Tablets 
Bonito-derived peptide 
LKPNM 
Hypotensive 
Nippon Supplement Inc., Japan 
http://www.nippon-sapuri.com/english/ 
 
 
1.3 Regulation and application of bioactive peptides in food  
Since bioactive peptides may be included in foods, several limitations and challenges have 
been reported for their development, their use and their impact on human nutrition. The main 
issue concerns the lack of knowledge of mechanism of action on molecular targets. In addition, 
the high level of complexity of protein hydrolysates generally makes difficult the extensive 
chemical characterization of their amino acid (AA) sequences even if high performance 
technologies are used. For these unclear aspects, their regulatory approval in many countries is 
extremely difficult. To date, in fact, there is no single regulatory legislation. In Europe, 
Regulation (EC) 1924/2006 covers health claims made for food products and the European 
Food Safety Authority (EFSA) must review all applications based on restricted scientific 
proofs. On the contrary, the Food Drug Administration (FDA, USA) and the Ministry of 
Health, Labour and Welfare (MHLW, Japan) adopt less restrictive regulation. Even if to date, 
any peptide-food derived ingredients were approved in Europe and the USA, Japanese 
legislators, already in 1991 enacted a set of “Foods for Specified Health Use” (FOSHU) 
measures, which regulated the use of food for therapy.17 Products carrying a FOSHU label are 
now certified with respect to their pharmaceutical activity;18 an example is the use of “Fine 
Rice”, rice grains as a treatment of rice-associated atopic dermatitis. The list of category 2 
FOSHU products includes soybean-derived peptides which control the level of cholesterol in 
the blood, while further plant-derived products are represented in categories #4 (blood pressure 
reduction) and #10 (serum triacylglycerol level and lipid reduction).  
The tight regulation required by entities such as EFSA regarding the approval of the use of 
peptide-based ingredients, highlights the need to investigate either their mechanism of action 
or their chemical compositions in order to prove scientific evidences on which a dossier should 
be efficiently based.     
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1.4  Bioactive Peptides: Definition and Sources  
In terms of chemical complexity, peptides fill the niche between typical small molecules and 
larger proteins. They refers to different short amino acid chains (2–20 AAs, in some cases up 
to 40 AAs) that, generally, are inactive within the sequence of the parent proteins until protein 
digestion, fermentation or food processing.19  
Until last decade, their production was focused almost exclusively on animal protein sources, 
and in particular milk. The latest researches, on the contrary, opened new possibilities for 
obtaining peptides from edible plant sources and from alternative and cheap matrices, such as 
agriculture surplus and wastes, by-product and non-conventional vegetables.  
Actually, among the seed of crop plant, soybean is considered a popular source of food proteins, 
which has been traditionally used in Asia. It offers a complete spectrum of (essential) amino 
acids. Numerous health claims, at least in part supported by proteomic analyses 20, were made 
for it.  
Cereals (supplying half the world’s protein needs) and legumes are both rich sources of proteins 
with a complementary spectrum of amino acids.21, 22 In addition, bioactive peptides were found 
in many other vegetables (algae, edible fungi, garlic, ginkgo biloba seeds, curcuma, sesame, 
peanut, spinach, sunflower, hempseeds, tubers and others) as the consequence of fermentation 
or enzymatic hydrolysis.23 Peas have been analysed for bioactive peptides, most of them using 
mass spectrometry technologies based on 2-D gels.24  By using more recent nano-LC based 
methods further, in part complementary details on the role of bioactive proteins and peptides 
from these sources can be covered to improve our basic knowledge. Such increasingly growing 
background information on the composition of bioactive peptides in food may eventually result 
in the design of efficient strategies to tailor nutritional interventions. 
 
1.5 Beneficial biological functionalities of plant-derived peptides 
Among the human health benefits claimed for plant peptides, the reduction in blood cholesterol 
level, the reduction in blood pressure, antioxidant properties and as well as immunomodulatory 
activities are reported. In this dissertation only lipid lowering properties are taken into account. 
1.5.1 Lipid lowering effects of bioactive protein hydrolysates 
An unfavourable profile of blood lipids is an important risk factor for the genesis of various 
cardiovascular diseases (CVDs). Not surprisingly, treatment for hyperlipidemia-accelerated 
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diseases often includes the improvement of serum lipid distribution through diet modifications. 
It is generally known that several dietary proteins can improve blood lipid profiles. To date 
hypocholesterolemic properties have been reported for soy25, whey26 and fish protein27 capable 
of altering the plasma profile from atherogenic to cardio protective. Although a number of 
published studies have already demonstrated potential beneficial effects of pulses on 
dyslipidemia, more research is needed to achieve a complete picture of their mechanism of 
action. 
The mechanisms of regulation of cholesterol levels are described in detail here. The cellular 
requirements for cholesterol modulation are mainly satisfied through two mechanisms: 
1) Exogenously by cholesterol influx pathways involving cholesterol uptake mediated by 
various lipoprotein receptors; 2) endogenously by cholesterol synthesis regulated by the rate-
limiting enzyme of this process, HMGCoAR. 
At the transcriptional level, cholesterol uptake and biosynthesis are closely regulated through 
a negative feedback control.  
1) The low-density lipoprotein receptor (LDLR) pathway is a negative feedback system that 
plays decisive roles in the regulation of plasma and intracellular cholesterol homeostasis. 
LDL Receptors enable the intake of plasma-derived LDL cholesterol and its metabolism. To 
maintain a cholesterol homeostasis, LDLR expression is tightly regulated by sterol 
regulatory element-binding protein-2 (SREBP-2) and SREBP cleavage-activating protein 
(SCAP) in transcriptional level and by proprotein convertase subtilisin/kexin type 9 
(PCSK9) in posttranscriptional level. PCSK9 stimulates LDLR degradation, resulting in 
LDL accumulation in plasma.28 
2) When there is an accumulation of cholesterol into the cell, the endogenous cholesterol 
biosynthesis mediated by HMGCoAR is reduced and the number of LDL receptors 
decreases. Conversely, when there is a depletion of intracellular cholesterol, the activity of 
HMGCoAR is elevated and there are more numerous LDL receptors on the cellular 
membrane.  
 
Soybean. Some investigations have shown that 7S globulin (β-conglycinin) component has a 
major role in the cholesterol-lowering properties of soybean. In particular, a peptic soy protein 
hydrolysate has been reported to show a stronger serum cholesterol lowering effect than intact 
soy protein in rats.29 In details, soy peptides have the potential to modulate cholesterol 
homeostasis by increasing receptor-mediated LDL uptake in HepG2 cells. A clinical trial 30 has 
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investigated the expression of LDL-receptor in patients affected by familial 
hypercholesterolemia, treated with animal proteins or with soy protein with cholesterol added 
to balance the two diets. The soy protein diet determined a marked LDL-C reduction as well 
as an 8-fold increase of LDL degradation, whereas there were minimal changes in LDL-C 
levels or LDL receptor activity after the animal protein diet. 
Recently, LPYPR, a peptide derived from soy glycinin, was found to endow serum cholesterol-
lowering effects in mice following oral administration.31 LPYPR is structurally homologous 
to enterostatin (VPDPR), an endogenous peptide exhibiting hypocholesterolemic effect.32 
Another glycinin-derived peptide, i.e. IAVPGEVA, endowed the same activity was identify 
by Pak.33  
The regulation of cholesterol homeostasis by peptides has been proposed to be due to the 
activation of LDL receptors and LDL degradation in liver cells at least in vitro. In details, recent 
paper34, suggests that IAVPGEVA, IAVPTGVA, and LPYP are able to interfere with the 
catalytic activity of HMGCoAR modulating the cholesterol metabolism, through the activation 
of the LDLR-SREBP-2 pathway, increasing the ability of HepG2 cells to uptake the LDL. In 
addition, these three soy peptides are also able to inhibit the activity of HMGCoAR due to an 
increase of its phosphorylation level on Ser 872 residue via the activation of the AMPK-
pathway. In parallel, other evidences have been reported for two other peptides isolated from 
soybean β-conglycinin, i.e., YVVNPDNDEN and YVVNPDNNEN, which are known to be 
also absorbed by human enterocytes.35 Both of them, similarly to IAVPGEVA, IAVPTGVA, 
and LPYP, are also able to up-regulate the LDLR protein levels sharing the same mechanism 
of action.  
 
Lupin. The main storage proteins in lupin are the acidic legumin (α-conglutin) and vicilin (β 
conglutin), as well as small amounts of γ-conglutin, a basic 7S globulin.36 To date, only a few 
studies, all in animal models, have investigated the mechanism of the hypocholesterolemic 
activity of lupin protein. The reduced plasma TAG levels in hypercholesterolemic rats treated 
with a white lupin protein isolate was in part due to the down-regulation of the SREBP-1c 
mRNA in the liver, which led to a reduction of hepatic fatty acid synthase.37 Another study, 
however, observed lower hepatic mRNA concentrations of genes involved in fatty acid 
synthesis, and a parallel up-regulation of genes involved in TAG hydrolysis.38 A third study 
showed that lupin-fed rats displayed significantly higher hepatic mRNA levels of SREBP-2, 
the major transcriptional regulator of intracellular cholesterol levels, and CYP7A1, the rate-
limiting enzyme in bile acid biosynthesis.39  
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Along-side in vivo studies, recent investigations have been aimed at the elucidation of the 
mechanism of action of lupin protein hydrolysates on cholesterol reduction. A study on human 
hepatic HepG2 cells has demonstrated that tryptic and peptic hydrolysates from a total lupin 
protein extract are able to interfere with the HMGCoAR activity, up-regulating the LDLR and 
SREBP-2 proteins via the activation of phosphoinositide 3-kinase (PI3K), protein kinase B 
(Akt), and glycogen synthase kinase-3β (GSK3β) pathways, increasing the LDL-uptake of 
HepG2 cells.40 In parallel, in a synergic way, lupin peptides reduce the PCSK9 protein level 
production and secretion. Figure 1.2 shows the hypocholesterolemic mechanism of action, 
mediated by lupin peptides in human hepatic HepG2 cells.  
 
 
 
 
Figure 1.2 Hypocholesterolemic mechanism of action mediated by lupin peptides in human 
hepatic HepG2 cells. Upon cell penetration, peptic and tryptic lupin peptides act as competitive 
inhibitors of HMGCoAR, leading to a reduction of intracellular cholesterol synthesis. When 
intracellular cholesterol level decreases, the transcription factor SREBP-2 is activated and LDLR and 
HMGCoAR genes are transcripted with subsequent increase of LDLR and HMGCoAR protein levels 
(A). In parallel, in a synergic way, lupin peptides reduce the PCSK9 protein level production and 
secretion. In particular, through the reduction of HNF1-alpha protein level, they lead to a decrease of 
intracellular precursor and mature PCSK9 protein levels. In agreement, the PCSK9 down-regulation is 
translated in a reduction of HepG2 cell ability to secrete mature PCSK9 in the extracellular medium, 
with the consequent stabilisation of active LDLR on hepatic cellular membrane (B). For this reason, the 
distinct modulation of the two pathways leads to hypocholesterolemic effects through an improved and 
synergic activity of LDLR, which can bind and carry the extracellular LDL in HepG2 cells. 41 
 
Hempseed. Recently, it has been proved that hempseed peptides endowed important activities, 
especially at cardiovascular level, as ACE inhibitors (WYT, SVYT, and IPAGV) and as 
antioxidants (WVYY and PSLPA).42 On the contrary, literature reports only a few evidences 
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on the ability of hempseed proteins to modulate the lipid profile.43, 44 Some efforts of this thesis 
have been addressed to fill this gap elucidating the mechanism through which hempseed 
hydrolysate mediates a cholesterol-lowering effect at HepG2 cells, by molecular and functional 
investigations on the LDLR-SREBP-2 pathway.  
 
1.6 Bioavailability of plant-derived peptides 
Peptides can escape the normal process of digestion and thus can be absorbed intact across the 
intestinal mucosa. The availability of peptides is of particular importance in the context of their 
therapeutic efficacy and their physiological effects depend on their ability to reach in an active 
form their target organs. An experimental assessment of the health benefits of plant-derived 
peptides is difficult to achieve, since ingested proteins are processed by a variety of proteases 
and peptidases during their passage through the gastro-intestinal tract. In addition, the activity 
of these compounds depends on their amino acid composition, bioavailability, interactions with 
other food components carried in the bloodstream, and on the resistance to the proteases 
activity. On the other hand, the inﬂuence of several diﬀerent physiological parameters, i.e. 
blood pressure, insulin and glucose homoeostasis, plasma cholesterol concentrations, and 
immune function can modulate certain peptide functions. Nevertheless, a body of evidence 
proves that dietary peptides that survive luminal digestion and endure the brush-border-
membrane peptidases hydrolysis can be detected in measurable amounts in the peripheral blood 
and urine.45,46 In other words, the processes underlying absorption, distribution, metabolism 
and excretion (ADME) are important pharmacological parameters to evaluate for the future use 
of naturally occurring peptide as pharmaceuticals.47  
 
1.6.1 Absorption 
The ability of peptides to enter the intestinal lymphatic system is affected by their molecular 
size and structural properties, such as hydrophobicity, which influence their transport route.48 
Generally, the small (di and tri peptides) and large (10–30 amino acids) peptides can cross the 
intestinal barrier intact and show their activity at the tissue level.49 However, the potency of 
bioactive peptides decrease as the chain length increases.49 Interestingly, small di- and 
tripeptides are absorbed more rapidly from the small intestine than free amino acids, showing 
further some stability to proteases.50  
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To date, in order to evaluate the phenomenon of absorption, several cell line models are 
employed. Most of the current intestinal models are using transformed cell line and among 
them the Caco-2 being the most widely used.  
 
1.6.1.1 The Caco-2 model 
The intestinal absorption model based on Caco-2 cells, originally derived from a human colon 
adenocarcinoma, is a well-defined in vitro system, extensively used to study absorption, 
metabolism and bioavailability of compounds. According to Biopharmaceutics Classification 
System (BCS) and FDA approval, Caco-2 cells can be used as a screening method for new 
drug candidates during drug discovery and development. Despite of being colonic cells, after 
being cultured, they form a polarized confluent monolayer that shows most of the 
morphological and functional characteristic of enterocyte-like cells: microvilli on the apical 
membrane, tight junction between adjacent cells and expression of intestinal enzyme and 
transporters. In order to mimic in vivo conditions, these cells are typically cultured on 
permeable supports that separate the apical and basolateral compartments, which resemble to 
the luminal and circulation flux of the intestine, respectively.51 Figure 1.3 reports the structural 
features of Caco-2 monolayer. The proposed Caco-2 absorption model provides information 
both about permeability in human intestine and the role of metabolism. In addition, 
measurements derived from permeability experiments with the monolayer show a good 
correlation with data from human in vivo absorption. 
 
Figure 1.3 - Diagram of a Caco-2 monolayer grown on a permeable filter support.52 
 
1.6.2 Metabolism  
Peptides are catabolized in free amino acids, used as building blocks for protein synthesis. Once 
ingested, peptides are subjected to metabolism, commonly due by the action of peptidases that 
are present in enterocytes brush-border, in plasma, in the endothelium and inside the target 
16 
 
cells. The proteases that characterise the epithelium are classified according to their catalytic 
site of action (endopeptidases or exopeptidases) and the nature of the catalytic site. 
Endopeptidases cleave the polypeptide chain at particularly susceptible peptide bonds 
distributed along the chain, whereas exopeptidases hydrolyse one amino acid (or dipeptide) at 
a time from either the N-terminus (aminopeptidases) or the C-terminus (carboxypeptidases). 
The four major classes of endopeptidases are serine proteases, cysteine proteases, aspartic 
proteases and metallo proteases and are characterised by different pH of actions.  
Peptide degradation persists also during their transport through the epithelium, because of the 
action of hydrolases in cellular cytosol. In several studies, the transport of short-chain peptides 
across enterocytes occurs at a very low level, indicating that the peptides are largely hydrolyzed 
by cytosol hydrolase.53 Small peptides, particularly those carrying a proline-proline dipeptide 
at their C-terminus, are the least prone to degradation by proteases and peptidases present in 
the stomach, secreted by pancreas, or contained in the brush border membrane in the small 
intestine. 54 Whereas the aromatic amino acids such as Try, Phe, and Trp; the positively charged 
ones (Arg and Lys); and Leu did not undergo any changes. Charge, molecular weight (MW), 
hydrophobicity and ability to form hydrogen bonds are properties connected with crossing 
through epithelium, susceptibility to degradative enzymes and consequently bioavailability.  
 
1.6.3 Distribution 
Detection of peptides in plasma is technically challenging, because of their low concentrations 
estimated at picograms per millilitre. Peptides comprised of up to 5–6 residues could be 
detected in the blood after feeding volunteers with peptide-enriched drinks.46 However, larger 
peptides can be found intact in plasma, as in the case of the immunomodulatory lunasin after 
consumption of soybean.55 The high bioavailability of lunasin has been also attributed to the 
simultaneous presence of protease inhibitors, allowing 30% of the peptide to reach the target 
tissues.56 The concentration detected in the blood was also proportional to the dose ingested, 
i.e. VY dipeptide was found increased as the ingestion of an enriched drink increased.57 It has 
been calculated that the half-life of the dipeptide VY was longer than the half-life of the 
tripeptide IPP. To date, the quantification of peptides in plasma has been performed through 
the application of MS-based techniques. A Multiple Reaction Monitoring (MRM) method was 
developed to quantify 17 ACE inhibitory peptides (2, 3, and 5 residues) in human plasma 
collected after ingestion of a peptide-enriched drink.46 Other authors have also applied a MRM 
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method to assess the bioavailability of IPP and seven other ACE inhibitory peptides contained 
in a peptide-enriched beverage, and the influence of meal intake on the bioavailability of IPP.58  
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CHAPTER 2 
 
 
2 Technological strategies in the discovery of 
bioactive peptides  
 
2.1 Peptidomic-based approach for the analysis of hydrolysed proteins  
In 2011, the term of peptidomics has been introduced by Schulz59 to indicate the comprehensive 
characterization of peptides present in a biological sample. This relatively young discipline has 
been successfully applied in several areas of research, with particular scientific interest in food 
nutrition for the discovery and quantification of nutritionally relevant bioactive peptides and 
their health benefits. A systematic approach to identify biologically and physiologically active 
peptides, as well as biomarkers, with their pharmacological features is the key of peptidomics.  
Understanding nature and bioactivity of nutritional peptides means comprehending an 
important level of environmental regulation of the human genome, because diet is the 
environmental factor with the most profound life-long influence on health.60 The peptidomic 
strategy provides useful information about the presence of bioactive peptides and covers the 
development of computational tools for: (i) the identification of peptides and their protein 
precursors, (ii) optimization of hydrolysis for the production of very active peptides, (iii) 
prediction of protein/peptide structure and bioactive peptide properties, and (iv) quantitative 
structure-activity relationship (QSAR) modelling.  
 
2.2 Classical downstream processing for discovering of bioactive peptides 
Bioactive peptide discovery traditionally consists of a stepwise approach, typically including 
(i) selection of an appropriate protein source of plant origin; (ii) proteolysis by enzymatic 
processing, fermentation or gastrointestinal digestion; (iii) initial in vitro screening for targeted 
bioactivity; (iv) fractionation of the peptide pool into more defined sub-fractions by 
chromatography or membrane separation; (v) further bioactivity screening followed by 
identification of the bioactive peptide(s) by mass spectrometry proposing possible structure-
function relationships; and (vi) production of synthetic peptide to validate bioactivity in vitro 
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and in vivo. Figure 2.1 reports graphically the main steps occurring in the classical discovery 
processes.  
 
 
 
Figure 2.1 - Integrated analytical workflow for peptidomic investigation. 
In conventional approaches the peptide composition of nutrients is determined by discovery 
peptidomics. The release of bioactive sequences is the first step followed by the checking for their 
biological activities. The large number of peptides contained in the samples, usually, leads their prior 
separation before identification by mass spectrometry (MS). Each fraction are then tested separately for 
bioactivity evaluation and further MS characterised. 
 
 
2.2.1 Release of bioactive peptides by enzymatic hydrolysis 
Bioactive peptides can be produced from precursor proteins where they occur as inactive amino 
acid sequences using the following methods: (a) enzymatic hydrolysis by digestive enzymes, 
(b) fermentation of precursor proteins with proteolytic starter cultures, and (c) proteolysis by 
enzymes derived from microorganisms. In many studies, the combination of (a) and (b) or (a) 
and (c) has proven effective in generation of short functional peptides.61 The choice of 
proteolytic enzymes or microorganisms used for protein processing has a crucial impact on the 
composition of the released peptides. However, the most common way to produce bioactive 
peptides is the use of single or multiple specific or unspecific proteases. Compared to 
microorganisms, enzymes generally require less time to generate a similar degree of hydrolysis 
and their reaction can be controlled giving reproducible MW profiles and peptide composition. 
Additionally, enzymes present substrate specificity which allows the development of protein 
hydrolysates with well-defined chemical and nutritional characteristics.62 Critical hydrolysis 
parameters, such as temperature, pH, aqueous or buffered solution, must be optimized for each 
protein/substrate and each selected enzyme or combination of them and maintained constant 
during proteolysis to ensure efficient release of peptides. Moreover, each bioactive peptide 
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shows different release kinetics during enzymatic hydrolysis. Mostly, larger one appear in early 
stage of hydrolysis and are then cleaved into smaller peptides showing different bioactivity.63  
 
2.2.2 Enrichment and fractionation of bioactive peptides 
Protein hydrolysates generally are tested as complex mixtures or as purified fractions. 
Extensive fractionation procedures using standard chromatographic techniques, such as size-
exclusion (SEC), ion-exchange (IEX), affinity or reversed phase HPLC, or the use of 
membrane ultrafiltration are applied to get simplified peptide pools more amenable to peptide 
identification. To reduce the complexity of hydrolysates, generally ultrafiltration by membrane 
is adopted. The use of membrane ultrafiltration produces peptides with specific molecular 
weight ranges. To obtain short-chain peptides, membranes with low molecular weight (LMW) 
cut-offs (1-10 kDa) are used for fractionation of the protein hydrolysate to obtain LMW 
peptides in the permeate and high molecular weight (HMW) peptides (>10 kDa) in the 
retentate. The LMW peptides have been reported to be more physiologically active as they are 
readily absorbed into blood circulation and transported to target organs, where they exert their 
health effects. Some experiments have shown that membrane ultrafiltration and successive 
chromatographic purifications usually increase potency of the resulting peptides when 
compared to the crude (unfractionated) protein hydrolysate.64 In some cases, however, the 
crude hydrolysate has shown superior bioactivities over the peptide fractions, which could be 
attributed to synergistic activities of the crude hydrolysate peptides, which are lost upon 
successive separation.65,66 The advantage of crude hydrolysates exhibiting stronger 
physiological activities than purified fractions is that it saves costs, as expensive purification 
protocols will be no longer necessary in order to obtain potent products. On the other hand, 
identification of the active peptide structures/sequences for the production of nutraceutical 
supplements would require successive chromatographic purifications to obtain pure peptide 
substances. 
 
2.3 The role of MS in biopeptides discovery   
Recently, mass spectrometry (MS)-based peptidomic approaches set a new standard in peptide 
research. The technological development of MS analysers has been fundamental in driving the 
proteomics research. MS experiments can be addressed directly to measure the molecular mass 
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of derived peptides (single-stage MS) or used to generate AA-sequence information, from 
tandem mass spectra (MS/MS or MSn) obtained either by post-source decay (PSD) or, 
especially in the hybrid arrays, by collision induced dissociation (CID). Very recent 
technological improvements further enlarge capabilities of tandem mass spectrometry 
strategies. Electron transfer dissociation (ETD) and electron capture dissociation (ECD) are 
emerged as new tools in the analytical instrumentation to sequence peptides from complex 
samples and to characterize their post-translational modifications PTMs.  
Hybrid instruments have been designed to combine the capabilities of different mass analysers. 
The LTQ-Orbitrap system, introduced a few years ago, deserves special mention with respect 
to comprehensive peptidomics or proteomics analyses. The high resolution (up to 150,000) and 
mass accuracy, mass-to-charge range up to 6000 and dynamic range greater than 1000 establish 
the Orbitrap technology as among the most versatile and powerful ones.  
 
Electrospray ionization (ESI) source and matrix-assisted laser desorption/ionization (MALDI) 
are the most important ionization sources used in peptidomics. Several examples regarding the 
use of LC-ESI-MS to identify bioactive peptides from vegetables can be found in literature. 
Sato et al.67,68 identified, respectively, seven and nine new ACE-inhibitory and anti-
hypertensive dipeptides from a wakame hydrolysates and a soy sauce-like seasoning. Hybrids 
LC-ESI-Q-TOF and LC-ESI-Q-IT were utilized by Puchalska et al.69 to identify anti-
hypertensive peptides after thermolysin digestion of maize and by Soares70 to identify the major 
HMGCoAR inhibitory peptides generated by the in vitro hydrolysis of Amaranthus cruentus 
protein, respectively.  
MALDI ionization is an alternative source used in peptidomic and proteomic investigations, 
however, the majority of peptidomic studies are conducted using LC-ESI-MS/MS approach. 
About half of the known bioactive peptides are shorter than 10 amino acids and these peptides 
fall into the low mass range, where MALDI matrix interference is overwhelming, which 
severely limits the applicability of MALDI MS in peptidomic studies.54 
 
2.3.1 Hypothesis-free discovery and hypothesis-driven targeted approaches in 
peptidomics 
In peptidomics, there are two different strategies aiming at the discovery and/or quantification 
of potentially bioactive peptides: hypothesis-free discovery and hypothesis-driven targeted 
approach, which are complementary.  
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The first are referred to as shotgun or data-dependent (DDA), widely used for obtaining a 
comprehensive protein or peptide profile of biological systems in a complex peptide mixture. 
The second one is referred as targeted MRM, and it used to probe a predefined subset of 
peptides. Figure 2.2 shows in details the different principles on which the data acquisition is 
based. 
 
Figure 2.2 - Comparison of conventional data-dependent analysis with targeted MRM-MS.  Triple 
quadrupole mass spectrometer was selected as configuration. (a) In a data-dependent MS experiment, 
digested proteins are loaded on a reversed-phase column attached to a liquid chromatography setup and 
eluted via electrospray to yield gas-phase ions. At any given point in the chromatographic separation 
many tens to hundreds of peptides are eluting nearly simultaneously. A full-scan MS spectrum is 
acquired. The ion observed in the MS spectrum are automatically selected on the basis of their signal 
intensity (Q1) for fragmentation by collision with inert gas (Q2). The complete array of fragment ions 
is detected (Q3), which constitutes the full-scan MS/MS spectrum (far right). (b) In a MRM-MS 
analysis, proteotypic peptides are predefined together with their most informative fragment ions. 
Peptides are selected for fragmentation (Q1 and Q2), and fragment ions are selected for detection (Q3) 
based on a user-specified list of targeted precursor-fragment pairs (‘transitions’).  
 
 
 
Although the DDA approach allows an exploratory data analysis, it suffers of some limitations: 
its sensitivity is strongly sample dependent and it suffers from inconsistent identification 
reproducibility across samples due to the biased intrinsic nature of the DDA approach. In 
addition, the peptide abundance covers very huge orders of magnitude, difficult to investigate 
only with the shotgun approach. More information are deductible on the most intense peptides 
deriving from very abundant proteins, but missing values are often observed for peptide 
deriving from less abundant proteins. The bioactive peptides are characterised by small 
sequences usually between 2 and 20 amino acids, that can belong, especially the shortest, to 
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hundreds of proteins. Since they are very small, often they are hidden behind the complex 
matrix of plant/food. The analysis of food-derived peptide, therefore, requires a different 
analytical approach, because these entities vary much more in their chemical nature than 
classical tryptic peptides generated in shotgun proteomics workflow for protein biomarker 
identification: multiple processing parameters come into play generating not only a large 
variety in peptide lengths, sequences, and terminal residues, but also a number of peptide 
modifications. Strategically speaking, the original hypothesis-free discovery workflow is 
being increasingly complemented or followed up by hypothesis-driven analysis or candidate-
based targeted analysis. A recent review puts the discovery and targeted proteomics approaches 
into perspective.71 The hypothesis-driven targeted approach (MRM) is able to target several 
dozen peptides (that need to be known before the measurement) consistently across multiple 
conditions.72, 73 By recording  the signal of the pre-selected analytes over LC separation, MRM 
leads to reproducible measurements across a large number of samples with high consistency 74 
allowing to increase the sensitivity of the detection, which is an important aspect in the 
detection of low expressed bioactive peptides.  
 
2.4 Quantitative peptidomics 
A better knowledge about the concentration of certain bioactive peptides identified in plant 
hydrolysates is crucial for future studies of bioavailability as well as to reach more realistic 
conclusions about the effect that could be expected for an active peptide in the organism. 
In fact, the effect and impact of a bioactive peptide in an organic system depend on the amount 
that is ingested and its ability to reach the bloodstream or the organ of interest. Thus, the 
quantitation data of identified bioactive peptides is a necessary aim for a better understanding 
of the effects and mechanisms involved in the action of these compounds.7 
The most used methodology in the quantitation of known bioactive peptides is currently the 
MRM, which has been used during decades for the quantitation of therapeutic peptides and 
biomarker candidates in plasma, serum and urine75, 76 and recently has been introduced in the 
area of food science.  
 
2.5 Technical issues in bioactive peptide discovery strategies 
The detection of peptides derived from plant proteins requires adaptation of common analytical 
workflows. Two important parameters, such as peptide length (up to 500 amino acids) and 
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dynamic range (e.g. twelve orders of magnitude in human blood plasma), are predominant in 
both fields, proteomics (biomarkers) and peptidomics (bioactives).71 In both cases the 
identification and validation is based on the peptide levels and usually it covers different 
analytical spaces. While proteomics comprises usually peptide molecular weights of approx. 
700 to 3000 Da with a dynamic range of twelve orders of magnitude, peptidomics certainly 
spans a greater peptide length distribution and possibly also a similar dynamic range. The major 
reason for this greater analytical complexity in nutritional peptidomics is the diverse selectivity 
and specificity of the food protein processing and digestion level, conferred by multiple in vitro 
and in vivo proteases. On the contrary, enzymes with a very selective cut action like trypsin are 
applied in protein biomarker identification. As a consequence, generated peptides share similar 
properties, e.g. charge state or length, which reduces the analytical range to be covered. In the 
case of bioactive peptides, they are released either through processes, such as fermentation or 
enzymatic hydrolysis,77 or in situ by the host digestive system or gut microbial enzymes or a 
combination of both.78 In vivo, due to their variable mode of action, endogenous proteases can 
produce a large variety of peptide lengths, sequences, terminal residues, and chemical 
modifications.79  
Whether pre-digested or not, in both cases enzymatic release becomes a very complex and 
unspecific mechanism involving several enzymes from food processing (e.g. Alcalase, 
Protamex, Flavorzyme) as well as the digestive system (e.g. pepsin, trypsin, chymotrypsin, 
elastase)80 with various activities.  
Such difference in the hydrolytic process further impacts analytics, because such peptides have 
broader physical and chemical properties (e.g. charge state, hydrophobicity, length) and need 
adapted separation methods and informatics analysis tools as compared to proteomics.  
To facilitate the identification of unspecifically digested proteins novel, robust and reliable 
performing algorithms for bioinformatic analysis of fragment spectra need to be developed. 
Promising approaches include de novo sequencing81,82 and protease unspecific database 
searches.83 De novo peptide sequencing from fragment ion spectra omits the need for creating 
and matching fragment ion lists generated from protein sequence databases by predefined rules, 
such as tryptic cleavage, thus enabling the identification of atypically digested peptides. In 
protease unspecific database search approaches, fragment ion lists for all possible cleavage 
sites are deduced from protein sequence databases. In this way both peptide termini can be 
arbitrary positioned in a protein, leading to a much larger search space than by applying only 
one specific digestion rule, thereby increasing the possibility of false identifications. The other 
common issue in the peptidomics field regards the ability of MS systems to accurately detect 
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mostly peptides ≥ 5 amino acid residues in length. In contrast, shorter peptides (2-4 amino 
acids) have been poorly reported, to date, in the literature. This is possibly due to analytical 
limitations. The under or over fragmentation of short peptides in tandem MS has made their 
detection complicated and challenging.84, 85 These issues are linked to the difficulty to obtain 
meaningful fragmentation during MS analysis. In addition, short peptides display a low 
structural diversity, which increases the probability of detecting isobaric fragments within the 
same sample or samples generated from different protein substrates, making searches against 
protein databases and the subsequent peptide identification quite complicated. The low level 
of confidence regarding the identification of these short sequences within dietary hydrolysates 
is still evident and a MRM atlas is not available as in the case in proteomics for key organism.86-
88 However, the combination of different fractionation approaches, derivatisation methods, 
front-end analytical separation, in silico tools and altered MS settings has proved beneficial in 
the identification of short peptide sequences within complex mixtures.89 Definitively, further 
technology development will be required to provide efficient tools for analysing bioactive 
peptides of the complex food peptidome.  
 
2.6 Bioinformatics-driven approaches and peptide function prediction  
The screening of bioactive peptides from novel substrates using the empirical approach is 
generally expensive and time-consuming, because it involves the selection of the best proteases 
that demonstrated the highest potential to liberate the bioactive peptides, confirming later their 
biological activities through in vitro assays. However, this conventional and “empirical” 
approach has strong limitations; the main drawbacks include the lack of standardised protocols 
for generation of peptides, the difficulty of systematically checking all hydrolysis parameters 
(i.e., pH, temperature, time, enzyme to substrate (E/S) ratio, total solids, etc.). These conditions 
may influence the release of bioactive peptides, as they can modify both substrate conformation 
and enzyme activity and therefore the accessibility of specific peptide bonds in proteins.89  
This entire workflow can be simplified by using bioinformatics, which provide a cost-effective 
strategy through the reduction of the many steps of the traditional workflow. The use of 
multifactorial design of experiments (DOE) and response surface methodology (RSM) are 
actually the new approaches used as an optimization tool for biopeptides releasing. 90  
Major contribution of bioinformatics to biopeptides discovery, however, not only concerns the 
first step of hydrolysis optimization, but is also related to the prediction of biological activity 
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and the evaluation of food peptides as potential precursor, as observed in the in silico analysis 
of 34 proteins as potential source of DPP-IV inhibitory peptides. 91  
Quantitative structure activity relationship (QSAR) modelling is strongly connected to the 
prediction of the bioactivity of peptides identified in complex sample and achieves a more 
target identification of bioactive peptide sequences identified by LC-MS.  
Actually, many bioactive peptide databases have been designed to store information such as 
sequences, MW, activity, reference to published work, IC50, source and more.  
All this information, according to the peptidome project, are conveyed together in order to 
establish the intellectual database for biological and pharmaceutical research by accumulating 
data of the endogenous peptides in cells, tissue and organism.  The most used until now is 
BioPep containing information on bioactive peptides (n = 2594), major allergens and their 
epitopes (n = 135) as well as sensory peptides including amino acids (n = 326).92 Figure 2.3 
represents in a pie chart the major activities described in the literature and available in the 
BioPep database. ACE inhibitors come first, followed by antibacterial, antioxidative, celiac 
toxic, inhibitory, opioid, neuropeptides as well as immunomodulating peptides. The 
hypocholesterolemic activity on the contrary is not taken into consideration.  
 
 
 
 
Figure 2.3 - Classification of known peptides based on their reported activity in the BioPep 
database (n=2594) 
 
 
 
27 
 
References 
 
1. Padhi, A.; Sengupta, M.; Sengupta, S.; Roehm, K. H.; Sonawane, A., Antimicrobial peptides and 
proteins in mycobacterial therapy: current status and future prospects. Tuberculosis (Edinb) 2014, 94 
(4), 363-73. 
2. Buchwald, H.; Dorman, R. B.; Rasmus, N. F.; Michalek, V. N.; Landvik, N. M.; Ikramuddin, S., 
Effects on GLP-1, PYY, and leptin by direct stimulation of terminal ileum and cecum in humans: 
implications for ileal transposition. Surg Obes Relat Dis 2014, 10 (5), 780-6. 
3. Giordano, C.; Marchiò, M.; Timofeeva, E.; Biagini, G., Neuroactive peptides as putative mediators 
of antiepileptic ketogenic diets. Front Neurol 2014, 5, 63. 
4. Robinson, S. D.; Safavi-Hemami, H.; McIntosh, L. D.; Purcell, A. W.; Norton, R. S.; Papenfuss, A. 
T., Diversity of conotoxin gene superfamilies in the venomous snail, Conus victoriae. PLoS One 2014, 
9 (2), e87648. 
5. Hancock, R. E.; Sahl, H. G., Antimicrobial and host-defense peptides as new anti-infective 
therapeutic strategies. Nat Biotechnol 2006, 24 (12), 1551-7. 
6. Li-Chan, E. C. Y., Bioactive peptides and protein hydrolysates: research trends and challenges for 
application as nutraceuticals and functional food ingredients. Curr. Opin. Food Sci 2015, 1, 28-37. 
7. Mora, L.; Gallego, M.; Reig, M.; Toldrá, F., Challenges in the quantitation of naturally generated 
bioactive peptides in processed meats. Trends Food Sci. Technol. 2017. 
8. Lemes, A. C.; Sala, L.; Ores, J. a. C.; Braga, A. R.; Egea, M. B.; Fernandes, K. F., A Review of the 
Latest Advances in Encrypted Bioactive Peptides from Protein-Rich Waste. Int J Mol Sci 2016, 17 (6). 
9. Kaspar, A. A.; Reichert, J. M., Future directions for peptide therapeutics development. Drug Discov 
Today 2013, 18 (17-18), 807-17. 
10. Sun, L., Peptide-Based Drug Development. Modern Chemistry and Applications 2013. 
11. Transparency; Research, M. Peptide Therapeutics Market: Global Industry Analysis, Size, Share, 
Growth, Trends and Forecast; 2012. 
12. Pang, G.; Xie, J.; Chen, Q.; Hu, S., How functional foods play critical roles in human health. Food 
Sci. Hum. Wellness, 2012; Vol. 1, pp 26-60. 
13. Coda, R.; Rizzello, C. G.; Pinto, D.; Gobbetti, M., Selected lactic acid bacteria synthesize 
antioxidant peptides during sourdough fermentation of cereal flours. Appl Environ Microbiol 2012, 78 
(4), 1087-96. 
14. Hata, Y.; Yamamoto, M.; Ohni, M.; Nakajima, K.; Nakamura, Y.; Takano, T., Placebo-controlled 
study of the effect of sour milk on blood pressure in hypertensive subjects. Am. J. Clin. Nutr. 1996, 64 
(5), 767-771. 
15. Mizushima, S.; Ohshige, K.; Watanabe, J.; Kimura, M.; Kadowaki, T.; Nakamura, Y.; Tochikubo, 
O.; Ueshima, H., Randomized controlled trial of sour milk on blood pressure in borderline hypertensive 
men. Am. J. Hypertens. 2004, 17 (8), 701-706. 
16. Seppo, L.; Jauhiainen, T.; Poussa, T.; Korpela, R., A fermented milk high in bioactive peptides has 
a blood pressure-lowering effect in hypertensive subjects. Am. J. Clin. Nutr. 2003, 77 (2), 326-330. 
28 
 
17. Hartmann, R.; Meisel, H., Food-derived peptides with biological activity: from research to food 
applications. Curr Opin Biotechnol 2007, 18 (2), 163-9. 
18. Arai, S.; Yasuoka, A.; Abe, K., Functional food science and food for specified health use policy in 
Japan: state of the art. Curr Opin Lipidol 2008, 19 (1), 69-73. 
19. Kussmann, M.; Van Bladeren, P. J., The Extended Nutrigenomics - Understanding the Interplay 
between the Genomes of Food, Gut Microbes, and Human Host. Front Genet 2011, 2, 21. 
20. Erickson, B. E., Proteomics data back up soy health claims. J Proteome Res 2005, 4 (2), 219. 
21. García, M. C.; Puchalska, P.; Esteve, C.; Marina, M. L., Vegetable foods: a cheap source of proteins 
and peptides with antihypertensive, antioxidant, and other less occurrence bioactivities. Talanta 2013, 
106, 328-49. 
22. Malaguti, M.; Dinelli, G.; Leoncini, E.; Bregola, V.; Bosi, S.; Cicero, A. F.; Hrelia, S., Bioactive 
peptides in cereals and legumes: agronomical, biochemical and clinical aspects. Int J Mol Sci 2014, 15 
(11), 21120-35. 
23. Rizzello, C. G.; Tagliazucchi, D.; Babini, E.; Rutella, G. S.; Saa, D. L. T.; Gianotti, A., Bioactive 
peptides from vegetable food matrices: Research trends and novel biotechnologies for synthesis and 
recovery. J. Funct Foods 2016, 27, 549-569. 
24. Bourgeois, M.; Jacquin, F.; Savois, V.; Sommerer, N.; Labas, V.; Henry, C.; Burstin, J., Dissecting 
the proteome of pea mature seeds reveals the phenotypic plasticity of seed protein composition. 
Proteomics 2009, 9 (2), 254-71. 
25. Hori, G.; Wang, M. F.; Chan, Y. C.; Komatsu, T.; Wong, Y.; Chen, T. H.; Yamamoto, K.; Nagaoka, 
S.; Yamamoto, S., Soy protein hydrolyzate with bound phospholipids reduces serum cholesterol levels 
in hypercholesterolemic adult male volunteers. Biosci Biotechnol Biochem 2001, 65 (1), 72-8. 
26. Nagaoka, S.; Kanamaru, Y.; Kuzuya, Y.; Kojima, T.; Kuwata, T., Comparative-studies on the 
serum-cholesterol lowering action of whey-protein and soybean protein in rats. Biosci Biotechnol 
Biochem 1992, 56 (9), 1484-1485. 
27. Wergedahl, H.; Liaset, B.; Gudbrandsen, O. A.; Lied, E.; Espe, M.; Muna, Z.; Mørk, S.; Berge, R. 
K., Fish protein hydrolysate reduces plasma total cholesterol, increases the proportion of HDL 
cholesterol, and lowers acyl-CoA:cholesterol acyltransferase activity in liver of Zucker rats. J Nutr 
2004, 134 (6), 1320-7. 
28. Zhang, Y.; Ma, K. L.; Ruan, X. Z.; Liu, B. C., Dysregulation of the Low-Density Lipoprotein 
Receptor Pathway Is Involved in Lipid Disorder-Mediated Organ Injury. Int J Biol Sci 2016, 12 (5), 
569-579. 
29. Sugano, M.; Goto, S.; Yamada, Y.; Yoshida, K.; Hashimoto, Y.; Matsuo, T.; Kimoto, M., 
Cholesterol-lowering activity of various undigested fractions of soybean protein in rats. J Nutr 1990, 
120 (9), 977-85. 
30. Lovati, M. R.; Manzoni, C.; Canavesi, A.; Sirtori, M.; Vaccarino, V.; Marchi, M.; Gaddi, G.; Sirtori, 
C. R., Soybean Protein-Diet Increases Low-Density-Lipoprotein Receptor Activity In Mononuclear-
Cells From Hypercholesterolemic Patients. J. Clin. Invest. 1987, 80 (5), 1498-1502. 
31. Yoshikawa, M.; Fujita, H.; Matoba, N.; Takenaka, Y.; Yamamoto, T.; Yamauchi, R.; Tsuruki, H.; 
Takahata, K., Bioactive peptides derived from food proteins preventing lifestyle-related diseases. 
Biofactors 2000, 12 (1-4), 143-6. 
29 
 
32. Takenaka, Y.; Utsumi, S.; Yoshikawa, M., Introduction of enterostatin (VPDPR) and a related 
sequence into soybean proglycinin A1aB1b subunit by site-directed mutagenesis. Biosci Biotechnol 
Biochem 2000, 64 (12), 2731-3. 
33. Pak, V. V.; Koo, M. S.; Kasymova, T. D.; Kwon, D. Y., Isolation and identification of peptides 
from soy 11S-globulin with hypocholesterolemic activity. Chem. Nat. Compd. 2005, 41 (6), 710-714. 
34. Lammi, C.; Zanoni, C.; Arnoldi, A., IAVPGEVA, IAVPTGVA, and LPYP, three peptides from soy 
glycinin, modulate cholesterol metabolism in HepG2 cells through the activation of the LDLR-SREBP-
2 pathway. J Funct Foods 2015, 14, 469-478. 
35. Amigo-Benavent, M.; Clemente, A.; Caira, S.; Stiuso, P.; Ferranti, P.; del Castillo, M. D., Use of 
phytochemomics to evaluate the bioavailability and bioactivity of antioxidant peptides of soybean β-
conglycinin. Electrophoresis 2014, 35 (11), 1582-9. 
36. Duranti, M.; Lovati, M. R.; Dani, V.; Barbiroli, A.; Scarafoni, A.; Castiglioni, S.; Ponzone, C.; 
Morazzoni, P., The alpha ' subunit from soybean 7S globulin lowers plasma lipids and upregulates liver 
beta-VLDL receptors in rat feed a hypercholesterolemic diet. J. Nutr 2004, 134 (6), 1334-1339. 
37. Spielmann, J.; Shukla, A.; Brandsch, C.; Hirche, F.; Stangl, G. I.; Eder, K., Dietary lupin protein 
lowers triglyceride concentrations in liver and plasma in rats by reducing hepatic gene expression of 
sterol regulatory element-binding protein-1c. Ann Nutr Metab 2007, 51 (4), 387-92. 
38. Bettzieche, A.; Brandsch, C.; Weisse, K.; Hirche, F.; Eder, K.; Stangl, G. I., Lupin protein influences 
the expression of hepatic genes involved in fatty acid synthesis and triacylglycerol hydrolysis of adult 
rats. Br J Nutr 2008, 99 (5), 952-62. 
39. Parolini, C.; Rigamonti, E.; Marchesi, M.; Busnelli, M.; Cinquanta, P.; Manzini, S.; Sirtori, C. R.; 
Chiesa, G., Cholesterol-lowering effect of dietary Lupinus angustifolius proteins in adult rats through 
regulation of genes involved in cholesterol homeostasis. Food Chem 2012, 132 (3), 1475-1479. 
40. Lammi, C.; Zanoni, C.; Scigliuolo, G. M.; D'Amato, A.; Arnoldi, A., Lupin peptides lower low-
density lipoprotein (LDL) cholesterol through an up-regulation of the LDL receptor/sterol regulatory 
element binding protein 2 (SREBP-2) pathway at HepG2 cell line. J Agric Food Chem 2014, 62 (29), 
7151-9. 
41. Lammi, C.; Zanoni, C.; Calabresi, L.; Arnoldi, A., Lupin protein exerts cholesterol-lowering effects 
targeting PCSK9: From clinical evidences to elucidation of the in vitro molecular mechanism using 
HepG2 cells. J Funct Foods 2016, 23, 230-240. 
42. Girgih, A. T.; He, R.; Malomo, S.; Offengenden, M.; Wu, J. P.; Aluko, R. E., Structural and 
functional characterization of hemp seed (Cannabis sativa L.) protein-derived antioxidant and 
antihypertensive peptides. J Funct Foods 2014, 6, 384-394. 
43. Gavel, N. T.; Edel, A. L.; Bassett, C. M.; Weber, A. M.; Merchant, M.; Rodriguez-Leyva, D.; Pierce, 
G. N., The effect of dietary hempseed on atherogenesis and contractile function in aortae from 
hypercholesterolemic rabbits. Acta Physiol Hung 2011, 98 (3), 273-83. 
44. Prociuk, M. A.; Edel, A. L.; Richard, M. N.; Gavel, N. T.; Ander, B. P.; Dupasquier, C. M.; Pierce, 
G. N., Cholesterol-induced stimulation of platelet aggregation is prevented by a hempseed-enriched 
diet. Can J Physiol Pharmacol 2008, 86 (4), 153-9. 
45. Grimble, G. K., The significance of peptides in clinical nutrition. Ann Review Nutrition 1994, 14, 
419-447. 
30 
 
46. van Platerink, C. J.; Janssen, H. G. M.; Horsten, R.; Haverkamp, J., Quantification of ACE inhibiting 
peptides in human plasma using high performance liquid chromatography-mass spectrometry. J 
Chromatogr B Analyt Technol Biomed Life Sci 2006, 830 (1), 151-157. 
47. Ménard, S.; Cerf-Bensussan, N.; Heyman, M., Multiple facets of intestinal permeability and 
epithelial handling of dietary antigens. Mucosal Immunol 2010, 3 (3), 247-59. 
48. Shimizu, M.; Tsunogai, M.; Arai, S., Transepithelial transport of oligopeptides in the human 
intestinal cell, Caco-2. Peptides 1997, 18 (5), 681-7. 
49. Roberts, P. R.; Burney, J. D.; Black, K. W.; Zaloga, G. P., Effect of chain length on absorption of 
biologically active peptides from the gastrointestinal tract. Digestion 1999, 60 (4), 332-7. 
50. Webb, K. E., Intestinal absorption of protein hydrolysis products: a review. J Anim Sci 1990, 68 (9), 
3011-22. 
51. Sambuy, Y.; De Angelis, I.; Ranaldi, G.; Scarino, M. L.; Stammati, A.; Zucco, F., The Caco-2 cell 
line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell 
functional characteristics. Cell Biol Toxicol 2005, 21 (1), 1-26. 
52. Hubatsch, I.; Ragnarsson, E. G. E.; Artursson, P., Determination of drug permeability and prediction 
of drug absorption in Caco-2 monolayers. Nature Protocols 2007, 2 (9), 2111-2119. 
53. Wang, B.; Li, B., Effect of molecular weight on the transepithelial transport and peptidase 
degradation of casein-derived peptides by using Caco-2 cell model. Food Chem 2017, 218, 1-8. 
54. Panchaud, A.; Affolter, M.; Kussmann, M., Mass spectrometry for nutritional peptidomics: How to 
analyze food bioactives and their health effects. J Proteomics 2012, 75 (12), 3546-59. 
55. Dia, V. P.; Torres, S.; De Lumen, B. O.; Erdman, J. W.; De Mejia, E. G., Presence of lunasin in 
plasma of men after soy protein consumption. J Agric Food Chem 2009, 57 (4), 1260-6. 
56. Hsieh, C. C.; Hernández-Ledesma, B.; Jeong, H. J.; Park, J. H.; de Lumen, B. O., Complementary 
roles in cancer prevention: protease inhibitor makes the cancer preventive peptide lunasin bioavailable. 
PLoS One 2010, 5 (1), e8890. 
57. Matsui, T.; Tamaya, K.; Seki, E.; Osajima, K.; Matsumoto, K.; Kawasaki, T., Val-Tyr as a natural 
antihypertensive dipeptide can be absorbed into the human circulatory blood system. Clin Exp 
Pharmacol Physiol 2002, 29 (3), 204-8. 
58. Foltz, M.; van Buren, L.; Klaffke, W.; Duchateau, G. S., Modeling of the relationship between 
dipeptide structure and dipeptide stability, permeability, and ACE inhibitory activity. J Food Sci 2009, 
74 (7), H243-51. 
59. Schulz-Knappe, P.; Zucht, H. D.; Heine, G.; Jürgens, M.; Hess, R.; Schrader, M., Peptidomics: the 
comprehensive analysis of peptides in complex biological mixtures. Comb Chem High Throughput 
Screen 2001, 4 (2), 207-17. 
60. Kussmann, M.; Fay, L. B., Nutrigenomics and personalized nutrition: science and concept. 
Personalized Medicine 2008, 5 (5), 447-455. 
61. Korhonen, H.; Pihlanto, A., Food-derived bioactive peptides - Opportunities for designing future 
foods. Current Pharmaceutical Design 2003, 9 (16), 1297-1308. 
62. Castro, H. C.; Abreu, P. A.; Geraldo, R. B.; Martins, R. C.; dos Santos, R.; Loureiro, N. I.; Cabral, 
L. M.; Rodrigues, C. R., Looking at the proteases from a simple perspective. J Mol Recognit 2011, 24 
(2), 165-81. 
31 
 
63. Zhao, Q.; Sannier, F.; Piot, J. M., Kinetics of appearance of four hemorphins from bovine 
hemoglobin peptic hydrolysates by HPLC coupled with photodiode array detection. Biochim Biophys 
Acta 1996, 1295 (1), 73-80. 
64. Udenigwe, C. C.; Aluko, R. E., Food protein-derived bioactive peptides: production, processing, 
and potential health benefits. J Food Sci 2012, 77 (1), R11-24. 
65. Girgih, A. T.; Udenigwe, C. C.; Aluko, R. E., In Vitro Antioxidant Properties of Hemp Seed 
(Cannabis sativa L.) Protein Hydrolysate Fractions. J Am Oil Chem Soc 2011, 88 (3), 381-389. 
66. Girgih, A. T.; Udenigwe, C. C.; Li, H.; Adebiyi, A. P.; Aluko, R. E., Kinetics of Enzyme Inhibition 
and Antihypertensive Effects of Hemp Seed (Cannabis sativa L.) Protein Hydrolysates. J Am Oil Chem 
Soc 2011, 88 (11), 1767-1774. 
67. Sato, M.; Hosokawa, T.; Yamaguchi, T.; Nakano, T.; Muramoto, K.; Kahara, T.; Funayama, K.; 
Kobayashi, A., Angiotensin I-converting enzyme inhibitory peptides derived from wakame (Undaria 
pinnatifida) and their antihypertensive effect in spontaneously hypertensive rats. J Agric Food Chem 
2002, 50 (21), 6245-6252. 
68. Nakahara, T.; Sano, A.; Yamaguchi, H.; Sugimoto, K.; Chikata, H.; Kinoshita, E.; Uchida, R., 
Antihypertensive Effect of Peptide-Enriched Soy Sauce-Like Seasoning and Identification of Its 
Angiotensin I-Converting Enzyme Inhibitory Substances (vol 58, pg 821, 2010). J Agric Food Chem 
2010, 58 (9), 5858-5858. 
69. Puchalska, P.; Marina, M. L.; García, M. C., Development of a reversed-phase high-performance 
liquid chromatography analytical methodology for the determination of antihypertensive peptides in 
maize crops. J Chromatogr A 2012, 1234, 64-71. 
70. Soares, R. A. M.; Mendonca, S.; de Castro, L. I. A.; Menezes, A.; Areas, J. A. G., Major Peptides 
from Amaranth (Amaranthus cruentus) Protein Inhibit HMG-CoA Reductase Activity. Int J Mol Sci. 
2015, 16 (2), 4150-4160. 
71. Domon, B.; Aebersold, R., Options and considerations when selecting a quantitative proteomics 
strategy. Nat Biotechnol 2010, 28 (7), 710-21. 
72. Olsen, J. V.; Ong, S. E.; Mann, M., Trypsin cleaves exclusively C-terminal to arginine and lysine 
residues. Mol Cell Proteomics 2004, 3 (6), 608-14. 
73. Lange, V.; Picotti, P.; Domon, B.; Aebersold, R., Selected reaction monitoring for quantitative 
proteomics: a tutorial. Mol Syst Biol 2008, 4, 222. 
74. Picotti, P.; Clément-Ziza, M.; Lam, H.; Campbell, D. S.; Schmidt, A.; Deutsch, E. W.; Röst, H.; 
Sun, Z.; Rinner, O.; Reiter, L.; Shen, Q.; Michaelson, J. J.; Frei, A.; Alberti, S.; Kusebauch, U.; 
Wollscheid, B.; Moritz, R. L.; Beyer, A.; Aebersold, R., A complete mass-spectrometric map of the 
yeast proteome applied to quantitative trait analysis. Nature 2013, 494 (7436), 266-70. 
75. Liu, Y.; Hüttenhain, R.; Surinova, S.; Gillet, L. C.; Mouritsen, J.; Brunner, R.; Navarro, P.; 
Aebersold, R., Quantitative measurements of N-linked glycoproteins in human plasma by SWATH-
MS. Proteomics 2013, 13 (8), 1247-56. 
76. Rauh, M., LC-MS/MS for protein and peptide quantification in clinical chemistry. J Chromatogr B 
Analyt Technol Biomed Life Sci 2012, 883-884, 59-67. 
77. Nakamura, Y.; Yamamoto, N.; Sakai, K.; Okubo, A.; Yamazaki, S.; Takano, T., Purification And 
Characterization Of Angiotensin I-Converting Enzyme-Inhibitors From Sour Milk. J Dairy Sci 1995, 
78 (4), 777-783. 
32 
 
78. De Leo, F.; Panarese, S.; Gallerani, R.; Ceci, L. R., Angiotensin converting enzyme (ACE) 
inhibitory peptides: production and implementation of functional food. Curr Pharm Des 2009, 15 (31), 
3622-43. 
79. Kussmann, M.; Affolter, M.; Nagy, K.; Holst, B.; Fay, L. B., Mass spectrometry in nutrition: 
understanding dietary health effects at the molecular level. Mass Spectrom Rev 2007, 26 (6), 727-50. 
80. Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M., Synthetic therapeutic peptides: science 
and market. Drug Discov Today 2010, 15 (1-2), 40-56. 
81. Frank, A.; Pevzner, P., PepNovo: de novo peptide sequencing via probabilistic network modeling. 
Anal Chem 2005, 77 (4), 964-73. 
82. Zhang, J.; Xin, L.; Shan, B.; Chen, W.; Xie, M.; Yuen, D.; Zhang, W.; Zhang, Z.; Lajoie, G. A.; 
Ma, B., PEAKS DB: de novo sequencing assisted database search for sensitive and accurate peptide 
identification. Mol Cell Proteomics 2012, 11 (4), M111.010587. 
83. Cox, J.; Neuhauser, N.; Michalski, A.; Scheltema, R. A.; Olsen, J. V.; Mann, M., Andromeda: a 
peptide search engine integrated into the MaxQuant environment. J Proteome Res 2011, 10 (4), 1794-
805. 
84. Dallas, D. C.; Guerrero, A.; Parker, E. A.; Robinson, R. C.; Gan, J.; German, J. B.; Barile, D.; 
Lebrilla, C. B., Current peptidomics: applications, purification, identification, quantification, and 
functional analysis. Proteomics 2015, 15 (5-6), 1026-38. 
85. Lahrichi, S. L.; Affolter, M.; Zolezzi, I. S.; Panchaud, A., Food peptidomics: large scale analysis of 
small bioactive peptides--a pilot study. J Proteomics 2013, 88, 83-91. 
86. Deutsch, E. W.; Lam, H.; Aebersold, R., PeptideAtlas: a resource for target selection for emerging 
targeted proteomics workflows. EMBO Rep 2008, 9 (5), 429-34. 
87. Picotti, P.; Lam, H.; Campbell, D.; Deutsch, E. W.; Mirzaei, H.; Ranish, J.; Domon, B.; Aebersold, 
R., A database of mass spectrometric assays for the yeast proteome. Nat Methods 2008, 5 (11), 913-4. 
88. Picotti, P.; Rinner, O.; Stallmach, R.; Dautel, F.; Farrah, T.; Domon, B.; Wenschuh, H.; Aebersold, 
R., High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat 
Methods 2010, 7 (1), 43-6. 
89. Nongonierma, A. B.; FitzGerald, R. J., Strategies for the discovery, identification and validation of 
milk protein-derived bioactive peptides. Trends Food Sci Technol 2016, 50, 26-43. 
90. Quirós, A.; Hernández-Ledesma, B.; Ramos, M.; Martín-Álvarez, P. J.; Recio, I., Short 
communication: Production of antihypertensive peptide HLPLP by enzymatic hydrolysis: optimization 
by response surface methodology. J Dairy Sci 2012, 95 (8), 4280-5. 
91. Lacroix, I. M. E.; Li-Chan, E. C. Y., Evaluation of the potential of dietary proteins as precursors of 
dipeptidyl peptidase (DPP)-IV inhibitors by an in silico approach. J Funct Foods 2012, 4 (2), 403-422. 
92. Iwaniak, A.; Dziuba, J.; Niklewicz, M., The biopep database - A tool for the in silico method of 
classification of food proteins as the source of peptides with antihypertensive activity. Acta Alimentaria 
2005, 34 (4), 417-425. 
33 
 
 
 
 
 
 
 
Part II. 
Scientific contributions 
 
34 
 
 
 
CHAPTER 3 
 
 
MANUSCRIPT 1 
 
 
A MULTIDISCIPLINARY INVESTIGATION ON THE 
BIOAVAILABILITY AND ACTIVITY OF PEPTIDES FROM 
LUPIN PROTEIN 
 
 
Carmen Lammi a, Gilda Aiello a, Giulio Vistoli a, Chiara Zanoni b, 
Anna Arnoldi a,*, Yula Sambuy c, Simonetta Ferruzza c, Giulia Ranaldi c 
 
a) Department of Pharmaceutical Sciences, University of Milan, Milan, Italy 
b) Dipartimento Cardiotoracovascolare, A.O. Ospedale Niguarda Cà Granda, Milan, Italy 
c) CREA, Food and Nutrition Research Center, Rome, Italy 
 
Abbreviations: ACE, angiotensin converting enzyme; AP, apical; APBS, adaptive Poisson-
Boltzmann solver; BL, basolateral; DPP-IV, dipeptidyl peptidase IV; HMGCoAR, 3-
hydroxy-3-methylglutaryl coenzyme A reductase; LDL, low density lipoprotein; MD, 
Molecular dynamic; MLPInS, molecular lipophilic potential interaction score; PEP, prolyl 
endopeptidase; Plp95, pairwise linear potential; SREBP-2, regulatory element binding 
proteins 2; TEER, trans-epithelial electrical resistance. 
 
Keywords: bioactive peptides, Caco-2 cells, HMGCoA reductase, intestinal absorption, 
Lupinus albus, plant protein.  
 35 
 
 
3.0 Abstract 
Lupin foods provide useful health benefits. Since tryptic and peptic peptides from lupin protein 
modulate cholesterol metabolism in HepG2 cells and increase LDL-uptake, this work had the 
goal of assessing whether these lupin peptides are absorbed by human intestinal Caco-2 cells. 
Cells were differentiated for 15 days and transport experiments were performed by incubating 
each lupin peptide mixture from the apical side. After 4 h, basolateral solutions were collected 
and analysed by HPLC-Chip-MS/MS. Eleven tryptic and eight peptic peptides, deriving from 
lupin storage proteins, were identified in the basolateral samples. An in vitro assay showed that 
basolateral peptides maintain their capacity to inhibit 3-hydroxy-3-methylglutaryl coenzyme 
A reductase (HMGCoAR) activity and in silico docking simulations permitted to hypothesise 
which peptides may bind more efficiently to the HMGCoAR catalytic site. This is the first 
investigation providing evidence that lupin peptides with specific structures are potentially 
absorbed in human intestinal cells.  
 
3.1 Introduction 
The absorption of nutrients from the small intestinal lumen to blood circulation is mainly 
performed by enterocytes. An in vitro strategy to address the bioavailability problem consists 
of evaluating the uptake and transport of target compound(s) by human intestinal Caco-2 cells. 
When these cells are seeded in culture on polycarbonate filters, they undergo spontaneous 
differentiation leading to the formation of a polarised cell monolayer, coupled by tight 
junctions and expressing several morphological and functional features of small intestinal 
enterocytes (Sambuy et al. 2005). In this two-compartment system, the cell monolayer 
separates the apical (AP) compartment, corresponding to the intestinal lumen, from the 
basolateral (BL) one, corresponding to the intestinal vascular and lymphatic circulation 
(Ferruzza et al. 2012, Sambuy et al. 2005).  
There is now much interest for bioactive food peptides that may positively influence major 
body functions, once they are released by digestion from parental proteins and absorbed (Cam 
and de Mejia 2012). The transport through intestinal cells is a major factor influencing their 
bioavailability. The hypothesis that small peptides may escape complete digestion and be 
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transported from intestinal lumen into blood circulation is gaining acceptance, mainly due to 
numerous studies describing the in vitro trans-epithelial transport of bioactive peptides (Miguel 
et al. 2008, Zhu et al. 2008, Foltz et al. 2007, Regazzo et al. 2010), although its occurrence in 
vivo is still controversial (Miner-Williams, Stevens and Moughan 2014). Differentiated human 
intestinal Caco-2 cells express carrier-mediated transport systems for amino acids and di- and 
tri-peptides (Thwaites et al. 1993, Miguel et al. 2008), show transcytosis activity (Heyman et 
al. 1990), and develop tight junctions involved in the paracellular passive route (Hidalgo, Raub 
and Borchardt 1989, Hashimoto and Shimizu 1993). In particular, this model has been used for 
evaluating the bioavailability of antioxidant peptides from soybean -conglycinin (Amigo-
Benavent et al. 2014). 
Lupin protein provides various health benefits (Arnoldi et al. 2015a, Duranti et al. 2008), 
particularly in the area of cholesterol reduction (Sirtori et al. 2012, Bähr et al. 2015), and 
hypertension (Arnoldi et al. 2015a) or hyperglycaemia prevention (Duranti et al. 2008). We 
have recently demonstrated that tryptic and peptic peptides from lupin protein are able to 
interfere with 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoAR) activity, up-
regulating LDL-receptor and sterol regulatory element binding proteins 2 (SREBP-2), and 
increasing LDL-uptake in HepG2 cells (Lammi et al. 2014b). Moreover, the same peptides 
inhibit the activity of angiotensin converting enzyme (ACE, EC 3.4.15.1) (Boschin et al. 2014b, 
Boschin et al. 2014a), an effect possibly involved in the hypotensive effect observed in vivo. 
From these findings the general question arose whether lupin peptides might be absorbed after 
food ingestion (Miner-Williams et al. 2014). As a first step to solve this issue, the present work 
was aimed at assessing whether any tryptic and peptic peptides from lupin protein may be 
absorbed by Caco-2 cells and transferred to the BL compartment and whether they maintain 
their hypocholesterolemic activity. The former objective was achieved by conducting transport 
experiments across differentiated human enterocytes and analysing BL solutions by HPLC-
Chip-MS/MS, whereas the latter by using in vitro biological assays and bioinformatics tools.  
 
3.2 Materials and methods 
3.2.1 Chemicals and reagents 
Formic acid, acetonitrile (ACN), sequence grade trypsin, and pepsin were from Sigma–Aldrich 
(Milan, Italy). LC-grade H2O (18 M cm) was prepared with a Milli-Q H2O purification 
system (Millipore, Bedford, MA, US). Centrifugal filter devices YM-30 (cut off 30 kDa) were 
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from Amicon Bioseparations (Millipore Corporation, Bedford, USA). Dulbeccos’s Modified 
Eagle Medium (DMEM) was from GIBCO (Thermo Fisher Scientific, Waltham, MA US).  
Foetal Bovine Serum (FBS) was from Hyclone Laboratories (Logan, UT, US). Stable L-
glutamine, 1% non-essential amino acids, and penicillin/streptomycin were from Euroclone 
(Milan, Italy). HMGCoAR assay Kit, red phenol, and PBS was from Sigma-Aldrich (St. Louis, 
MO, USA). Polycarbonate filters, 12 mm diameter, 0.4 µm pore diameter were from Transwell 
Corning Inc. (Lowell, MA, US). 
 
3.2.2 Preparation of the pepsin and trypsin peptide mixtures 
The pepsin and trypsin hydrolysates from lupin protein are the same used in a previous paper 
investigating cholesterol metabolism modulation in HepG2 cells (Lammi et al. 2014b). The 
procedure for protein extraction from seeds of Lupinus albus (cultivar Ares) and the conditions 
of protein hydrolysis are reported in detail there. In brief, proteins were extracted from defatted 
lupin flour with 100 mM Tris-HCl/0.5 M NaCl buffer, pH 8.2 for 2 h at 4 °C. After 
centrifugation at 6,500 g, for 20 min at 4 °C, the supernatant was dialysed against 100 mM 
Tris-HCl buffer pH 8.2 for 24 h at 4 °C. After assessing the protein concentration by Bradford 
assay, the total protein extract was dissolved in Tris-HCl buffer 100 mM at pH 8, then the pH 
was adjusted to the optimal hydrolysis conditions for each enzyme (pH = 2 for pepsin and = 8 
for trypsin) by adding 1 M NaOH or 1 M HCl. After 18 h incubation and enzyme inactivation, 
the mixtures were ultra-filtered through 3,000 Da cut-off centrifuge filters (Amicon Ultra-0.5, 
Millipore, Billerica, MA, USA) at 12,000 g for 30 min at 4 °C. The peptide concentration in 
the permeates was measured according to a literature method (Kito and Ito 2008), based on 
chelating the peptide bonds by Cu (II) in alkaline media and monitoring the change of 
absorbance at 330 nm. In brief, the reagent contained 0.6 M sodium citrate, 0.9 M sodium 
carbonate, and 0.07 M copper sulfate, 2.4 M NaOH at pH 10.6. A solution containing X μL 
peptide mixture, (500 − X) μL water, 500 μL 6% (w/w) NaOH in water, and 50 μL active 
reagent was prepared. The reaction was carefully mixed, incubated for 15 min at 20 °C, and 
then the optical density of the solution was measured at 330 nm. A sterile solution of peptone 
from casein at 10 mg/mL in water was used as standard for the calibration curve; the assay was 
linear in the range 100−1000 μg of peptides in cuvette. 
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3.2.3 Cell culture and differentiation 
Caco-2 cells, obtained from INSERM (Paris), were sub-cultured at low density (Natoli et al. 
2011). Cells were routinely sub-cultured at 50% density and maintained at 37 °C in a 90% / 
10% air / CO2 atmosphere in DMEM containing 25 mM glucose, 3.7 g/L NaHCO3, 4 mM 
stable L-glutamine, 1% non-essential amino acids, 100 U/L penicillin, 100 µg/L streptomycin 
(complete medium), supplemented with 10% heat inactivated foetal bovine serum (FBS) 
(Hyclone Laboratories, Logan, UT, US). For differentiation, cells were seeded on 
polycarbonate filters, 12 mm diameter, 0.4 µm pore diameter (Transwell, Corning Inc., Lowell, 
MA, US) at a 3.5x105 cells/cm2 density in complete medium supplemented with 10% FBS in 
both AP and BL compartments for 2 days to allow the formation of a confluent cell monolayer. 
Starting from day 3 after seeding, cells were transferred to complete medium in both 
compartments, supplemented with 10% FBS only in BL compartment, and allowed to 
differentiate for 15 days with regular medium changes three times weekly (Ferruzza et al. 
2012). 
 
3.2.4 Trans-epithelial transport of peptic and tryptic lupin peptides 
Prior to experiments, the cell monolayer integrity and differentiation were checked by TEER 
measurement as described in details in the paragraph 2.5. Cells were then washed twice and 
peptides transport was assayed. In particular, transport experiments were performed in 
transport buffer solution (137 mM NaCl, 5.36 mM KCl, 1.26 mM CaCl2, 1.1 mM MgCl2, 5.5 
mM glucose). In order to reproduce the pH conditions existing in vivo in small intestinal 
mucosa, AP solutions were maintained at pH 6.0 (buffered with 10 mM morpholinoethane 
sulfonic acid), and BL solutions were maintained at pH 7.4 (buffered with 10 mM N-2-
hydroxyethylpiperazine-N-4-butanesulfonic acid). Prior to transport experiments, cells were 
washed twice with 500 µL PBS with Ca++ and Mg++. Peptides transport was assayed by loading 
the AP compartment with peptic or tryptic lupin peptides (1 mg/mL) in AP transport solution 
(500 µL) and the BL compartment with the BL transport solution (700 µL). After 4 h 
incubation, AP and BL media were collected and stored at -80 °C. Five independent transport 
experiments were performed, each in duplicate. 
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3.2.5 Cell monolayer integrity evaluation 
The trans-epithelial electrical resistance (TEER) was measured at 37 °C using the voltmeter 
apparatus Millicell (Millipore Co., USA,), immediately before and at the end of the 4 h 
transport experiments. After incubations, no significant changes in TEER values were 
observed. At the end of transport experiments, cells were incubated from the AP side with 1 
mM phenol-red in PBS with Ca++ and Mg++ for 1 h at 37 °C. The BL solution was then collected 
and NaOH (70 µL, 0.1 N) was added before reading the absorbance at 560 nm by a microplate 
reader Synergy H1 from Biotek (Winooski, VT, USA). Phenol-red passage was quantified 
using a standard phenol-red curve. 
 
3.2.6 HPLC-Chip-MS/MS analysis 
The original peptic and tryptic lupin mixtures given to cells in transport medium and the 
medium collected at the end of the experiment from AP and BL chambers (500 µL and 700 
µL, respectively) were freeze-dried and residues were solubilised in HPLC water (100 µL). 
Samples were purified by ultrafiltration, using membranes with a 3-kDa molecular weight cut-
off (MWCO) (Millipore, USA). Filtered peptide mixtures were analysed on a SL IT mass 
spectrometer interfaced with a HPLC-Chip Cube source (Agilent Technologies, Palo Alto, CA, 
USA). The chromatographic chip incorporated a 40 nL enrichment column (Zorbax 300SB-
C18, 5 µm pore size), and a 43 mm x 75 µm analytical column packed (Zorbax 300SB-C18, 5 
µm pore size). The samples (5 µL), previously acidified with formic acid, were loaded onto the 
enrichment column at a flow rate 4 µL/min using isocratic 100% C solvent phase (99% water, 
1% ACN and 0.1% formic acid). After clean-up, the chip valve was switched to separation and 
the peptides were eluted into the mass spectrometer at the constant flow rate of 300 nL/min. 
The LC solvent A was 95% water, 5% ACN, 0.1% formic acid; solvent B was 5% water, 95% 
ACN, 0.1% formic acid. The nano-pump gradient program was as follows: 5% solvent B (0 
min), 50 % solvent B (0-50 min), 95% solvent B (50-60 min) and back to 5% in 10 min. The 
drying gas temperature was 300 °C, flow rate 3 L/min (nitrogen). Data acquisition occurred in 
positive ionization mode. Capillary voltage was -1950 V, with endplate offset -500V. Mass 
spectra were acquired in the mass range from m/z 300-2200, with target mass 700 m/z, average 
of 2 spectra, ICC target 30000, and maximum accumulation time 150 ms. LC/MS analysis was 
performed in data dependent acquisition Auto MS(n) mode.  
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3.2.7 Mass spectral data elaboration and database searching  
Mass spectrometric data were processed using a Spectrum Mill MS Proteomics Workbench 
(Rev B.04.00, Agilent). The extraction of MS/MS spectra was conducted accepting a minimum 
sequence length of 3 amino acids and merging scans with same precursor within a mass 
window of ±0.4 m/z in a time frame of ± 5 s. Cysteine carbamidomethylation and methionine 
oxidation were set as fixed and variable modifications, respectively; trypsin or pepsin were 
chosen as digestive enzymes; 2 missed cleavage were allowed. MS/MS search was conducted 
against the subset of Lupinus protein sequences (8669 entries) downloaded from UNIProtKB 
(http://www.uniprot.org/). The mass tolerance of parent and fragments of MS/MS data search 
was set at 2.5 Da for precursor ions and 0.7 for fragment ions respectively. Threshold used for 
peptide identification score ≥8; Scored Peak Intensity SPI% ≥70%; Local False Discovery 
Rate ≤ 0.1%. MS/MS spectra were also reprocessed to assign candidate peptides in NCBI 
database using Mascot search program (http://www.matrixscience.com), as reported in Table 
S1 and S2 (Supporting Information).  
 
3.2.8 Determination of the P-abs and T-abs peptidic concentration 
The peptide concentration in the 100 μL of absorbed BL solution was measured according to a 
literature method (Levashov, Sutherland, Besenbacher, & Shipovskov, 2009), which is based 
on chelating the peptide bonds by Cu (II) in alkaline media and monitoring the change of 
absorbance at 330 nm, following an experimental method (Levashov et al., 2009). Briefly, a 
solution of X μL peptide mixture, (100 − X) μL water, 95 μL 6% (w/w) NaOH in water, and 
9.5 μL of active reagent (containing 0.6 M sodium citrate, 0.9 M sodium carbonate, and 0.07 
M copper sulphate, 2.4 M NaOH, pH 10.6) was prepared. The reaction mixture was mixed, 
incubated for 15 min at 20 °C and then the absorbance was measured at 330 nm using the 
Synergy H1 fluorescent plate reader (Biotek, Bad Friedrichshall, Germany). As standard for 
the calibration curve, a sterile solution of peptone from casein at 10 mg/mL in water was used. 
 
3.2.9 HMGCoAR activity assay 
BL effluents of Caco-2 cells after 4 h transport were tested for their ability to inhibit 
HMGCoAR activity. The recovered BL samples (700 µL) were lyophilised and then suspended 
in 100 µL water to obtain the BL peptic and tryptic solutions at the concentration of 0.25 and 
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0.32 μg/μL, respectively. The HMGCoAR activity was evaluated using a commercial Kit by 
Sigma-Aldrich (Milan, Italy), providing HMGCoAR, NADPH, buffer, and substrate solution. 
The experiments were carried out at 37 °C. Each reaction (200 µL) was prepared adding in the 
following order: assay buffer (154 µL), BL samples from treatments with peptic or tryptic 
peptides or from control cells (C) (28 µL), NADPH (4 µL), substrate solution (12 µL), and 
HMGCoAR (catalytic domain) (2 µL). The samples were mixed and the absorbance at 340 nm 
read by a microplate reader Synergy H1 from Biotek (Winooski, VT, USA) at time 0 and after 
10 min. The HMGCCoA-dependent oxidation of NADPH and sample inhibitory properties 
were measured by absorbance reduction. Three independent experiments were performed in 
triplicate. Statistical analyses were carried out by one-way ANOVA (Graphpad Prism 6) 
followed by Dunnett’s test and or t test. Values were expressed as means ± SEM; P-values < 
0.05 were considered to be significant.  
 
3.2.10 In silico docking simulations of BL peptides to the HMGCoAR 
catalytic site 
The selection and refinement of HMGCoAR structure was carried out as already described 
elsewhere (Lammi et al. 2015b). Since HMGCoAR inhibitors are characterised by a net 
negative charge, docking simulations were focused on negatively charged BL peptides only. 
These peptides were modelled by using FUGUE, an on line resource able to generate reliable 
structures also for relatively short peptides, whose conformations would be, however, hardy 
predictable by simple conformational analyses (Shi, Blundell and Mizuguchi 2001). Regardless 
of the utilised template, all peptides were modelled in a folded hairpin-like conformation, 
which is reasonably suited to be accommodated within the HMGCoAR catalytic pocket. 
Docking simulations were performed by using the software PLANTS (Protein-Ligand ANT 
System), which calculates reliable ligand poses by ant colony optimization algorithms (Korb, 
Stützle and Exner 2009). The search was focused on a 15 Å radius sphere around the optimised 
pose of the reference soy peptide YVVNPDNDEN, a known HMGCoAR inhibitor (Pak et al. 
2008), as computed in a previous study  (Lammi et al. 2015b). An energy constrain of -5.0 
kcal/mol was imposed to guide ligands in assuming a pose similar to YVVNPDNDEN. For 
each ligand, 10 poses were computed and scored by using Plp95 function with a search speed 
equal to 1. The best complexes were minimized by keeping fixed all atoms outside a 15 Å 
radius sphere around the bound ligand and optimised complexes were finally used to calculate 
docking scores. 
 42 
 
 
3.2.11 Potential biological activities of available peptides  
In order to forecast the potential biological activities of identified peptides, their sequences 
were submitted to a search using the open access informatic resource BIOPEP 
(http://www.uwm.edu.pl/biochemia/index.php/pl/biopep). 
 
3.3 Results  
3.3.1 Trans-epithelial transport of lupin peptides 
Differentiated Caco-2 cells were incubated with peptic and tryptic lupin peptides added to AP 
compartments at a 1 mg/mL concentration. After 4 h treatment, AP and BL media were 
collected and submitted to HPLC-Chip-MS/MS analysis. For monitoring cell monolayer 
permeability and excluding non-specific peptide passage, TEER measurements were taken at 
both experiment beginning and end. Moreover, phenol-red passage across the monolayer was 
assayed at the experiment end (Ferruzza et al. 2003). Both assays demonstrated that the 
incubation with lupin peptides did not affect monolayer permeability (data not shown). Only 
filters showing TEER values and phenol red passage similar to untreated control cells were 
considered for peptide transport analysis. 
 
3.3.2 Peptide sequencing by LC-MS/MS 
The starting peptic and tryptic peptide mixtures and AP and BL samples taken at the end of 
transport experiments were analysed by HPLC-Chip-MS/MS. Figure 3.1 shows exemplary 
chromatographic profiles of BL peptic and tryptic peptides. The peptide identification was 
carried out through MS/MS ion search, using the SpectrumMill search engine. The results from 
peptide sequencing were then subjected to a further evaluation using Mascot search program, 
consulting the Uniprot_viridiplantae database. Most peptides were sequenced, but no protein 
hit was assigned. Due to very incomplete lupin protein sequencing, only some peptides were 
assigned to known lupin proteins.  
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Figure 3.1 - MS/MS total ion current of lupin BL samples:  
A) tryptic peptides, B) peptic peptides 
 
 
3.3.3 Characterisation of bioavailable lupin peptides 
Table 3.1 shows a consolidated list of lupin tryptic and peptic peptides detected and identified 
in starting peptide mixtures and AP and/or BL samples. Among the sixteen tryptic peptides 
identified in the starting mixture, eleven derive from 7S globulins, i.e. β-Conglutin (Q6EBC1) 
or Vicilin-like protein (Q53HY0); four peptides derive from 11S globulins, i.e. α-Conglutin 
(F5B8V8) and Legumin-like protein (Q53I54); and one peptide derives from δ-Conglutin 
(Q333K7), a main lupin albumin. Among the twelve peptic peptides identified, nine derive 
from 7S globulins, i.e. β-Conglutin (Q6EBC1) and Vicilin-like protein (Q53HY0), and three 
from 11S globulins, i.e. -Conglutin (F5B8V7). All detected peptides have lengths between 7-
23 amino acid residues, mass weights in the range 930 - 2720 Da, and contain predominantly 
acidic and neutral residues. 
Out of the sixteen peptides detected in the starting tryptic peptide mixture, nine were detected 
also in AP samples, whereas eleven were detected also in BL media. Ten peptides (T1 - T6, 
T9, T11, T13, and T16) were detected in all situations (starting peptide mixture, AP and BL 
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samples). Five peptides (T7, T8, T12, T14, and T15) were detected only in starting peptide 
mixtures, perhaps because they were hydrolysed by Caco-2 cells and became undetectable due 
to the low molecular weights of the resulting fragments. In fact, short peptides are often singly 
charged, which impairs an efficient fragmentation during MS/MS sequence analysis. One 
peptide (T10) was detected in BL samples, but not in AP ones after the transport experiments. 
The outcomes of peptic peptide treatments are similar: six peptides were identified in all 
situations (P1, P2, P6 - P8, and P12), four disappeared both in AP and BL samples (P4, and 
P9 - P11), and two were detected only in BL samples (P3 and P5). 
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Table 3.1 LC-ESI-MS/MS based identification of tryptic and peptic peptides from transport experiments 
Protein name a Accession no a 
m/z b 
(charge) 
Observed b 
Mr (Da) 
Expected b 
Mr (Da) 
Start-end b   Peptide sequence b 
Short 
name 
M c AP c BL c 
 Trypsin derived peptides 
β-Conglutin Precursor Q6EBC1 622.59 (3) 1863.76 1863.85 275-289 R.IILGNEDEQEYEEQR.R T1 +d + + 
  874.82 (2) 1746.92 1746.84 480-495 R.AVNELTFPGSAEDIER.L T2 + + + 
  576.18 (3) 1726.57 1726.00 154-168 R.IVEFQSKPNTLILPK.H T3 + + + 
  523.65 (3) 1567.62 1567.83 371-384 K.INEGALLLPHYNSK.A T4 + + + 
  520.23 (3) 1556.73 1556.80 169-182 K.HSDADYVLVVLNGR.A T5 + + + 
  525.45 (2) 1050.52 1050.50 336-344 R.SNEPIYSNK.Y T6 + + + 
β 6-Conglutin F5B8W4 395.44 (2) 789.58 789.41 391-397 K.SGPFNLR.S T7 + nde nd 
Vicilin-like protein Q53HY0 727.13 (3) 2718.38 2718.97 496-518 R.LIKNQQQSYFANALPQQQQQSEK.E T8 + nd nd 
  528.37 (3) 1580.76 1580.75 291-304 R.GQEQSHQDEGVIVR.V T9 + + + 
  489.93 (3) 1493.77 1493.66 451-463 R.LLGFGINAYENQR.N T10 + nd + 
  732.05 (2) 1462.29 1462.69 483-495 K.ELTFPGSAEDIER.L T11 + + + 
α-Conglutin F5B8V8 715.68 (3) 2145.30 2146.04 46-64 R.IESEGGVTETWNSNKPELR.C T12 + nd nd 
Legumin-like protein Q53I54 843.44 (3) 2526.06 2526.22 41-63 R.LNALEPDNTVQSEAGTIETWNPK.N T13 + + + 
  643.62 (3) 1929.75 1929.82 268-282 R.HGREEEEEEEEEDER.R T14 + nd nd 
  638.46 (3) 1912.87 1912.96 340-357 R.HNIGESTSPDAYNPQAGR.F T15 + nd nd 
δ-Conglutin Q333K7 934.47 (2) 1866.92 1866.93 117-131 R.QEEQLLEQELENLPR.T T16 + + + 
 Pepsin derived peptides 
β-Conglutin Precursor Q6EBC1 844.48 (2) 1686.94 1686.82 349-362 F.YEITPDRNPQVQDL.D P1 + + + 
  787.91 (2) 1573.75 1573.65 349-361 F.YEITPDRNPQVQD.L P2 + + + 
  783.53 (2) 1564.68 1564.60 239-251 F.YDFYPSSTKDQQS.Y P3 + nd + 
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a) According to “UniProtKB” (http://www.uniprot.org/) 
b) The identification of protein parent was performed using SpectrumMill Workbench. The MS/MS data were processed using a 
mass tolerance of 2.5 Da and 0.7 Da for the precursor and fragment ions, respectively. 
c) M, starting peptide mixture of tryptic or peptic peptides; AP, apical chamber samples; BL, basolateral chamber samples. 
d) +, detected.  
e) nd, not detected.
  609.83 (2) 1218.65 1217.41 228-238 K.LAIPINNPGYF.Y P4 + nd nd 
  555.26 (2) 1107.60 1107.24 164-173 T.LILPKHSDAD.Y P5 + nd + 
  532.80 (2) 1063.57 1063.56 204-213 A.LRIPAGSTSY.I P6 + + + 
  469.84 (2) 935.43 935.98 484-492 E.LTFPGSAED.I P7 + + + 
Vicilin-like protein Q53HY0 901.98 (2) 1801.86 1801.89 349-363 F.YEITPDRNPQVQDLD.I P8 + + + 
  651.86 (2) 1301.72 1301.53 377-387 L.LLPHYNSKAIF.I P9 + nd nd 
α 2-Conglutin F5B8V7 564.34 (2) 1226.68 1226.58 153-163 I.IAIPPGIPYWT.Y P10 + nd nd 
  1052.60 (1) 1052.63 1052.62 152-161 D.IIAIPPGIPY.W P11 + nd nd 
  1042.52 (1) 1042.56 1042.35 155-163 A.IPPGIPYWT.Y P12 + + + 
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3.3.4 Absorbed peptic and tryptic lupin peptides are able to inhibit 
HMGCoAR activity 
Since we have recently shown that tryptic and peptic peptides from lupin protein inhibit the 
activity of HMGCoAR (Lammi et al. 2014b), in order to verify whether the absorbed peptides 
are still able to inhibit this enzyme, the BL samples inhibitory capacity was evaluated using the 
purified HMGCoAR catalytic domain. Figure 3.2 shows that both peptic and tryptic BL 
peptides inhibited the HMGCoAR activity in a significant way: BL peptic peptides by 33% at 
0.9 µg/μL, whereas tryptic peptides by 20% at 1.1 µg/μL.  
 
Figure 3.2 - Effect of absorbed peptides on the catalytic domain of HMGCoAR. Bars indicate the 
effects of peptic and tryptic peptides contained in BL solutions on HMGCoAR activity. The data points 
represent the averages ± SEM of three independent experiments in triplicate. ** P <0.001 and *** P < 
0.0001 vs C. P = Peptic peptides, T= Tryptic peptides, and C = BL medium of control samples. 
 
 
 
3.3.5 In silico evaluation of the capacity of BL peptides to interact with the 
HMGCoAR catalytic site 
Table 3.2 lists the docking scores as computed for minimised complexes of BL peptides within 
the HMGCoAR catalytic site. It reports pairwise linear potential Plp95 scores, used by the 
docking program, as well as adaptive Poisson-Boltzmann solver (APBS) scores, and molecular 
lipophilic potential interaction scores (MLPInS), focused on ionic and apolar interactions, 
respectively (Vistoli et al. 2010, Baker et al. 2001). Moreover, it reports score values 
normalised per peptide length, since docking scores tend unavoidably to increase with ligand 
size, and it includes also score values for the reference peptide YVVNPDNDEN. Table 3.2 
includes also average score values for tryptic and peptic peptides. 
The wide ranges of these scores suggest that the putative capacities of simulated peptides to 
bind the HMGCoAR catalytic pocket greatly differ. Although on average these peptides show 
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worse docking scores compared to the reference peptide (especially concerning normalized 
values), some tryptic and peptic peptides have noteworthy score values. In detail, P5 and P7 
show better normalised Plp95 score values than the reference peptide, while T1 displays the 
best APBS score value which is, however, slightly worse than the reference peptide when 
normalised per peptide length. MLP scores show clear agreements with APBS scores, 
suggesting that the best complexes are stabilised by a proper balance of both hydrophobic and 
ionic interactions, the former mostly elicited by ligand apolar residues within N-terminal 
portion, the latter mainly centred on C-terminus (see below).  
 
Table 3.2. Docking scores for the simulated negatively charged BL peptides as well as the 
score values normalised per the number of residues and the corresponding score values for the 
reference peptide YVVNPDNDEN. The corresponding averages for tryptic and peptic peptides 
are also reported (Plp95 is expressed in kcal/mol, APBS in kJ/mol, MLP is dimensionless) 
Peptide residues Plp95 Score APBS Score MLP Score Plp95 norm APBS norm MLP norm 
reference 10 -320.55 -125.10 -67.49 -32.06 -12.51 -6.75 
T1 15 -366.70 -164.88 -79.54 -24.45 -10.99 -5.30 
T2 16 -377.97 -98.86 -72.68 -23.62 -6.18 -4.54 
T5 14 -358.65 -54.75 -44.03 -25.62 -3.91 -3.14 
T9 14 -369.90 -75.95 -58.24 -26.42 -5.42 -4.16 
T11 13 -338.37 -51.13 -34.98 -26.03 -3.93 -2.69 
T13 15 -413.98 -92.62 -51.29 -27.60 -6.17 -3.42 
T16 15 -327.18 -69.57 -47.72 -21.81 -4.64 -3.18 
P1 13 -359.27 -51.87 -49.04 -27.64 -3.99 -3.77 
P5 10 -329.43 -109.74 -73.94 -32.94 -10.97 -7.39 
P7 9 -338.27 -101.47 -60.96 -37.59 -11.27 -6.77 
P8 15 -438.14 -43.79 -41.64 -29.21 -2.92 -2.78 
Mean Ts 13.88 -359.16 -91.61 -57.00 -26.40 -6.89 -4.24 
Mean Ps 11.75 -366.28 -76.71 -56.40 -31.84 -7.29 -5.18 
 
 
 
Figure 3.3 - Comparison of computed poses for reference peptide YVVNPDNDEN (tube in red) 
with P5 (tube in mauve) and P7 (tube in lime). For clarity, hydrogen atoms and apolar residues are 
not shown. 
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Figure 3.3 shows that the poses of P5 (in mauve) and P7 (in lime) are very similar to that of 
the reference peptide YVVNPDNDEN (in red), a result easily explainable considering their 
comparable length and similar sequences characterised by apolar side chains in N-terminus and 
ionic residues in C-terminus. In detail, the three complexes appear to be stabilised by a set of 
common interactions, which can be subdivided into three groups. A) The positively charged 
N-terminus elicits ion-pairs with Glu559 and Asp767, reinforced by H-bonds with surrounding 
Thr557 and Thr558. B) Negatively charged residues located at C-terminal tail (including the 
C-terminus itself) are engaged in ionic contacts with Arg568, Arg571, and Lys722. C) 
Hydrophobic residues located at N-terminus are involved in hydrophobic interactions with 
apolar residues (e.g., Leu76, Ile536, Leu562, Met655, and Met657, not shown for clarity). 
Additionally, P5 includes a central positively charged residue (Lys5), which stabilises a salt 
bridge with Asp690. Overall, the interaction patterns stabilised by P5 and P7, almost 
superimposable to that of the reference peptide, suggest that these peptic peptides might have 
a comparable HMGCoAR inhibitory activity. 
Albeit longer, peptide T1 assumes a pose rather similar to those of peptic ligands due to a very 
folded conformation stabilised by an intramolecular salt bridge between Glu6 and Arg15 
further reinforced by bridging contacts elicited by Asn5. As schematised by Figure 3.4, T1 is 
able to stabilise an impressive set of ionic contacts, which can explain the best APBS value 
computed for T1. Figure 3.4 shows that every charged T1 residue is engaged in ion-pairs 
further stabilised by a rich set of H-bonds elicited by remaining polar residues. Moreover, 
apolar residues located at N-terminus are involved in already mentioned hydrophobic contacts.  
 
 
Figure 3.4 - Schematic 2D representation of main contacts stabilizing the putative complex for 
T1. The dashed line defines the key intramolecular ion-pair stabilizing the folded conformation of the 
bound peptide. 
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3.4 Discussions  
3.4.1 Absorbed peptides features  
The application of the multidisciplinary approach, including cell cultures, proteomics and 
bioinformatics tools, has allowed achieving a very important goal, since it has demonstrated 
that eleven tryptic peptides and eight peptic peptides are bioavailable in this in vitro model of 
the small intestine. Considering the overall characteristics of peptides identified in BL samples, 
they are very heterogeneous being constituted by 9 - 23 amino acid residues, within a 935-2526 
Da mass range. Apparently, they do not have any common characteristics, neither length nor 
charge. They contain predominantly acidic and neutral residues: eleven have a calculated pI < 
pH 4.5, five have a neutral pI, however, three have a pI > pH 7 (Table 3.1S, Supporting 
information). Acidic peptides are negatively charged, whereas neutral and basic ones have 0 
and 1 net charges, respectively; their net charges range from -5 to 1. Longer peptides, in 
general, appear to be absorbed less than shorter ones, but there are exceptions to this rule, since 
peptide T13, containing 23 amino acid residues, is absorbed, while T7, the smallest tryptic 
peptide, is not absorbed.  
The mechanisms of absorption across intestinal epithelium may vary from passive diffusion of 
hydrophobic molecules across membranes to active transport, either by membrane transporters 
or vesicular-mediated transcytosis, and finally to permeation across tight junction complexes. 
Nonspecific permeation between adjacent cells, governed by tight junctions, can be excluded, 
since phenol red, a paracellular passage marker, did not cross the Caco-2 barrier during 
transport experiments. The transport of these peptides to the BL compartment takes place with 
a certain degree of selectivity. A few peptides (T10, P3, and P5), transported to BL 
compartments, were no longer detectable in AP media: this may possibly depend on their rapid 
transport to BL compartment and efficient parallel degradation in the AP medium by brush 
border peptidases. Peptide P10 was not absorbed, possibly because it was transformed in P12, 
by removal of N-terminal isoleucine and alanine residues catalysed by dipeptidyl-peptidase IV 
(DPP-IV; EC 3.4.14.5), a highly specialised aminopeptidase removing dipeptides only from 
peptides with proline or alanine in the N-terminal penultimate position (Augustyns et al. 2005). 
P12, in turn, was absorbed.  
 
Globulins, accounting for about 90% of total lupin protein (Duranti et al. 2008), are mainly 
constituted by 7S and 11S globulins. The peptides identified in BL samples derive mostly from 
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7S globulins, whereas only a few come from 11S globulins, and just one peptide originates 
from -conglutin, a main lupin albumin. Apparently, detected peptides do not reflect the 
relative abundance of these proteins in lupin seed, since 7S and 11S globulins are normally 
present in comparable amounts (Duranti et al. 2008), but instead their relative stability. In fact, 
7S globulins are much more easily hydrolysed by proteases and more sensible to thermal 
treatments than 11S globulins (Sirtori et al. 2010) . 
 
3.4.2 Role of absorbed peptides in cholesterol metabolism  
Recently, we have demonstrated that tryptic and peptic peptides from lupin protein produce 
hypocholesterolemic effects through inhibiting HMGCoAR activity in human hepatic HepG2 
cells (Lammi et al. 2014b). The consequent reduction of intracellular cholesterol levels leads 
to activation of SREBP-2, which in turn increases the expression of LDL receptor (LDLR): the 
LDLR activity increase leads to an improved ability of HepG2 cells to uptake extracellular 
LDL with a final hypocholesterolemic effect.  
A main achievement of the present work is having provided evidence that the peptides 
transported by Caco-2 cells in the BL compartment maintain their initial capacity of 
functioning as inhibitors of the HMGCoAR activity. In fact, testing in vitro their ability to 
directly inhibit the activity of HMGCoAR, we have demonstrated that the absorption process 
did not apparently impair their inhibition capacity. Surprisingly, the activity of BL peptic 
peptides seemed even improved versus the starting samples (Lammi et al. 2014b), possibly 
suggesting a selective absorption of the most bioactive components.  
The docking simulations of BL peptides with HMGCoAR may possibly explain this finding. 
In fact, although the different peptide lengths impair a precise comparison, all normalised 
average values (Table 3.2) suggest that peptic peptides should generate more stable complexes 
with HMGCoAR compared to tryptic ones. This difference can be explained by the positively 
charged residue in C-terminus of all tryptic peptides, which is unfit within a subpocket 
surrounded by several positively charged residues and hampers a satisfactory pose for whole 
peptides. By contrast, most peptic peptides end with an aspartate residue, which is clearly 
suitable for the positively charged subpocket of HMGCoAR. Finally, the docking results 
revealed that tryptic and peptic peptides are influenced by different factors. For peptic peptides, 
the most interesting complexes are afforded by the shortest peptides, which conveniently mimic 
the reference peptide, while the best complexes for tryptic peptides are generated by those 
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ligands with a high negative charge, which should counteract the potential repulsive contacts 
exerted by the unfit C-terminus.  
 
3.4.3 Potential bioactivity according to bioinformatic prediction  
BIOPEP (www.uwm.edu.pI/biochemia) (Minkiewicz et al. 2012) is an open access database 
that permits to hypothesise potential biological activities of peptides depending on the presence 
of some short amino acid sequences. Unfortunately, it does not take in consideration the 
inhibition of HGMCoAR activity. The BL peptide sequences were searched in BIOPEP, 
obtaining the results shown in Table 3.1S (Supporting information): the software proposed one 
or more activities for each peptide, mostly related to cardiovascular disease or diabetes 
prevention.  
All detected peptides are potentially ACE-inhibitors. The active domains LTF, ILP, and LLP 
occur within peptides T2, T3, and T4, and P5, whereas the domain ALEP appears in peptide 
T13. These data are in agreement with the ACE inhibitory activity observed in previous studies 
(Boschin et al. 2014a, Boschin et al. 2014b). Since ACE inhibitory and antioxidant peptides 
share some common structural requirements (Yea et al. 2014), some peptides exhibit 
multifunctional activities, for example peptide T4 containing the sequences LLPH and PHY. 
Hydrophobic His-containing peptides often possess antioxidant capacity (Chen, Muramoto and 
Yamauchi 1995), probably because they could act as metal-ion chelators, active-oxygen 
quenches, and hydroxy-radical scavengers (Saito et al. 2003). The antioxidant character is also 
associated with the presence of hydrophobic and aromatic or heteroaromatic amino acids, such 
as Trp, Tyr, and Phe (Tanzadehpanah, Asoodeh and Chamani 2012), such as in peptides T5 
and T6, containing YVL and IY domains.  
Another activity frequently proposed by BIOPEP is the ability to function as glucose uptake 
stimulating peptides, owing to the sequences LIL, IL, II, IV, LL, VL, and LV. Moreover, some 
peptides might also potentially function as inhibitors of the enzyme DPP‑IV (da Silva Júnior, 
de Godoy-Matos and Kraemer-Aguiar 2015). Interestingly, some recent antidiabetic drugs 
inhibit the action of this enzyme (Koska et al. 2015) and the hypoglycaemic activity of lupin 
protein is supported by numerous experimental evidences (Duranti et al. 2008).  
Finally, four peptides T2, T11, P7, and P12, containing the sequences PG, were proposed by 
BIOPEP as potential inhibitors of prolyl endopeptidase (PEP) activity. This highly conserved 
serine protease is involved in several central nervous system functions (Lafarga, O'Connor and 
Hayes 2015) and its inhibition has potential applications in the prevention and treatment of 
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mental disorders. This is a completely unexplored area of potential bioactivity for lupin protein. 
Although very explorative, the search in BIOPEP has provided some tentative explanation of 
preceding experimental and clinical results and some hints of new potential areas of functional 
application of lupin foods. 
In conclusion, for the first time this investigation has provided evidence that lupin peptides 
with specific structures are potentially absorbed in human intestinal cells maintaining their 
biological activity. These findings may help explaining the beneficial effects observed in vivo 
in animal and human studies (Arnoldi et al. 2015a, Duranti et al. 2008). It is, however, useful 
to add that a recent literature has shown that -conglutin, a specific hypoglycaemic lupin 
protein, is absorbed intact in Caco-2 cells (Capraro et al. 2011). 
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SUPPORTING INFORMATION  
 
Table 3.1S Calculated pI’s and net charges of BL peptides and their potential bioactivities according to BIOPEP 
database search 
Short 
name 
Peptide sequence  
pI 
a 
Net 
Charge a 
Potential bioactive peptides b Biological functions b 
T1 IILGNEDEQEYEEQR 3.6 -5 LG, EY ACE-inhibitor 
    IL, II 
Glucose uptake stimulating 
peptide 
    EY, II, IL, NE, QE, YE DPP IV inhibitor 
T2 AVNELTFPGSAEDIER 3.8 -3 LTF, TF, PG, GS, IE ACE inhibitor 
    EL Antioxidative peptide 
    AV, NE, LT, TF, PG, AE DPP IV inhibitor 
    PG Prolyl endopeptidase inhibitor  
T3 IVEFQSKPNTLILPK 9.5 1 VE, KP, ILP ACE inhibitor 
    KP Antioxidative 
    VE, FQ, QS, SK, PN, NT, LI, IL, PK DPP IV inhibitor 
    IV, LI, IL 
Glucose uptake stimulating 
peptide 
    EF Hypotensive (Renin inhibitor) 
T4 INEGALLLPHYNSK 7.5 1 EG, GA, LLP, PH, HY ACE inhibitor 
    LLPH, PHY Antioxidative 
    IN, NE, EG, AL, LL, LP, HY, YN, SK DPP IV inhibitor 
    LL 
Glucose uptake stimulating 
peptide 
    LLL 
Stimulating vasoactive 
substance release 
T5 HSDADYVLVVLNGR 5.4 0 DA, LN, NG, GR ACE inhibitor 
    YVL Antioxidative 
    HS, AD, LV, VL, LN, NG DPP IV inhibitor 
    VL, LV 
Glucose uptake stimulating 
peptide 
    DY Ion flow regulating peptide 
T6 SNEPIYSNK 6.3 0 IY, NK ACE inhibitor 
    IY Antioxidative 
    NE, EP, PI, YS DPP IV inhibitor 
T9 GQEQSHQDEGVIVR 4.4 -1 GQ, EG, GV, VR ACE inhibitor 
    GQ, QE, QS, SH, QD, EG, VI DPP IV inhibitor 
    IV 
Glucose uptake stimulating 
peptide 
    GQ Neuropeptide inhibitor 
T10 LLGFGINAYENQR 6.3 0 LG, GF, FG, GI, AY ACE inhibitor 
    AY Antioxidative 
    LL, GF, GI, IN, NA, AY, YE, NQ DPP IV inhibitor 
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    LL 
Glucose uptake stimulating 
peptide 
T11 ELTFPGSAEDIER 3.8 -3 LTF, TF, FP, PG, GS, IE ACE inhibitor 
    EL Antioxidative 
    LT, TF, FP, PG, AE DPP IV inhibitor 
    PG Prolyl endopeptidase inhibitor 
T13 
LNALEPDNTVQSEAGTIE
TWNPK 
3.8 -3 LN, ALEP, EA, AG, GT, IE ACE inhibitor 
    TW Antioxidative 
    
LN, NA, AL, EP, DN, NT, TV, QS, AG, 
TI, ET, TW, WN, NP, PK 
DPP IV inhibitor 
    SE 
Stimulating vasoactive 
substance release 
T16 QEEQLLEQELENLPR 3.7 -4 PR ACE inhibitor 
    EL Antioxidative 
    QE, QL, LL, NE DPP IV inhibitor 
    LL 
Glucose uptake stimulating 
peptide 
    EE 
Stimulating vasoactive 
substance release 
P1 YEITPDRNPQVQD 3.9 -2 EI, PQ ACE inhibitor 
    YE, EI, TP, DR, NP, PQ, QV, VQ, QD DPP IV inhibitor 
P3 YDFYPSSTKDQQS 4.1 -1 FY, YP ACE inhibitor 
    KD Antioxidative 
    YD, YP, PS, TK, DQ, QQ, QS DPP IV inhibitor 
P5 LILPKHSDAD 5.4 0 ILP, DA ACE inhibitor 
    LI, IL, LP, PK, HK, HS, AD DPP IV inhibitor 
    LI, LI 
Glucose uptake stimulating 
peptide 
P6 LRIPAGSTSY 9.3 1 IPA, AG, GS, SY ACE inhibitor 
    RI, IPA, AG, TS, SY DPP IV inhibitor 
P7 LTFPGSAED 3.5 -2 LTF, FP, PG, GS ACE inhibitor 
    LT, TF, FP, PG, AE DPP IV inhibitor 
    PG Prolyl endopeptidase inhibitor 
P8 YEITPDRNPQVQDLD 3.7 -3 EI, PQ ACE inhibitor 
    YE, EI, TP, DR, NP, PQ, QV, QD DPP IV inhibitor 
P12 IPPGIPYWT 6.0 0 IPP, PG, GI, IPY, YW ACE inhibitor 
    IP, PG, PPG, GI, PY, YW, WT DPP IV inhibitor 
    PG Prolyl endopeptidase inhibitor 
a) Predicted by the peptide property calculator (http:// www.genscript.com) 
b) Bioactive properties obtained by BIOPEP data analysis 
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4.0 Abstract 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been recently identified as a new 
useful target for hypercholesterolemia treatment. This work demonstrates that natural peptides, 
deriving from the hydrolysis of lupin proteins and absorbable at intestinal level, are able to 
inhibit the protein-protein interaction between PCSK9 and the low density lipoprotein receptor 
(LDLR). In order to sort out the best potential inhibitors among these peptides, a refined in 
silico model of the PCSK9/LDLR interaction was developed. Docking simulation, permitted 
to select the two best candidates (T9 and P5) among the absorbed peptides that were 
synthesized and evaluated for their inhibitory activity. In order to quantify the absorbed amount 
of P5 and T9 through the BL compartment, label-free MRM mass spectrometric-based assays 
were developed. From a functional point of view, the most active was P5 that induced a 
concentration dependent inhibition of the PCSK9-LDLR binding, with an IC50 value equal to 
1.6 ± 0.33 μM. Tested at a 10 μM concentration, this peptide increased by 66 ± 21.4% the 
ability of HepG2 cells to take up LDL from the extracellular environment.  
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4.1 Introduction  
An increased level of low-density lipoproteins (LDL) predisposes to the development of 
cardiovascular disease (CVD) and stroke. Currently, the main agents for lowering LDL levels 
are statins. They reduce the regulatory pool of intracellular cholesterol by competitively 
inhibiting HMGCoAR, the rate-limiting enzyme of endogenous cholesterol biosynthesis. This 
in turn activates the LDL receptor (LDLR) transcription, a process under the control of sterol 
regulatory element binding protein 2 (SREBP-2) (Brown & Goldstein, 2009; Dubuc, 
Chamberland, Wassef, Davignon, Seidah, Bernier, et al., 2004). However, intolerance to statins 
produces numerous side effects, such as myopathy with a spectrum of consequences ranging 
from myalgia to rhabdomyolysis (Wong, Chuang, Wong, Pham, Neff, & Marrett, 2013). To 
overcome these issues, alternative or adjunctive therapies are thus advisable to use. In this 
context, proprotein convertase subtilisin/kexin type 9 (PCSK9) has been recently identified as 
a new useful target for hypercholesterolemia treatment (Seidah & Prat, 2007). 
PCSK9 is expressed primarily in liver, kidney, and intestine (Seidah & Prat, 2012) and plays 
an important role in regulating the degradation of hepatic LDLR receptor (Gencer, Lambert, & 
Mach, 2015; D. W. Zhang, Lagace, Garuti, Zhao, McDonald, Horton, et al., 2007).  
Notably, since PCSK9 and LDLR are co-regulated by SREBP-2 (Ambegaonkar, Tipping, 
Polis, Tomassini, & Tershakovec, 2014), increased PCSK9 expression in response to statin-
induced cellular cholesterol depletion may limit the efficacy of statin treatment (Careskey, 
Davis, Alborn, Troutt, Cao, & Konrad, 2008; Welder, Zineh, Pacanowski, Troutt, Cao, & 
Konrad, 2010).  
The development of therapies that inhibit PCSK9 function holds promise for improved 
management of hypercholesterolemia and CVD risk.  
In light of these observations and of the fact that circulating PCSK9 may cause the degradation 
of hepatic LDLR, this protein is considered an attractive target for LDL-cholesterol lowering 
drugs. The current inhibitors under development are based on different strategies, i.e. 
monoclonal antibodies (mAbs) (such as evolocumab and alirocumab) (Everett, Smith, & Hiatt, 
2015)19, gene silencing compounds (Graham, Lemonidis, Whipple, Subramaniam, Monia, 
Crooke, et al., 2007), and natural product such as berberine (Dong, Li, Singh, Cao, & Liu, 
2015), and peptidomimetics (Shan, Pang, Zhang, Murgolo, Lan, & Hedrick, 2008).  
The ability of PCSK9 to mediate LDLR degradation involves protein-protein interactions 
(PPIs) between LDLR and the PCSK9.  In this context, PPIs, which are inherently challenging 
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small molecule targets, have been successfully inhibited by peptides, which can recapitulate 
key protein contacts (Ross, Katt, & Hamilton, 2010).  
To date, numerous studies have demonstrated the health benefits in the area of 
hypercholesterolemia prevention provided by lupin peptides. Tryptic and peptic peptides 
deriving from lupin protein hydrolysis are able to modulate cholesterol metabolism in HepG2 
cells by inhibiting HMGCoAR via a statin-like mechanism (Lammi, Zanoni, Scigliuolo, 
D'Amato, & Arnoldi, 2014). Another investigation in human Caco-2 cells has provided 
evidence that at least some of these peptic and tryptic peptides may be absorbed in the small 
intestine, since they are transferred from the apical (AP) to the basolateral (BL) compartment 
in differentiated Caco-2 cells grown in a two-compartment system (Lammi, Aiello, Vistoli, 
Zanoni, Arnoldi, Sambuy, et al., 2016). Table 4.1 shows the sequences of the transferred 
peptides that here will be referred to as “absorbable lupin peptides”. 
Finally, another study in mild hypercholesterolemic subjects has demonstrated that the level of 
circulating PCSK9 is reduced in a statistically significant way after a 4-week consumption of 
a lupin protein isolate (30 g protein/day) (Lammi, Zanoni, Calabresi, & Arnoldi, 2016). The 
same paper reported also an investigation in human HepG2 cells showing that lupin peptides 
reduce the synthesis and secretion of mature PCSK9 as well as the level of hepatic nuclear 
factor 1-alpha (HNF1-alpha) (Lammi, Zanoni, Calabresi, & Arnoldi, 2016). 
 
In this context, the present work was aimed at evaluating whether “absorbable lupin peptides” 
may directly inhibit the PCSK9-LDLR PPI. After sorting out the best potential inhibitors 
among “absorbable peptides” by computational assays, peptic and tryptic peptides were 
synthesised in order to evaluate their inhibitory activity of the PCSK9-LDLR interaction, and 
their capability of reducing the LDL uptake by HepG2 cells. In a parallel way, a label-free 
quantification of the best PCSK9-LDLR PPI peptide inhibitors in BL medium using an MS-
based approach was developed.  
 
Table 4.1 Peptides identified in the basolateral compartment of Caco-2 cells grown in two 
compartment systems 
Peptides Sequence Uniprot Code Protein Source Proteolytic enzyme 
T1  
T2  
T3  
T4  
T5  
T6  
T9  
IILGNEDEQEYEEQR 
AVNELTFPGSAEDIER 
IVEFQSKPNTLILPK 
INEGALLLPHYNSK 
HSDADYVLVVLNGR  
SNEPIYSNK  
GQEQSHQDEGVIVR 
Q6EBC1 
Q6EBC1 
Q6EBC1 
Q6EBC1 
Q6EBC1 
Q6EBC1 
Q53HY0 
β2-conglutin  
β2-conglutin  
β2-conglutin  
β2-conglutin  
β2-conglutin  
β2-conglutin  
β1-conglutin  
Trypsin  
Trypsin  
Trypsin  
Trypsin  
Trypsin  
Trypsin  
Trypsin  
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T10  
T13  
T16  
P1  
P3  
P5  
P6  
P7  
LLGFGINAYENQR 
LNALEPDNTVQSEAGTIETWNPK 
QEEQLLEQELENLPR 
YEITPDRNPQVQDL 
YDFYPSSTKDQQS 
LILPKHSDAD  
LRIPAGSTSY  
LTFPGSAED 
Q53HY0 
Q53I54 
Q333K7 
Q6EBC1 
Q6EBC1 
Q6EBC1 
Q6EBC1 
Q6EBC1 
β1-conglutin  
α-conglutin  
δ-conglutin  
β2-conglutin  
β2-conglutin  
β2-conglutin  
β2-conglutin  
β2-conglutin 
Trypsin  
Trypsin  
Trypsin  
Pepsin  
Pepsin  
Pepsin  
Pepsin  
Pepsin 
 
4.2 Methods 
4.2.1 Preparation of the pepsin and trypsin peptide mixtures  
The peptic (P-tot) and tryptic (T-tot) hydrolysates from lupin protein are the same used in a 
previous paper, in which their capability to modulate cholesterol metabolism in HepG2 cells 
was investigated (Lammi, Zanoni, Scigliuolo, D'Amato, & Arnoldi, 2014). The procedure for 
protein extraction from Lupinus albus (cultivar Ares) seeds, the conditions of enzymatic 
hydrolysis, and the final composition of the resulting peptide mixtures are reported in detail in 
the same paper. In the tryptic sample, 12 peptides were assigned to L. albus vicilin-like protein 
(Q53HY0), 10 peptides to L. albus beta‐conglutin precursor (Q6EBC1), 4 peptides to L. 
angustifolius conglutin beta (B0YJF8)], 4 peptides to L. angustifolius conglutin-beta 
(Q53I55)], and 2 to L. albus conglutin-delta seed storage protein precursor (Q99235). In the 
peptic hydrolysate, 21 peptides were assigned to L. albus vicilin-like protein (Q53HY0), 18 
peptides to L. albus beta‐conglutin (Q6EBC1), 7 peptides to L. angustifolius conglutin-alpha 3 
(F5B8V8], and 8 peptides to L. albus conglutin-gamma (Q9FSH9). These mixtures were 
submitted to absorption experiments in Caco-2 cells grown in two-compartment trans-well 
systems (Lammi, et al., 2016). The absorbed peptic (P-abs) and tryptic peptides (T-abs), i.e. 
those transferred in the basolateral compartments, are shown in Table 4.1. The details for the 
preparation and quantification of the peptides and the analytical procedure for their 
identification based on mass spectrometry are described in detail in the previous manuscript.  
 
4.2.2 In vitro PCSK9-LDLR binding assay 
P-tot peptides (1.0 and 2.5 μg/μL), T-tot peptides (0.5 and 1.0 μg/μL), P-abs (12.5 ng/μL) and 
T-abs peptides (16.0 ng/μL) were tested using the in vitro PCSK9-LDLR binding assay 
(CycLex Co., Nagano, Japan) following the manufacture instructions. Briefly, plates are pre-
coated with a recombinant LDLR-AB domain, which contains the binding site for PCSK9. 
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Before starting the assay, tested peptides and/or the vehicle were diluted in reaction buffer and 
added in micro centrifuge tubes. Afterwards, the reaction mixtures were added in each well of 
the microplate and the reaction was started by adding His-tagged PCSK9 wild type solution (3 
μL). The microplate was allowed to incubate for 2 h at room temperature (RT) shaking at 300 
rpm on an orbital microplate shaker. Subsequently, wells were washed 4 times with wash 
buffer. After the last wash, the biotinylated anti-His-tag monoclonal antibody (100 μL) was 
added and incubated at RT for 1 h shaking at 300 rpm. After incubation, wells were washed 
for 4 times with wash buffer. After the last wash, 100 μL of HRP-conjugated streptavidin were 
added and the plate was incubated for 20 min at RT. After incubation, wells were washed 4 
times with wash buffer. Finally, the substrate reagent (tetra-methylbenzidine) was added and 
the plate was incubated for 10 min at RT shaking at ca. 300 rpm. The reaction was stopped 
with 2.0 N sulfuric acid and the absorbance at 450 nm was measured using the Synergy H1 
fluorescent plate reader (Biotek, Bad Friedrichshall, Germany). 
 
4.2.3 In vitro PCSK9-LDLR binding assay of synthetic T9 and P5  
T9 (GQEQSHQDEGVIVR) and P5 (LILPKHSDAD) were synthesized by the company 
PRIMM (Milan, Italy). They were > 95% pure by HPLC.  
Synthetic peptides, i.e. T9 (32–320 μM) and P5 (0.001–100 μM), were tested using the in vitro 
PCSK9-LDLR binding assay (CycLex Co., Nagano, Japan) following the manufacture 
instructions as reported above. The absorbance at 450 nm was measured using the Synergy H1 
fluorescent plate reader (Biotek, Bad Friedrichshall, Germany). In particular, for the in vitro 
screening of the synthetic PCSK9-LDLR inhibitors, T9 and P5, at different concentrations, 
were added to the appropriate amount of His-tagged PCSK9 in the wells that had been coated 
with recombinant LDLR-AB domain in a similar fashion as described above, followed by 
evaluation of inhibitory effect on PCSK9-LDLR interaction by measuring the amount of His-
tagged PCSK9 on the wells which is correlated to the absorbance signals at 450 nm, which 
were measured using the Synergy H1 fluorescent plate reader (Biotek, Bad Friedrichshall, 
Germany). 
 
4.2.4 Cell line culture  
The HepG2 cell line was bought from ATCC (HB-8065, ATCC from LGC Standards, Milan, 
Italy). HepG2 cells were cultured in DMEM high glucose with stable L-glutamine 
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supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin (complete growth 
medium) and incubated at 37 °C under 5% CO2 atmosphere. HepG2 cells were used for no 
more than 20 passages after thawing, because the increase of the number of passages may 
change the cell characteristics and impair assay results. 
 
4.2.5 Fluorescent LDL uptake cell based assay 
HepG2 cells (3 × 104/well) were seeded in 96-well plates and kept in complete growth medium 
for 2 d before treatment. The third day, they were treated with T9 (160 and 320 μM) or P5 (10 
μM), or vehicle (H2O) for 24 h. At the end of the treatment, the culture medium was replaced 
with 50 μL/well LDL-DyLight™ 550 working solution (Cayman Chemical Company, Ann 
Arbor, MI, US). The cells were additionally incubated for 2 h at 37 °C and then the culture 
medium was aspirated and replaced with PBS (100 μL/well). The degree of LDL uptake was 
measured using the Synergy H1 fluorescent plate reader from Biotek (excitation and emission 
wavelengths 540 and 570 nm, respectively). 
 
4.2.6 Statistical analysis of biological assays 
Data are presented as mean ± standard error using GraphPad Prism 6 (CA, USA). Statistical 
analyses were carried out by one-way ANOVA followed by Dunnett’s test. P-values < 0.05 
were considered to be significant. 
 
4.2.7 HPLC-Chip-MRM analysis of peptide T9 and P5 in T-abs and P-abs  
The LC-MRM analysis was carried out in positive ionization mode on a SL series Ion Trap 
mass spectrometer equipped with a nano-ESI source interfaced with a HPLC-Chip Cube source 
(Agilent Technologies, Palo Alto, CA, USA). The chromatographic separation was performed 
on a LC-chip containing a 40 nL enrichment column (Zorbax 300SB-C18, 5 μ m pore size), a 
43 mm × 75 μ m analytical column packed (Zorbax 300SB-C18, 5 μ m pore size). Both P-abs 
and T-abs (1 μL) were loaded onto the enrichment column at a flow rate 4 μL/min for 2 min 
using isocratic 100% C solvent phase (99% water, 1% ACN and 0.1% FA). After clean-up, the 
chip valve was switched to separation and trapped peptides were eluted into the mass 
spectrometer at the constant flow rate of 0.3 μL/min using H2O, 0.1% HCOOH (A) and ACN, 
0.1% HCOOH (B) as elution solvent.  
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The nano-pump gradient used for P5 determination was the following: 3% solvent B (0 min), 
30% solvent B (0–4 min) and back to 3% in 1 min. The gradient used for T9 was the following: 
0% solvent B (0 min), 60% solvent B (0–8 min). A column re-equilibration time of 2 min was 
used after each analysis in both peptide assays. The nano-ESI source operated under the 
following conditions: drying gas temperature 300 °C, flow rate 3 L/min (nitrogen), capillary 
voltage 1950 V, with endplate offset − 500V. The LC-MS/MS analysis, under MRM condition, 
were carried out monitoring one diagnostic transition for P5, m/z 554.8 → m/z 770.0, selecting 
the most intense y-fragment ion, corresponding to y7; and two diagnostic transitions for T9 m/z 
528.4 → m/z 543.3 and m/z 387.1, corresponding to y5 and y3 respectively.  
 
4.2.8 Quantification of T9 in T-abs and P5 in P-abs 
The concentration of T9 and P5 respectively in T-abs and P-abs was estimated using external 
calibration curves. The concentrations of P5 in the standard solution ranged from 5 to 50 ng/μL, 
whereas those of T9 ranged from 10 to 100 ng/mL. The automated software QuantAnalysis 
(version 1.7) was used to build the calibration curves by integrating at each calibration level 
(CL) the area of the m/z 770.0, the main product ion of double charged m/z 554.8 P5 precursor 
ion and the area of m/z 543.3 and m/z 387.1 of the triple charged m/z 528.4 T9.  The equations 
of the curves were calculated using five calibration points with three set of replicate (n = 3).  
 
4.2.9 Analytical parameter evaluation 
The accuracy was evaluated by adding known amounts of P5 and T9 to BL control samples, 
respectively. The repeatability of the method was obtained by injecting P-abs and T-abs 
samples and the one calibration level three times each. The limit of detection (LOD) and the 
limit of quantification (LOQ) were calculated by applying the Eqs. SLOD = SRB+3 σRB and SLOQ 
= SRB+10 σRB, respectively, following the directives of FDA guide for method validation, 
where SLOD is the signal at the limit of detection, SLOQ is the limit of quantification, SRB is the 
signal of blank control, and σRB is the standard deviation.  
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4.3 Results 
4.3.1 Absorbed peptic and tryptic lupin peptides maintain their capacity to 
interfere with the PCSK9/ LDLR PPI 
As already explained in the introduction, peptic peptides (P-tot) and tryptic peptides (T-tot) 
from lupin proteins reduce the synthesis and secretion of mature PCSK9 in HepG2 cells 
(Lammi, Zanoni, Calabresi, & Arnoldi, 2016). In parallel, other experiments, performed in 
Caco-2 cells grown in two-compartment systems, have indicated that some of these peptic and 
tryptic peptides might be absorbed in the small intestine (Lammi, et al., 2016). Precisely, Caco-
2 cells have been incubated for 4 h in the AP chamber with 500 μL of a 1.0 μg/μL solution of 
P-tot or T-tot peptides and, at the end of treatment, BL solutions (700 μL) have been collected 
and absorbed peptic and tryptic peptides identified by HPLC-Chip ESI-MS/MS. The BL 
solutions were then dried and diluted to 100 μL to obtain the solutions P-abs and T-abs at the 
concentration of 0.25 and 0.32 μg/μL, respectively. Both solutions were used for the present 
experiments. 
The first experiment had the objective of comparing the ability of total and absorbed peptides 
to inhibit the PCSK9-LDLR binding. In vitro experiments were performed using a solid-phase 
binding assay between recombinant His-tagged PCSK9 and recombinant LDLR-AB domain. 
The results are shown in Figure 4.1. P-tot peptides reduced the PCSK9-LDLR binding by 22 
± 6.5% and 25 ± 13.7% (p < 0.001) at 1.0 and 2.5 μg/μL, respectively (Chart 1A), whereas T-
tot peptides by 26 ± 3% and 23 ± 2% at 0.5 and 1.0 μ g/μL, respectively. P-abs peptides (12.5 
ng/μL) and T-abs peptides (16.0 ng/μL) inhibited the PCSK9-LDLR interaction by 81 ± 7.6% 
and 58 ± 4.1% (p < 0.0001), respectively, versus the untreated sample (Chart 1B).  
 
 
 
Figure 4.1 - Effects of peptic and tryptic lupin peptides on the PCSK9-LDLR binding inhibition. 
(a) In vitro screening of the inhibitory activity of total lupin peptides, i.e. P-tot (1.0 and 2.5 μg/μL) and 
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T-tot (0.5 and 1.0 μg/μL), on PCSK9-LDLR PPI; and (b) of absorbed lupin peptides, i.e. P-abs and T-
abs (diluted 1:20). The commercial assay provides a plate pre-coated with a recombinant LDLR-AB 
domain, which is the PCSK9 binding site. For screening direct inhibitors of the PCSK9-LDLR 
interaction, lupin peptides were added to the proper amount of His-tagged PCSK9 in each well coated 
with LDLR-AB domain. Biotinylated anti-His-tag monoclonal antibody specifically reacted with 
recombinant His-tagged PCSK9 trapped with LDLR-AB domain immobilized on the microplate 
surface. The inhibitory effects were analysed measuring the amount of His tagged PCSK9 on the well. 
In particular, the inhibitory effect, calculated as % PCSK9-LDLR binding inhibition, determines a 
reduction of absorbance measured at 450 nm using the Synergy H1 fluorescent plate reader from Biotek 
versus vehicle control. Data points represent averages ± SEM of three independent experiments in 
duplicate. * * *p < 0.0001 * * p < 0.001 versus C. C, control vehicle. 
 
4.3.2 In silico model of the human PCSK9 and lupin peptides  
In order to establish which peptides were mainly responsible for the PCSK9/LDLR PPI 
inhibition, the 3D structure of PCSK9 was modelled. In this sense, all peptides were modelled 
and used for docking calculations into the LDLR anchor domain of PCSK9. At the end of 
simulations, the energy minimized structures of small peptides T1, T2, and T16 showed helix 
conformation, T3, T4, T5, T6, and T9 were folded as random coils, P1, P3, P5, P7, T10, and 
P6 showed γ -turn conformations, while peptide T13 was shaped as β –hairpin Figure 4.2 show 
the three-dimensional structures of lupin small-peptides.  
 
 
Figure 4.2 - Three-dimensional structure of lupin small-peptides at the end of MD simulations 
and subsequent energy minimization. 
 
 
The docking simulation permitted estimating their theoretical binding energy values on 
PCSK9. The lowest theoretical binding energy values were calculated for T9 and P5 (Figure 
4.3), which were further synthetized (Lammi, Zanoni, Aiello, Arnoldi, & Grazioso, 2016).  
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Figure 4.3 - Docking and MD simulations results for T9 (panel A) and P5 (panel B). T9 and P5 are 
represented as magenta and green stick models, respectively. The showed conformations of T9 and P5 
were retrieved minimizing MD frames in which the systems displayed geometrical stability. PCSK9 is 
displayed as cyan thin stick model and only residues within a radius of 4 Å from docked peptides are 
shown and labeled in the pictures. PCSK9 surface is colored according to the atoms electrostatic charges 
(blue for positive and red for negative), suitably calculated by Pymol tools. The materials and method 
section for the Docking, MD simulations and peptide binding energy estimations are reported in the 
published paper.  
 
4.3.3 Isolated lupin peptides inhibit the PCSK9-LDLR binding 
In order to assess the efficacy of the bioinformatics prediction, T9 and P5, identified as the 
best potential inhibitors among T-abs and P-abs peptides, were synthesized and tested for their 
capacity to inhibit the PCSK9-LDLR binding.  
T9 significantly reduced the PCSK9-LDLR binding by 19 ± 8.47%, 33 ± 5.33%, and 53 ± 
1.02% (p < 0.05 and p < 0.001) at 32, 160, and 320 μM concentrations, respectively, versus the 
untreated sample (Figure 4.4a). P5 (tested in the range 0.001–100 μM) induced a concentration 
dependent inhibition of the PCSK9-LDLR binding, with an IC50 value equal to 1.6 ± 0.33 μM 
(Figure 4.4b).  
 
 
 
Figure 4.4 - Peptides T9 and P5 inhibit the PCSK9-LDLR binding. Inhibitory effects of (a) T9 (32, 
160, and 320 μM) and (b) P5 (0.001–100 μM) on the PCSK9-LDLR PPI in vitro. The employed assay 
provides a plate precoated with a recombinant LDLR-AB domain, which is the PCSK9 binding site. 
For screening, the peptides were added to proper amount of His-tagged PCSK9 in each well coated with 
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LDLR-AB domain. Biotinylated anti-His-tag monoclonal antibody specifically reacts with recombinant 
His-tagged PCSK9 trapped with LDLR-AB domain immobilized on the microplate surface. The 
inhibitory effects of T9 and P5 were analysed measuring the amount of His-tagged PCSK9 on the well. 
The T9 and P5 inhibition, calculated as %PCSK9-LDLR binding inhibition, was measured from the 
absorbance reduction at 450 nm, using the Synergy H1 fluorescent plate reader (Biotek) versus vehicle 
(control). P5 showed a concentration-response behaviour, with an IC50 equal to 1.6 μM. Data points 
represent averages ± SEM of three independent experiments in duplicate. * p < 0.05 * * P < 0.001 
versus C. C, vehicle. 
 
 
4.3.4 Through the inhibition of PCSK9-LDR PPI, T9 and P5 increase the 
ability of HepG2 cells to uptake LDL from the extracellular environment 
For a deeper insight of the activity of T9 and P5, the change of the functional capability of 
HepG2 cells to uptake extracellular LDL was investigated after treatment with these peptides 
by performing fluorescent-LDL uptake experiments. As shown in Figure 4.5, each peptide 
increased the LDL-uptake versus the control in a statistically significant way (p < 0.001). In 
fact, the treatment with P5 (10 μM) led to an increase of the LDL-uptake by 66 ± 21.4%, 
whereas that with T9 (100 μM) increased the LDL-uptake by 55 ± 24.4%, versus the untreated 
sample. Therefore, both P5 and T9 are able to improve the HepG2 ability to absorb 
extracellular LDL, although their potency is very different, being the latter about ten times less 
active than the former. These results indicate that the capacity of T9 and P5 to impair the 
binding of secreted PCSK9 to the LDLR stabilizes the active LDLR on cell membrane, leading 
to an improved ability of hepatic cells to uptake extracellular LDL with a final 
hypocholesterolemic effect.  
 
 
Figure 4.5 - Fluorescent LDL-uptake assay after lupin peptide treatments of HepG2.  
Specific fluorescent LDL uptake signal was analysed by Synergy H1 (Biotek). Data points represent 
averages ± SEM of three independent experiments in triplicate. ** p< 0.001 versus C. C, vehicle.  
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4.3.5 LC-MRM assays for the T9 and P5 quantification  
In order to quantify the degree of transport of both peptides T9 and P5 across the epithelium 
barrier, quantitative analysis carried out by using an HPLC-CHIP connected with an ion trap 
set in MRM mode. Exploiting the high sensitivity and specificity than the data-dependent full 
scan mode, in which a subset of high signal peptides seen in the first MS stage (MS1) are 
subjected to the second MS/MS stage (MS2), the MRM mode has been set to monitor few 
transitions per peptides. High structural specificity was achieved monitoring the transition m/z 
554.8 → m/z 770.0, which represents the most intense product ion among all fragments in 
MS/MS spectrum of P5. Two transitions, m/z 528.4→ m/z 543.3 and m/z 528.4→m/z 387.1 
were instead used to quantify T9. Figure 4.6 reports the MS2 spectra of P5 and T9, 
respectively.  
 
 
 
Figure 4.6 - MS/MS spectra of P5, A) and T9, B) respectively. 
 
The CE values reported for all fragments were automatically optimized by the instrument 
software. QuantAnalysis data package was used to build calibration curves by integrating at 
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each calibration level the signal of the main product ion in the MS2 spectrum of each precursor 
ion. Table 4.2 reports A) the details of the calibration curve, B) the peptide area values for each 
replicate analysis of calibration curves. The correspondent area averages, standard deviations, 
and RSDs% at each calibration levels are reported. By analysing the P-abs and T-abs, the P5 
concentration in the P-abs solution was calculated to be 28.64 ± 0.43 ng/μL, corresponding to 
11.5% of the total peptic peptides absorbed by CaCo-2 cells. The relative standard deviation 
(RSD%) value resulted 1.5%. T9 concentration in the T-abs was 25.02 ± 1.1 ng/mL, 
corresponding to 0.01% of the total tryptic peptides absorbed by Caco-2. 
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Table 4.2 Analytical parameters of quantification   
A) Description of standard peptide curves for P5 and T9, respectively: concentrations, ng and 
injection volumes (IV) for each calibration level (CL) loaded on the HPLC-Chip column. 
Standard peptide curve P5 
CL Concentration (ng/ μL) IV (μL) C (ng) 
1 5 1 5 
2 10 1 10 
3 20 1 20 
4 30 1 30 
5 50 1 50 
Standard peptide curve T9 
CL Concentration (ng/ mL) I.V. (μL) C (ng) 
1 10 1 10 
2 35 1 35 
3 50 1 50 
4 75 1 75 
5 100 1 100 
 
B) Peptide area averages (average), standard deviations (DV) and the RSDs% values at each 
calibration levels (CL) are reported. The RSD% ranged from 1.4 to 18.2%.  
P5 CL C (ng) Replicates Area Average DV RSD% 
 
1 
 
5 
1 
2 
3 
4.46E+05 
4.37E+05 
5.97E+05 
 
4.93E+05 
 
 
8.97E+04 
 
 
18.2 
 
2 
 
10 
1 
2 
3 
1.13E+06 
1.28E+06 
1.26E+06 
 
1.22E+06 
 
8.09E+04 
 
6.6 
 
3 
 
20 
1 
2 
3 
4.09E+06 
4.43E+06 
4.09E+06 
 
4.20E+06 
 
 
1.95E+05 
 
 
4.6 
 
 
4 
 
30 
1 
2 
3 
6.34E+06 
6.46E+06 
6.51E+06 
 
6.44E+06 
 
 
8.85E+04 
 
 
1.4 
 
 
5 
 
50 
1 
2 
3 
1.30E+07 
1.18E+07 
1.12E+07 
 
1.20E+07 
 
 
9.21E+05 
 
 
7.7 
 
T9 CL C (ng) Replicates Area Average DV RSD% 
1 10 1 
2 
3 
1.24E+05 
1.58E+05 
1.61E+05 
 
1.47E+05 2.04E+04 13.8 
2 35 1 
2 
3 
3.59E+05 
4.28E+05 
3.46E+05 
 
3.78E+05 4.40E+04 11.6 
3 50 1 
2 
3 
7.15E+05 
7.03E+05 
7.00E+05 
7.06E+05 8.81E+04 7.8 
4 75 1 
2 
3 
8.29E+05 
8.60E+05 
8.32E+05 
8.40E+05 1.73E+04 2.1 
5 100 1 
2 
3 
1.18E+06 
1.51E+06 
1.50E+06 
 
1.40E+06 1.84E+05 13.2 
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The accuracy of the method was determined prepared by spiking blank matrix fortified with 
T9 and P5 standard peptides. The accuracy was higher than 110% at 8 ng/μL for P5, and 97.5% 
at 75 ng/mL for T9. The calculated values of LOQ and LOD, corresponding to 3.92 and 3.71 
ng/μL, respectively, confirm the reliability of the quantification method in the case of P5 and   
8.62 and 7.91 ng/mL in the case of T9. 
 
4.4 Discussion 
The discovery of PCSK9 in 2003 (Abifadel, Varret, Rabès, Allard, Ouguerram, Devillers, et 
al., 2003) opened a new scenario in the lipid field. In fact, whereas previously statins were 
considered the best hypocholesterolemic drugs, subsequently PCSK9 inhibitors became 
another therapeutic option. In this context, numerous studies have focused their attention on 
mAbs (Everett, Smith, & Hiatt, 2015), gene silencing compounds (Graham, et al., 2007), 
peptidomimetics (Shan, Pang, Zhang, Murgolo, Lan, & Hedrick, 2008) and berberine (Dong, 
Li, Singh, Cao, & Liu, 2015). At the best of our knowledge, instead, this is the first paper 
providing experimental evidence that some peptides deriving from food protein hydrolysis may 
function as effective inhibitors of the PCSK9-LDLR PPI.  
Our investigation was focused on lupin protein, since a very recent paper has shown that in 
hypercholesterolemic subjects, who had consumed dietary bars containing lupin proteins for a 
month, the total cholesterol decrease was accompanied by a parallel decrement of circulating 
PCSK9 (Lammi, Zanoni, Calabresi, & Arnoldi, 2016). Other relevant evidences available 
before starting the present investigation were the following:  
1) peptic and tryptic peptides, obtained digesting a total protein extract from lupin seed with 
pepsin and trypsin are able to inhibit the interaction of PCSK9 with the LDLR in an in vitro 
system (Lammi, Zanoni, Calabresi, & Arnoldi, 2016); 2) some of these peptides, identified by 
HPLC-ESI-MS/MS, are absorbed in a Caco-2 model of the small intestine (Lammi, et al., 
2016). These evidences prompted us to investigate whether the absorbed peptides (P-abs and 
T-abs) maintained the inhibitory activity of P-tot and T-tot, i.e. whether at least some bioactive 
peptides had been absorbed. In this context, the demonstration that the capacity of these 
peptides to inhibit the PCSK9/LDLR interaction is not impaired by the absorption is certainly 
a main achievement of this work. The fact that at least some bioactive peptides are absorbed is 
not obvious, considering that only part of the original peptides were absorbed in the Caco-2 
model (Lammi, et al., 2016), since at the end of treatment some were still detectable only in 
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the AP compartment and other disappeared in both compartments owing to metabolic 
degradation.  
A natural development of this research was the application of in silico tools for potentially 
sorting out the most bioactive peptides. The first step was the modelling a refined human 
PCSK9 3D-structure, starting from X-ray available literature data (Shan, Pang, Zhang, 
Murgolo, Lan, & Hedrick, 2008). Afterward, the peptides 3D-structures were calculated and 
refined starting from the structures of the proteins to whom they belong. Their conformations 
are very variable, since three have helix conformations, five γ -coil conformations, one β-
hairpin conformation, and six are random coils. Finally, the docking study permitted to estimate 
their theoretical binding energy values on PCSK9 and therefore to get a classification in which 
T9 was the best candidate among tryptic peptides and P5 the best among peptic peptides. 
Interestingly, both derive from the hydrolysis of lupin β-conglutin, a 7S vicilin-like storage 
globulin. T9 consists of 14 amino acidic residues, whereas P5 of 10 amino acidic residues. 
The following experiments, performed on the synthetic peptides, confirmed that indeed they 
are able to impair the interaction of PCSK9 with the LDLR. P5 resulted to be the most active, 
with an IC50 value equal to 1.6 μM, whereas T9 was much less active, since its IC50 falls around 
320 μM. This different activity also reflect the ability of both P5 and T9 to be absorbed through 
epithelium barrier, P5 in fact is much more easily absorbed than T9 which could be subjected 
to a metabolic degradation. The experiment on the ability of HepG2 cells to uptake LDL from 
the extracellular environment confirmed the better efficacy of P5.  
Our calculations permitted to sort out at least one lupin peptide with a great potential interest 
as inhibitor of the interaction of PCSK9 with the LDLR, owing to the very low IC50 value equal 
to 1.6 μM. It is useful to observe that Pep2-8 (Ac-TVFTSWEEYLDWV-amide), the best 
inhibitor singled out by Zhang and co-workers in a recent paper (Y. Zhang, Eigenbrot, Zhou, 
Shia, Li, Quan, et al., 2014), has an IC50 value equal to 0.81 ± 0.08 μM, i.e. only slightly better 
than that of P5. Interestingly, Pep2-8 contains 13 amino acid residues and its C-terminal 
truncated analogues loose activity, whereas P5 contains only 10 residues. P5 is thus one of the 
shortest peptides ever described in literature endowed with this specific activity. 
Finally, it is important to recapitulate the very original approach of our investigation: 
 
1) Detection of a PCSK9 decrease in the plasma of hypercholesterolemic subjects at the end 
of a dietary intervention study based on dietary bars containing lupin protein.  
2) Demonstration that lupin peptides reduce the PCSK9 synthesis and secretion in HepG2 
cells; 
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3)  Mass spectrometry based identification of lupin peptides which are absorbed in Caco-2 
cells; 
4) Demonstration that they retain the original capacity of impairing the PCSK9/LDLR 
interaction; 
5) Classification of their potential activity by docking studies with the PCSK9-LDLR 
complex and selection of the best candidates; 
6) Identification of the very potent peptide P5; 
7) Development and optimization of an efficient workflow for their quantification in Caco-
2 cells; 
8) Owing to the unusual process of the identification and its original sequence, indeed P5 
may be a promising candidate for designing new potent inhibitors of the PCSK9/LDLR 
PPI. 
In conclusion, this is the first experimental evidence that a peptide deriving from a plant protein 
has this specific biological activity. 
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5.0 Abstract 
IAVPGEVA, IAVPTGVA, and LPYP, three peptides deriving from glycinin, a main fraction of 
soy globulins, are known to inhibit the activity of 3-hydroxy-3-methylglutaryl CoA reductase and 
modulate cholesterol metabolism in HepG2 cells. In order to evaluate whether these peptides can 
be transported across the epithelium barrier, experiments using human intestinal Caco-2 cell 
monolayers grown in two-chambers systems were performed. The apical chamber was treated with 
each single peptide for a time spanning from 15 up to 120 min. The development of a highly 
sensitive method based on LC-MRM permitted to quantify the peptides in the basolateral chambers 
and to calculate the apparent permeability coefficients (Papp) that were equal to 3.34 ± 0.06   
10-8, 2.75 ± 0.08  10-8, and 1.41 ± 0.03  10-8 cm sec-1, for IAVPGEVA, IAVPTGVA, and LPYP, 
respectively. At the end of experiment, a detailed characterization of the metabolites was also 
performed either in the apical or in the basolateral chamber. 
 
Keywords: bioactive peptides, Caco-2 cells, HMGCoA reductase, intestinal absorption, mass 
spectrometry, plant protein, soybean.  
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Abbreviations used: AP, apical; BL, basolateral; HMGCoAR, 3-hydroxy-3-methylglutaryl 
coenzyme A reductase; LDL, low density lipoprotein, LC, liquid chromatography; MRM, 
multiple reaction monitoring; TEER, trans-epithelial electrical resistance.  
 
5.1 Introduction  
Cardiovascular diseases are among the main causes of death and disability and 
hypercholesterolemia is a crucial feature that increases the risk of adverse events. Although 
drugs, with particular reference to statins, remain the main tool for lowering high cholesterol 
levels, some functional foods may have a useful preventive role in the presence of a moderate 
hypercholesterolemia.1-3 In particular, numerous studies have shown that soybean protein, 
among the main bioactive components of this bean, is able to reduce total and low-density 
lipoprotein (LDL) cholesterol levels in highly and mildly hypercholesterolemic subjects,1, 4, 5 
through a positive effect on LDL receptors (LDLR). 6 
The two major components of soybean protein are glycinin, a non-glycosylated 11S globulin 
(legumin), and β-conglycinin, a glycosylated 7S globulin (vicilin). Since proteins are 
hydrolyzed during gastrointestinal digestion, some researches have been dedicated to 
investigate the activity of soy protein hydrolysates. In this context, two peptides, LPYP and 
IAVPGEVA, have been isolated and characterized after digesting glycinin with trypsin and 
pepsin, respectively, and were shown to inhibit the activity of 3-hydroxy-3-methylglutaryl CoA 
reductase (HMGCoAR), a main enzyme in cholesterol biosynthesis.7 Subsequently, the 
alignment of IAVPGEVA with the glycinin sequence permitted the identification of another 
bioactive peptide, i.e. IAVPTGVA.7 Kinetic experiments showed that these peptides act as 
competitive inhibitors of HMGCoAR.8 With a pharmaceutical approach, the same authors have 
exploited these peptides as leads for the synthesis of more active analogues,9 without 
examining their biological effects in detail.  
In order to fill this gap, recently our group has performed a series of experiments aimed at 
identifying the molecular mechanism at the basis of their hypocholesterolemic properties. 
These studies have confirmed that IAVPGEVA, IAVPTGVA, and LPYP are able to inhibit the 
activity of HMGCoAR and have demonstrated that the inhibition of this enzyme leads to a 
favorable modulation of LDLR pathway in human hepatic HepG2 cells. Indeed, the treatment 
of these cells with each peptide at the concentration of 500 μM, induced the activation of the 
sterol regulatory element binding proteins 2 (SREBP-2), which lead to an increase of the LDLR 
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protein levels. Moreover, the up-regulation of the LDLR enhances the ability of HepG2 cells 
to uptake LDL particles from the extracellular environment producing a final 
hypocholesterolemic effect.9 In the meanwhile, another investigation has shown that the same 
peptides also exert hypoglycemic effects in HepG2 cells.10 
Intestinal permeability plays a critical role in the oral bioavailability of any active compound. 
Several studies have investigated the transepithelial transport of antihypertensive peptides 
derived from different food sources, such as egg or milk.11-14 A single transport study has 
investigated the transport across human intestinal Caco-2 cell monolayers of peptides generated 
by digestion of soy protein.15 YVVNPDNDEN and YVVNPDNNEN were among the 22 
peptides deriving from β-conglycin transferred from the apical (AP) to the basolateral (BL) 
compartment in this experiment. Interestingly, these peptides induce hypocholesterolemic 
effects in HepG2 cells by a statin-like mechanism.16  
Whereas numerous published works are focused on the qualitative identification of absorbable 
peptides, we chose a quantitative approach combined advanced analytical techniques, such as 
microfluidic HPLC and targeted mass spectrometry (MS). In particular, the use of multiple 
reaction monitoring (MRM), coupled with spiking with an internal standard, enable the fast 
development of highly specific, precise, and robust quantitative analyses.17-19 Indeed, MRM 
has emerged as an important analytical tool in pre-clinical and clinical small-molecule drug 
development and monitoring as well as in nutritional investigations.20 
The detailed objectives of the present work were the development of a sensitive LC-MRM 
method for the quantitation of IAVPGEVA, IAVPTGVA, and LPYP, the evaluation of the 
transepithelial transport of these peptides across the Caco-2 monolayer, and the investigation 
of their degradation in Caco-2 cells. These absorption data, as well as previously obtained 
functional data,16 will be useful for the translation of these findings from in vitro systems to in 
vivo models.     
 
5.2 Materials and Methods 
5.2.1 Chemicals and reagents. IAVPGEVA, IAVPTGVA, LPYP, and YVVNPDNDEN were 
synthesized (> 95% purity by HPLC) by PRIMM (Milan, Italy). Dulbecco’s Modified Eagle 
Medium (DMEM) was from GIBCO (Thermo Fisher Scientific, Waltham, MA USA). Fetal 
Bovine Serum (FBS) was from Hyclone Laboratories (Logan, UT, USA). Stable L-glutamine, 
1% non-essential amino acids, and penicillin/streptomycin were from Euroclone (Milan, Italy). 
Formic acid and acetonitrile (ACN) were from Sigma-Aldrich (Milan, Italy). LC-grade H2O 
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(18 MΩ cm) was prepared with a Milli-Q H2O purification system (Millipore, Bedford, MA, 
USA). 
 
5.2.2 Cell cultures. Caco-2 cells, obtained from INSERM (Paris), were sub-cultured at low 
density.21 Cells were routinely sub-cultured at 50% density and maintained at 37 °C in a 90% 
/ 10% air / CO2 atmosphere in DMEM containing 25 mM glucose, 3.7 g/L NaHCO3, 4 mM 
stable L-glutamine, 1% non-essential amino acids, 100 U/L penicillin, 100 µg/L streptomycin 
(complete medium), supplemented with 10% heat inactivated fetal bovine serum (FBS) 
(Hyclone Laboratories, Logan, UT, US). For differentiation, cells were seeded on 
polycarbonate filters, 12 mm diameter, 0.4 µm pore diameter (Transwell, Corning Inc., Lowell, 
MA, US) at a 3.5x105 cells/cm2 density in complete medium supplemented with 10% FBS in 
both AP and BL compartments for 2 days to allow the formation of a confluent cell monolayer. 
Starting from day 3 after seeding, cells were transferred to complete medium in both 
compartments, supplemented with 10% FBS only in the BL compartment, and allowed to 
differentiate for 15 days with regular medium changes three times weekly.22  
 
5.2.3 Cell monolayer integrity evaluation. The trans-epithelial electrical resistance (TEER) 
was measured at 37 °C using the voltmeter apparatus Millicell (Millipore Co., USA,), 
immediately before and at the end of the 2 h absorption experiments. After incubations, no 
significant changes in TEER values were observed. At the end of absorption experiments, cells 
were incubated from the AP side with 1 mM phenol-red in PBS with Ca++ and Mg++ for 1 h at 
37 °C. The BL solutions were then collected and 10 % in volume of 0.1 N NaOH was added 
before reading the absorbance at 560 nm by a microplate reader Synergy H1 from Biotek 
(Winooski, VT, USA). Phenol-red passage was quantified using a standard phenol-red curve. 
Only filters showing TEER values and phenol red passages similar to untreated control cells 
were considered for peptide transport analysis.  
 
5.2.4 Trans-epithelial absorption of soy peptides. Prior to experiments, the cell monolayer 
integrity and differentiation were checked by TEER measurement as described in details above. 
Cells were then washed twice and peptide absorption assayed. Peptide absorption were 
performed in transport buffer solution (137 mM NaCl, 5.36 mM KCl, 1.26 mM CaCl2, 1.1 mM 
MgCl2, 5.5 mM glucose). In order to reproduce the pH conditions existing in vivo in small 
intestinal mucosa, AP solutions were maintained at pH 6.0 (buffered with 10 mM 
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morpholinoethane sulfonic acid), and BL solutions were maintained at pH 7.4 (buffered with 
10 mM N-2-hydroxyethylpiperazine-N-4-butanesulfonic acid). Prior to absorption 
experiments, cells were washed twice with 500 µL PBS with Ca++ and Mg++, and cell were 
loaded from the AP side with each soy peptide (500 µM) dissolved in AP transport solution 
(500 µl) and the BL compartment contained BL transport solution (700 µL). The plates were 
incubated for different time periods, i.e. 15, 30, 60, 90 and 120 min at 37 °C, 5% CO2. At the 
end of incubation the incubation time, AP and BL media were collected and stored at -80 °C. 
Three independent experiments were performed, each in duplicate.  
 
5.2.5 LC/ESI-MRM analysis. An aliquot (10 µL) of each BL and AP solution was spiked 
with the peptide YVVNPDNDEN as an internal standard (IS) and then desalted with C18 resin 
ZipTip (Millipore Corporation, Bedford, MA, USA). Each sample was lyophilized under 
vacuum and re-dissolved in 10 µL (0.1% formic acid), vortexing and centrifuging at 6000 g 
thrice. MRM-based analysis of purified peptides was carried out on a SL IT mass spectrometer 
interfaced with a HPLC Chip Cube source (Agilent Technologies, Palo Alto, CA, USA). Data 
were processed with MSD Trap control 4.2, and Data analysis 4.2 version (Agilent 
Technologies). The chromatographic separation was performed using a 1200 HPLC system 
equipped with a binary pump. The peptide enrichment was performed on a 40 nL enrichment 
column (Zorbax 300SB-C18, 5 µm pore size), followed by separation on a 43 mm × 75 µm 
analytical column packed (Zorbax 300SB-C18, 5 µm pore size). Solvent A was 95% LC water, 
5% ACN, 0.1% formic acid; solvent B was 5% LC water, 95% ACN, 0.1% formic acid. Peptide 
enrichment was performed injecting 1 µL at the constant flow rate of 4 µL/min, while the 
analytical separation was at 300 nL/min. The nanopump gradient program were as follows: 
IAVPGEVA analysis, 3% solvent B (0 min), 80% solvent B (0–4 min), and back to 5% in 1 
min; IAVPTGVA analysis, 3% solvent B (0 min), 60% solvent B (0–6 min), and back to 5% 
in 2 min; LPYP analysis, 5% solvent B (0 min), 80% solvent B (0–5 min), and back to 5% in 
1 min. A post time acquisition of 5 minutes at the initial chromatographic conditions was used 
after each run. Data acquisition was accomplished in positive ionization mode. Capillary 
voltage was −1950 V, with endplate offset −500 V, skimmer -40 V, drying gas flow 5 L/min, 
drying gas temperature 300 C, nebulizer gas pressure 18 psi, scan range m/z 150–2000, 
averages of five spectra, ion charge control (ICC) target 30000. The MRM acquisition was set 
in two segments: IAVPGEVA analysis, the former (0-2.5 min) was used for the IS at m/z 589.7 
and the latter (2.5 – 5.0 min) for the target peptide precursor ion at m/z 755.6; IAVPTGVA 
analysis, same scheduled time intervals to monitor the IS at m/z 589.7 and the target peptide 
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precursor ion at m/z 727.2; LPYP analysis, the former from (0-3.25 min) to monitor the IS at 
m/z 589.7 and the latter (3.25-5.0 min) to monitor the target peptide precursor ion at m/z 489.3. 
A blank was analyzed between every sample to ensure absence of carryover effects. The 
peptides were identified by comparing their retention times, MS profile and MS/MS 
fragmentation spectra with those of authentic standards.  
 
5.2.6 Calibration curves and quantification of soy peptides. The standard peptides 
(IAVPGEVA, IAVPTGVA, and LPYP) in 0.1% formic acid were used to build a calibration 
curve for each peptide using YVVNPDNDEN as IS. In case of IAVPGEVA, the calibration 
curve was constructed over a concentration range from 5 to 250 ng/mL adding 37.5 ng/mL of 
IS; in case of IAVPTGVA, it was constructed over a concentration range from 5 to 1000 ng/mL 
adding 250 ng/mL of IS, and in case of LPYP over a concentration range from 0.5 to 100 ng/mL 
adding 37.5 ng/mL of IS. The ratios between the areas of each peptide and the IS were 
calculated and plotted versus the concentration ratios to build the calibration curves. The 
equations for the curves were calculated using six calibration points with three set of replicate 
(n = 3) per curve. The data analysis for the standard curves were performed by exporting the 
peak area ratios from LC/MSD Trap Software 5.3 into the automated software QuantAnalysis 
(version 1.7).  
 
5.2.7 Accuracy and precision evaluation. To ensure appropriate performance of the 
developed method, quality control samples were prepared by spiking the standard peptides in 
a basolateral sample originating from control Caco-2 cells at the concentrations of 0.1, 0.15, 
0.1 ng/µL for IAVPGEVA, IAVPTGVA, and LPYP, respectively, followed by sample 
purification according to the protocol previously described. The IS was spiked into each sample 
prior to ZipTip desalting. Results were calculated for three independent samples, analyzing 
each one three times. 
 
5.2.8 Apparent permeability measurement. The apparent permeability coefficients (Papp, 
cm s−1) of the peptides under investigation were calculated using an equation proposed by 
Stuknyte and coworkers:23 Papp = dQ/dT  1/(S  C0), where dQ/dT is the amount of the each 
peptide measured in the acceptor BL chamber as a function of time (μmol sec−1), S is the 
surface area of the monolayer (here 1.12 cm2), and C0 is the initial concentration in the donor 
AP chamber (μM).  
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5.2.9 Statistical analysis. All analyses were run in triplicate on each biological replicate. 
Statistical analysis, including determination of linear regression, average, standard deviation 
(SD) and coefficient of variance (CV), was performed using Graphpad Prism 6. Values were 
expressed as means ± SEM.  
 
 
5.3 Results 
5.3.1 Optimization of a HPLC-MRM method for the quantitation of the soy peptides. The 
first step of the work consisted in the validation of the analytical method based on chip-HPLC 
ESI-MS/MS. The chromatographic separation was conducted by optimizing a gradient for each 
peptide. The HPLC–MS/MS analyses, under MRM conditions, were carried out monitoring 
two most intense diagnostic transitions for each peptide in order to assure the greatest 
specificity. In details, the MRM transitions for IAVPGEVA were those from the mono-charged 
precursor ion [M+H]+ (m/z 755.6) to the product-ions y5 and b7 with m/z 472.1 and 666.3, 
respectively. The MRM transitions for IAVPTGVA were from the mono-charged precursor 
ion [M+H]+ (m/z 727.4) to the product-ions y5 and b7 with m/z 444.1 and 638.3, respectively. 
The transition of LPYP were from the mono-charged precursor ion [M+H]+ (m/z 489.3) to the 
product-ions y2 and b3 with m/z 278.9 and 374.0, respectively. Similarly, the MRM transitions 
for YVVNPDNDEN were from the double-charged precursor ion [M+2H]2+ (m/z 589.7) to the 
single-charged product-ions y7 and b3 with m/z 817.3 and 362.0, respectively. The assay was 
optimized by dividing the methods into several time segments and the specific MRM transitions are 
monitored in each segmentation according to the corresponding retention time. Figure 5.1 displays 
the scheduled chromatograms of each monitored peptides. Figure 5.2 shows the product ion 
spectra of IAVPGEVA, IAVPTGVA, LPYP, and YVVNPDNDEN (used as IS).  
While building the calibration curves, the peak areas of all monitored transitions from parent 
to product ions of each peptide were normalized by the peak area of the corresponding MRM 
transitions of the IS.  
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Figure 5.1 - Extract ion chromatograms (EICs) of three soy peptides. A) EIC of IS and IAVPGEVA 
(tR 1.25 min, and 3.5 min for IS and IAVPGEVA, respectively), B) EIC of IS and IAVPTGVA (tR 1.15 
min, and 4.0 min for IS and IAVPTGVA, respectively), C) EIC of IS and LPYP (tR 2.2 min, and 3.45 
min for IS and LPYP, respectively).  
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Figure 5.2 – Soy peptide fragment ion spectra. ESI (+) MS/MS product ion spectra of A) 
IAVPGEVA; B) IAVPTGVA; C) LPYP; and D) IS.   
 
5.3.2 Evaluation of the analytical parameters.  The validation parameters of the established 
LC-MRM method are shown in Table 5.1, which reports the concentration ranges, the 
correlation coefficients, the limits of detection (LOD) and the limits of quantitation (LOQ) for 
each peptide. The calibration curve was linear over the concentration range from 5 to 250 
ng/mL for IAVPGEVA, over the concentration range from 5 to 1000 ng/mL for IAVPTGVA, 
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and over the concentration range from 0.5 to 100 ng/mL for LPYP. Figure 5.3 shows the 
calibration curve of each peptide used for the quantitative evaluation. Table 5.1S in 
Supplementary Information to this work, reports the data on which the curves were built. The 
correlation coefficient (R2) was greater than 0.99 for each calibration curve, indicating good 
linearity.  
 
Figure 5.3 – Calibration curves. Plot A, B, C show the reference peptide curves with the linear 
equations for IAVPTGVA, IAVPGEVA and LPYP respectively.  
 
The sensitivity of the method was assessed by the LOQ’s [signal-to-noise (S/N) =10], which 
were 3.28 ng/mL, 3.06 ng/mL, and 0.36 ng/mL for IAVPGEVA, IAVPTGVA and LPYP, 
respectively, and the LOD’s (S/N = 3), which were 3.20 ng/mL, 2.94 ng/mL, and 0.22 ng/mL, 
respectively. The accuracy of the method was evaluated by the analysis of quality control 
samples prepared as reported in the Material and Method section. Accuracy of 101.4%, 108.4% 
and 97.0% were obtained for IAVPGEVA, IAVPTGVA and LPYP, respectively, whereas the 
coefficient of variations (CV%), representing the precision of the LC-MRM method, evaluated 
by 3 independent analyses, were 4.6 %, 4.2 % and 1.9 %, respectively, reported in Table 5.1.  
Table 5.1 Calibration range, linearity (R2) and LOQ-LOD of the LC–ESI-MS/MS method 
a Correlation coefficient using seven calibration points (n = 3) 
Peptide 
Calibration Range 
ng/mL 
IS 
ng/mL 
Linearity 
(R2)a 
LOQ-LOD 
ng/mL 
CV% Accuracy% 
IAVPTGVA 5 - 1000 37.5 0.993 3.06 - 2.94 4.2 108.4 
IAVPGEVA 5 - 250 37.5 0.997 3.28 - 3.20 4.6 101.4 
LPYP 0.5 - 100 37.5 0.999 0.36 - 0.22 1.9 97.0 
 88 
 
 
5.3.3 Permeation experiments and calculation of apparent permeability coefficients. In 
order to evaluate the absorption, differentiated Caco-2 cells were incubated adding the AP 
compartment with each soy peptide (500 µM). The BL media were collected after 15, 30, 60, 
90 and 120 min treatments and submitted to LC-MRM analysis, whereas the AP media were 
analyzed after 120 min. For monitoring cell monolayer integrity and excluding non-specific 
peptide passage, the TEER values were monitored at the beginning and end of each experiment. 
Moreover, phenol-red passage across the monolayer was assayed at the experiment end.24 Both 
assays demonstrated that the incubation with soy peptides did not affect the monolayer integrity   
(data not shown).  
Specific MRM transitions based on chromatographic retention times (tR) and MS/MS spectra 
were used to detect and quantify the absorbed exogenous peptides.  
Figure 5.4 shows the time-dependent concentrations of the peptides quantified in the BL 
chamber.  In case of IAVPGEVA, the concentrations were 18.1 ± 1.40 ng/mL at 15 min, 25.6 
± 0.24 ng/mL at 30 min, 31.7 ± 0.08 ng/mL at 60 min, 36.8 ± 0.01 ng/mL at 90 min, and 45.9 
± 1.35 ng/mL at 120 min. In case of IAVPTGVA, the concentrations were 14.3 ± 0.4 ng/mL at 
15 min, 20.6 ± 0.2 ng/mL at 30 min, 25.4 ± 0.4 ng/mL at 60 min, 39.3 ± 0.7 ng/mL at 90 min, 
and 40.4 ± 0.5 ng/mL at 120 min. In case of LPYP, they were 5.0 ± 0.1 ng/mL at 15 min, 7.0 
± 0.02 ng/mL at 30 min, 11.0 ± 0.05 ng/mL at 60 min, 14.3 ± 0.04 ng/mL at 90 min and 15.1 
± 0.53 ng/mL at 120 min. The final values of the transport percentage at 120 min versus the 
amount of each peptide incubated at time 0 in the AP sides were 0.05% for IAVPTGEVA, 
0.02% for IAVPTGVA, and 0.009% for LPYP. 
In order to investigate the rate of peptide transport from AP to BL side, the Papp values of 
IAVPGEVA, IAVPTGVA, and LPYP were calculated at 15 min using a literature method.23 
As shown in Figure 5.5, the peptide IAVPGEVA had the highest Papp value equal to 3.34 ± 
0.06  10-8 cm sec-1, followed by that of IAVPTGVA equal to 2.75 ± 0.08  10-8 cm sec-1,  and 
LPYP equal to 1.41 ± 0.03  10-8 cm sec-1.  
 
 89 
 
 
Figure 5.4 - Time-dependent increase of peptide concentrations at BL side. Calculated 
concentration (ng/mL) of IAVPGEVA, IAVPTGVA, and LPYP upon trans-epithelial absorption across 
Caco-2 monolayer. Bars represent averages ± SD of three independent experiments (three replicate per 
sample). 
 
 
 
 
Figure 5.5 - In vitro permeability. Bar graphs indicate the Papp x 10-8 cm sec-1 calculated for each 
peptide. The data points represent the averages ± SEM of three independent experiments in triplicate. 
 
5.3.4 Degradation by brush border peptidases. Under the hypothesis that the low transport 
rates might be attributed to a competing in situ degradation induced by the hydrolytic activity 
of brush border membrane peptidases, the AP solutions collected at 120 min were analyzed 
looking for metabolic degradation products. This was possible for IAVPGEVA and 
IAVPTGVA, whereas in case of LPYP this investigation was impaired by the intrinsic 
difficulty of obtaining certain attribution of very short unspecific peptides.   
The complete sequence coverage assignment of all MS/MS spectra permitted the unambiguous 
identification of each metabolite (data reported in Figure 5.6).  
Figures 5.7A, B display the extracted ion chromatograms of both precursor peptides and their 
hydrolytic fragments in the AP chamber at 120 min.  The susceptibility of these peptides to 
hydrolysis are very different. In fact, the metabolism of IAVPGEVA produces only one 
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breakdown fragment (m/z 642.3), with a tR of 1.2 min, deriving from the loss of an isoleucine 
at the N-terminal. On the opposite, IAVPTGVA produces three breakdown fragments: 
AVPTGVA (m/z 614.2), with a tR of 1.2 min, again deriving from the loss of an isoleucine at 
the N-terminal position; IAVPT (m/z 498.9), with a tR of 3.65 min, due to loss of a three amino 
acids fragment at the C-terminal position; and IAVP (m/z 398.7), with tR = 3.8 min, deriving 
from the loss of a four amino acids fragment at the C-terminal position. Since the percentages 
of intact parent peptide were only 19.2% for IAVPGEVA and 12.9% for IAVPTGVA, both 
peptides had been significantly hydrolyzed by brush border peptidases.  
The analyses of the metabolites in the BL solutions at 120 min (Figures 5.4C, D) clearly 
indicated that the breakdown fragments observed in the AP solution had been translocated 
across the Caco-2 monolayer.  
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Figure 5.6 - MS/MS spectra of metabolites. ESI (+) MS/MS spectrum of metabolite A) AVPTGVA 
(m/z 614.2), B) IAVPT (m/z 498.9) C) IAVP (m/z 398.7) and D) AVPGEVA (m/z 642). The sequence 
ions and internal fragments are indicated in red in the spectrum.   
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Figure 5.7 - AP and BL Extracted ion chromatogram (EIC) of precursor peptides and hydrolytic 
fragments after 120 min. A) EIC of AVPGEVA (m/z 642. 3) and IAVPGEVA (m/z 755.6) and B) EIC 
of IAVP (m/z 398.7), IAVPT (m/z 498.9), AVPTGVA (m/z 614.2) and IAVPTGVA (m/z 727.2) at AP 
side. C) EIC of AVPGEVA (m/z 642. 3) and IAVPGEVA (m/z 755.6) and D) EIC of IAVP (m/z 398.7), 
IAVPT (m/z 498.9), AVPTGVA (m/z 614.2) and IAVPTGVA (m/z 727.2) at BL side.  
 
 
5.3.5 Comparative stability of breakdown fragments through Caco-2 monolayers. With 
the purpose of a better comprehension of the degradation process, the relative abundances of 
the parent peptide and its metabolites in the AP solution at 120 min were calculated comparing 
the Peak Intensity of each peptide. In the case of IAVPGEVA, the parent peptide was equal to 
86.5% and the unique breakdown fragment AVPGEVA was 13.5%. In the case of IAVPTGVA, 
the parent peptide accounted for 91.4%, the most abundant breakdown fragment AVPTGVA 
accounted for 6.9 %, IAVPT accounted for 1.1%, and IAVP for 0.6 %.  
Applying the same considerations to the BL solutions, in case of IAVPGEVA, the percentage 
of the parent peptide was 82.5% and that of the unique metabolite AVPTGVA was 17.5%, 
whereas in case of IAVPTGVA, the parent peptide was 83.8% and the breakdown fragments 
were AVPTGVA equal to 5.8%, IAVP equal to 0.24%, and IAVPT equal to 0.21%. 
These results show that while they were formed, the metabolites were also transported at least 
in part across the cell monolayer. Figures 5.8A, B compare the relative abundance of the parent 
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peptides and their fragments in the AP and BL chambers for IAVPGEVA and IAVPTGVA, 
respectively. Interestingly, whereas the relative abundance of the fragment AVPTGVA in AP 
and BL chambers are very similar (6.9% and 5.8%, respectively), the smaller hydrolytic 
fragments IAVPT and IAVP are much less abundant in the BL chamber than in the AP 
chamber. This may possibly indicate that the transport of IAVPT and IAVP are slower than 
that of AVPTGVA. 
  
 
Figure 5.8 - Peptide relative abundance.  Peptide spectral intensity of A) IAVPGEVA and its 
fragment AVPGEVA at AP and BL side; B) IAVPTGVA and IAVP, IAVPT, AVPTGVA at AP and 
BL side. The data points represent the averages ± SD of three independent experiments in triplicate. 
 
5.4 Discussion  
The intestinal absorption is a critical issue for the bioavailability of any active compound. The 
intestinal epithelium is composed of a large number of well-differentiated and polarized 
epithelial cells with microvilli structure on the AP surface.25 Because of their similarity to 
intestinal epithelium, Caco-2 cell monolayers are usually selected as cellular model for 
transport studies. Using this model, it is possible to evaluate the transport of a bioactive 
compound from the AP side of the cell monolayer, mimicking the lumen, to the BL side, 
mimicking the circulation flux. The Caco-2 system seems to represent a good model for 
screening and ranking bioactive peptides with respect to their absorbability.26  
The soy peptides investigated in this work have interesting hypocholesterolemic9 and 
hypoglycemic activities.10 Our objective was to verify whether they are able to be absorbed by 
the intestinal model and to obtain quantitative data on the transport across the Caco-2 cell 
monolayer. For this reason, a selective and specific LC-MRM method was developed that 
permitted to build a linear regression curve for the quantification of each peptide. Indeed these 
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soy peptides are transported across the Caco-2 monolayer with a linear trend of absorption 
during the 120 min of the experiment as clearly suggested by Figure 5.4.  
Following the biopharmaceutical classification system,27 the absorption is considered very 
poor when the Papp value is lower than 0.2  10-6 cm s-1, whereas it is moderate when the Papp 
value falls between 0.2 and 2.0  10-6 cm s-1, and good when the Papp value is larger than 2.0 
 10-6 cm s-1. Our data indicate that the absorption of IAVPTGVA, IAVPGEVA, and LPYP is 
low, since the order of magnitude in all Papp values were in the range of 10
-8 cm sec-1. These 
values are in accordance to recent transepithelial transport studies of food derived peptides 
performed in the same model showing very low apparent permeability Papp ranging from 10
-6 
to 10-9 cm sec-1.28, 29 The Papp values of IAVPGEVA and IAVPTGVA were very similar, being 
3.34 ± 0.06 and 2.75 ± 0.08  10-8 cm sec-1, respectively; whereas the Papp of LPYP resulted to 
be slower being equal to 1.41 ± 0.03  10-8 cm sec-1.  The presence of two proline residues may 
most likely hinder its passage through the epithelium.30 
Compared to the values suggested by biopharmaceutical classification system, these Papp values 
appear to be rather low. The permeability may be influenced by at least three independent 
factors: 1) the higher relative tightness of the Caco-2 cell monolayer compared to other more 
relevant physiological systems able to mimic the intestinal barrier; 2) the cytosolic degradation 
by intracellular peptidases during the transport across the Caco-2 monolayer; 3) the equilibrium 
between the absorption process and the degradation of intact peptides by the active endo-
peptidases localized on the cellular brush-border.  
The transepithelial transport of short-chain peptides has been already demonstrated to be very 
low in several in vitro studies,28 suggesting that their efflux across the BL membrane in very 
limited. However, the comparison of the Papp values obtained in different models of intestinal 
absorption points toward an underestimation of Papp in the Caco-2 model due to a higher 
tightness of the Caco-2 cell monolayer compared to the intact mammalian intestinal tissue.31 
Moreover, the variation among the cell-lines used in different labs, the different passage 
number, protocols, or cell seeding densities may lead to a different tightness of the monolayers 
resulting in different permeability.32 For this reason, the comparison between the Papp values 
of these soy peptides and those of other peptides may be controversial.  
Literature reports some cases of peptides with good permeability, such as ovalbumin-derived 
peptides, i.e. YAEERYPIL and YAEER, whose Papp were estimated to be 52  10-6 cm sec-1 
and 84  10-6 cm sec-1, respectively.33 
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Here, the transport mechanisms were not investigated, since to achieve this goal an ex vivo 
model in Ussing chambers would have been more suitable than Caco-2 cells.29 However, 
published data suggest that molecules with a large molecular weight or size are confined to the 
transcellular pathway.34 Indeed, these peptides might be transported by a trans-cytotic route, 
during which the cytosolic peptidase may partially hydrolyze the intact peptides affecting the 
permeability in the BL compartments making, therefore, difficult the measurement of the real 
transport rate of intact peptides.  
In this context, due to the low Papp of these peptides, the second objective of the work was the 
evaluation the susceptibility of IAVPTGVA and IAVPGEVA to the activities of peptidases, 
since it is well known that Caco-2 cells express membrane-bound exo- and endopeptidases.35 
The effect of the metabolic degradation was evaluated at maximum incubation time: a 
remarkable degradation or cellular internalization was observed, since the residual percentages 
of intact IAVPGEVA and IAVPTGVA were estimated to be only 19.2% and 12.9%, 
respectively.  
These octapeptides differ only for a two-amino acids sequence in position 5-6, i.e. TG and GE. 
Our results indicate that this structural diversity greatly influences their susceptibility to the 
metabolic degradation (Figure 5.7A, B). Both undergo the loss of an isoleucine from the N-
terminal, due to the activity of an amino-exopeptidase,36 but at diverse rate, since the metabolite 
released from IAVPGEVA was two-fold more abundant than the metabolite from IAVPTGVA. 
Interestingly, only IAVPTGVA appeared to be susceptible to the action of endopeptidases, 
which resulted in the production of more numerous breakdown fragments. The observed 
differences depend greatly on their structural characteristics: IAVPGEVA is an acidic peptide, 
endowed of -1 net charge, whereas the net charge of IAVPTGVA is 0. Both contain 
predominantly hydrophobic residues and consist of two portions,37 the first of which is 
relatively rigid, because comprises only hydrophobic amino acids (IAVP), while the second is 
a relatively flexible, because it includes glutamic acid in IAVPGEVA and threonine 
IAVPTGVA. The tridimensional structure of these peptides has been investigated by circular 
dichroism (CD) spectra in water-TFE,37 revealing a β-turn II conformation for IAVPGEVA 
and a β-turn I conformation for IAVPTGVA. This structural diversity may be possibly 
responsible for their different stability towards peptidases.  
The second evidence concerns the ability of the breakdown fragments to cross the intestinal 
barrier to reach the BL side. In particular, both breakdown fragments deriving by the loss of 
isoleucine are absorbed with a rate that is probably similar to that of their intact precursor, since 
the relative percentages between the AP and BL compartment are very similar. On the contrary, 
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the two shortest breakdown fragments IAVPT and IAVP are 5-fold and 2.6-fold less abundant 
in BL than in the AP side. Up-to-now, several attempts have been carried out in order to 
establish the correlations between peptide structure and transport,38 but the complex 
characteristics of intestinal transport are not yet completely understood as well as the effects of 
metabolism. However, it is important to consider that the degradation does not determine an 
automatic activity loss. In particular, a recent study has demonstrated how hydrolytic fragments 
derived from meat peptides maintain their activity after cellular transport.39 
In conclusion, this paper provides the first evidence of the transepithelial absorption of three 
soy peptides across Caco-2 cell monolayers. The MS-based approach allowed detecting soy 
peptides as intact compound as well as fragments after absorption across the intestinal Caco-2 
cell model. Of course, we are aware that further research is needed to clarify the transport 
mechanism of the parent peptides and derived metabolites.  
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SUPPLEMENTARY INFORMATION  
Table 5.1S Data of the standard curves. Peptide area averages were obtained by averaging area ratios of replicate (Rep. No) for each 
calibration point (CL). Related standard deviation (SD) and RSD% were reported.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CL = calibration points         
Rep = number of technical replications      A ratio = Area of each replicate / Area of IS 
C (A) = concentration of IAVPGEVA      Average = Average area ratio of a calibration point 
C (B) = concentration of IAVPTGVA       SD = standard deviation 
C (C) = concentration of LPYP       CV% = Coefficient of variations
 STANDARD PEPTIDE CURVES 
CL Rep C (A) IAVPGEVA C (B) IAVPTGVA C (C) LPYP 
 No (ng/mL) Aratio Average SD RSD % (ng/mL) Aratio Average SD RSD % (ng/mL) Aratio Average SD RSD % 
1 1 5 0.686    5 0.064    0.5 0.036    
 2  0.610 0.593 0.103 17.309  0.056 0.061 0.004 6.736  0.026 0.031 0.008 24.421 
 3  0.483     0.062         
2 1 10 0.879    10 0.115    1 0.046    
 2  0.988 0.931 0.055 5.860  0.116 0.112 0.005 4.619  0.051 0.048 0.003 5.356 
 3  0.927     0.106     0.047    
3 1 75 6.136    50 0.801    2 0.064    
 2  6.321 6.057 0.311 5.138  0.697 0.757 0.054 7.074  0.083 0.074 0.009 12.622 
 3  5.714     0.772     0.076    
4 1 100 9.403    150 2.059    5 0.196    
 2  9.574 9.240 0.439 4.754  2.053 2.009 0.081 4.043  0.202 0.200 0.004 1.954 
 3  8.742     1.916     0.203    
5 1 150 13.432    250 3.129    10 0.434    
 2  12.733 13.145 0.366 2.782  2.905 2.824 0.352 12.464  0.384 0.395 0.035 8.921 
 3  13.270     2.439     0.366    
6 1 200 18.599    500 6.844    50 2.109    
 2  20.076 18.816 1.168 6.205  7.217 6.774 0.482 7.110  1.878 2.101 0.220 10.453 
 3  17.772     6.262     2.317    
7 1 250 24.252    1000 11.288     3.807    
 2  22.653 23.447 0.799 3.410  11.811 11.550 0.370 3.203 100 4.579 4.150 0.393 9.482 
 3  23.437          4.063    
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6.0 Abstract 
This paper presents an investigation on hempseed proteome. The experimental approach, based 
on combinatorial peptide ligand libraries (CPLLs), SDS-PAGE separation, nLC-ESI-MS/MS 
identification, and database search, permitted identifying in total 181 expressed proteins. This 
very large number of identifications was achieved by searching in two databases: Cannabis 
sativa L. (56 gene products identified) and Arabidopsis thaliana (125 gene products identified). 
By performing a protein-protein association network analysis using the STRING software, it 
was possible to build the first interactomic map of all detected proteins, characterized by 137 
nodes and 410 interactions. Finally, a Gene Ontology analysis of the identified species 
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permitted to classify their molecular functions: the great majority is involved in the seed 
metabolic processes (41%), responses to stimulus (8%), and biological process (7%). 
Biological significance: Hempseed is an underexploited non-legume protein-rich seed. 
Although its protein is known for its digestibility, essential amino acid composition, and useful 
techno-functional properties, a comprehensive proteome characterization is still lacking. The 
objective of this work was to fill this knowledge gap and provide information useful for a better 
exploitation of this seed. 
 
Keywords: Cannabis sativa, hempseed, interactomic maps, foodomics  
 
6.1 Introduction  
Plant foods are gaining increasing popularity, owing to the growing public awareness of their 
better environmental sustainability in respect to animal foods. Numerous seeds are used in 
human nutrition, but current research is mainly focused on protein-rich ones, such as legumes. 
They provide high quality proteins as well as useful health benefits, particularly in the area of 
cardiovascular prevention (Arnoldi, Boschin, Zanoni, & Lammi, 2015; Arnoldi, Zanoni, 
Lammi, & Boschin, 2015; Bazzano, Thompson, Tees, Nguyen, & Winham, 2011; Lammi, 
Zanoni, Scigliuolo, D'Amato, & Arnoldi, 2014). In the meanwhile, however, other seeds are 
deserving increasing attention.  
Hempseed, i.e. the seed of the non-drug cultivars of industrial hemp, is certainly an 
underexploited protein-rich seed. Although its use as human food dates back probably to 
prehistory, together with the fiber utilization in textiles, the cultivation of this plant has been 
banned for some decades in most developed countries, owing to the morphological similarity 
with marijuana. In fact, hemp and marijuana are both strains of the same species Cannabis 
sativa L. (Sawler, Stout, Gardner, Hudson, Vidmar, Butler, et al., 2015), although they are 
characterized by very different contents of Δ9-tetrahydrocannabinol (THC). The distinction 
between these populations, however, is not limited to the genes underlying THC production, 
since these plants are significantly differentiated at genome-wide level (Sawler, et al., 2015).  
In the last years, however, the cultivation of the non-drug cultivars of industrial hemp is legal 
again in many countries and the global market is rapidly increasing, since well characterized 
low-THC cultivars are available (THC content < 200 mg/kg) (Oomah, Busson, Godfrey, & 
Drover, 2002). Many factors favor the reintroduction of the cultivation of this plant: it is a 
multipurpose crop with numerous applications in different industrial sectors (Vonapartis, 
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Aubin, Seguin, Mustafa, & Charron, 2015) and it is particularly sustainable, since it rarely 
requires irrigation and the fast growth reduces the use of herbicides 
(http://eiha.org/media/2014/10/13-06-European-Hemp-Industry.pdf). 
The great interest for hempseed depends on its nutritional content (whole seed): 35.5% oil, 
24.8% protein, 20-30% carbohydrates, 27.6% total fiber (5.4% digestible and 22.2% non-
digestible fiber) and 5.6% ash (Callaway, 2004). Moreover, the concentration of the main 
antinutritional factors, such as phytic acid, condensed tannins, and trypsin inhibitors, is low 
(Russo & Reggiani, 2015). Currently, the main industrial interest is for the oil that has 
numerous applications either in food or body care products, being rich in polyunsaturated fatty 
acids (Russo & Reggiani, 2015). In the meanwhile, however, there is an increasing attention 
for hempseed protein owing to its digestibility (Wang, Tang, Yang, & Gao, 2008), satisfactory 
essential amino acid composition (Wang, Tang, Yang, & Gao, 2008), and techno-functional 
properties (Malomo & Aluko, 2015; Malomo, He, & Aluko, 2014; Tang, Ten, Wang, & Yang, 
2006).  Moreover, hempseed protein has also potential applications in nutraceutics and 
functional foods, since the treatment with suitable enzymes permits to produce hydrolyzed 
proteins providing useful health benefits, as hypotensive agents (Girgih, Alashi, He, Malomo, 
& Aluko, 2014; Girgih, Alashi, He, Malomo, Raj, Netticadan, et al., 2014; Girgih, He, Malomo, 
Offengenden, Wu, & Aluko, 2014) and antioxidants (Girgih, et al., 2014; Girgih, Udenigwe, 
& Aluko, 2011, 2013).  
Literature indicates that a major protein in hempseed is edestin, a storage protein (Odani, 1998). 
Edestin, a hexameric 11S protein, is easily digested and contains significant amounts of all 
essential amino acids (Callaway, 2004), especially sulfur amino acids (Odani, 1998) and 
arginine (Tang, Ten, Wang, & Yang, 2006).  
Hempseed proteome has been investigated only once in the Korean cultivar Cheungsam (Park, 
Seo, & Lee, 2012): the use of conventional techniques, such as 2-dimensional electrophoresis, 
mass spectrometry, and search in the nr-NCBI protein database permitted to identify 168 
unique protein spots (Park, Seo, & Lee, 2012). However, only one was assigned to C. sativa, 
whereas most of them were assigned to Medicago sativa, Oryza sativa or other plants. The 
current improved availability of genome information about C. sativa as well as the increasing 
interest for this seed prompted us to investigate again hempseed proteome. This research was 
performed on the seeds of the French cultivar Futura. 
In order to get as much as possible a comprehensive information, combinatorial peptide ligand 
libraries (CPLLs) were used for protein equalization (Righetti, Boschetti, Kravchuk, & Fasoli, 
2010; Righetti, Fasoli, & Boschetti, 2011). This is a powerful and highly sensitive technique 
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allowing access to low- and very-low-abundance proteins, which enlarges very much the 
possibility of protein identification. This technique has been applied, for example, to the 
analysis of the proteomes of donkey milk (Cunsolo, Muccilli, Fasoli, Saletti, Righetti, & Foti, 
2011) and champagne (Cilindre, Fasoli, D'Amato, Liger-Belair, & Righetti, 2014), or to the 
detection of corn allergens (Fasoli, Pastorello, Farioli, Scibilia, Aldini, Carini, et al., 2009).  
 
6.2 Materials and Methods 
6.2.1 Chemicals 
ProteoMiner™ (combinatorial hexapeptide ligand library beads, CPLL), Laemmli buffer, 40% 
acrylamide/bis solution, N,N,N′,N′-tetramethylethane-1,2-diamine (TEMED), molecular mass 
standards and electrophoresis apparatus for one-dimensional electrophoresis were from Bio-
Rad Laboratories Inc. (Hercules, CA, US). β-Mercaptoethanol, dithiothreitol (DTT), 
ammonium persulfate, 3-[3-cholamidopropyl-dimethylammonio]-1-propanosulfonate 
(CHAPS), acetonitrile (ACN), trifluoroacetic acid (TFA), sodium dodecyl sulfate (SDS), 
iodoacetamide (IAA), formic acid (FA)  and all other chemicals used in the experimental work 
were pure analytical grade products, purchased from Sigma-Aldrich Corporation (St Louis, 
MO, US). Complete protease inhibitor cocktail tablets were from Roche Diagnostics (Basel, 
CH); modified porcine trypsin from Promega (Madison, WI, USA).  
 
6.2.2 Hempseed proteome extraction and CPLL treatment 
Hempseed (C. sativa cultivar Futura) were kindly provided by Dr. I. Galasso, Institute of 
Agricultural Biology and Biotechnology, CNR (Milan, Italy). In order to prepare defatted flour, 
hempseed were ground with a domestic grinder, added with hexane (1:20 w/v), and kept 
overnight under gentle stirring. The slurry was centrifuged at 10,000 rpm and 4 °C for 40 min 
and the organic solvent was then completely removed by filtration and drying. The protein 
extract (HPE) was obtained from 3 g of defatted flour treating with 30 mL native buffer 
containing 50 mM Tris-HCl (pH 7.2), 50 mM NaCl, 1% m/v CHAPS and protease inhibitor 
cocktail under stirring overnight. The slurry was centrifuged at 9,000 rpm for 10 min to separate 
the insoluble debris from the clarified protein solution. The supernatant was collected and 
centrifuged at 18,500 rpm for 30 min. The protein was precipitated with 20% TCA in water on 
ice for 1 h and then centrifuged at 9,000 rpm for 30 min. The resulting pellet was dissolved in 
15 mL of 50 mM Tris-HCl (pH 7.2), 50 mM NaCl, and 1% w/v CHAPS and directly submitted 
 106 
 
to analysis (raw sample). Protein concentrations were determined using the Bradford assay 
reagent (Bio-Rad, Laboratories Inc, CA, US) with bovine serum albumin as the standard. The 
absorbance of the standards and unknown sample was determined at 595 nm and it was 
estimated to be 8.4 µg/µL. In parallel, this solution was treated with CPLLs for protein 
equalization. The first protein capture was performed overnight in batch mode at pH 7.2 using 
50 µL of ProteoMiner at room temperature under gentle rocking. The second capture was 
conducted consecutively on the same sample: the treatment with 50 µL of ProteoMiner was 
performed at pH 2.2 after addition of 0.1% v/v TFA and formic acid. Beads of both captures 
were recovered by filtering with Micro Bio-Spin chromatographic columns (Bio-Rad) under 
vacuum and then washed twice with their buffer in order to eliminate unbound protein excesses. 
The captured proteins from each sample were desorbed (twice, the former time with 50 µL, the 
latter with 40 µL) with an extraction buffer containing 4% w/v SDS and 20 mM DTT  for 15 
min, under boiling conditions (Candiano, Dimuccio, Bruschi, Santucci, Gusmano, Boschetti, 
et al., 2009). The procedure was repeated twice and each of these replicates was submitted to 
the following procedures. 
 
6.2.3 SDS-PAGE Analysis 
Five microliters of each CPLL eluate (labelled as E2.2 and E7.2, respectively) and the untreated 
sample (raw) dissolved in Laemmli buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 
0.004% bromophenol blue, and 0.125 M Tris–HCl, pH 6.8) were loaded onto the SDS-PAGE 
gel. The gel was composed by a 4% polyacrylamide stacking gel over a 12% resolving 
polyacrylamide gel. The cathodic and anodic compartment were filled with Tris–glycine 
buffer, pH 8.3, containing 0.1%, m/v, SDS. The electrophoresis was conducted at 100 V until 
the dye front reached the gel bottom. Staining was performed with colloidal Coomassie Blue 
and destaining with 7% (v/v) acetic acid in water. The three sample lanes (E2.2, E7.2 and Raw) 
of the SDS-PAGE gels were manually cut in 10 slices along the gel migration path and 
subjected to the standard procedure of reduction and alkylation, followed by trypsin digestion 
(Cunsolo, Muccilli, Fasoli, Saletti, Righetti, & Foti, 2011). The recovered peptides were 
lyophilized and then dissolved in 10 μL water/acetonitrile (99:1 v/v) added with 0.1% FA. 
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6.2.4 Mass spectrometry and Data Analysis  
Mass spectrometry data were acquired on a SL series Ion Trap mass spectrometer interfaced 
with a HPLC-Chip Cube source (Agilent Technologies, Palo Alto, CA, USA). The 
chromatographic separations of tryptic digests were performed on a LC-chip containing a 40 
nL enrichment column (Zorbax 300SB-C18, 5 µm pore size), a 43 mm x 75 µm analytical 
column packed (Zorbax 300SB-C18, 5 µm pore size) capillary tubing connections and a nano-
electrospray needle. The reconstituted sample (1 µL) was loaded onto the enrichment column 
at a flow rate 4 µL/min for 2 min using isocratic 100% C solvent phase (99% water, 1% ACN 
and 0.1% FA). After cleanup, the chip valve was switched to separation and trapped peptides 
were eluted into the mass spectrometer at the constant flow rate of 0.3 µL/min. The LC solvent 
A was 95% water, 5% ACN, 0.1% formic acid; solvent B was 5% water, 95% ACN, 0.1% 
formic acid. The nano-pump gradient program was as follows: 5% solvent B (0 min), 50 % 
solvent B (0-50 min), 95% solvent B (50-60 min) and back to 5% in 10 min to re-equilibrate 
the column. The nano-ESI source operated under the following conditions: drying gas 
temperature 300 °C, flow rate 3 L/min (nitrogen), capillary voltage 1950 V, with endplate offset 
-500V. Mass spectra were acquired in positive ionization mode, in the mass range from m/z 
300-2200, with target mass 700 m/z, average of 2 spectra, ICC target 30,000 and maximum 
accumulation time 150 msec. The detection of cationic peptide ions was performed by data 
dependent acquisition Auto MS(n) mode with a dynamic exclusion set at 2 spectra and released 
after 0.1 min. Each sample was analysed twice. 
The MS/MS spectra was analysed by Spectrum Mill MS Proteomics Workbench (Rev B.04.00, 
Agilent technology). MS/MS search, concatenated with the reverse one, was conducted against 
the subset C. sativa and Arabidopsis thaliana protein sequences database, downloaded from 
the National Center for Biotechnology Information (NCBI) containing 531 and 229,367 
entries, respectively. In addition, it was conducted also against the UniProtKB database 
(containing 182 and 83,307 entries respectively for C. sativa and A. thaliana) including 
sequences derived from Swiss-Prot and TrEMBL (Translated EMBL Nucleotide Sequence 
Data Library). The cysteine carbamidomethylation was set as fixed modification, whereas 
oxidation of methionine and transformation of N-terminal glutamic acid residues in the 
pyroglutamic acid were included as variable modifications. Trypsin was chosen as digestive 
enzymes, 2 missed cleavage were allowed; peptide mass tolerance was set to 2.5 Da, fragment 
mass tolerance to 0.7 Da; Local False Discovery Rate  ≤ 0.1%. The threshold used for peptide 
identification was Score Peak Intensity % ≥ 70%, accepting only peptides with the difference 
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between forward and reverse scores ≥ 2. Proteins were considered detected, if they were 
identified by at least two peptides. The Table 6.1S (A, B, C) (Supporting Information) reports 
a list of all identified proteins, MS/MS scores, sequence coverages, and number of unique 
peptides.  
The software STRING (Search Tool for the Retrieval of Interacting Genes, v.10 web server, 
http://stringdb.org/) (Jensen, Kuhn, Stark, Chaffron, Creevey, Muller, et al., 2009), set on A. 
thaliana as organism database, was used to generate a functional association network of the 
potentially interacting proteins. The pathways classification was performed after the automatic 
enrichment in STRING, based on the information provided by the KEGG-Pathway Database. 
The assignment of biological processes, cellular components, and molecular functions of 
identified proteins was performed using the web available software QuickGo 
(www.ebi.ac.uk/QuickGo). 
 
6.3 Results and Discussion  
6.3.1 Protein identification 
The workflow adopted for a comprehensive proteome discovery included proteome extraction, 
pre-fractionation via CPLL technology, protein separation by SDS-PAGE electrophoresis, and 
characterization by MS analysis. Figure 6.1 shows the SDS-PAGE profiles of the untreated 
sample (raw) versus those of the CPLL eluates after capture at two different pH values, i.e. pH 
7.2 and 2.2 (lanes labelled as E7.2 and E2.2, respectively). The two latter profiles were more 
resolved, more intense and with improved densities in respect to the raw sample, which showed 
a series of poorly resolved bands, distributed in the mass regions from 10 to 20 kDa. Therefore, 
the CPLL treatment had a very positive contribution on protein capture, making more visible 
the bands in the range 50-75 kDa for eluate E7.2 and those in the range 10-50 kDa for eluate 
E2.2. The fact that eluate E7.2 exhibits a separation pattern different from eluate E2.2 is not 
surprising, since the capture efficiency strongly depends on the ionic environment. 
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Figure 6.1 - SDS-PAGE profiles of the untreated (raw) sample versus the eluates of CPLL capture 
at the two pH values (lanes E7.2, E2.2). Each lane was cut into segments, the proteins digested, and 
submitted to MS analysis. Mr: molecular mass ladder. Staining with micellar Coomassie blue. 
 
 
The MS Analysis, as reported in Table 6.1, reveals the total number of identified proteins using 
Spectrum Mill search engine against two different database search, i.e. C. sativa and A. 
thaliana. Although the C. sativa database would be the most appropriate for identifying 
species-specific gene products, it suffers from the inherent limitation due to an incompletely 
sequenced DNA (only 531 entries). In order to overcome this inadequacy and to expand the 
dataset of identified proteins, also the A. thaliana database research was performed. The use of 
this very common database is justified by the phylogenetic proximity of these species: in fact, 
C. sativa, species belonging to the family of Cannabaceae, shows a close phylogenetic 
relationship to A. thaliana (Brassicaceae) since both belong to the same Rosidae subclass. 
Moreover, the very high number of entries (229,367) contained in NCBI protein sequence 
database makes A. thaliana the species chosen by most plant biologists as a model organism to 
analyse plant gene expression as well as plant development. In conjunction with CPLL capture, 
this procedure allowed the identification of 56 species-specific gene products plus other 125 
gene products identified by homology to the model species A. thaliana. Recognizing in total 
181 unique gene products, these findings represent a main improvement in the exploration of 
the hempseed proteome in respect to the previous investigations. Among the entities identifies 
through the database of C. sativa, this work provided the first experimental detection of the 
two isoforms of edestin, i.e. Ede1 and Ede2, which had been previously deduced at gene levels 
(Docimo, Caruso, Ponzoni, Mattana, & Galasso, 2014). Edestin does not appear in the protein 
entities previously identified (Park, Seo, & Lee, 2012). 
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Figure 6.2 - Venn diagrams of the total number of identified species in the raw extract of 
hempseed versus those detected in all eluates after CPLL treatment considering both database. 
The IDs in the raw sample consist of 39 unique gene products assigned to the C. sativa database, 
whereas 78 unique gene products were assigned to A. thaliana database. The contribution to the total 
identifications of the eluates from the pH 2.2 and 7.2 CPLL captures are the following: 6 unique proteins 
were identified at pH 2.2 and 1 at pH 7.2 for C. sativa, whereas 22 unique proteins were detected at pH 
2.2 and 6 at pH 7.2 for A. thaliana.  
 
The relative contribute in terms of MS-recognized proteins carried out by protein equalization 
is represented by Venn diagrams (Figure 6.2), which compare the proteins identified in the 
combined CPLLs eluates with those of the untreated extracts, considering both databases 
searches. The efficiency of CPLL treatment allowed the detection of 17 unique proteins of C. 
sativa and 47 of A. thaliana after CPLL treatment. This technology permitted a 55% increment 
in the proteome discovery, attributed to minor proteins of HPEs, unrevealed without the CPLL 
treatment. The high efficiency is due to the use of a native buffer devoid of ionic and chaotropic 
detergents, such as SDS or urea, which could prevent the successful interaction between 
proteins and ligand peptides on the beads. However, it must be underlined that these mild 
conditions did not allow extracting highly hydrophobic proteins, which may be considered a 
limitation of this approach. The outstanding result of the equalization is also due to the different 
pH conditions in which the sample was incubated with CPLLs, initially under physiological 
condition at pH 7.2 and afterwards at pH 2.2, leading to the identification of 11 and 17 protein 
species, respectively, using the C. sativa database search. The most efficient capture occurred 
at pH 2.2. This observation implies the extensive hydrophobic interactions occurring at low pH 
between proteins and the hexapeptide ligands that are very similar to reverse-phase 
chromatography based interactions.  
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Table 6.1 Identified proteins from hempseed raw, pH 2.2, and 7.2 samples 
N. Acc. N.  Identified proteins (gene name) a Taxonomy MW (kDa) Sample 
1 A7IZZ2 (+)-alpha-pinene synthase, (N/A) b C. sativa 72.4 E2.2 - E7.2 - Raw 
2 A7IZZ1 (-)-limonene synthase (TPS1) C. sativa 72.9 E2.2 - E7.2 
3 H9A1V3 Acyl-activating enzyme 1 (N/A) C. sativa 80.5 E2.2 - E7.2 
4 H9A1V4 Acyl-activating enzyme 2 (N/A) C. sativa 75.1 E2.2 - Raw 
5 H9A1V5 Acyl-activating enzyme 3 (N/A) C. sativa 59.7 Raw 
6 H9A1V8 Acyl-activating enzyme 6 (N/A) C. sativa 62.9 Raw 
7 H9A1V9 Acyl-activating enzyme 7 (N/A) C. sativa 67.2 E2.2 - Raw 
8 H9A1W1 Acyl-activating enzyme 9 (N/A) C. sativa 62.2 E2.2 - Raw 
9 H9A1W3 Acyl-activating enzyme 11 partial (N/A) C. sativa 37.2 E2.2 - E7.2 
10 H9A8L1 Acyl-activating enzyme 12 (N/A) C. sativa 84.4 E2.2 - Raw 
11 H9A8L2 Acyl-activating enzyme 13 (N/A) C. sativa 79.6 E2.2 - Raw 
12 H9A8L3 Acyl-activating enzyme 14 (N/A) C. sativa 81.2 Raw 
13 H9A8L4 Acyl-activating enzyme 15 (N/A) C. sativa 87.8 E7.2 – Raw 
14 A0A0C5APY2 Acetyl-CoA carboxylase carboxyltransferase beta subunit (accD) C. sativa 57.0 E2.2 - E7.2 - Raw 
15 A0A0C5ARS5 ATP synthase CF1 beta subunit (atpB) C. sativa 53.8 E2.2 
16 E5DK51 Atp1 partial (atp1) C. sativa 37.7 E2.2 
17 I6XT51 Betv1-like protein (N/A) C. sativa 17.6 E2.2 
18 A0A0E3TJM8 Cannabidiolic acid synthase homolog (CBDAS2) C. sativa 62.7 E2.2 - E7.2 
19 C6KI62 Chalcone synthase-like protein 1 (CAN383) C. sativa 43.4 E2.2 - E7.2 - Raw 
20 I6WIE9 Chalcone isomerase-like protein (N/A) C. sativa 23.9 E7.2 - Raw 
21 A0A0C5ARS7 Chloroplast envelope membrane protein (cemA) C. sativa 27.5 E7.2 
22 P00053 Cytochrome c (N/A) C. sativa 12.2 Raw 
23 A0A088MFF4 Delta 12 desaturase (FAD2A) C. sativa 44.9 Raw 
24c A0A090DLH8, 
A0A090CXP7  
Edestin 1 (ede1A.ede1C), Edestin 1 (ede1B) C. sativa 58.8 E2.2 - E7.2 - Raw 
25 A0A090CXP9 Edestin 2 (ede2A) C. sativa 56.0 E2.2 - E7.2 - Raw 
26d A0A090DLI7, 
A0A090CXP8 
Edestin 2 (ede2B), Edestin 2 (ede2C) C. sativa 56.0 E2.2 - E7.2 - Raw 
27 A0A0C5APZ4 Hypothetical chloroplast RF21 (ycf2) C. sativa 272.8 E2.2 - E7.2 - Raw 
28 A0A0C5AUH7 Hypothetical chloroplast RF34 (ycf3) C. sativa 19.7 E7.2 - Raw 
29 L0N5C8 Hypothetical protein (N/A) C. sativa 61.7 E2.2 - E7.2 
30 E5DKP2 MatR. Partial (matR) C. sativa 60.1 E7.2 - Raw 
31 A0A0C5AUE3 Maturase K (matK) C. sativa 61.0 Raw 
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32 A0A0C5AUJ6 NADH-plastoquinone oxidoreductase subunit 5 (ndhF) C. sativa 86.0 E2.2 
33 A0A0C5AS19 NADH-plastoquinone oxidoreductase subunit 7 (ndhH) C. sativa 45.7 E2.2 - E7.2 - Raw 
34 E5DL82 NADH dehydrogenase subunit 5 partial (nad5) C. sativa 39.9 E2.2 - E7.2 - Raw 
35 V5KWZ6 Phenylalanine ammonia lyase (PAL) C. sativa 77.6 E2.2 - E7.2 - Raw 
36 A0A0C5AUH1 Photosystem II CP43 chlorophyll apoprotein (psbC) C. sativa 52.0 E2.2 - E7.2 
37 A9XV91 Photosystem II CP47 chlorophyll apoprotein. partial (psbB) C. sativa 53.8 E2.2 - Raw 
38 F1LKH7 Polyketide synthase protein (PKSG2) C. sativa 43.1 Raw 
39 U6EFF4 Putative LysM domain containing receptor kinase (lyk2) C. sativa 66.6 E2.2 - E7.2 - Raw 
40 A0A0C5AS13 Ribosomal protein L2 (rpl2) C. sativa 30.1 E2.2 - E7.2 - Raw 
41 A0A0C5AUJ2 Ribosomal protein L16 (rpl16) C. sativa 13.4 E2.2 - E7.2 
42 A0A0C5AS20 Ribosomal protein L23 (rpl23) C. sativa 10.7 E2.2 - Raw 
43 A0A0C5ART6 Ribosomal protein S3 (chloroplast) (rps3) C. sativa 17.8 E2.2 - E7.2 - Raw 
44 E5DLX2 Ribosomal protein S3. partial (mitochondrion) (rps3) C. sativa 57.3 E2.2 - E7.2 - Raw 
45 A0A0C5ARS4 Ribosomal protein S4 (rps4) C. sativa 23.7 E2.2 - Raw 
46 A0A0C5ARU3 Ribosomal protein S7 (rps7) C. sativa 17.4 E2.2 
47 A0A0C5APY7 Ribosomal protein S8 (rps8) C. sativa 15.5 E2.2 - Raw 
48 A0A0C5ART4 Ribosomal protein S11 (rps11) C. sativa 15.0 E2.2 
49 A0A0C5AUK1 Ribosomal protein S15 (rps15) C. sativa 10.9 E2.2 - E7.2 - Raw 
50 A0A0C5ART1 Ribosomal protein S18 (rps18) C. sativa 12.0 E2.2 - E7.2 
51 A0A0C5B2I6 Ribulose 1.5-bisphosphate carboxylase/oxygenase large subunit (rbcL) C. sativa 53.3 E2.2 - E7.2 - Raw 
52 I0B4C2 Ribulose-1.5-bisphosphate carboxylase/oxygenase large subunit.partial (rbcL) C. sativa 24.4 E2.2 - E7.2 
53 A0A0C5AUI9 RNA polymerase alpha subunit (rpoA) C. sativa 38.3 E7.2 – Raw  
54 A0A0C5ARQ8 RNA polymerase beta subunit  (rpoB) C. sativa 121.6 E2.2 - E7.2  
55 A0A0C5ARX9 RNA polymerase beta' subunit (rpoC2) C. sativa 159.4 E2.2 - E7.2 - Raw 
56 I1V0C2 Tetrahydrocannabinolic acid synthase. partial (N/A) C. sativa 62.3 E2.2 - Raw 
57 Q0WNZ5 5-methyltetrahydropteroyltriglutamate (MS3) A. thaliana 91.0 Raw 
58 O23058 A_IG005I10.23 protein (A_IG005I10.23) A. thaliana 88.7 E2.2 - E7.2 
59 Q42560 Aconitate hydratase 1 (ACO1) A. thaliana 98.8 E2.2 - Raw 
60 C0SVH8 Acyl-CoA N-acyltransferase with RING/FYVE/PHD-type zinc finger protein 
(At4g14920)  
A. thaliana 129.2 E2.2 - Raw 
61 P92935 ADP.ATP carrier protein 2 (AATP2) A. thaliana 67.9 E2.2 - E7.2 
62 O22241 Arogenate dehydratase 4 (ADT4) A. thaliana 46.4 E7.2 
63 Q9M8K5 AT3g06130/F28L1_7 (F28L1.7) A. thaliana 49.4 E2.2 - Raw 
64 Q9FG23 At5g06830 (At5g06830) A. thaliana 62.2 Raw 
65 B9DG14 AT5G41100  (At5g41100) A. thaliana 65.2 E7.2 
66 Q8VZF6 AT5g45560/MFC19_23 (EDR2L) A. thaliana 82.6 E7.2 - Raw 
 113 
 
67 F4J394 ATP binding microtubule motor family protein (At3g51150) A. thaliana 120.1 E2.2 - E7.2 
68 F4IMB5 ATPase. F1 complex. alpha subunit protein (At2g07698) A. thaliana 86.3 E2.2 - Raw 
69 Q8L7G0 Auxin response factor 1 (ARF1) A. thaliana 74.3 Raw 
70 Q38810 cDNA-5-encoded protein. partial (N/A) A. thaliana 33.1 E2.2 - E7.2 
71 Q9C9U2 Cell division protein kinase (CDKD-1) A. thaliana 45.3 E7.2 - Raw 
72 O80891 Cellulose synthase-like protein B4 (CSLB4) A. thaliana 86.2 E2.2 
73 Q9SB75 Cellulose-synthase-like C5 (CSLC5) A. thaliana 80.1 E2.2 - Raw 
74 Q9LIM5 Chloroplast protein HCF243 (hcf243) A. thaliana 76.8 E2.2 
75 O80458 Cis-prenyltransferase (DPS) A. thaliana 35.3 E2.2 - Raw 
76 Q8VY07 Clathrin binding protein-like (EPSIN1) A. thaliana 62.7 Raw 
77 Q9FKV9 Cyclin-dependent protein kinase-like protein (At5g44290) A. thaliana 73.6 E2.2 - Raw 
78 Q9SB89 DEAD-box ATP-dependent RNA helicase 27 (RH27) A. thaliana 72.3 Raw 
79 Q8GXD6 DEAD-box ATP-dependent RNA helicase 49 (RH49) A. thaliana 63.4 E7.2 
80 Q38K61 Disease resistance protein. Partial (At4g10780) A. thaliana 31.6 E2.2 
81 Q19DM3 Disease resistance protein. Partial (At5g44870) A. thaliana 25.7 E2.2 
82 X2L4T4 DM2D (N/A) A. thaliana 140.0 Raw 
83 Q42572 DNA ligase 1 (LIG1) A. thaliana 94.2 E7.2 - Raw 
84 Q9FNI6 DNA repair protein RAD5 protein (At5g22750) A. thaliana 115.6 E7.2 
85 F4JRX3 DNA topoisomerase. type IA. core (At4g31210) A. thaliana 142.4 E7.2 - Raw 
86 F4I5J7 DNAJ heat shock N-terminal domain-containing protein (At1g77020) A. thaliana 43.0 E2.2 - Raw 
87 O04478 Endoglucanase 7 (KOR2) A. thaliana 70.1 E2.2 - E7.2 - Raw 
88 P42762 Erd1 protein precursor (CLPD) A. thaliana 103.7 E2.2 - Raw 
89 O23026 EST gb|T04104 comes from this gene/T1G11.16 protein (T1G11.16) A. thaliana 45.3 E2.2 - Raw 
90 Q76E23 Eukaryotic translation initiation factor 4G (EIF4G) A. thaliana 188.7 E2.2 - Raw 
91 Q8S905 F15H18.12 (NACK1) A. thaliana 114.6 E2.2 - Raw 
92 Q9SSQ2 F6D8.29 (At1g52490) A. thaliana 50.6 Raw 
93 Q9SHM9 F7F22.11 (N/A) A. thaliana 70.2 E7.2 - Raw 
94 O81490 F9D12.11 protein  (F9D12.11) A. thaliana 151.0 E2.2 
95 Q9SA52 g5bf  (CSP41B) A. thaliana 42.9 E7.2 - Raw 
96 Q9T0F7 Glucuronoxylan 4-O-methyltransferase 2 (GXM2) A. thaliana 33.4 E7.2 
97 C0Z2I0 Glyceraldehyde-3-phosphate dehydrogenase (At1g13440) A. thaliana 37.6 Raw 
98 Q94FQ0 Glycine-rich protein GRP17 (N/A) A. thaliana 53.4 E7.2 - Raw 
99 F4IAH9 Glyoxalase I homolog (GLX1) A. thaliana 36.5 E2.2 - Raw 
100 Q8S8N9 Golgin candidate 1 (GC1) A. thaliana 79.9 E7.2 
101 F4IVL6 Gravitropism defective 2  (GRV2) A. thaliana 281.4 Raw 
102 Q56X77 Guanylate kinase (At2g41880) A. thaliana 23.4 E2.2 
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103 Q9LKR3 Heat shock 70 kDa protein 11 (MED37A) A. thaliana 73.9 E7.2 - Raw 
104 O65719 Heat shock 70 kDa protein 4 (MED37C) A. thaliana 71.6 E2.2 - E7.2 - Raw 
105 Q9LHA8 Heat shock 70 kDa protein 5 (HSP70-5) A. thaliana 71.5 E7.2 - Raw 
106 Q9S9N1 Heat shock protein 60-3A (At3g13860) A. thaliana 71.3 E7.2 - Raw 
107 Q93ZM7 Heat shock protein 70-3 (HSP70-3) A. thaliana 60.8 E2.2 - E7.2 - Raw 
108 Q56XE8 Hexokinase-4 (At3g20040) A. thaliana 55.3 E2.2 - E7.2 
109 Q6NR90 Histone H4 (At1g07660) A. thaliana 11.4 Raw 
110 O48701 Hypothetical protein (F3I6.28) A. thaliana 79.0 E2.2 - Raw 
111 Q84MA1 Hypothetical protein (At1g06560) A. thaliana 66.4 E2.2 
112 Q9ZQQ4 Hypothetical protein (At2g14410) A. thaliana 76.9 E7.2 - Raw 
113 Q9S755 Hypothetical protein (F3L24.2) A. thaliana 22.5 E2.2 - E7.2 
114 O81893 Inositol-tetrakisphosphate 1-kinase 2 (ITPK2) A. thaliana 44.4 E2.2 - Raw 
115 O82762 KH domain-containing protein (At2g25970) A. thaliana 64.7 E2.2 - E7.2 
116 G4WT86 Late flowering protein (FRI) A. thaliana 68.8 E2.2 - Raw 
117 Q5XF33 Magnesium-chelatase subunit ChlI-2 (CHLI2) A. thaliana 47.0 E2.2 - Raw 
118 Q9FNB0 Magnesium-chelatase subunit H (CHLH) A. thaliana 154.0 E2.2 - E7.2 - Raw 
119 Q84M98 Meiotic endonuclease 1A (EME1A) A. thaliana 62.1 E2.2 - E7.2 
120 Q9SG92 Methylesterase 17 (MES17) A. thaliana 31.2 E2.2 
121 Q9FLR3 No apical meristem (NAM) -like protein (NAC080) A. thaliana 37.8 Raw 
122 O48689 Paired amphipathic helix repeat-containing protein (F3I6.15) A. thaliana 85.9 E2.2 - Raw 
123 O80958 Pentatricopeptide repeat protein (LOJ)  A. thaliana 98.5 E2.2 - Raw 
124 Q9ZVX5 Pentatricopeptide repeat-containing protein (At2g16880) A. thaliana 84.6 E2.2 
125 Q84TI3 PHD-finger TITANIA 2 (OBE4) A. thaliana 132.4 E2.2 - E7.2 
126 Q8LFV7 Phosphoglycerate kinase (N/A) A. thaliana 42.2 E2.2 - E7.2 - Raw 
127 Q9XIE6 Phospholipid-transporting ATPase 3 (ALA3) A. thaliana 139.2 E2.2 
128 Q9M8D3 Phosphoribosylformylglycinamidine synthase (At1g74260) A. thaliana 155.3 E2.2 
129 Q8S8D3 Phox (PX) domain-containing protein (At2g25350) A. thaliana 73.1 E7.2 - Raw 
130 F4K7T1 P-loop containing nucleoside triphosphate hydrolases superfamily protein (t5g62760) A. thaliana 74.6 E2.2 
131 Q0WR59 Probable inactive receptor kinase (At5g10020)  A. thaliana 115.7 E2.2 - Raw 
132 Q42290 Probable mitochondrial-processing peptidase subunit beta (At3g02090) A. thaliana 59.7 E2.2 - E7.2 
133 Q9C533 Probable protein S-acyltransferase 22 (PAT22) A. thaliana 67.0 E7.2 - Raw 
134 P59583 Probable WRKY transcription factor 32 (WRKY32) A. thaliana 52.2 E2.2 - Raw 
135 O81147 Proteasome subunit alpha type-6-B (PAA2) A. thaliana 27.5 E2.2 - E7.2 
136 P0C7Q8 Protein (DA1) A. thaliana 61.5 Raw 
137 Q8VZG2 Protein HYPER-SENSITIVITY-RELATED 4  (HSR4) A. thaliana 66.4 Raw 
138 O49610 Protein kinase-like (M4E13.90) A. thaliana 52.6 E2.2 - Raw 
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139 F4J8K6 Protein ribosomal RNA processing 5 (At3g11964) A. thaliana 213.0 Raw 
140 Q66GI4 Proteinaceous RNase P 1 (PRORP1) A. thaliana 65.8 E7.2 - Raw 
141 Q3EAS6 Putative DNA repair protein recA homolog 4 (At3g32920) A. thaliana 24.5 E2.2 - E7.2 
142 Q84W97 Putative kinesin (At2g47500) A. thaliana 109.3 E2.2 - E7.2 
143 Q9LR53 Putative protein kinase (At1g03740) A. thaliana 84.9 E2.2 - E7.2 
144 Q8VZQ9 Putative protein (REM3) A. thaliana 117.0 E2.2 
145 Q9SU68 Putative protein (T17F15.80) A. thaliana 173.3 E2.2 
146 Q93YS2 Putative protein phosphatase 2C 51 (At3g63340) A. thaliana 120.9 E2.2 - Raw 
147 Q9ZQE9 Putative retroelement pol polyprotein (At2g15650) A. thaliana 156.3 E7.2 - Raw 
148 F4IF81 Putative serine/threonine protein kinase  (At1g79640) A. thaliana 76.9 E2.2 - E7.2 - Raw 
149 Q9SIL1 Putative TNP1-like transposon protein (At2g12390) A. thaliana 110.7 E2.2 - E7.2 - Raw 
150 Q8L622 Putative uncharacterized protein (At5g45030) A. thaliana 66.2 E2.2 
151 A0MEZ6 Putative uncharacterized protein (N/A) A. thaliana 16.0 E2.2 - Raw 
152 F4K4D6 PWWP domain-containing protein (At5g27650) A. thaliana 118.4 E2.2 
153 Q9FGN6 Receptor-like kinase MOL1 (LRR-RLK) A. thaliana 100.0 E2.2 
154 P17094 Ribosomal protein (ARP1) A. thaliana 44.8 Raw 
155 F4KE59 RING/FYVE/PHD zinc finger-containing protein (At5g16680) A. thaliana 143.6 E2.2 - Raw 
156 Q9LJX4 RNA binding protein-like (APUM5) A. thaliana 107.7 E2.2 
157 Q5D869 RNA polymerase IV largest subunit (NRPE1) A. thaliana 220.4 E2.2 - E7.2 
158 B0LC03 RPS2 (rps2) A. thaliana 106.1 E2.2 - Raw 
159 F4J3S1 Shugoshin C terminus (At3g10440) A. thaliana 64.5 E2.2 - Raw 
160 Q9FWR3 Similar to tRNA-splicing endonuclease positive effector SEN1  (F17F16.1) A. thaliana 242.4 E2.2 - E7.2 
161 F4JXC5 Subtilisin-like protease SBT5.4 (SBT5.4) A. thaliana 84.1 E2.2 - Raw 
162 O82496 T12H20.15 protein (T12H20.15) A. thaliana 81.5 E2.2 - E7.2 - Raw 
163 Q9LQ91 T1N6.6 (T1N6.6) A. thaliana 96.4 E2.2 - Raw 
164 Q9LPA7 T32E20.13 (N/A) A. thaliana 156.5 E2.2 - Raw 
165 Q9SCZ3 TIR-NBS-LRR class disease resistance protein (F26O13.200) A. thaliana 142.8 E2.2 - E7.2 
166 O04251 Transcription coactivator protein (At4g02110) A. thaliana 146.9 E2.2 
167 Q9LHE4 Transcription factor-like protein (At3g20010) A. thaliana 116.7 E2.2 - E7.2 - Raw 
168 Q9SSP7 Ubiquitin carboxyl-terminal hydrolase-related protein (F6D8.35) A. thaliana 131.5 Raw 
169 Q56Y19 Uncharacterized protein (At2g43235) A. thaliana 49.1 E2.2 - E7.2 
170 Q8S8L1 Uncharacterized protein (At2g24255) A. thaliana 38.5 E2.2 - Raw 
171 Q9FHT3 Uncharacterized protein (At5g37320) A. thaliana 55.3 E2.2 
172 F4K4M9 Uncharacterized protein (At5g43230) A. thaliana 95.0 Raw 
173 Q9FH23 Uncharacterized protein (N/A) A. thaliana 168.2 E2.2 - Raw 
174 Q9LXU4 Uncharacterized protein (T24H18_120) A. thaliana 96.7 E2.2 - E7.2 
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175 Q9FHW3 Unnamed protein product (N/A) A. thaliana 14.8 E7.2 - Raw 
176 P93736 Valine--tRNA ligase (TWN2) A. thaliana 127.7 E2.2 - Raw 
177 Q94BQ3 WD and tetratricopeptide repeats protein 1 (At5g10940) A. thaliana 84.9 Raw 
178 F4HZB2 WD/BEACH domain protein SPIRRIG (SPI) A. thaliana 404.3 E2.2 - Raw 
179 P56785 ycf1 (TIC214) A. thaliana 214.8 Raw 
180 O64533 YUP8H12R.20 (YUP8H12R.209 A. thaliana 150.3 Raw 
181 O49281 Zinc finger protein (F22K20.5) A. thaliana 122.6 E2.2 
 
a) According to “UniProtKB” (http://www.uniprot.org/) 
b) N/A: not available 
c) Not unique  identification  of  Edestin 1 (ede1A.ede1C)  and Edestin 1 (ede1B) 
d) Not unique  identification  of  Edestin 2 (ede2B) and  Edestin 2 (ede2C) 
 
 117 
 
6.3.2 Protein-protein association network analysis 
In order to forecast protein-protein relations among all identified protein species, an 
interactomic network was obtained using the open-access STRING Software. Many protein–
protein associations in STRING are based on systematic genome comparisons focused on 
conserved genomic neighborhoods, gene fusion events, and co-occurrence of genes across 
genomes. From a functional perspective, ‘association’ can mean direct physical binding as well 
as indirect interaction, such as participation in the same metabolic pathway or cellular process 
(von Mering, Jensen, Snel, Hooper, Krupp, Foglierini, et al., 2005). Using A. thaliana as 
reference organism, this paper provides the first interactomic map for C. sativa, showing in 
total 137 nodes connected by 410 interactions, some of which are characterized by narrow and 
dense connections (see Figure 6.1S in Supporting Information).  
With the aim of grouping the interactions between the different proteins identified, cluster 
networks were created by using the K-means algorithm, which is included in the STRING 
website, selecting a value of 5 for the analysis (Figure 6.3). Hempseed protein network was 
characterized by five groups, among which the most compact was integrally constituted by 
ribosomal proteins (RPS7, RPS8, RPS11, rps15), whereas the others were characterized by 
genes involved in embryo development, vegetative growth, glucose sensing during plant 
development (GAPC2, TPS1, ERD1), and the kinase activity (LYK2, GK-1).  
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Figure 6.3 - Protein-protein interactomic network of the hempseed obtained by clustering K-
MEANS using STRING software. Different coloured edges represent the existence of different types 
of evidence. A green line indicates neighbourhood evidence; a blue line, concurrence evidence; a purple 
line, experimental evidence.  
 
Furthermore, in order to investigate biomolecular pathway maps, the KEGG-Pathway 
Enrichment was obtained by STRING (Table 6.2). Confirming our gene ontology results, this 
procedure revealed that established pathways include energy metabolism, carbohydrate, lipid 
and nucleotide metabolism, as well as amino acid metabolism and biosynthesis. The richest 
category is attributable to metabolic processes, representing 67.1% of all analysed proteome 
dataset. The second most populated one is related to genetic information processes (37.1%), 
including proteins involved in DNA transcription, translation, and replication and repair 
activities. Mainly ribosomal proteins, the most expressed proteins in our dataset, belong to this 
group.  
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Table 6.2 KEGG-Analysis achieved using STRING software: list of established pathways 
and number of genes in which they are involved.  
 
KEGG-Pathways N. of genes 
Metabolic pathways (67.1%)  
Carbohydrate metabolism  
   Pyruvate metabolism 2 
   Starch and sucrose metabolism 2 
   Glyoxylate and dicarboxylate metabolism 1 
   Fructose and mannose metabolism 1 
   Galactose metabolism 1 
   Glycolysis / Gluconeogenesis 1 
   Propanoate metabolism 1 
   Inositol phosphate metabolism 1 
   Amino sugar and nucleotide sugar metabolism 1 
Energy metabolism  
   Oxidative phosphorylation 4 
   Photosynthesis 3 
   Carbon fixation in photosynthetic organisms 1 
Lipid metabolism  
   Fatty acid biosynthesis 1 
   Fatty acid metabolism 1 
Nucleotide metabolism  
   Purine metabolism 5 
   Pyrimidine metabolism 3 
Amino acid metabolism and biosynthesis  
   Cysteine and methionine metabolism 3 
   Phenylalanine metabolism 1 
   Phenylalanine, tyrosine and tryptophan biosynthesis 1 
   Biosynthesis of amino acids 2 
Other amino acid metabolism  
   Selenocompound metabolism 1 
Metabolism of cofactors and vitamins  
   Porphyrin and chlorophyll metabolism 2 
Metabolism of terpenoids and polyketides  
   Terpenoid backbone biosynthesis 1 
Biosynthesis of secondary metabolites  
   Phenylpropanoid biosynthesis 1 
   Carbon metabolism 3 
   Microbial metabolism in diverse environments 3 
Genetic information processing (37.1%)  
Transcription  
   RNA polymerase 3 
   Spliceosome 3 
   Basal transcription factors 1 
Translation  
   Ribosome 6 
   RNA transport 2 
   Aminoacyl-tRNA biosynthesis 1 
Replication and repair  
   DNA replication 1 
   Nucleotide excision repair 2 
   Homologous recombination 1 
   Mismatch repair 1 
   Base excision repair 1 
Folding, sorting and degradation  
   Protein processing in endoplasmic reticulum 3 
   RNA degradation 1 
Environmental Information Processing (2.9%)  
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Signal transduction  
   Plant hormone signal transduction 1 
   Phosphatidylinositol signaling system 1 
Transport and catabolism  
   Endocytosis 4 
Enviromental adaptation  
   Plant-pathogen interaction 1 
 
 
6.3.3 Protein biology 
By grouping all identified hempseed proteins on the basis of their supposed molecular function, 
cellular location and biological processes in which they are involved, Gene Ontology analysis 
has allowed to ascertain the C. sativa proteome functionality. Figure 6.4 reports the 
classification of the 181 identified species through Gene Ontology analysis into biological 
processes (Figure 6.4A), molecular functions (Figure 6.4B), and cellular components (Figure 
6.4C). Nevertheless, protein location shows a certain heterogeneity, since 14% of all protein 
identified is found in the chloroplasts, 15% in the membranes, 10% in the plastids, 7% in the 
nucleus (Figure 6.4C). Proteins involved in glycolysis, such as Phosphoglycerate kinase and 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDHs) were identified. The latter is a key 
enzyme during glycolysis and its expression is up-regulated during all four seed germination 
stages, as recently demonstrated for wheat seeds (He, Zhu, Dong, Zhang, Cheng, Li, et al., 
2015). In addition to its role as a cytosolic glycolytic enzyme, GAPDHs has been implicated 
in embryo development, pollen development, root growth, and mediation of reactive oxygen 
species response (Guo, Devaiah, Narasimhan, Pan, Zhang, Zhang, et al., 2012). Moreover, 14% 
of metabolic proteins are involved in translation activities and 12% in oxidation-reduction 
processes, such as Cytochrome c (CYC_CANSA), NADH-plastoquinone oxidoreductase 
subunit (ndhF_CANSA), and NADH dehydrogenase (nad5_CANSA). This last is a well-
known electron transport oxidoreductase enzyme, which mediates several physiological 
processes including signalling and regulation of growth, transport activities, and defence 
against pathogens (Lüthje, Döring, Heuer, Lüthen, & Böttger, 1997). The photosynthetic-
protein group includes Photosystem II CP43, CP47 and Ribulose-1,5-bisphosphate 
carboxylase/oxygenase (RuBisCO). Some proteins belonging to the category “response to 
stimulus” and directly involved in stress response were also detected, such as the Heat shock 
protein family (HSP70 and HSP60). The members of this wide glycoprotein gene family, 
among which HSP70 is the most conservative, prevent aggregation and assist refolding of non-
native proteins under both normal and stress conditions (Frydman, 2001). Although the 
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production of HSPs has been often described under heat stress, their expression and function 
in fundamental processes, such as seed development, have been also confirmed (Koo, Park, 
Kim, Suh, Lee, Lee, et al., 2015). Generally, HSPs are highly expressed in mature and dry 
seeds, as in the late stages of seed development, whereas they tend to disappear during 
germination.  
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Figure 6.4 - Pie charts of (A) biological processes, (B) molecular functions, and (C) cellular 
components refer to the 181 unique gene products described in hempseeds. 
 
6.4 Conclusion 
Taking advantage of high-throughput technologies, this work has provided very innovative 
information on hempseed proteome, since it was possible to identify in total 181 unique gene 
products, 56 specific protein species identified through the C. sativa database search and 125 
protein species through the A. thaliana database search. This represents a main improvement 
in respect to available literature were all assignments were based on other plant databases (Park, 
Seo, & Lee, 2012). In addition, it provides the first interactomic map of C. sativa, composed 
by a complex grid formed by 137 nodes connected via 410 interactions, useful to explore 
proteins relations and to understand the C. sativa biological pathways. The relevance of this 
work is underlined by the increasing interest for including hempseed ingredients in regular 
foods and, potentially, in functional ones. In fact, recent investigantions have shown that 
peptides deriving from the gastrointestinal simulated digestion of hempseed proteins are 
characterized by useful antioxidant (Girgih, He, Malomo, Offengenden, Wu, & Aluko, 2014) 
and antihypertensive properties (Girgih, Alashi, He, Malomo, & Aluko, 2014).  
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SUPPORTING INFORMATION 
 
 
Figure 6.1S - The protein functional interactomic network of the hempseed proteins obtained by 
STRING software. Different colored edges represent the existence of different types of evidence. A 
green line indicates neighborhood evidence; a blue line, concurrence evidence; a purple line, 
experimental evidence.  
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Table 6.1S A) List of 56 unique gene products identified by C. sativa database search. 
         
Accession 
Description 
 OS= C. sativa 
MS/MS 
Search 
Score 
ΣCoverage 
Σ# 
Peptides 
Σ# 
Unique 
Peptides 
TPSI 
Score 
pH2.2 
Coverage 
pH2.2 
# 
Peptides 
pH2.2 
Score 
pH7.2 
Coverage 
pH7.2 
# 
Peptides 
pH7.2 
Score 
RAW 
Coverage 
RAW 
extract 
# 
Peptides 
RAW 
extract 
# 
AAs 
calc. 
pI 
A7IZZ2 (+)-alpha-pinene synthase  12.58 6.9 7 7 6.12E+07 6.85  5.20 5 4.80  3.40 2 4.37  4.30 2 615 5.9 
A7IZZ1 (-)-limonene synthase  6.35 6.5 2 2 8.51E+06 3.20  4.30 2 3.15  2.20 2       622 6.4 
H9A1V3 Acyl-activating enzyme 1  9.41 5.6 5 4 5.31E+07 7.24  5.60 2 7.43  2.70 3       720 6.9 
H9A1V4 Acyl-activating enzyme 2  9.33 5.4 4 4 1.24E+07 9.33  5.40 2       5.65  2.20 2 662 6.7 
H9A1V5 Acyl-activating enzyme 3  11.25 13.4 5 4 3.22E+08             11.25  5.70 2 543 8.7 
H9A1V8 Acyl-activating enzyme 6  11.95 4.9 2 2 4.98E+07             11.95  4.90 2 569 7.9 
H9A1V9 Acyl-activating enzyme 7  8.98 4.8 5 3 3.00E+07 5.37  3.10 3       3.61  4.80 2 597 6.2 
H9A1W1 Acyl-activating enzyme 9  11.04 5.8 2 2 4.02E+07 5.34  2.10 2       5.70  2.70 2 597 6.2 
H9A1W3  Acyl-activating enzyme 11 10.79 5.6 4 2 5.68E+07 7.24  5.60 3 3.55  3.20 4       334 6.5 
H9A8L1 Acyl-activating enzyme 12  10.10 3.1 3 3 4.17E+07 5.52  3.10 2       4.58  2.70 2 757 6.9 
H9A8L2 Acyl-activating enzyme 13  6.83 3.3 4 3 3.47E+07 3.63 1.9 2       3.20 3.30 2 715 6.4 
H9A8L3 Acyl-activating enzyme 14  11.50 4.9 2 2 6.18E+07             11.50  2.70 2 727 6.7 
H9A8L4 Acyl-activating enzyme 15  22.34 9.2 8 7 1.32E+07       8.82 1.1 2 13.20  15.70 4 776 5.9 
A0A0C5APY2 
Acetyl-CoA carboxylase 
carboxyltransferase beta 
subunit  
11.48 4.6 4 3 5.07E+08 6.38  1.60 2 4.47  1.60 3 5.56  3.00 2 497 4.8 
A0A0C5ARS5 
ATP synthase CF1 beta 
subunit  
16.83 15.8 4 3 2.56E+08 16.83  15.80 3             498 5.2 
E5DK51 Atp1, partial  31.75 15.4 6 4 1.87E+08 31.75  15.40 6             349 7.1 
I6XT51 Betv1-like protein  27.16 21.1 11 3 1.09E+09 9.52  7.40 11             161 5.2 
A0A0E3TJM8 
Cannabidiolic acid synthase 
homolog  
11.94 8.4 2 2 9.94E+06 5.58  4.50 2 6.36  3.80 2       544 8.8 
C6KI62 
Chalcone synthase-like 
protein 1  
11.17 8.8 3 3 7.27E+07 3.70  2.00 2 5.30  4.50 2 5.79  4.30 2 392 6.5 
I6WIE9 
Chalcone isomerase-like 
protein  
8.43 11.1 2 2 9.61E+06       3.10  4.60 2 5.33  6.50 2 214 8.2 
A0A0C5ARS7 
Chloroplast envelope 
membrane protein  
4.38 5.6 2 2 4.68E+06       4.38  5.60 2       231 6.1 
P00053 Cytochrome c  7.7 27.9 2 2 7.89E+06             7.7 27.9 2 111 9.8 
A0A088MFF4 Delta 12 desaturase  15.28 9.3 4 2 5.49E+08             15.28  9.30 4 387 8.7 
A0A090DLH8, 
A0A090CXP7 
Edestin 1 GN=ede1A, 
ede1C-ede1B 
312.36 46.9 407 21 5.69E+10 128.11  17.60 75 137.96  27.00 79 273.67  46.90 217 511 8.8 
A0A090CXP9 Edestin 2 GN=ede2A 120.43 22.8 66 17 2.32E+09 44.93  8.90 15 91.66  19.10 26 200.14  32.70 121 491 8.9 
A0A090DLI7, 
A0A090CXP8 
Edestin 2 GN=ede2B-ede2C 132.45 25.8 70 18 2.41E+09 44.93  8.90 15 103.68  22.10 29 214.66  35.80 135 491 9.0 
A0A0C5APZ4  
Hypothetical chloroplast 
RF21  
48.36 6.2 25 17 1.10E+09 26.02  2.90 12 5.02  0.70 7 5.62  0.70 6 2302 8.7 
A0A0C5AUH7 
Hypothetical chloroplast 
RF34  
12.24 13.6 4 4 2.48E+08       3.64  11.30 2 12.24  13.60 3 168 5.6 
L0N5C8 Hypothetical protein  16.57 18.3 6 3 9.46E+07 11.45  18.30 4 5.12  3.10 2       168 5.6 
E5DKP2 MatR, partial  16.27 10.2 5 5 3.65E+07       4.27  2.80 2 3.50  4.40 3 535 10.2 
A0A0C5AUE3 Maturase K  15.62 11.8 4 4 7.67E+06             4.71  11.80 4 509 9.4 
A0A0C5AUJ6 
NADH-plastoquinone 
oxidoreductase subunit 5  
8.21 2.7 3 2 5.99E+07 8.21  2.70 3             755 9.1 
A0A0C5AS19 
NADH-plastoquinone 
oxidoreductase subunit 7  
11.49 12.8 4 3 1.82E+08 3.66  4.00 2 3.25  2.20 2 4.58  6.60 3 393 5.2 
E5DL82 
NADH dehydrogenase 
subunit 5, partial  
12.45 7.7 3 3 2.16E+08 3.24  7.70 3 6.36  4.10 2 7.45  7.10 2 361 8.5 
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V5KWZ6 
Phenylalanine ammonia 
lyase  
9.47 8.3 3 3 1.14E+07 4.48  3.20 2 4.63  2.90 2 4.39  1.60 2 707 6.0 
A0A0C5AUH1 
Photosystem II CP43 
chlorophyll apoprotein  
12.04 8.4 3 3 2.57E+07 5.50  3.30 2 6.54  5.00 2       473 6.6 
A9XV91 
Photosystem II CP47 
chlorophyll apoprotein, 
partial  
4.94 6.3 5 3 3.03E+06 4.10  4.30 3       4.94  6.30 2 488 6.1 
F1LKH7 Polyketide synthase protein  5.15 4.1 2 2 1.56E+07             5.15  4.10 3 385 6.0 
U6EFF4 
Putative LysM domain 
containing receptor kinase  
5.80 2.8 4 2 4.91E+07 6.00  2.80 2 5.80  2.80 2 4.68  3.60 2 599 6.6 
A0A0C5AS13 Ribosomal protein L2  7.11 3.6 7 3 1.79E+08 6.58  3.60 2 5.62  3.60 3 6.60  3.60 2 275 10.9 
A0A0C5AUJ2 Ribosomal protein L16  5.20 18.4 2 2 8.09E+07 3.01  9.20 2 5.20  18.40 2       119 11.3 
A0A0C5AS20 Ribosomal protein L23  20.04 55.9 6 5 2.44E+08 10.66  37.60 4       13.08  36.50 2 93 10.4 
A0A0C5ART6 
Ribosomal protein S3 
(chloroplast)  
11.08 23.8 6 5 2.10E+08 5.19  5.00 2 10.51  17.40 3 5.32  2.80 2 155 9.7 
E5DLX2 
Ribosomal protein S3, 
partial (mitochondrion)  
5.32 2.8 10 8 5.41E+07 3.83  3.40 4 4.91  3.20 5 5.32  2.80 3 494 10.2 
A0A0C5ARS4 Ribosomal protein S4  7.15 13.3 4 3 7.66E+07 3.56  4.90 2       3.59  8.40 2 202 10.4 
A0A0C5ARU3 Ribosomal protein S7  6.49 23.8 2 2 3.08E+07 6.49  23.80 2             155 11.2 
A0A0C5APY7 Ribosomal protein S8  5.50 13.4 2 2 3.68E+07 3.49  6.70 2       5.70  13.40 2 134 11.1 
A0A0C5ART4 Ribosomal protein S11  10.26 16.6 2 2 2.40E+07 9.81  16.60 2             138 12.1 
A0A0C5AUK1 Ribosomal protein S15  8.03 32.2 7 2 7.74E+06 4.36  11.10 4 3.60  11.10 2 3.67  21.10 2 90 10.7 
A0A0C5ART1 Ribosomal protein S18  15.27 30.6 5 2 3.26E+08 9.23  15.80 13 6.04  18.80 2       101 11.9 
A0A0C5B2I6 
Ribulose 1,5-bisphosphate 
carboxylase/oxygenase 
large subunit   
20.65 6.1 8 6 4.00E+08 9.24  4.40 3 6.47  1.60 3 5.68  2.30 2 475 6.1 
I0B4C2 
Ribulose-1,5-bisphosphate 
carboxylase/oxygenase 
large subunit, partial  
9.77 11.5 7 3 3.96E+08 3.30  7.80 4 6.47  3.70 3       216 7.8 
A0A0C5AUI9 
RNA polymerase alpha 
subunit  
14.89 19.5 4 4 1.48E+07       6.16  7.45 2 8.30  12.00 2 331 7.7 
A0A0C5ARQ8 
RNA polymerase beta 
subunit   
17.38 5.7 4 3 9.68E+07       9.48  4.75 3 5.55  4.05 2 1070 8.7 
A0A0C5ARX9 
RNA polymerase beta' 
subunit  
17.28 4.8 13 9 1.04E+09 10.52  3.00 7 8.48  1.60 2 12.40  2.90 4 1393 9.1 
I1V0C2 
Tetrahydrocannabinolic acid 
synthase, partial  
11.62 9.9 3 3 2.87E+07 5.58  4.50 2       6.83  5.30 2 545 8.7 
 
Total Protein Spectral Intensity, TPSI 
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Table 6.1S B) List of 125 proteins identified by the use of A. thaliana database search. 
         
Accession 
Description 
OS=A. thaliana 
 
MS/MS 
Search 
Score 
ΣCoverage 
Σ# 
Peptides 
Σ# 
Unique 
Peptides 
TPSI 
Score 
pH2,2 
Coverage 
pH2,2 
#  
Peptides 
pH2,2 
Score 
pH7.2 
Coverage 
pH7.2 
# 
Peptides 
pH7.2 
Score 
RAW 
Coverage 
RAW 
# 
Peptides 
RAW 
# 
AAs 
calc. 
pI 
O65719 Heat shock 70 kDa protein 3  88.85 18.3 12 7 3.97E+08 36.70  7.0 3 13.16  2.5 2 52.10  11.1 8 649 4.97 
Q9LHA8 Heat shock 70 kDa protein 4  74.67 16.4 11 6 3.37E+08 22.52  5.2 3 13.16  2.5 2 52.20  11.1 8 650 5.14 
Q9S9N1 Heat shock 70 kDa protein 5  58.03 9.2 20 4 2.54E+08       13.16  86.7 2 58.03  9.2 19 646 5.30 
Q9LKR3 Heat shock 70 kDa protein 11  21.72 4.6 6 2 4.41E+07       21.48  4.6 2 13.40  2.3 4 669 5.08 
Q8LFV7 Phosphoglycerate kinase  45.26 14.7  6 3 1.54E+08 24.22  11.4 3 12.19  3.5 2 34.40  7.4 3 401 5.49 
Q9LHE4 Transcription factor-like protein  28.86 5.5 7 3 2.81E+08 17.17  2.9 4 11.17  1.1 2 10.91  2.5 2 1047 8.80 
Q0WR59 Probable inactive receptor kinase  26.37 6.3 3 3 3.99E+08 8.38  1.8 2       17.99  4.5 3 1048 6.21 
Q0WNZ5 5-methyltetrahydropteroyltriglutamate--
homocysteine methyltransferase 3  
24.95 3.6 6 2 1.14E+08             24.95  3.6 6 812 8.44 
F4HZB2 WD/BEACH domain protein SPIRRIG  23.52 1.4 3 3 3.69E+07 6.15  0.4 2       17.37  1.1 2 3601 5.75 
O80891 Cellulose synthase-like protein B4  22.27 8.4 3 3 1.39E+08 22.27  8.4 3             755 7.29 
Q9LIM5 Chloroplast protein HCF243  21.45 3.6 6 2 5.91E+08 21.45  3.6 6             684 6.04 
O23058 A_IG005I10.23 protein  20.30 5.1 2 2 7.11E+07 9.83  1.9 2 10.47  3.1 2       770 5.65 
O81490 F9D12.11 protein   20.10 3.5 3 3 5.73E+07 13.59  2.1 3             1322 9.34 
Q5XF33 Magnesium-chelatase subunit ChlI-2  20.09 6.8 2 2 1.19E+08 10.69  4.2 2       9.40  2.6 2 423 5.36 
Q9M8D3 Phosphoribosylformylglycinamidine 
synthase  
19.49 3.9 3 3 1.36E+08 19.49  3.9 3             1407 5.21 
Q9SHM9 F7F22.11  19.34 6.0 2 2 6.93E+07       10.84  2.7 2 8.50  3.3 2 612 9.64 
P59583 Probable WRKY transcription factor 32  18.97 8.1 3 2 1.19E+09 18.97  8.1 2       9.59  2.5 2 466 5.75 
Q9SSQ2 F6D8.29  18.35 7.8 5 2 7.23E+08             18.35  7.8 5 423 9.80 
Q9SIL1 Putative TNP1-like transposon protein  18.24 2.5 3 2 1.30E+09 8.75  1.4 2 9.49  1.1 2 7.14  1.4 2 984 6.71 
Q9SU68 Putative protein  11.07 2.4 2 2 1.08E+07 18.16  2.4 2             1613 5.93 
Q9ZQQ4 Hypothetical protein  21.72 5.3 2 2 4.41E+07       8.64  2.3 2 9.45  2.9 2 679 5.71 
Q6NR90 Histone H4 - like protein  17.99 21.3 3 2 4.88E+07             17.99  21.3 3 103 11.48 
Q66GI4 Proteinaceous RNase P 1  17.93 5.4 2 2 2.70E+07       9.26  1.5 2 8.67  3.9 2 572 9.64 
Q9FG23 At5g06830  17.93 4.5 3 2 2.15E+08             17.52  4.5 3 549 4.72 
Q84TI3 PHD-finger TITANIA 2  17.89 4.0 5 2 2.28E+09 14.67  4.0 3 10.26  2.2 2       1162 5.87 
P56785 ycf1  17.82 1.9 2 2 6.01E+07             17.82  1.9 2 1786 9.85 
C0Z2I0 Glyceraldehyde-3-phosphate 
dehydrogenase  
17.81 10.2 2 2 3.09E+07             17.81  10.2 2 343 8.46 
O48689 Paired amphipathic helix repeat-
containing protein  
17.80 5.2 3 2 2.74E+08 8.86  3.3 2       8.94  1.9 3 744 9.83 
O04251 Transcription coactivator protein  17.66 3.0 3 2 2.69E+08 17.66  3.0 3             1329 8.75 
O80958 Pentatricopeptide repeat protein 17.55 4.3 2 2 7.32E+07 8.64  1.6 2       8.91  2.4 2 867 6.06 
F4J8K6 Protein ribosomal RNA processing 5  17.44 1.2 2 2 4.90E+08             17.44  1.2 2 1896 8.75 
O82762 KH domain-containing protein  17.40 5.3 2 2 4.46E+07 9.79  2.5 2 7.61  2.8 2       632 5.32 
O23026 EST gb|T04104 comes from this 
gene/T1G11.16 protein  
17.38 5.2 3 2 9.94E+07 8.55  5.0 2       8.83  5.3 3 398 9.11 
O04478 Endoglucanase 7  17.37 5.4 9 2 4.47E+08 9.72  3.5 3 10.07  3.5 3 16.05  5.4 3 623 9.44 
Q38810 cDNA-5-encoded protein, partial  17.37 14.5 2 2 2.35E+07 9.59  5.5 2 7.78  9.0 2       289 9.15 
Q9FH23 Uncharacterized protein  9.83 2.1 2 2 2.78E+07 8.42  1.0 2       8.89  1.1 2 1487 5.79 
Q9FWR3 Similar to tRNA-splicing endonuclease 
positive effector SEN1   
17.24 1.5 2 2 2.18E+07 8.76  0.8 2 8.48  0.7 2       2142 8.52 
Q84M98 Meiotic endonuclease 1A  17.11 5.8 2 2 2.68E+07 6.99  3.8 2 10.12  2.0 2       549 8.43 
Q8VZF6 AT5g45560/MFC19_23  17.04 6.6 2 2 9.36E+07       8.84  2.9 2 8.20  3.6 2 719 6.21 
Q94FQ0 Glycine-rich protein GRP17  16.95 12.1 2 2 4.38E+07       7.60  5.2 2 9.35  6.9 2 543 10.38 
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P42762 Erd1 protein precursor  16.63 4.3 2 2 6.59E+07 9.40  1.9 2       7.23  2.4 2 945 5.89 
Q9M8K5 AT3g06130/F28L1_7  16.57 9.5 2 2 1.44E+08 7.67  4.6 2       8.90  4.9 2 473 8.34 
F4IMB5 ATPase, F1 complex, alpha subunit 
protein  
16.56 4.1 2 2 2.69E+07 10.21  1.2 2       6.35  2.8 2 777 5.43 
Q8S8D3 Phox (PX) domain-containing protein  16.36 4.6 2 2 6.67E+07       6.72  2.3 2 9.64  2.3 2 643 5.09 
O80458 Cis-prenyltransferase  16.32 8.9 2 2 2.00E+07 6.30  4.0 2       10.02  4.9 2 303 8.57 
Q84W97 Putative kinesin  16.21 3.2 3 2 2.11E+08 16.21  3.2 2 6.99  1.4 2       983 8.71 
Q9SA52 g5bf  16.17 6.6 2 2 2.35E+07       9.11  4.5 2 7.06  5.0 2 378 8.36 
Q9FNB0 Magnesium-chelatase subunit H  20.09 2.0 3 2 1.19E+08 9.65  1.0 2 6.50  0.9 2 9.49  1.0 2 1381 5.80 
Q9LXU4 Uncharacterized protein  9.83 4.4 3 2 2.78E+07 6.28  1.7 2 16.01  4.4 2       861 6.68 
Q5D869 RNA polymerase IV largest subunit  15.88 2.0 2 2 4.70E+07 8.95  0.9 2 6.93  1.1 2       1976 5.88 
Q9LQ91 T1N6.6  15.76 3.4 2 2 3.49E+07 8.73  1.7 2       7.03  1.8 2 832 9.12 
Q9SB75 Cellulose-synthase-like C5  15.73 3.4 3 2 1.06E+08 9.26  2.1 2       6.47  1.3 2 692 9.10 
Q9C533 Probable protein S-acyltransferase 22  15.69 5.7 3 2 3.81E+08       8.28  2.3 2 7.41  3.4 3 596 9.59 
Q8L7G0 Auxin response factor 1  15.66 4.5 2 2 2.78E+08             15.66  4.5 3 665 5.84 
Q76E23 Eukaryotic translation initiation factor 
4G  
15.63 1.5 2 2 5.56E+07 9.51  0.6 2       6.12  0.9 2 1727 7.59 
Q9XIE6 Phospholipid-transporting ATPase 3  15.59 2.9 2 2 5.28E+08 15.59  2.9 2             1213 8.30 
Q19DM3 Disease resistance protein, partial  15.58 17.5 2 2 1.01E+08 15.58  17.5 2             222 9.16 
O81893 Inositol-tetrakisphosphate 1-kinase 2  15.53 7.6 3 2 5.90E+08 6.14  3.8 2       9.39  3.8 2 391 6.15 
Q9FHW3 Unnamed protein product  88.85 30.3 2 2 3.97E+08       6.52  15.2 2 8.93  15.1 2 132 6.98 
Q9ZQE9 Putative retroelement pol polyprotein  15.42 1.1 2 2 4.52E+07       7.33  0.9 2 8.09  1.1 2 1347 8.46 
F4JXC5 Subtilisin-like protease SBT5.4  15.41 6.6 2 2 5.91E+07 8.26  4.0 2       7.15  2.6 2 778 9.24 
O82496 T12H20.15 protein  15.41 3.6 4 2 1.26E+08 14.47  3.6 2 9.19  3.1 2 7.10  3.1 2 705 5.53 
F4IAH9 Glyoxalase I homolog  15.34 8.3 2 2 5.52E+07 7.96  5.0 2       7.38  3.4 2 322 5.40 
O48701 Hypothetical protein] 15.38 5.3 2 2 4.41E+07 9.15  1.3 2       6.23  4.0 2 707 8.36 
Q9LR53 Putative protein kinase  15.26 5.5 2 2 5.81E+07 7.94  2.3 2 7.32  3.1 2       740 9.64 
P0C7Q8 Protein DA1  15.21 8.4 2 2 2.12E+08             15.21  8.4 2 532 5.98 
Q8L622 Putative uncharacterized protein  15.19 7.0 2 2 1.21E+08 15.19  7.0 2             607 5.12 
Q9S755 Hypothetical protein  15.18 15.6 2 2 5.07E+07 8.62  9.6 2 6.56  6.0 2       198 9.45 
O64533 YUP8H12R.20  15.15 2.7 2 2 1.19E+08             15.15  2.7 3 1325 7.77 
Q93ZM7 Heat shock protein 60-3A  15.07 7.6 2 2 2.55E+08       8.26  2.6 2 6.81  5.0 2 572 5.85 
Q42290 Probable mitochondrial-processing 
peptidase subunit beta 
15.05 9.5 4 2 2.08E+09 14.87  9.5 2 13.52  4.7 2       535 6.45 
Q8S905 F15H18.12  15.05 2.2 2 2 6.51E+07 8.71  0.9 2       6.34  1.4 2 1003 8.57 
Q42572 DNA ligase 1  15.17 4.5 2 2 4.09E+08       6.10  1.6 2 9.07  2.9 2 839 9.08 
O49281 Zinc finger protein  15.04 2.9 2 2 1.21E+08 15.04  2.9 2             1108 9.19 
Q38K61 Disease resistance protein, partial  15.58 12.8 2 2 1.01E+08 15.58  12.8 2             272 6.09 
P93736 Valine--tRNA ligase  15.01 3.3 2 2 1.29E+08 6.15  1.5 2       8.95  1.8 2 1115 6.70 
F4IVL6 Gravitropism defective 2  15.01 0.9 2 2 8.65E+07             15.01  0.9 2 2554 5.74 
Q8VY07 Clathrin binding protein-like  14.98 5.0 2 2 1.70E+07             14.98  5.0 2 577 4.87 
Q9SSP7 Ubiquitin carboxyl-terminal hydrolase-
related protein  
14.95 3.2 2 2 3.05E+07             14.95  3.2 2 1136 5.72 
Q9C9U2 Cell division protein kinase   14.93 8.0 2 2 4.26E+08       8.63  4.0 2 6.30  3.8 2 398 9.49 
Q9SB89 DEAD-box ATP-dependent RNA 
helicase 27  
14.86 3.1 2 2 2.43E+07             14.86  3.1 2 633 8.99 
Q8GXD6 DEAD-box ATP-dependent RNA 
helicase 49  
13.00 4.1 2 2 3.35E+07       13.00  4.1 2       558 9.51 
Q9LJX4 RNA binding protein-like  14.83 3.0 2 2 1.01E+08 14.83  3.0 2             962 5.67 
F4K7T1 P-loop containing nucleoside 
triphosphate hydrolases superfamily 
protein  
17.24 4.5 3 2 2.18E+07 14.24  4.5 3             661 6.44 
Q56XE8 Hexokinase-4  14.76 3.8 2 2 2.30E+07 8.49  1.6 2 6.27  2.2 2       502 8.53 
A0MEZ6 Putative uncharacterized protein  14.67 21.0 2 2 2.54E+07 8.25  9.0 2       6.42  15.0 2 133 6.86 
B0LC03 RPS2  14.59 4.7 2 2 7.18E+07 7.64  2.2 2       6.95  2.5 2 909 6.13 
B9DG14 AT5G41100  14.58 8.0 2 2 2.34E+07       14.58  8.0 2       586 8.79 
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F4J3S1 Shugoshin C terminus 14.52 7.3 2 2 3.82E+07 7.98  2.3 2       6.54  4.0 2 572 9.56 
Q42560 Aconitate hydratase 1  14.45 4.4 2 2 6.91E+07 6.64  1.9 3       7.81  2.5 2 898 5.98 
F4K4M9 Uncharacterized protein  14.37 4.7 2 2 1.75E+07             14.37  4.7 3 848 9.09 
F4K4D6 PWWP domain-containing protein  14.29 4.1 2 2 8.59E+07 14.29  4.1 2             1072 6.34 
Q9ZVX5 Pentatricopeptide repeat-containing 
protein  
14.20 4.1 2 2 5.66E+07 14.20  4.1 2             743 6.06 
O81147 Proteasome subunit alpha type-6-B  14.18 13.0 2 2 3.69E+07 7.27  5.7 2 6.91  7.3 2       246 5.75 
Q9FNI6 DNA repair protein RAD5 protein  14.13 3.4 3 2 5.61E+07       14.13  3.4 3       1029 6.41 
F4KE59 RING/FYVE/PHD zinc finger-
containing protein  
14.12 2.5 2 2 9.25E+07 7.82  1.4 2       6.30  1.1 2 1311 6.29 
Q8VZG2 Protein HYPER-SENSITIVITY-
RELATED 4   
14.06 5.0 2 2 2.94E+07             14.06  5.0 2 576 6.30 
Q9SCZ3 TIR-NBS-LRR class disease 
resistance protein  
14.01 2.7 3 2 4.54E+07 6.68  1.4 2 7.33  1.3 3       1253 9.08 
X2L4T4 DM2D   13.98 4.1 2 2 1.18E+08             13.98  4.1 2 1216 6.18 
Q56X77 Guanylate kinase  13.96 15.7 2 2 1.77E+07 13.96  15.7 2             203 5.78 
Q8VZQ9 Putative protein  13.92 2.6 2 2 1.44E+08 13.92  2.6 2             1021 9.68 
Q94BQ3 WD and tetratricopeptide repeats 
protein 1  
13.78 4.7 2 2 1.45E+08             13.78  4.7 2 757 5.54 
Q9FLR3 No apical meristem (NAM) -like protein  13.71 8.8 2 2 4.41E+07             13.71  8.8 2 329 9.17 
Q9T0F7 Glucuronoxylan 4-O-methyltransferase 
2  
13.71 11.7 2 2 3.14E+07       13.71  11.7 2       290 6.76 
Q3EAS6 Putative DNA repair protein recA 
homolog 4  
13.70 24.3 2 2 1.86E+09 6.90  11.5 2 6.80  12.8 2       226 9.39 
P17094 Ribosomal protein  13.66 11.8 2 2 2.79E+07             13.66  11.8 2 389 10.29 
Q9FKV9 Cyclin-dependent protein kinase-like 
protein  
13.62 3.7 3 2 8.73E+07 13.62  3.7 3       6.55  2.0 2 644 9.31 
F4I5J7 DNAJ heat shock N-terminal domain-
containing protein  
13.52 13.2 2 2 2.60E+08 6.92  6.1 2       6.60  7.1 2 379 5.39 
F4J394 ATP binding microtubule motor family 
protein  
13.49 3.2 2 2 1.45E+07 6.29  1.4 2 7.20  1.8 2       1054 6.24 
Q84MA1 Hypothetical protein 13.49 5.5 2 2 1.84E+08 13.49  5.5 2             599 6.64 
Q8S8L1 Uncharacterized protein  13.45 14.8 2 2 6.78E+08 7.38  7.1 2       6.07  7.7 2 336 6.04 
Q9FHT3 Uncharacterized protein 13.35 5.7 2 2 1.27E+08 13.35  5.7 3             485 6.00 
Q93YS2 Putative protein phosphatase 2C 51  13.27 3.0 2 2 1.05E+08 6.94  1.6 2       6.33  1.4 2 1075 6.17 
G4WT86 Late flowering protein  13.04 3.9 2 2 5.81E+07 6.26  2.1 2       6.78  1.8 2 609 9.27 
O49610 Protein kinase-like  12.97 10.1 2 2 3.06E+08 12.97  10.1 2             461 6.38 
Q9LPA7 T32E20.13  12.91 2.5 2 2 4.15E+07 6.78  1.0 2       6.13  1.5 2 1335 6.15 
P92935 ADP,ATP carrier protein 2  12.90 5.5 2 2 1.09E+08 6.10  2.1 3 6.80  3.4 2       618 9.70 
C0SVH8 Acyl-CoA N-acyltransferase with 
RING/FYVE/PHD-type zinc finger 
protein  
12.73 3.0 2 2 3.90E+07 6.22  2.1 2       6.51  0.9 2 1138 9.16 
F4IF81 Putative serine/threonine protein 
kinase   
12.70 5.5 2 2 5.85E+07             12.70  5.5 2 687 5.72 
Q56Y19 Uncharacterized protein  12.56 6.4 2 2 7.95E+07 6.09  3.7 2 6.47  2.7 2       437 9.83 
Q8S8N9 Golgin candidate 1   12.40 5.4 2 2 1.79E+07       12.40  5.4 2       713 5.18 
O22241 Arogenate dehydratase 4  12.33 4.9 2 2 1.19E+07       12.33  4.9 2       424 6.05 
Q9FGN6 Receptor-like kinase MOL1  12.32 4.4 2 2 1.05E+07 12.32  4.4 2             895 6.60 
F4JRX3 DNA topoisomerase, type IA, core  12.30 1.4 2 2 6.32E+06       6.10  0.9 2 6.20  0.5 2 1284 9.54 
Q9SG92 Methylesterase 17  12.19 11.9 2 2 3.68E+07 12.19  11.9 2             276 5.08 
 
Total Protein Spectral Intensity, TPSI 
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Table 6.1S C) List of identified peptides belonging to C. sativa proteins.  
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PART-I 
7.0 Abstract 
The seed of industrial hemp is an underexploited protein source. In view of a possible use in 
functional foods, a hempseed protein concentrate was hydrolyzed with pepsin, trypsin, 
pancreatin, or a mixture of these enzymes. A detailed peptidomic analysis using data-dependent 
acquisition showed that the numbers of peptides identified ranged from 90 belonging to 33 
parent proteins in the peptic hydrolysate to 9 belonging to 6 proteins in the pancreatin digest. 
The peptic and tryptic hydrolysates resulted to be the most efficient inhibitors of 3-
hydroxymethyl-coenzyme A reductase activity, when tested on the catalytic domain of the 
enzyme. Using the open access tools PeptideRanker and BIOPEP, a list of potentially bioactive 
peptides was generated: the alleged activities included the antioxidant property, the glucose 
uptake stimulating activity, the inhibition of dipeptidyl peptidase-IV (DPP-IV) and of 
angiotensin converting enzyme I (ACE). 
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Keywords: bioactive peptides, Cannabis sativa, LC-MS/MS, hempseed hydrolysates, 
HMGCoAR, peptidomics 
 
Abbreviations Used: AAC, amino acid composition; ACE,  angiotensin converting enzyme 
I; ACN, acetonitrile; DPP-IV,  dipeptidyl peptidase-IV; HCA, hierarchical cluster analysis; 
HMGCoAR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; MW, molecular weight; 
MWCO, molecular weight cut-off; SDS-PAGE, sodium dodecyl sulphate – polyacrylamide.  
HPC, protein concentrate; TPSI, Total Protein Spectral Intensity. 
 
7.1 Introduction 
Currently, there is a growing interest for the production of food protein hydrolysates containing 
bioactive peptides for potential applications in functional foods. So far, much research has been 
focused on the use of animal proteins (milk, egg, fish, meat) as raw materials for the production 
of such bioactive peptides.1 However, edible plants and mainly their seeds represent cheap and 
environmentally sustainable protein sources currently investigated for the same purpose.2  
Certainly, a complete information on peptide sequences is crucially relevant in order to elucidate 
the correlation between the composition of such hydrolysates and the observed biological activities 
and to elucidate the molecular mechanisms involved. This knowledge is, therefore, a key factor in 
the development of applications in nutraceuticals and functional foods. In fact, the specific 
bioactivity of food peptides against various molecular targets depends on their structural 
properties, such as amino acid composition, length and physicochemical characteristics of the 
amino acid side chains, as well as their bulkiness, hydrophobicity, and charge.3 Given a single 
starting material, different peptide profiles may be achieved under varying hydrolytic conditions, 
since enzymatic activity is a function of structural characteristics of the substrate on which the 
proteases act.4 To date, the characterization of the relative similarities and differences between 
such peptide profiles remains largely unstudied. In this context, the advent of peptidomics based 
on advanced analytical techniques, in particular mass spectrometry, allows to elucidate the full 
components present in a specific peptide mixture. Indeed, continued advances in tandem MS 
technologies provide today more and more accurate identifications and quantifications of such 
peptides.5 Accordingly, this technology has attracted the attention of food scientists and 
nutritionists as a promising approach for the characterization of food protein hydrolysates.6-8  
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While proteomics usually comprises molecular weights from approx. 700 to 3000 Da with a 
dynamic range of twelve orders of magnitude, peptidomics certainly spans over a greater peptide 
length distribution showing instead a similar dynamic range.8 Moreover, the high concentration of 
low molecular weight peptides in food hydrolysates is undoubtedly an analytical challenge to 
peptidomic analysis, and research in this area is yielding significant results especially for the 
identification of small peptides.  
The seed of industrial hemp, i.e. the non-drug cultivars of Cannabis sativa, is certainly an 
underexploited protein-rich seed.9 Hempseed proteins are an excellent natural source of highly 
digestible amino acids when compared to other protein sources, such as borage meal, canola meal, 
and heated canola meal.10, 11 Interestingly, recent investigations have demonstrated that peptides 
produced by enzymatic hydrolysis of hempseed proteins provide several biological activities, 
including the antihypertensive one12, 13 and antioxidant one.12, 14, 15  
In addition, a few literature evidences indicate that the inclusion of hempseed protein in the diet 
of suitable animal models modulates their lipid profile in a favorable way.16-18 Since proteins are 
hydrolyzed during digestion, the activity may be due to specific peptides encrypted in the protein 
sequences that are released by digestion and absorbed at intestinal level. This has stimulated our 
interest for assessing whether the enzyme selection and technical conditions may modulate the 
hypocholesterolemic properties of hempseed peptides.19 In fact, the bioactivity of food protein 
hydrolysates depends strictly on these parameters.20  
Based on these considerations, the overall objective of the present study was to compare the 
efficiency of some enzymes and/or enzyme combinations in the production of bioactive protein 
hydrolysates from hempseed. In details, the specific objectives were: (i) the optimization of the 
release of the peptides from hempseed protein using different enzymes; (ii) the identification and 
characterization of each hydrolysate by a shotgun MS based approach; iii) the evaluation of the 
inhibitory activity of each hydrolysate on 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase 
(HMGCoAR), a key enzyme in cholesterol metabolism; and (iv) the prediction of additional 
biological activities using in silico bioinformatics tools.  
7.2 Materials and Methods 
7.2.1 Reagents  
All chemicals and reagents were of analytical grade.  LC-grade H2O (18 MΩ cm) was prepared 
with a Milli-Q H2O purification system (Millipore, Bedford, MA, USA). Acetonitrile (ACN), 
tris(hydroxymethyl)aminomethane (Tris-HCl), hydrochloric acid (HCl), ammonium 
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bicarbonate, and HMGCoAR assay Kit were provided by Sigma-Aldrich (St. Louis, MO, 
USA). Pepsin from porcine gastric mucosa (P7012, lyophilized powder, ≥ 2,500 units/mg 
protein), trypsin from bovine pancreas (T1426, lyophilized powder, ≥ 10,000 units/mg protein), 
and pancreatin from porcin pancreas (P1625, powder, 3 x ≥ USP specification) were from 
Sigma-Aldrich (St. Louis, MO, USA). Bovine serum albumin (BSA) and β-mercaptoethanol 
were from Thermo Fisher Scientific (Life Techonoly, Milan Italy). Mini-Protean apparatus, 
precision plus protein standards, Bradford reagent and Coomassie Blue G-250 were purchased 
from Bio-Rad (Hercules, CA, USA).  
 
7.2.2 Protein concentrate preparation  
The seeds of the species C. sativa (cultivar Futura) were provided by the Institute of Agricultural 
Biology and Biotechnology, CNR (Milan, Italy). The hempseed protein concentrate (HPC) was 
prepared applying the method described previously with some modifications.21 Briefly, 2 g of 
defatted hempseed flour were homogenized with 15 mL of 100 mM Tris-HCl/0.5 M NaCl buffer, 
pH 8.0. The extraction was performed in batch at 4 °C overnight. The solid residue was eliminated 
by centrifugation at 5,800 g for 30 min at 4 °C and the supernatant was dialyzed against 100 mM 
Tris-HCl buffer, pH 8.0 for 36 h at 4 °C. The protein content of HPC, assessed according to the 
Bradford method using BSA as standard, was 15.4 mg/mL.  
 
7.2.3 Preparation of the hempseed protein hydrolysates 
The HPC, dissolved in 100 mM Tris-HCl/0.5 M NaCl buffer pH 8.0, was hydrolyzed using three 
single enzymes: i.e. pepsin, trypsin, pancreatin or, in order to mimic the gastrointestinal digestion, 
a combination of the same enzymes. The peptic hydrolysis was performed adjusting the pH to 2 
by adding 1 M HCl to the HPC. The enzyme solution (4 mg/mL in NaCl 30 mM) was added in a 
1:50 enzyme/hempseed protein ratio (w/w). The mixture was incubated for 16 h and the enzyme 
inactivated changing the pH to 7 by adding 1 M NaOH. Tryptic and pancreatic hydrolysis was 
performed directly in the buffer solution adding trypsin (4 mg/mL in HCl 1 mM) and pancreatin 
(4 mg/mL in H2O) in a 1:50 enzyme/HPC ratio (w/w). After 16 h incubation, the digestion was 
stopped changing the pH to 3 by adding 1 M HCl. The simulated gastrointestinal digestion was 
initiated by the addition of pepsin [1:20 (w/w) enzyme/hempseed protein ratio] stirring the mixture 
for 2 h at pH 2. After that, the reaction mixture was adjusted to pH 8.5 with 1 M NaOH followed 
by the addition of a mixture of trypsin and pancreatin, each at a 1:25 enzyme/HPC (w/w) ratio. 
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The mixture was incubated at 37 °C for 4 h. The enzymatic reaction was terminated by adjusting 
the mixture to pH 3 with 1 M HCl. Each digestion was stopped by holding at 95 °C for 10 min to 
ensure a complete inactivation of residual enzyme activity.  
All digestion processes were performed at 37 °C and all obtained hydrolysates were purified 
separating the undigested proteins, the high molecular-weight polypeptides and the intact enzymes 
by ultrafiltration through membranes with a 3-kDa molecular weight cut-off (MWCO) (Millipore, 
USA) at 12,000 g for 30 min at 4 °C. Finally, the permeated peptides were collected and stored at 
-20 °C until used in further experiments.  
 
7.2.4 Evaluation of the percent peptide yield and DH of the hydrolysates 
The peptide concentration (µg/µL) of each hydrolysate was determined according to a literature 
method,22 which is based on chelating the peptide bonds by Cu(II) in alkaline media and 
monitoring the change of absorbance at 330 nm according to Lammi et al., 2016.23 The percent 
peptide yield from the HPC was determined as the ratio between peptide concentration and the 
protein concentration of the non-hydrolyzed HPC, estimated by Bradford assay. The degree of 
hydrolysis was determined by the OPA assay, according to Nielsen et al., 200124 with some 
modifications. This assay is based on the formation of an adduct between the α-amino groups of 
peptides and the OPA reagent. The assay consisted of mixing 200 µL of OPA reagent with 26.6 
µL of hydrolysates. After 1.5 min of incubation at 25 °C, the absorbance was measured at 340 nm 
using the Synergy H1 fluorescent plate reader (Biotek, Bad Friedrichshall, Germany).  
 
7.2.5 Tricine SDS-PAGE Separation 
To monitor the efficacy of  hydrolysis, Tris-Tricine SDS-PAGE was used following a literature 
method.25 A 16.0% resolving gel using 40% acrylamide/bis solution (19:1) and 6 M urea was 
prepared and overlaid with 5% stacking gel. A fixed volume (500 µL) of each hydrolysate was 
dried and dissolved in 15 µL of 2X loading buffer containing SDS, β-mercaptoethanol, glycerol 
and Coomassie G-250 stain. The mixture was heated in a boiling water bath for 5 min, vortexed 
for 30 sec, and allowed to cool to room temperature. All the 15 µL of the sample were loaded onto 
the gel. A mixture of proteins (range 26.7 kDa -1.4 kDa, Biorad) was used as a broad range MW 
marker. The cathodic compartment were filled with Tris–Tricine buffer, pH 8.3, containing 0.1%, 
m/v SDS, whereas the anodic compartment was filled with Tris-HCl, pH 8.9. Electrophoreses were 
run on a Mini-Protean II Cell at 100 V until the dye front reached the gel bottom. The resolved 
 145 
 
protein bands were stained by immersing the gel in a solution containing 45% methanol, 10% 
glacial acetic acid, and 0.25% Coomassie Brilliant Blue R-250 for 1.5 h. To visualize the bands, 
the gel was destained in a solution containing 45% methanol and 10% glacial acetic acid until they 
were clearly visible. 
 
7.2.6 MS/MS peptide profiling 
The peptide solutions (100 µL) were desalted on SepPak C18 cartridge (Thermo Fisher Scientific, 
Life Technology, Milan Italy) conditioned with MeOH and rinsed with 0.1% FA. Peptides were 
eluted from the SPE column with 280 μL ACN:H2O (80:20, v/v) containing 0.1% FA and then 
dried in a Speed-Vac (Martin Christ). Each sample was reconstituted with 20 μL of a solution of 
2% ACN, 0.1% FA, properly diluted, and analyzed on a SL IT mass spectrometer interfaced with 
a HPLC-Chip Cube source (Agilent Technologies, Palo Alto, CA, USA). Each sample was loaded 
onto a 40 nL enrichment column (Zorbax 300SB-C18, 5 µm pore size), and separated onto a 43 
mm × 75 µm analytical column packed (Zorbax 300SB-C18, 5 µm pore size). Separation was 
carried out in gradient mode at a flowrate of 300 nL/min. The LC solvent A was 95% water, 5% 
ACN, 0.1% formic acid; solvent B was 5% water, 95% ACN, 0.1% formic acid. The nano pump 
gradient program was as follows: 5% solvent B (0 min), 80% solvent B (0–40 min), 95% solvent 
B (40–45 min), and back to 5% in 5 min. A reconditioning at the initial chromatographic conditions 
was conducted for 5 minutes. The drying gas temperature was 300 °C, flow rate 3 L/min (nitrogen). 
Data acquisition occurred in positive ionization mode. Capillary voltage was −1950 V, with 
endplate offset −500 V. Full scan mass spectra were acquired in the mass range from m/z 300 to 
2000 Da. LC-MS/MS analysis was performed in data-dependent acquisition AutoMS(n) mode. In 
order to increase the number of identified peptides, three technical replicates (LC–MS/MS runs) 
were run for each of the three experimental replicates. 
 
7.2.7 Database searching, protein identification and validation 
The MS/MS data were analyzed by Spectrum Mill Proteomics Workbench (Rev B.04.00, Agilent), 
consulting the C. sativa (531 sequences) protein sequences database downloaded from the National 
Center for Biotechnology Information (NCBI). The enzymes selected were pepsin and trypsin for 
the analysis of the peptic and tryptic hydrolysates, respectively; whereas none specific cleavage 
was selected for analyzing the pancreatic and co-digested hydrolysates. Two missed cleavages 
were allowed to each enzyme used; peptide mass tolerance was set to 1.2 Da and fragment mass 
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tolerance to 0.9 Da. For quality assignment, a sequence tag lengths > 4 was used. Threshold used 
for peptide identification score ≥ 6; Scored Peak Intensity SPI% ≥ 70%; autovalidation strategy 
both in peptide mode and in protein polishing mode was performed using FDR cut-off ≤ 1.2 %. 
Protein abundance was performed at protein level using Total Protein Spectral Intensity (TPSI) 
based on the summation of peptide intensities, calculated from extracted ion chromatograms from 
each precursor ions.  
 
7.2.8 Amino acid composition 
The amino acid compositions of the hempseed hydrolysates and the isoelectric points (pI) were 
determined using ProtParam tool (http://web.expasy.org/protparam/).26 Hierarchical clustering 
analysis (HCA) and its visualization were performed using Cluster 3.0 and Java TreeView, 
respectively. HCA allows the presentation of cluster results in a dendrogram, where the similarity 
among the samples is determined from the value on the distance axis at which they join in a single 
cluster (the smaller the distance, the more similar the sample). Euclidean distance was used to 
calculate the matrix of all samples. The complete linkage method was then used in the assignment 
of clusters.  
 
7.2.9 HMGCoAR activity assay 
The HMGCoAR inhibitory activity of each hydrolysate was evaluated using a commercial assay 
Kit providing HMGCoAR (catalytic domain), NADPH, assay buffer, and substrate solution. The 
experiments were carried out at 37 °C following the manufacturer’s instructions. Each reaction 
(200 μL) was prepared by adding the reagents in the following order: 1X assay buffer; 0.2, 0.3, 
0.5, and 1.0 mg/mL of co-digested peptides,  with 1.0, and 2.0 mg/mL of the peptides digested 
with pancreatin, 0.1, 0.25, 0.35, 0.5, and 1.0 mg/mL of the peptides digested with pepsin, or 0.2, 
0.5, and 1.0 mg/mL of the peptides digested with trypsin or vehicle (C); NADPH (4 μL); substrate 
solution (12 μL); and finally HMGCoAR (2 μL). Subsequently, the samples were mixed, and the 
absorbance at 340 nm was read by a microplate reader (Synergy H1 from Biotek, Bad 
Friedrichshall, Germany) at 0 and 10 min. The HMGCoA-dependent oxidation of NADPH and 
the inhibition properties of hempseed peptides were measured by the absorbance reduction, which 
is directly proportional to the enzyme activity.  
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7.2.10 Profile of potential biological activities and peptide ranking 
The potential bioactivities of hempseed peptides were predicted using the open access tool 
PeptideRanker (http://bioware.ucd.ie/compass/biowareweb/),27 a web-based tool used to predict 
the probability of biological activity of peptide sequences. Using N-to-1 neural network 
probability, PeptideRanker provides peptide scores in the range of 0–1. The maximum scores 
indicate the most active peptides, whereas the minimum scores denote the least active peptides. 
Here, only those peptides with a score higher than 0.6 were considered as potentially “bioactive”. 
Subsequently, the lists of best-ranked peptides were submitted to the web-available database 
BIOPEP (http://www.uwm.edu.pl/biochemia/index.php/pl/biopep/). 
 
7.2.11 Statistical analysis in the HMGCoAR activity assay 
Statistical analyses were carried out by One-way ANOVA (Graphpad Prism 6) followed by 
Dunnett’s test. Values were expressed as means ± SD; P-values < 0.05 were considered to be 
significant.  
 
7.3 Results 
7.3.1 Hydrolysis trend, yield, and DH of hempseed hydrolysates 
In order to produce protein hydrolysates endowed with potential biological activities, HPC was 
digested using one enzyme, i.e. pepsin, trypsin, or pancreatin, or a mixture of the same enzymes 
in order to mimic the gastrointestinal digestion. The highest peptide yield was observed for the 
pancreatic hydrolysate (43%), followed by the tryptic hydrolysate (24.6%), the co-digested 
hydrolysate (18.2%) and the peptic one (16%). The DH values were 19.7% for peptic hydrolysate, 
46.6% for tryptic, 47.5% for pancreatic, and 34% for codigested. These results indicate a direct 
correlation between the peptide yields and the DH values, the trends across all hydrolysates are 
comparable.  
In order to monitor the efficiency of the hydrolysis, a tricine-SDS-PAGE was used to resolve the 
peptide pool composition of each hydrolysates. Figure 7.1 shows the profile of the molecular 
weight distribution at the end of digestion. The peptic hydrolysate showed many continuous, 
intense and unresolved bands in the range from 3.5 to 26.6 kDa, the co-digested hydrolysate 
displayed another band-rich profile, whereas the tryptic and pancreatic presented only small bands 
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between 6.5 and 26.6 kDa. The absence of intense bands indicated that these hydrolysates 
contained mostly very short peptides (MW smaller than 3.5 kDa) that had diffused through the gel. 
The results of the percent peptide yields and DH were in agreement with these findings: in fact, 
consistently, yields and DH were larger when the bands were more difficult to visualize on the 
gels.  
 
Figure 7.1 - Tricine-SDS-PAGE of hempseed protein hydrolysates. M (marker) 26.6-3.5 kDa. Pep, 
Tryp, Panc, Cod represent the four hydrolysates.  
 
7.3.2 Chemical characterization of the protein hydrolysates 
The characterization of the four hydrolysates was carried out by HPLC-Chip MS/MS analysis. 
The results are summarized in Table 7.1S (Supplementary materials), which reports the 
identified peptides according to their parent proteins. The chromatograms of each hydrolysate 
are reported in Figure 7.1S (Supplementary materials). The peptic hydrolysate was the richest 
both in terms of identified peptides and proteins. In fact, it was possible to detect 90 peptides 
belonging to 33 C. sativa proteins, whereas in the codigested sample 62 peptides belonging to 
25 proteins were identified. In the tryptic digest, it was possible to detect 25 peptides 
accounting for 6 proteins, while only 9 peptides deriving from 6 proteins were identified in the 
pancreatic hydrolysate. Therefore, the composition in terms of proteins and peptides is very 
specific for each hydrolysate. Figure 7.2A shows the percent distribution of the peptides 
deriving from specific parent proteins in each hydrolysate. The peptic hydrolysate contained 
peptides derived from numerous proteins, with a small prevalence of the two isoforms of 
Edestin (6% from Edestin 1 and 6% from Edestin 2), as well as DNA-directed RNA 
polymerase subunit beta (6%) and Protein Ycf2 (6%). The percentage of peptides deriving 
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from Edestin increased greatly in the tryptic hydrolysate (40% from Edestin 1 and 24% from 
Edestin 2). Phenylalanine ammonia-lyase and Ribulose 1,5-bisphosphate 
carboxylase/oxygenase were instead the most abundant parent proteins in the pancreatic 
hydrolysate, accounting for 34% and 22%, respectively. On the contrary, Photosystem I P700 
chlorophyll (10%), Edestin 2 (8%), NADH-ubiquinone oxidoreductase (6%), and 4-
coumarate:CoA ligase (6%) were the parent proteins of most peptides in the co-digested 
hydrolysate. The Venn diagram (Figure 7.2B) highlights the distribution of the parent proteins 
among the hydrolysates. Only 13 proteins are common to the peptic and the co-digested 
hydrolysates, whereas none protein is shared by all hydrolysates. These results suggest a very 
high selectivity of the hydrolytic processes that produced peptide mixtures with different 
compositions.  
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Figure 7.2 - A) Percent distribution of identified peptides according to their parent proteins. B) 
Venn diagrams of the total number of identified proteins in each hydrolysate.  
 
Based on MS/MS results, the clustering of the molecular weights (MW) distribution of the peptides 
released after HPC digestion is reported in Figure 7.3A. Pepsin hydrolysis produced a high 
number of peptides that fall into the ranges of 1000-1500 and 2000-2500 Da, whereas the simulated 
gastrointestinal digestion yielded predominantly peptides in the 1500-2000 Da range. Hierarchical 
clustering analysis (HCA) was applied to classify all samples according to their amino acid 
composition (AAC) as reported in Figure 7.3B. The tryptic, peptic, and co-digested hydrolysates 
showed a similar AAC, whereas the pancreatic mixture displayed a different AAC. The amino acid 
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similarity among all hydrolysates is the driven factory on which the clusters are built. Each step in 
the clustering process is illustrated by a joint of the tree. Glu, Gly, Pro, Phe, Val, and Try are 
frequently occurring in the peptic, tryptic, and co-digested hydrolysates, whereas they are poorly 
expressed in the pancreatic mixture. On the contrary, Met, Arg, Ala, and Cys were the most 
abundant amino acid residues in the pancreatic mixture.  
 
 
 
Figure 7.3 - A) MW distribution (in Da) of the identified peptides in each hydrolysate. B) Hierarchical 
clustering analysis (HCA) with dendrogram of amino acid data set composition of each hydrolysate. 
 
 
7.3.3 Inhibitory effects of the hydrolysates on the HMGCoAR activity 
In order to evaluate experimentally the ability of the different hydrolysates to inhibit the 
activity of HMGCoAR, 23 an in vitro assay was performed using the purified catalytic domain 
of this enzyme. Peptide concentrations ranging from 0.2 to 2.0 mg/mL were tested. Figure 7.4 
shows that, after incubation with the peptic hydrolysate (0.25, 0.5, and 1.0 mg/mL), the 
HMGCoAR activity was inhibited by 24.5 ± 1.7% (p<0.001), 61.1 ± 0.7% (p<0.001), and 80.0 
± 4.0% (p<0.001), respectively, versus the control. After the incubation with the tryptic 
hydrolysate (0.2, 0.5, and 1 mg/mL), the HMGCoAR activity was inhibited by 24.6 ± 4.6% 
(p<0.05), 58.4 ± 1.1% (p<0.001), 93.3 ± 9.3% (p<0.001), respectively, versus the control. After 
incubation with the co-digested hydrolysate (0.2, 0.5, and 1.0 mg/mL), the HMGCoAR activity 
was inhibited by 16.2 ± 12.6% (p<0.01), 50.6 ± 2.3% (p<0.001), 47.4 ± 1.5% (p<0.001). 
Finally, after incubation with the pancreatic hydrolysate the HMGCoAR activity was not 
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significantly inhibited at 1.0 mg/mL, whereas a moderate but significant inhibition by 11.7 ± 
6.4% (p<0.05) was observed at 2.0 mg/mL.  
 
 
Figure 7.4 - Effect of the hydrolysates on the catalytic domain of HMGCoAR. Bars indicate the 
effects of each hydrolysate on the HMGCoAR activity at the following concentrations: (A) peptic 
hydrolysate (0.1, 0.25, 0.35, 0.5, and 1.0 mg/mL); (B) tryptic hydrolysate (0.2, 0.5, and 1 mg/mL); (C) 
pancreatic hydrolysate (1.0, 2.0 mg/mL); (D) co-digested hydrolysate (0.2, 0.5, and 1.0 mg/mL). 
HMGCoAR, physiologically, catalyzes the four-electron reduction of HMG-CoA to coenzyme A (CoA) 
and mevalonate (HMG-CoA + 2NADPH + 2H+ > mevalonate + 2NADP+ + CoA-SH). In this assay, 
the decrease in absorbance at 340 nm, which represents the oxidation of NADPH by the catalytic subunit 
of HMGCoAR in the presence of the substrate HMG-CoA, was measured spectrophotometrically. Data 
points represent averages ± SD of three independent experiments in triplicate. (*) p < 0.05, (**) p < 
0.001, and (***) p < 0.0001 versus control (C). 
 
 
7.3.4 Peptide ranking, protein abundance and bioactivity searching 
In order to extend the investigation to other potential bioactivities, the peptidome maps were 
ranked by the tool PeptideRanker. At the end of this process, only those peptides showing score 
values higher than 0.6 were considered as potentially bioactive. The data reported in Table 7.1 
demonstrate that there is not any correlation between high-scored peptides and the total protein 
spectral intensity (TPSI) of the proteins from which they are released. In particular, as shown in 
Figure 7.5, a great number of potentially bioactive peptides belong to less abundant proteins. For 
example, QIQFEGFCRF (score 0.92) derives from DNA-directed RNA polymerase subunit beta, 
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which is one of the least abundant proteins detected in the hydrolysates. On the contrary, only one 
peptide derived from Edestin 2, DIFNPRGG (score 0.74), was supposed to be bioactive.  
In order to hypothesize their possible bioactivities, the best scored peptides were submitted to 
BIOPEP search (Table 7.1). The alleged biological activities included the inhibition of dipeptidyl 
peptidase-IV (DPP-IV) and of angiotensin converting enzyme I (ACE), the antioxidant property, 
and the glucose uptake stimulating activity. Most bioactive peptides were detected in the 
hydrolysates deriving from the peptic and/or the simulated gastrointestinal digestion. Following 
the bioinformatic prediction, bioactivities are prevalently provided by short sequences of two or 
three amino acids included in their structures.  
 
Figure 7.5 - PeptideRanker score of potentially bioactive peptides vs. Total Protein Spectrum 
Intensity (TPSI) of parent proteins. 
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Table 7.1 Predicted bioactive peptides by PeptideRanker and BIOPEP 
Protein Acc. N. Peptide sequence  
TPSI x 
106 
Enzy
me 
Scor
ea 
Potential bioactive peptidesb Biological functionsb 
A0A0C5ARZ4 SHLNWVCIFLGFHSFGLYI 67,6 Pep 0.94 GLY 
Regulating phospho inositol 
mechanism peptide 
     
GF, IF, GL, HL, FG, LG, SF, LN, 
GLY, IFL 
ACE-inhibitor 
     HL, LY Antioxidative 
     
FL, WV, HL, GL, GF, HS, LN, 
NW, SF, SH, YI 
Dipeptidyl peptidase IV inhibitor 
A0A0C5ARQ8 QIQFEGFCRF 29,9 Pep 0.92 RF. GF, EG ACE-inhibitor 
     EG, GF, IQ, QF, QI Dipeptidyl peptidase IV inhibitor 
A0A0C5ARZ4 IPDKANLGFRFP 67,6 Pep 0.87 RF, FP, IP, GF, FR, LG, KA ACE-inhibitor 
     KA, IP, FP, FR, GF, NL  Dipeptidyl peptidase IV inhibitor 
A0A0C5B2L0 SSEKGMIATFCCITGLL 38,4 Cod 0.86 IA, GM, GL, KG, TG, EK, TF ACE inhibitor  
     LL Glucose uptake stimulating peptide  
     SE 
Stimulating vasoactive substance 
release  
     IA, EK, GL, AT, KG, MI, TF, TG Dipeptidyl peptidase IV inhibitor 
H9A8L3 IPWTQLSPIRCAAESWAHM 44,1 Pep 0.80 IR, LSP, IP, AA, TQ, AH, WA ACE inhibitor 
     AH, PWT, PW, IR  Antioxidative 
     IR Renin inhibitor 
     WA 
Activating ubiquitin-mediated 
proteolysis 
     
IP, SP, WA, AA, WT, AE, AH, ES, 
IR, PI, PW, QL, SW, TQ 
Dipeptidyl peptidase IV inhibitor 
C6KI62 PIGISDWNSLFWIVHP 41,9 Cod 0.79 LF, IG, GI, HP ACE inhibitor  
     IV  Glucose uptake stimulating peptide 
     HP, SL, WI, WN, GI, PI, VH  Dipeptidyl peptidase IV inhibitor 
A0A0C5APZ1 
LPDTHGEAHYSTCMLLAGILLKM
G 
40,2 Pep 0.78 
HY, LA, GI, AG, MG, HG, GE, 
EA, AH, IL, ST 
ACE inhibitor  
     II, IL Glucose uptake stimulating peptide 
     AH, LK Antioxidative 
  
   
LA 
Activating ubiquitin-mediated 
proteolysis 
  
   LA, LP, LL , AG, AH, GE, GI, HY, 
IL, MG, ML, TH, YS  
Dipeptidyl peptidase IV inhibitor 
A0A088MFF4 PGRVLSLFVTLTLGWPLY 69,9 Pep 0.74 PG Prolyl endopeptidase inhibitor 
     LY, LF, PL, GW, GR, LG, PG  ACE inhibitor  
     VL Glucose uptake stimulating peptide 
   
  
PG 
Peptide regulating the stomach 
mucosal membrane activity 
     LY, WPL Antioxidative 
  
   WP, SL, PL, GW, LT, PG, TL, VL, 
VT 
Dipeptidyl peptidase IV inhibitor 
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a. From PeptideRanker 
A0A090CXP8 DIFNPRGG 359,0 Cod 0.74 PR, IF, GG  ACE inhibitor 
     NP, FN, GG, RG Dipeptidyl peptidase IV inhibitor 
A6P6W0 RIWGEKYFGKNFNRLVKVK 63,0 Pep 0.73 
RL, FGK, IW, VK, FG, GK, WG, 
GE, NF, KY, EK 
ACE inhibitor 
     LV Glucose uptake stimulating peptide 
     VKV, WG  Antioxidative 
  
   EK, WG, FN, GE, IW, KV, KY, 
LV, NF, NR, RI, RL, RL, VK, YF  
Dipeptidyl peptidase IV inhibitor 
A7IZZ1 VRFEPQFSYFRI 40,9 Pep 0.71 RF, FR, VR, SY, PQ, FEP ACE inhibitor 
     EP, VR, FR, PQ, QF, RI, SY, YF  Dipeptidyl peptidase IV inhibitor 
E5DL82 PRNSWISCNMRLNAITL 64,8 Cod 0.70 RL, PR, LN, AI  ACE inhibitor 
   
  WI, LN, MR, NA, NM, RL, RN, 
SW, TL 
Dipeptidyl peptidase IV inhibitor 
H9A1V5 NDVKKFIAGQVASFKRL 30,8 Cod 0.69 
RL, VK, IA, KR, AG, GQ, SF, KF, 
FKR 
ACE inhibitor 
     GQ  Neuropeptide  
     KK  Bacterial permease ligand  
     KF Renin inhibitor  
  
   VA, GQ, IA, AG, AS, KF, KK, KR, 
ND, QV, RL, SF, VK 
Dipeptidyl peptidase IV inhibitor 
H9A8L2 SPIGGGPEQLVMFVVLKNGY 39,9 Cod 0.68 GP  Prolyl endopeptidase inhibitor  
     MF, GY, GP, IG, GG, NG ACE inhibitor 
     GP Antithrombotic  
     VL, LV  Glucose uptake stimulating peptide  
  
   
GP 
Peptide regulating the stomach 
mucosal membrane activity  
     LK  Antioxidative peptide  
  
   GP, VV, SP, GG, GY, LV, MF, 
NG, PI, QL, VL, VM 
Dipeptidyl peptidase IV inhibitor 
H9A8L2 GAVLNIAECCLLPTSYPRKDD 39,9 Pep 0.67 
YPR, PR, YP, LLP, IA, GA, SY, 
IAE, LN, PT, AV, AVL 
ACE inhibitor 
     VL, LL  Glucose uptake stimulating peptide  
     KD  Antioxidative peptide  
  
   LP, LL, YP, GA, IA, AE, AV, LN, 
PT, RK, SY, TS, VL  
Dipeptidyl peptidase IV inhibitor 
A0A0E3TIL1 NPRENFLKCFSKHIPNNVA 31,9 Pep 0.66 PR, IP, NF, CF  ACE inhibitor 
     LK Antioxidative peptide  
  
   VA, IP, NP, FL, HI, KH, NF, NN, 
NV, PN, SK 
Dipeptidyl peptidase IV inhibitor 
E5DL82 LICILLFIGAVGKS 64,8 Cod 0.64 LF, VG, IG, GA, GK, LLF, AV, IL  ACE inhibitor 
     IL, LI, LL  Glucose uptake stimulating peptide  
     LL, GA, AV, IL, KS, LI, VG  Dipeptidyl peptidase IV inhibitor 
A0A0C5AUJ6 GPTPISALIHAATM 465,0 Pep 0.63 GP  Prolyl endopeptidase inhibitor  
     GP, AA, PT, TP, TP ACE inhibitor 
     LI  Glucose uptake stimulating peptide  
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b. From BIOPEP
  
   
GP  
Peptide regulating the stomach 
mucosal membrane activity  
  
   GP, HA, TP, AL, AA, AT, IH, LI, 
PI, PT, TM 
Dipeptidyl peptidase IV inhibitor 
A6P6W0 GEKYFGKNFNRLVKVKT 63,0 Cod 0.63 
RL, FGK, VK, FG, GK, GE, NF, 
KY, EK 
ACE inhibitor 
     LV Glucose uptake stimulating peptide  
     VKV Antioxidative  
  
   EK, FN, GE, KT, KV, KY, LV, NF, 
NR, RL, VK, YF  
Dipeptidyl peptidase IV inhibitor 
A0A0C5B2I8 ATGRIVCANCHLANKPVDIEVP 19,4 Cod 0.61 
LA, VP, HL, GR, TG, NK, KP, IE, 
EV 
ACE inhibitor 
     IV Glucose uptake stimulating peptide  
     HL, KP Antioxidative  
  
   
LA  
Ubiquitin-mediated proteolysis 
activating peptide  
  
   LA, VP, KP, HL, AT, EV, PV, RI, 
TG, VD 
Dipeptidyl peptidase IV inhibitor 
H9A1V5 ALSKNSMVKKFNLSSIKYIG 30,8 Pep 0.61 VK, IG, KY, KF, IKY ACE inhibitor 
     KF  Renin inhibitor  
  
   AL, FN, KF, KK, KY, MV, NL, SI, 
SK, VK, YI  
Dipeptidyl peptidase IV inhibitor 
E5DKP2 YSIQKVFSAGRLVGGEKGPYSV 60,7 Tryp 0.60 GP  Prolyl endopeptidase inhibitor 
  
   RL, VF, GP, VG, AG, GR, KG, GE, 
GG, QK, EK, KGP, EKGP  
ACE inhibitor 
     LV  Glucose uptake stimulating peptide  
  
   
GP  
Peptide regulating the stomach 
mucosal membrane activity  
     GGE  Antioxidative  
  
   GP, EK, AG, GE, GG, IQ, KG, KV, 
LV, PY, RL, SI, SV, VF, VG, YS  
Dipeptidyl peptidase IV inhibitor 
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 7.4 Discussion 
The first objective of the study was the characterization of the composition of the four 
hydrolysates, an important step in the pathway to evaluate their potential use as functional 
ingredients. Having this final goal, all enzymatic digestions were performed avoiding the use of 
reducing and alkylating agents in order to produce, as far as possible, unmodified and natural 
peptides. This choice of course partially impaired the hydrolytic efficiency of the enzymes.  
All employed enzymes were endopeptidases that, with the exception of trypsin, randomly 
hydrolyze peptide bonds within the protein sequences, producing peptides differing in amino acid 
sequences and sizes. The resulting hydrolysates were diverse in terms of composition and percent 
yield of peptides. Pancreatin gave the highest percent yield: this may be attributed to the endo- and 
exo-peptidase activities of this enzyme, which increases protein digestion through hydrolysis of 
more peptide bonds, when compared to enzymes only endowed with an endopeptidase activity.28 
Another high percent yield was observed with trypsin, even if this enzyme is well known for the 
high selectivity and specificity in site cutting recognition. A higher peptide yield is the expected 
outcome for increased protein breakdown and a marker of the hydrolytic process efficacy. The 
consequence of the high hydrolytic efficiency of these enzymes was the relatively small number 
of peptides that were identified in their hydrolysates, probably due to an extensive production of 
very short peptides, i.e. di-, tri- and tetra peptides, which are difficult to detect using a data-
dependent shotgun approach.  
The identified peptides ranged from 7 to 29 amino acid residues, i.e. between 747 Da and 3211 
Da, in agreement with the ultrafiltration separation that had been performed with a cut-off of 3 
kDa. These values correspond to peptides slightly longer than those reported in other studies after 
similar digestions of various animal proteins.29 Possibly, this might be explained by the protease 
inhibitors present in most plant seeds. In addition, the missing reduction and alkylation of the 
disulfide bonds reduced the proteolytic activity of each enzyme resulting in longer peptides.   
In order to investigate the different features of the hydrolysates, the HCA of the AAC of all 
identified peptides was employed combining the heat map with a dendrogram. The clustering 
provides the basis for guiding reasonable enzyme selection in order to produce hydrolysates 
endowed of specific chemicals features. As shown by Figure 7.3B, peptic and co-digested 
hydrolysates form two very close clusters according to their amino acid similarity. The AAC of 
the tryptic hydrolysate has also some similarity with the peptic and co-digested hydrolysates, but 
it falls at a wider distance. On the contrary, the pancreatic hydrolysate is well separated from the 
others.  
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The peptic and codigested clusters are near, possibly the effects of pepsin prevails since this 
enzyme is the first applied in the codigestion. The tryptic cluster falls at a certain distance, since 
its cut sites are different from those recognized by pepsin. Finally, the pancreatic one is the most 
distant, since in this case the peptide hydrolysate is generated either by endo- or exopeptidase 
action. 
 
Apparently, their substantial structural diversities reflect also their different capability of inhibiting 
the activity of HMGCoAR, a key enzyme in the synthesis of endogenous cholesterol and the main 
target of statins, which interact with this enzyme as competitive inhibitors.30 The experiments 
performed using the purified catalytic domain of this enzyme showed that the tryptic and peptic 
hydrolysates were the best inhibitors (Figure 7.4), whereas the pancreatin hydrolysate was the 
least active, in line with the clustering provided by the HCA analysis. The pancreatic hydrolysate 
contains numerous residues of hydrophilic amino acids, such as Glu, Ser, Arg, and Lys, whereas 
it is completely devoid of Pro and Val, which are abundant in the other hydrolysates. This may be 
related to a synergistic effect of the hydrophobic peptides present in the mixtures, since the 
hypocholesterolemic effect is correlated to an increased hydrophobicity.31  
In a previous paper, we have investigated the interaction of some soy peptides with the catalytic 
domain of HMGCoAR using in silico modeling studies.32 Medium size peptides, containing 8-10 
amino acid residues and characterized by a hydrophobic N-terminus and a negatively charged C-
terminus, appeared to be particularly favorable for interacting with HMGCoAR. The negatively 
charged C-terminal portion is primarily involved in the inhibition by mimicking most of the polar 
interactions that are clearly seen also in statins,32 whereas the hydrophobic N-terminal portion is 
inserted in a deeper and rather polar sub-pocket that corresponds roughly to that harboring the 
NADPH cofactor. In fact, HMGCoAR contains a second relevant domain that is capable of 
accepting NADPH: a peptide that prevents this binding impairs the catalytic activity of the 
enzyme.32  
In order to predict other potential activities, it was decided to use cost effective and time-saving 
computer simulated approaches, such as PeptideRanker and BIOPEP. It is important, however, to 
underline that these tools take into consideration only some possible biological activities, 
excluding for example the inhibition of HMGCoAR. At the end of the procedure, 22 peptides were 
postulated to be bioactive. In agreement with the features of BIOPEP, the main proposed activities 
were the inhibition of dipeptidyl peptidase-IV (DPP-IV) and of angiotensin converting enzyme I 
(ACE), the antioxidant properties, and the glucose uptake stimulating activity. The forecasted 
activities are linked to specific short sequences, mostly composed by two or three amino acid 
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residues, encrypted in their sequences. Specifically, PWT, WPL, and VKV provide antioxidant 
activities, which could depend on the presence of substantial amounts of hydrophobic, branched-
chain, or aromatic amino acid residues. The hydrophobicity is also important to enhance their 
permeability into the target organs through hydrophobic associations with the cell membrane lipid 
bilayer, promoting the achievement of potent antioxidant effects.33 In the meanwhile, the 
compresence of hydrophobic or aromatic amino acids at the C-terminus as well as of hydrophobic 
and negative ionizable functions (Thr, Glu, Asp, Ser, Met) positively contributes to an effective 
ACE inhibition.1, 34, 35 Specifically, the sequences LSP, FEP, and IAE fall in this category. 
However, also branched-chain aliphatic amino acids at the C-terminus as well as hydrophobic 
amino acids at the N-terminus, such as IFL, LLP, AVL, LLF, contribute to high ACE-inhibitory 
activities.28, 36 Finally, also the small sequence GP is expected to provide bioavailability and ACE-
inhibitory activity owing to its short sequence, hydrophobicity, and theoretical stability to pepsin 
and trypsin cleavage.37 The ACE inhibitory activity as well as the antioxidant activity of hempseed 
hydrolysates are confirmed experimentally by literature.28  
Another proposed activity is the inhibition of DPP-IV. This enzyme is a new molecular target 
correlated with the development of type 2 diabetes.38 The peptides capable of inhibit the DPP-IV 
activity have in general a hydrophobic character and a length from 2 to 8 amino acids. Very often, 
they contain a Pro residue in their sequence located at the first, second or third or fourth N-terminal 
position, which is flanked by Leu, Val, Phe, Ala or Gly.39, 40 A paper has investigated the DPP-IV 
inhibitory activity of hempseed protein hydrolysates obtained treating a HPC with different 
enzymes obtaining a first indication of a moderate activity also on this enzyme.41  
In conclusion, it seems possible to affirm that there are good prospective that hempseed 
hydrolysates may be used as multipurpose ingredients in functional foods. Of course, when 
discussing the bioactivities of food peptides an open issue remains their bioavailability. In case of 
hempseed peptides, this problem is still to be taken into consideration. However, it is useful to 
remind that different authors have confirmed the bioavailability of peptides deriving from other 
food proteins. 23, 42-44 
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Table 7.1S LC-ESI-MS/MS based identification of hydrolysates of hempseed proteins 
Accession n. a Protein Name Start-end Sequences pIb Net 
Charge b 
Hydrophobicity % c m/z (Da) 
(charge) 
[M+H]+ 
(Da) 
Peptic          
A0A090CXP8 Edestin 2  176-187 (D)WVYNNGDSPLVL(I) 0.7 -1 50 688.60 (2) 1376.69 
  361-370 (V)LYKNGMMAPH(F) 9.7 1.1 50 581.74 (2) 1161.56 
  380-403 (I)YVTRGSARLQVVDDNGRNVFDGEL(R) 4.3 -1 33.3 894.16 (3) 2680.34 
  435-447 (N)DNAMRNPLAGKVS(A) 10.2 1 46.2 458.55 (3) 1372.70 
  235-247 (R)RESGEQTPNGNIF(S) 4.2 -1 23.1 724.68 (2) 1448.67 
A0A090CXP7 Edestin 1 450-460 (A)WVSPLAGRTSV(I) 10.7 1 54.6 586.80 (2) 1172.64 
  178-187 (L)LDTSNVNNQL(D) 0.7 -1 30 559.84 (2) 1117.55 
  279-288 (D)LVSPLRSSQE(H) 6.9 0 40 558.08 (2) 1115.61 
  63-73 (L)IESWNPNHNQF(Q) 5.1 -0.9 36.4 693.73 (2) 1385.62 
  461-469 (V)IRALPEAVL(A) 6.9 0 77.8 491.16 (2) 981.61 
A0A090DLH8 Edestin 1 392-409 (M)YVLRGRARVQVVNHMGQKC(F) 11.2 4 36.8 738.37 (3) 2214.19 
H9A1V3 Acyl-activating enzyme 1 625-639 (I)ERVCNEVDDRVFETT(A) 3.8 -3.1 26.7 623.95 (3) 1868.84 
  170-190 (G)GYLNSAKNCLNVNSNKKLNDT(M) 9.6 1.9 23.8 789.33 (3) 2367.17 
H9A1V4 Acyl-activating enzyme 2 280-298 (H)IFDRVIEELFILHGASIGF(W) 4.3 -1.9 57.9 725.95 (3) 2176.18 
  28-44 (Y)RSMYAKDGFPPPIDGLD(C) 4.0 -1 47.1 627.21 (3) 1878.91 
  442-453 (G)PPVPNVDVCLES(V) 0.7 -2.1 58.3 442.71 (3) 1325.64 
H9A1V5 Acyl-activating enzyme 3 293-312 (L)ALSKNSMVKKFNLSSIKYIG(S) 10.8 4 40 743.33 (3) 2228.25 
  360-382 (N)SGSAGMLASGVEAQIVSVDTLKP(L) 3.9 -1 47.8 739.89 (3) 2217.14 
H9A1V7 Acyl-activating enzyme 5 253-266 (G)YTWGTAAVGATNVC(L) 3.1 -0.1 42.9 491.20 (3) 1470.67 
  497-512 (F)VTLKKGAVRVTVTEKE(I) 10.4 2 37.5 586.93 (3) 1758.05 
  54-62 (T)RCLRVASCI(E) 8.8 1.9 44.4 511.27 (2) 1020.55 
H9A1W0 Acyl-activating enzyme 8 352-373 (D)QNGSAQLAGVSGEVCIRGPNVT(K) 6.1 -0.1 36.4 738.96 (3) 2214.09 
  166-189 (D)VALFLHTSGTTSRPKGVPLTQLNL(A) 11.4 2.1 45.8 850.97 (3) 2550.44 
H9A1W2 Acyl-activating enzyme 10 138-154 (Q)NIAAKTSAQFSLIPSVP(S) 9.7 1 58.8 582.30 (3) 1743.96 
H9A1W3 Acyl-activating enzyme 11  260-268 (F)EMKKMVELI(E) 7.0 0 55.6 560.8 (2) 1120.61 
  8-14 (F)IFRSKLP(D) 11.4 2 57.1 430.58 (2) 860.54 
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H9A8L2 Acyl-activating enzyme 13 160-180 (P)GAVLNIAECCLLPTSYPRKDD(D) 4.2 -1.1 42.9 760.06 (3) 2278.12 
  289-309 (P)LYSRVVEAAPDRVIVLPATGS(N) 6.9 0 57.1 738.54 (3) 2213.23 
  535-547 (Y)PDDQACTGEVGLI(P) 0.5 -3.1 38.5 459.05 (3) 1374.62 
H9A8L3 Acyl-activating enzyme 14 374-392 (A)IPWTQLSPIRCAAESWAHM(D) 7.1 0 57.9 752.00 (3) 2254.09 
  598-615 (I)KRTVGGYFIVQGRADDTM(N) 9.5 1 33.3 672.24 (3) 2014.02 
  631-652 (V)CDRADESIVETAAVSVSPVDGG(P) 3.3 -4.1 40.9 744.98 (3) 2234.02 
A7IZZ2 (+)-alpha-pinene synthase, 
chloroplastic 
270-283 (I)RAEAKWFIEEYEKT(Q) 4.6 -1 35.7 600.89 (3) 1799.90 
  592-606 (G)DGHASQDSHSRKRIS(D) 10.1 1.2 13.3 560.90 (3) 1680.82 
  319-336 (H)SELGKNKMVYARDRLVEA(F) 9.4 1 38.9 693.56 (3) 2079.10 
  185-201 (I)FNDFKDETGKFKASIKN(D) 9.5 1 29.4 663.93 (3) 1989.01 
A0A0C5ARX6 ATP synthase subunit alpha 123-131 (I)STSESRLIE(S) 4.2 -1 22.2 511.23 (2) 1021.52 
  134-154 (P)APGIISRRSVYEPLQTGLIAI(D) 9.9 1 52.4 751.82 (3) 2254.29 
A0A0C5ARS5 ATP synthase subunit beta 382-405 (G)EEHYETAQRVKQTLQRYKELQDII(A) 5.5 -0.9 25 1007.12 
(3) 
3018.56 
  144-158 (D)TKLSIFETGIKVVDL(L) 6.6 0 46.7 554.85 (3) 1662.97 
E5DK51 ATP synthase subunit alpha 151-166 (E)TLYCVYVAIGQKRSTV(A) 9.4 1.9 37.5 620.24 (3) 1857.99 
  287-309 (D)VSAYIPTNVISITDGQICLETEL(F) 0.6 -3.1 43.5 846.10 (3) 2536.29 
A6P6W0 Cannabidiolic acid synthase-
like 1 
504-522 (A)RIWGEKYFGKNFNRLVKVK(T) 11.1 5 36.8 794.75 (3) 2382.36 
  91-104 (V)SHIQGTILCSKKVG(L) 9.7 2 28.6 491.22 (3) 1470.81 
A0A088MFF4 Delta 12 desaturase 179-196 (P)PGRVLSLFVTLTLGWPLY(L) 10.3 1 61.1 677.78 (3) 2032.16 
  331-345 (Y)NAMEATKAVKPILGE(Y) 6.6 0 53.3 524.23 (3) 1571.85 
A0A0C5ARQ8 RNA polymerase subunit 
beta 
1047-1063 (L)RSLALELNHFLVSEKNF(Q) 7.5 0.1 47.1 672.75 (3) 2017.09 
  549-568 (M)QRQAVPLSRSEKCIVGTGLE(S) 8.6 0.9 35 743.36 (3) 2228.18 
  743-752 (L)TPQMAKESSY(A) 6.5 0 30 380.81 (3) 1141.52 
  358-377 (T)STTLTTTFESFFGLHPLSQV(L) 5.1 -0.9 40 738.8 (3) 2213.11 
  17-26 (N)QIQFEGFCRF(I) 6.1 -0.1 40 666.86 (2) 1331.62 
A0A0C5AS14 Hypothetical chloroplast RF1 341-355 (Q)ENSKLEILNEKKGVN(Y) 7.1 0 26.7 572.56 (3) 1714.93 
  259-279 (T)DVEIETTSETKGTKQEQGGST(E) 3.9 -3 9.5 742.45 (3) 2225.04 
A7IZZ1 (-)-limonene synthase, 
chloroplastic 
180-200 (L)RQYGFEVPQEIFNNFKNHKTG(E) 9.4 1.1 28.6 851.36 (3) 2553.26 
  349-360 (G)VRFEPQFSYFRI(M) 9.8 1 50 794.79 (2) 1588.83 
E5DKP2 MatR 382-400 (G)VQLAETLGTAGVRGPQVSV(L) 6.8 0 47.4 627.62 (3) 1882.04 
  242-250 (R)KLAAPLKTH(Y) 10.7 2.1 55.6 489.57 (2) 978.61 
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A0A0C5AUJ6 NADH-plastoquinone 
oxidoreductase subunit 5 
603-622 (M)DWNWYEFLTNATFSVSIASL(G) 0.6 -2 50 788.88 (3) 2364.12 
  256-269 (E)GPTPISALIHAATM(V) 7.8 0.10 64.3 690.19 (2) 1379.74 
A0A0C5APZ1 NAD(P)H-quinone 
oxidoreductase chain 4 
234-257 (W)LPDTHGEAHYSTCMLLAGILLKMG(A) 6.1 -0.9 45.8 876.6 (3) 2628.30 
  230-238 (P)LHTWLPDTH(G) 6.0 -0.8 44.4 373.88 (3) 1119.56 
Q8RVK9 Naringenin-chalcone 
synthase 
353-368 (K)CVEDGLNTTGEGLEWG(V) 0.5 -4.1 25 560.86 (3) 1679.72 
  301-324 (W)IAHPGGPAILDQVESKLALKTEKL(R) 7.8 0.1 50 843.79 (3) 2528.45 
  236-250 (P)IFELVSAAQTILPDS(D) 0.7 -2 60 535.27 (3) 1603.86 
  183-201 (K)GARVLVVCSEITAVTFRGP(N) 8.9 0.9 52.6 678.37 (3) 2032.10 
V5KXG5 4-coumarate:CoA ligase 262-281 (G)ATILIMPKFEIGSLLGLIER(Y) 7.1 0 60 738.78 (3) 2214.29 
  17-23 (I)IFRSKLP(D) 11.4 2 57.1 430.58 (2) 860.54 
F1LKH7 Polyketide synthase 2 371-385 (G)LTVERVVLRSVPINY(-) 9.8 1 53.3 586.93 (3) 1758.03 
  303-310 (A)ILDKVEEK(L) 4.3 -1 37.5 487.31 (2) 973.56 
F1LKH8 Polyketide synthase 4 2-16 (M)NHLRAEGPASVLAIG(T) 7.4 0.1 53.3 502.22 (3) 1504.82 
  256-266 (A)GLIFDLHKDVP(M) 5.0 -0.9 54.6 627.28 (2) 1253.69 
A0A0C5APZ4 Protein Ycf2 1630-1650 (P)FSLRLALSLSRGILVIGSIGT(G) 12.1 2 52.4 725.26 (3) 2173.31 
  1902-1921 (Q)DHGILFYQIGRAVAQNVLLS(N) 7.8 0.1 50 738.97 (3) 2214.20 
  1092-1102 (T)ISPIELQVSNI(F) 0.9 -1 54.6 404.94 (3) 1212.68 
  536-547 (S)ENKEIVNIFKII(T) 7.0 0 50 487.41 (3) 1459.85 
  143-152 (L)YLPKGKKISE(S) 10.1 2 30 581.39 (2) 1162.68 
A0A0C5ARZ4 Photosystem I P700 
chlorophyll a apoprotein A1 
436-454 (I)SHLNWVCIFLGFHSFGLYI(H) 7.2 0.1 52.6 751.46 (3) 2253.13 
  102-122 (W)LSDPTHIGPSAQVVWPIVGQE(I) 3.9 -1.9 52.4 744.39 (3) 2230.15 
  561-572 (L)IPDKANLGFRFP(C) 10.1 1 58.3 458.58 (3) 1374.75 
A0A0C5APY0 Photosystem I P700 
chlorophyll a apoprotein A2 
188-207 (S)LAWTGHLVHVAIPGSRGESV(R) 8.0 0.2 50 695.75 (3) 2086.12 
  247-257 (T)SQGAGTSILTL(L) 3.4 0 36.4 524.2 (2) 1047.57 
  241-258 (S)SHLFGTSQGAGTSILTLL(G) 7.5 0.1 38.9 601.63 (3) 1802.97 
  352-369 (H)MYSLPAYAFIAQDFTTQA(A) 0.7 -1 55.6 680.29 (3) 2037.96 
  695-708 (R)DKPVALSIVQARLV(G) 10.2 1 64.3 503.33 (3) 1508.92 
U6EFF4 Putative LysM domain 
containing receptor kinase 
398-417 (H)LRGSGRDPLTWSSRVQIALD(S) 10.5 1 40 743.19 (3) 2227.20 
  125-144 (V)HRVNMFKPTRIPAGSPINVT(V) 12.1 3.1 50 745.35 (3) 2235.22 
  115-142 (A)FANLTTEDWVHRVNMFKPTRIPAGSPIN(V) 9.9 1.1 50 1071.23 
(3) 
3211.65 
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A0A0E3TIL1 THCA synthase 87-102 (T)PSNNSHIQATILCSKK(V) 10.3 2 31.3 580.67 (3) 1740.91 
  29-47 (A)NPRENFLKCFSKHIPNNVA(N) 9.6 2 42.1 743.33 (3) 2228.14 
  504-522 (A)RIWGEKYFGKNFNRLVKVK(T) 11.1 5 36.8 794.75 (3) 2382.36 
Tryptic          
A0A090CXP7 Edestin 1 245-258 (R)YLEEAFNVDSETVK(R) 3.5 -3 35.7 822.32 (2) 1643.78 
  194-208 (R)FYLAGNPEDEFEQLR(R) 3.5 -3 40 914.4 (2) 1827.86 
  275-284 (K)GTLDLVSPLR(S) 6.6 0 50 535.76 (2) 1070.62 
  417-431 (R)QGQIVTVPQNHAVVK(Q)  9.84 1.1 46.7 540.12 (3) 1617.91 
  176-192 (V)SLLDTSNVNNQLDDNPR(R) 3.4 -2 29.4 958.19 (2) 1914.92 
  198-208 (A)GNPEDEFEQLR(R) 3.5 -3 27.3 667.24 (2) 1333.60 
  485-504 (K)YNREETVLLTSSTSSRREDR(Y)  6.84 0 15 800.87 (3) 2399.19 
  56-73 (R)VEAEAGLIESWNPNHNQF(Q) 3.8 -2.9 44.4 685.85 (3) 2054.96 
  246-258 (Y)LEEAFNVDSETVK(R)  3.54 -3 38.5 740.98 (2) 1480.72 
  150-160 (R)EGDIVAIPAGV(A) 0.7 -2 63.6 520.65 (2) 1040.56 
A0A090CXP8 Edestin 2 284-294 (R)GEDLQIIAPSR(I) 3.9 -1 45.5 599.82 (2) 1198.64 
  320-334 (R)QNIDRPSQADIFNPR(G) 6.5 0 40 591.18 (3) 1770.89 
  397-404 (R)NVFDGELR(E) 3.9 -1 37.5 475.38 (2) 949.47 
  256-268 (L)AESFNVDTELAHK(L) 4.3 -1.9 38.5 487.49 (3) 1460.70 
  163-176 (K)EGDMVAMPAGVADW(V) 0.48 -3 64.3 724.73(2) 1448.62 
  427-439 (F)EWIAVKTNDNAMR(N) 6.9 0 46.2 774.39 (2) 1547.76 
A0A0C5ARX1 Photosystem II protein D1 196-222 (H)PFHMLGVAGVFGGSLFSAMHGSLVTSS(L) 8.4 0.2 51.9 898.35 (3) 2693.32 
  64-92 (I)REPVSGSLLYGNNIISGAIIPTSAAIGLH(F) 7.51 0.1 48.3 974.32 (3) 2920.59 
  332-350 (M)HERNAHNFPLDLAALEVPS(T) 5.1 -1.8 52.6 710.87 (3) 2130.07 
H9A8L3 Acyl-activating enzyme 14 708-722 (K)LLRRVLRDQIKHELS(A)  11.12 2.1 40 938.85 (2) 1876.12 
  214-240 (T)LKQLREQVISVAKALDAMFSKGDAIAI(D) 9.8 1 55.6 972.27 (3) 2915.64 
H9A1W0 Acyl-activating enzyme 8 412-425 (R)IKELINRGGEKISP(I) 9.9 1 35.7 777.94 (2) 1553.90 
  424-440 (I)SPIEVDAVLLSHPDISH(A) 4.2 -2.8 52.9 610.51 (3) 1828.95 
E5DKP2 MatR 386-411 (A)ETLGTAGVRGPQVSVLWGTVKHIRQG(S) 11.2 2.1 38.5 916.57 (3) 2746.51 
  38-59 (F)YSIQKVFSAGRLVGGEKGPYSV(P) 9.9 2 36.4 781.76 (3) 2342.25 
Pancreatic          
A0A0C5ARS5 ATP synthase subunit beta 72-89 (N)NRVRAVAMSATDGLMRGM(D) 11.8 2 50 646.18 (3) 1935.97 
C6KI62 
Chalcone synthase-like 
protein 1 92-110 (P)SLNTRQDMLVVEIPKLGKE(A) 6.8 0 42.1 724.24 (3) 2170.19 
V5KWZ6 
Phenylalanine ammonia-
lyase 489-503 (S)SRKSAESIEILKLMS(T) 9.7 1 40 846.86 (2) 1691.94 
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  357-371 (E)VIRFSTKSIEREINS(V) 10.1 1 33.3 890.50 (2) 1778.98 
  495-510 (E)SIEILKLMSTTFLVAL(C) 6.6 0 62.5 890.23 (2) 1779.03 
E5DLX2 Ribosomal protein S3 318-332 (C)WKLMGKDKVMELIEK(F) 9.6 1 46.7 616.30 (3) 1848.01 
A0A0C5B2I6 
Ribulose bisphosphate 
carboxylase large chain 213-233 (G)HYLNATAGTCEEMMKRAIFAR(E) 8.6 1 42.9 805.13 (3) 2413.16 
  84-95 (R)CYHIEPVAGEEN(Q) 3.84 -3 33.3 680.69 (2) 1360.58 
H9A1V8 Acyl-activating enzyme 6 54-76 (T)YRRCRQFASALTTHSIALGSTVA(V) 10.86 3 39.1 837.39 (3) 2509.31 
Co-digested         
A0A090CXP8 Edestin 2 73-80 (Y)WDIQNTED(D) 0.7 -3 25 510.71 (2) 1020.43 
  113-120 (F)YVIQGRGI(H) 9.6 1 37.5 453.06 (2) 905.52 
  79-90 (T)EDDELHCAGVET(A) 3.3 -5 25 687.88 (2) 1374.55 
  329-336 (A)DIFNPRGG(R) 6.7 0 37.5 438.07 (2) 875.44 
  449-456 (A)MRAMPDDV(L) 3.7 -1 62.5 467.66 (2) 934.41 
A0A090CXP7 Edestin 1 212-221 (G)GRGARFDERI(R) 10.6 1 30 589.35 (2) 1176.62 
  69-89 (P)NHNQFQCAGVAVVRYTIQQNG(L) 8.4 1 33.3 801.72 (3) 2404.16 
H9A1V3 Acyl-activating enzyme 1 242-255 (H)VDAVVIYLAIVLAG(Y) 0.7 -1 78.6 708.26 (2) 1415.85 
  667-678 (T)IDLNQLRLSFNL(G) 6.7 0 50 482.80 (3) 1445.81 
H9A1V5 Acyl-activating enzyme 3 395-411 (K)GPNMMQGYFNNPQATKL(T) 9.7 1 41.2 637.40 (3) 1910.89 
  497-513 (E)NDVKKFIAGQVASFKRL(R) 10.9 3 47.1 641.19 (3) 1921.10 
H9A8L2 Acyl-activating enzyme 13 259-285 (A)PKEIASRLHVSQAKAIFTQDFILRGGR(K) 11.4 3.1 44.4 
1013.38 
(3) 3038.70 
  635-654 (V)SPIGGGPEQLVMFVVLKNGY(D) 6.6 0 50 702.39 (3) 2105.11 
H9A8L3 Acyl-activating enzyme 14 311-330 (P)DKVIVLPAIGSNVGIQLREQ(D) 7.0 0 50 717.00 (3) 2149.24 
  537-556 (L)VILDEHGNPFPDDQACIGEV(G)  3.25 -5 45 723.31 (3) 2168.00 
E5DK51 ATP synthase subunit alpha 271-284 (G)AGSLTALPVIETQA(G) 0.9 -1 57.1 686.28 (2) 1370.75 
  90-110 (I)ERKSVHEPMQTGLKAVDSLVP(I) 7.8 0.1 42.9 774.31 (3) 2321.23 
A0A0C5ARX6 ATP synthase subunit alpha 149-168 (Q)TGLIAIDSMIPIGRGQRELI(I) 6.6 0 50 718.21 (3) 2153.21 
  441-459 (T)GTNGYLDSLEIGQVRKFLL(E) 6.9 0 36.8 708.44 (3) 2123.15 
A0A0C5AS06 
ATP-dependent Clp protease 
proteolytic subunit 26-40 (R)LYRERLLFLGQEVDS(E) 4.3 -1 40 919.74 (2) 1837.98 
A6P6W0 
Cannabidiolic acid synthase-
like 1 366-383 (F)KKEILLDRSGGRKAAFSI(K) 10.9 3 38.9 663.77 (3) 1989.16 
  507-523 (W)GEKYFGKNFNRLVKVKT(K)  10.76 4 29.4 677.11 (3) 2028.14 
  86-101 (T)TPLNVSHIQGTILCSK(K)  8.55 1 37.5 856.32 (2) 1710.92 
C6KI62 
Chalcone synthase-like protein 
1 292-307 (N)PIGISDWNSLFWIVHP(G) 4.9 -0.9 62.5 627.45 (3) 1880.97 
  61-76 (R)ICEKTTIKKRHLYLTE(D) 9.6 2 25 659.21(3) 1976.10 
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A0A0C5B2L0 
Cytochrome c biogenesis 
protein CcsA 40-56 (D)SSEKGMIATFCCITGLL(V)  5.98 -0.1 41.2 591.68 (3) 1773.86 
  287-298 (N)SAIVASIGFLII(W) 3.4 0 75 602.8 (2) 1203.74 
A0A0C5B2I8 Cytochrome f 203-212 (N)NNVYNATAAG(I) 3.2 0 40 497.42 (2) 994.46 
  50-71 (E)ATGRIVCANCHLANKPVDIEVP(Q) 6.9 0 50 774.31 (3) 2320.19 
A0A0C5ARX9 
DNA-directed RNA 
polymerase subunit beta'' 1235-1241 (T)SKVVVSE(D) 6.6 0 42.9 748.35 (1) 747.43 
  790-804 (I)YEIADGINLETLFPQ(D) 0.7 -3 46.7 574.91 (3) 1722.86 
A0A0C5ARQ8 
DNA-directed RNA 
polymerase subunit beta 706-720 (I)TNEIPHLEAHLLRNL(D) 6.1 -0.8 46.7 590.83 (3) 1769.97 
  122-134 (I)VINQILQSPGIYY(R)  3.55 0 46.2 754.88 (2) 1507.82 
  246-263 (K)ELQKKFFQQRCELGRIGR(R) 10.7 2.9 27.8 745.89 (3) 2236.21 
A7IZZ1 
(-)-limonene synthase, 
chloroplastic 204-221 (K)ANISNDIMGALGLYEASF(H)  0.7 -2 50 629.08 (3) 1885.90 
  197-213 (N)HKTGEFKANISNDIMGA(L)  7.56 0.1 35.3 611.27 (3) 1832.90 
A0A0C5AUE3 Maturase K 387-398 (N)VVGQPLSKSTWA(D) 10.1 1 50 637.32 (2) 1272.70 
  288-295 (S)ILASKDMP(L) 6.6 0 62.5 438.07 (2) 874.47 
Q8RVK9 Naringenin-chalcone synthase 312-331 (D)QVESKLALKTEKLRATRHVL(S) 10.9 3.1 40 774.45 (3) 2320.38 
  218-238 (D)GSAALIVGSDPIPEVEKPIFE(L) 3.5 -3 57.1 723.36 (3) 2168.15 
E5DL82 
NADH-ubiquinone 
oxidoreductase chain 5 122-131 (I)SCNMRLNAIT(L) 8.6 0.9 40 590.31 (2) 1179.56 
  82-100 (P)VNRVGDFGLAPGISGRFTL(F) 10.7 1 47.4 659.21 (3) 1976.07 
  132-145 (T)LICILLFIGAVGKS(A) 8.8 0.9 64.3 724.25 (2) 1446.88 
  116-132 (A)PRNSWISCNMRLNAITL(I) 11.1 1.9 47.1 663.83 (3) 1989.02 
V5KXG5 4-coumarate:CoA ligase 335-360 (P)NVTLGQGYGMTEAGPVLTMSLAFAKE(A) 4.2 -1 46.2 895.43 (3) 2685.33 
  7-22 (E)ITKQEQQQDIIFRSKL(P)  9.93 1 31.3 659.18 (3) 1975.10 
  291-306 (V)PPIVLAIAKYPDLHKY(D) 9.8 1.1 62.5 613.30 (3) 1838.06 
  154-162 (L)VKFVCVDSP(V) 5.9 -0.1 55.6 497.68 (2) 993.51 
A0A0C5ARZ4 
Photosystem I P700 
chlorophyll a apoprotein A1 695-722 (E)LIESIVWAHNKLKVAPATQPRALSIVQG(R) 10.7 2.1 57.1 
1013.77 
(3) 3039.75 
  304-326 (L)VAGHMYRTNWGIGHGIKDILEAH(K) 8.0 0.3 39.1 859.42 (3) 2575.30 
  44-61 (T)TWIWNLHADAHDFDSHTS(D) 4.9 -2.7 38.9 718.23 (3) 2152.95 
  697-721 (I)ESIVWAHNKLKVAPATQPRALSIVQ(G) 10.7 2.1 56 919.31 (3) 2756.56 
  92-117 (H)GARFSNYEAWLSDPTHIGPSAQVVWP(I)  5.17 -0.9 50 962.73 (3) 2885.40 
  695-719 (E)LIESIVWAHNKLKVAPATQPRALSI(V) 10.7 2.1 60 919.28 (3) 2755.60 
A0A0C5APY0 
Photosystem I P700 
chlorophyll a apoprotein A2 170-197 (K)NAESRLNHHLSGLFGVSSLAWTGHLVHV(A) 7.7 0.4 42.9 
1013.22 
(3) 3038.57 
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  361-369 (F)IAQDFTTQA(A) 0.7 -1 44.4 497.68 (2) 994.48 
A0A0C5APZ4 Protein Ycf2 664-678 (S)KKKYLLVLPPIFYEE(N) 9.3 1 53.3 627.21 (3) 1880.09 
  1304-1322 (N)LISEISSKCLHNLLLSKEM(I) 7.1 0 42.1 739.27 (3) 2215.18 
  1780-1798 (R)CSTRNILVIASTHIPQKVD(P) 9.1 1 42.1 718.35 (3) 2152.15 
A0A0C5B2I6 
Ribulose bisphosphate 
carboxylase large chain 84-95 (R)CYHIEPVAGEEN(Q) 3.8 -3 33.3 680.73 (2) 1360.58 
5DLX2 Ribosomal protein S3 308-331 (E)QLLGQLRKKCWKLMGKDKVMELIE(K) 10.1 2.9 41.7 963.27 (3) 2887.61 
  79-93 (E)SIRLDDREKQNEIRI(W) 6.8 0 26.7 629.40 (3) 1885.03 
a) According to “UniProtKB” (http://www.uniprot.org/) 
b) According to “Protein Peptide Calculator” (http://pepcalc.com/) 
c) According to “Peptide2.0” (http://peptide2.com/ 
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Figure 7.1S - Chromatograms of peptic, tryptic, pancreatic and codigested hydrolysates.  
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8.0 Abstract 
Peptic hempseed protein hydrolysate exerts hypocholesterolemic effects with a statin-like 
mechanism on HepG2 cells. In the range 0.1-1.0 mg/mL, it inhibits the catalytic activity of 3-
hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoAR) in a dose-dependent manner. 
Immunoblotting detection showed increments in the protein levels of regulatory element 
binding proteins 2 (SREBP-2), low-density lipoprotein receptor (LDLR), and HMGCoAR. 
However, the parallel activation of the phospho-5'-adenosine monophosphate-activated protein 
kinase (AMPK) pathway, produced an inactivation of HMGCoAR by phosphorylation. The 
functional ability of HepG2 cells to uptake extracellular LDL was raised by 50.5 ± 2.7%, 221.5 
± 1.6%, and 109 ± 3.5%, respectively, versus the control at 0.25, 0.5, and 1.0 mg/mL 
concentrations. 
 
8.1 Introduction   
Literature indicates that peptides, obtained through hydrolysis of hempseed protein with 
different enzymes, may function as hypotensive agents 1, 2 and antioxidant.1, 3, 4 On the contrary, 
literature reports only a few evidences on the ability of hempseed to modulate the lipid profile.5-
7 The inhibition of cholesterol biosynthesis is the most efficient way to reduce serum 
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cholesterol levels. Since intracellular cholesterol production is a multistep pathway in which 
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoAR) mediates the rate-limiting 
step, this enzyme is an important drug target. 
Starting from the hypothesis that most activities observed should depend on specific peptides 
encrypted in the protein sequences, we decided to investigate the hypocholesterolemic 
properties of peptic hydrolysates produced as reported in the Part-I of this manuscript, using 
human hepatic HepG2 cells as model system. More specifically, the present work had the goal 
to elucidate of the mechanism through which this hydrolysate mediates a cholesterol-lowering 
effect at HepG2 cells, by molecular and functional investigations on the LDLR-SREBP-2 
pathway. 
 
8.2 Materials and Methods  
Cell culture conditions. The HepG2 cell line was bought from ATCC (HB-8065, ATCC from 
LGC Standards, Milan, Italy). The HepG2 cell line was cultured in DMEM high glucose with 
stable L-glutamine supplemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL 
streptomycin (complete growth medium) and incubated at 37 °C under 5% CO2 atmosphere. 
HepG2 cells were used for no more than 20 passages after thawing, because the increase of the 
number of passages may change the cell characteristics and impair assay results. 
 
Western blot analysis. A total of 1.5 x 105 HepG2 cells/well (24-well plate) were treated with 
0.25, 0.5, and 1.0 mg/mL of peptic peptides for 24 h. After each treatment, cells were scraped 
in 40 µL ice-cold lysis buffer [RIPA buffer + inhibitor cocktail + 1:100 PMSF + 1:100 Na-
orthovanadate] and transferred in an ice-cold microcentrifuge tube. After centrifugation at 
16,060 g for 15 min at 4 °C, the supernatant was recovered and transferred into a new ice-cold 
tube. Total proteins were quantified by Bradford method and 50 μg of total proteins loaded on 
a pre-cast 7.5% Sodium Dodecyl Sulfate - Polyacrylamide (SDS-PAGE) gel at 130 V for 45 
min. Subsequently, the gel was pre-equilibrated with 0.04% SDS in H2O for 15 min at room 
temperature (RT) and transferred to a nitrocellulose membrane (Mini nitrocellulose Transfer 
Packs) using a Trans-blot Turbo at 1.3 A, 25 V for 7 min. Target proteins, on milk blocked 
membrane, were detected by primary antibodies as follows: rabbit anti-SREBP-2, rabbit anti-
LDLR, anti-HMGCoAR, anti-phospho-AMPK (Thr172), anti-phospho-HMGCoAR (Ser872), 
and anti-β-actin. Secondary antibodies conjugated with HRP and a chemiluminescent reagent 
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were used to visualize target proteins and their signal was quantified using the Image Lab 
Software (Bio-Rad). The internal control β-actin was used to normalize loading variations.  
 
Fluorescent LDL uptake cell based assay. A total of 3 x 104 HepG2 cells/well were seeded 
in 96-well plates and kept in complete growth medium for 2 d before treatment. On the third 
day, cells were treated with 0.25 mg/mL peptic peptides or vehicle (100 mM Tris) for 24 h. At 
the end of the treatment periods, the culture medium was replaced with 50 μL/well LDL-
DyLight™ 550 working solution. The cells were additionally incubated for 2 h at 37 °C, then 
the culture medium was aspirated and replaced with PBS 100 μL/well. The degree of LDL 
uptake was measured using the Synergy H1 fluorescent plate reader from Biotek (excitation 
and emission wavelengths 540 and 570 nm, respectively).  
 
Statistically Analysis. Statistical analyses were carried out by One-way ANOVA (Graphpad 
Prism 6) followed by Dunnett’s test. Values were expressed as means ± sem; P-values < 0.05 
were considered to be significant.  
 
8.3 Results 
Preparation and analysis of the peptic hydrolysate from hempseed protein. The 
hydrolysate preparation is reported in the Part-I (§ 7.2.2) of the same manuscript. Regarding 
the peptic hydrolysate composition, the highest number of detected peptides belongs to the 
main storage proteins in hempseed: 6 peptides were shared by all isoforms of Edestin 2 (ede2A; 
2B; 2C), 6 peptides were shared by the isoforms of Edestin 1 (ede1A,B; 1B) and only 1 by the 
isoforms of Edestin 1 (ede1A,B; 1D). Numerous peptides belonged to the most heterogeneous 
protein family identified here, i.e. the acyl-activating enzyme superfamily: 5 unique peptides 
belonged to DNA-directed RNA polymerase subunit beta, Photosystem I P700 chlorophyll, 
apoprotein A2, and Protein Ycf2, whereas 4 peptides to (+)-alpha-pinene synthase. This protein 
is involved in the terpene metabolism and naringenin-chalcone synthase and is better known 
as flavanone synthase. In total 3 peptides belonged to Putative LysM domain containing 
receptor kinase and THCA synthase, whereas 2 unique peptides belonged to ATP synthase 
(alpha and beta subunit), cannabidiolic acid synthase-like 1, Delta 12 desaturase, Hypothetical 
chloroplast RF1, (-)-limonene synthase, MatR, NADH-plastoquinone oxidoreductase (4 and 5 
subunit), 4-coumarate:CoA ligase, and Polyketide synthase family, respectively. (Table 7.1S 
Part-I).  
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Effects on the LDLR pathway modulation. HepG2 cells were treated with 0.25, 0.5, and 1.0 
mg/mL of the hempseed peptic hydrolysate and each sample was investigated with 
immunoblotting experiments. The treatment induced an up-regulation of the protein level of 
the N-terminal fragment of SREBP-2 (mature form with a molecular weight of 68 kDa) by 34.8 
± 19% (p < 0.001), 29.1 ± 7.7% (p < 0.001), and 33.5 ± 6% (p < 0.001) at 0.25, 0.5, and 1 
mg/mL, respectively, versus the control (Figure 8.1 A-C). As a consequence, up-regulations 
of the LDLR and HMGCoAR protein levels were also observed. In particular, as shown in 
Figure 8.1 A-C, after the treatment with the peptic hydrolysate at 0.25, 0.5, and 1.0 mg/mL, 
the LDLR protein level was increased by 35.6 ± 10.4% (p <0.01), 54.7 ± 41.4% (p< 0.0001), 
and 63.0 ± 41.3% (p< 0.0001), respectively, versus the control, whereas the HMGCoAR 
protein level was augmented by 32.2 ± 15.6% (p <0.05), 54.1 ± 10.4% (p <0.01), and 67.7 ± 
38.9% (p< 0.0001), respectively, versus the control (Figure 8.1 B-C).  
 
Effects on AMPK pathway activation. Suitable immunoblotting experiments were performed 
in order to evaluate the effect of the treatment with hempseed peptic hydrolysate on AMPK 
activation and HMGCoAR inactivation (AMPK substrate). The lysates from treated and 
untreated HepG2 cells were therefore analyzed using specific antibodies for AMPK 
phosphorylated at threonine 172 (Figure 8.1 D) and for HMGCoAR phosphorylated at serine 
872 (AMPK phosphorylation site) (Figure 8.1 E). Figure 8.1 F shows that treatment with 
hempseed peptic hydrolysate significantly increased AMPK phosphorylation by 95.2 ± 38.7% 
(0.50 mg/mL, p <0.0001) and by 120.3 ± 18.4% (1 mg/mL, p <0.0001) versus the control. As 
a consequence of the AMPK activation, the phosphorylation levels of HMGCoAR were also 
increased by 67.0 ± 15.8% at 0.5 mg/mL (p <0.0001) and 56.0 ± 37.3% at 1 mg/mL 
(p<0.0001), versus the control (Figure 8.1 F). 
 
 175 
 
 
 
Figure 8.1 - Effects of hempseed peptides on SREBP-2-LDLR pathway. HepG2 cells (1.5 × 105) 
were treated with peptic hempseed peptides (0.25, 0.5, 1.0 mg/mL) for 24 h. SREBP-2, LDLR, 
HMGCoAR, phospho-AMPK (Thr172), phospho-HMGCoAR (Ser872), and β-actin immunoblotting 
signals were detected using specific anti-SREBP-2, anti-LDLR, anti-HMGCoAR, anti-phospho-AMPK 
(Thr172), anti-phospho-HMGCoAR (Ser872), and anti-β-actin primary antibodies, respectively (A-B-
D-E). Each protein signal was quantified by ImageLab software (Bio-Rad) and normalized with β-actin 
signals (C-F). Bars represent averages ± SEM of six independent experiments (two duplicates per 
sample). (∗) p < 0.05, (∗∗) p < 0.001, and (∗∗∗) p < 0.0001 versus control (C). 
 
Modulation of the LDL-uptake in HepG2 cells. The functional ability of HepG2 cells to 
uptake extracellular LDL after the treatments with the same peptic hydrolysate was 
investigated by performing fluorescent LDL uptake experiments. As shown in Figure 8.2, 
hempseed peptides increased the LDL-uptake in a statistically significant way versus the 
control. In fact, after treatments with 0.25, 0.5, and 1.0 mg/mL, the LDL-uptake was increased 
by 50.5± 2.7% (p < 0.001), 221.5 ± 1.6% (p < 0.001), and 109 ± 3.5% (p < 0.001), respectively. 
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Figure 8.2 - Fluorescent LDL-uptake assay after treatment of HepG2 with hempseed peptides. 
Cells (3 × 104) were treated with hempseed peptides (0.25, 0.5, 1.0 mg/mL) for 24 h. LDL-Dylight 550 
(10 μg/mL) was incubated for an additional 2 h. Excess LDL-Dylight 550 was removed and cells were 
washed two times with PBS. Specific fluorescent LDL-uptake signal was analyzed by Synergy H1 
(Biotek). Data points represent averages ± SEM of three independent experiments in triplicate. (∗∗∗) p 
< 0.0001 versus control (C). 
 
8.4 Discussion 
Molecular and cellular investigation of the hypocholesterolemic properties of the peptic 
hempseed hydrolysate. This paper provides evidence of the hypocholesterolemic effects 
mediated by the peptic hempseed protein hydrolysate suggesting also a mechanistic 
explanation. HMGCoAR is the rate-controlling enzyme of cellular cholesterol biosynthesis 
pathway and therefore it constitutes the target of numerous investigations aimed at lowering 
the rate of cholesterol biosynthesis.8-10  
The LDLR expression and the receptor protein localization at cellular membranes are strictly 
correlated to the intracellular cholesterol biosynthesis pathway. In facts, the transcription of the 
LDLR and the genes required for cholesterol and fatty acid synthesis are controlled by 
membrane-bound transcription factors called SREBPs,11 and intracellular cholesterol acts with 
a negative feedback inhibition mechanism.12 The SREBP-2 isoform is responsible for the 
LDLR and HMGCoAR transcription and the SREBP-2 maturation is regulated by the 
intracellular cholesterol homeostasis. Thus, the up-regulation of LDLR represents a useful 
strategy to control plasma LDL cholesterol levels. Our findings demonstrate that hempseed 
peptides with molecular weights lower than 3000 Da are able to up-regulate the LDLR protein 
levels through an increase of SREBP-2 protein.  
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In addition, a detailed investigation of the LDLR pathway revealed that the peptic hydrolysate 
increases the HMGCoAR protein levels in a significant way versus the control (Figure 8.1 A-
C). However, this does not mean an increase of cholesterol synthesis, since the peptic 
hydrolysate is also able to inactivate HMGCoAR, by increasing its phosphorylation mediated 
by the activation of the AMPK pathway (Figure 8.1 D-F). One mechanism of HMGCoAR 
activity regulation is achieved through phosphorylation of Ser872 by AMPK, which decreases 
the enzyme.13 In fact, physiologically HMGCoAR is present in the cell in a non-phosphorylated 
active form (30%) and a phosphorylated inactive form (70%).14 By increasing the 
phosphorylation of AMPK, some natural compounds, such as soy15 and lupin peptides,16 are 
able to produce a direct inhibition of HMGCoAR.17 Furthermore, also statins are able to 
activate AMPK,18 with the consequence of a synergistic inhibition of the HMGCoAR activity. 
In line with these observations, this work provides evidence according to which a peptic 
hydrolysate from hempseed protein is not only able to directly inhibit the reductase activity, 
but also to modulate the HMGCoAR regulation by the activation of the AMPK pathway. 
Finally, in agreement with immunoblotting results, the increase of LDLR protein levels leads 
to an increase of LDL uptake (Figure 8.2). The induction of the LDL clearance is strictly 
correlated to an increase of LDLR protein level. The cholesterol-lowering effects of hempseed 
peptides in human hepatic HepG2 cells have some similarities with the behaviour of lupin 
peptides15. In facts, also the peptides obtained by the hydrolysis of a total lupin protein extract 
with pepsin, are able to mediate hypocholesterolaemic effects in the same cells through the 
activation of the LDLR pathway. Other hypocholesterolemic peptides with a statin-like 
mechanism may be found in soy 19.  
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9.0 Abstract 
An investigation on the proteome of the sweet kernel of apricot, based on equalisation with 
combinatorial peptide ligand libraries (CPLLs), SDS-PAGE, nLC-ESI-MS/MS, and database 
search, permitted identifying 175 proteins. Gene ontology analysis indicated that their main 
molecular functions are in nucleotide binding (20.9 %), hydrolase activities (10.6 %), kinase 
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activities (7 %), and catalytic activity (5.6%). A protein-protein association network analysis 
using STRING software permitted to build an interactomic map of all detected proteins, 
characterised by 34 interactions. In order to forecast the potential health benefits deriving from 
the consumption of these proteins, the two most abundant, i.e. Prunin 1 and 2, were 
enzymatically digested in silico predicting 10 and 14 peptides, respectively. Searching their 
sequences in the database BIOPEP, it was possible to suggest a variety of bioactivities, 
including dipeptidyl peptidase-IV (DPP-IV) and angiotensin converting enzyme I (ACE) 
inhibition, glucose uptake stimulation and antioxidant properties. 
 
Keywords: apricot; combinatorial peptide ligand libraries (CPLL); GO analysis; LC-MS/MS; 
proteomics; prunin. 
 
9.1 Introduction  
Prunus armeniaca L. (synonym Armeniaca vulgaris Lam., subclass Rosidae, order Rosales, 
family Rosaceae, subfamily Prunoideae), widely known as “apricot”, is an edible plant widely 
cultivated for its delicious fruits. The term armeniaca is supposed to derive from Armenia, 
where this plant has been grown since ancient times. Apricot is currently cultivated in many 
countries with suitable climates. Algeria and Italy are among major world producers, with 
annual yields equal to 269,308 and 247,146 tonnes, respectively (FAO, 2012). 
The fruit is a drupe, with a thin downy skin, enclosing a yellowish-orange flesh (mesocarp) and 
an inner large, compressed, smooth, woody stone, containing the kernel. Although the fruit is 
certainly the most important product of this plant, also the kernel has some interest, being a 
rich source of dietary protein, oil, and fibre (Femenia, Rossello, Mulet, & Canellas, 1995). 
Its use in human diet is limited, however, since it contains D(-)-mandelonitrile -gentiobioside, 
a toxic bitter cyanogenic glycoside generally named amygdalin (Varsha, Akash, Jasmine, Raj, 
Jain, & Chaudhary, 2012; Yildirim & Askin, 2010). Its concentration is nonetheless variable 
and also some non-toxic cultivars derived from a sweet population from China are available 
(Lu, Lu, Gao, Lu, Lu, & Gao, 1994). Bitter kernels may contain up to 5.5% amygdalin 
(Yildirim & Askin, 2010), while sweet ones less than 1% (Karsavuran, Charehsaz, Celik, 
Asma, Yakinci, & Aydin, 2014). Whereas bitter kernels are exploited as raw material in 
cosmetic and pharmaceutical applications, sweet ones may be consumed as nuts (Yildirim & 
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Askin, 2010). They are currently eaten as roasted salted titbit and appetisers or ground to a 
flour used in different food formulations (Ozboy-Ozbas, Seker, & Gokbulut, 2010;  Seker, 
Ozboy-Ozbas, Gokbulut, Ozturk, & Koksel, 2009; Seker, Ozboy-Ozbas, Gokbulut, Ozturk, & 
Koksel, 2010), often together with almond flour. Often, however, they are discarded by food 
processing industry, although their use would help maximising available resources and might 
result in generating innovative foods (Ozcan, 2000). 
The oil of apricot kernels has been widely characterised (Turan, Topcu, Karabulut, Vural, & 
Hayaloglu, 2007; Yildirim, Yildirim, Askin, & Kankaya, 2010) and shown to possess 
hypocholesterolaemic and antioxidant properties (Kutlu, Durmaz, Ates, & Erdogan, 2009). 
Other components extensively characterised are sugars, fibre and phytochemicals (Turan, 
Topcu, Karabulut, Vural, & Hayaloglu, 2007; Yildirim, Yildirim, Askin, & Kankaya, 2010). 
Literature indicates that this kernel has antioxidant (Durmaz & Alpaslan, 2007) and 
antimicrobial properties (Lee, Ahn, Kwon, Lee, Kwak, & Min, 2014). 
The fruit proteome has been investigated during ripening (D'Ambrosio, Arena, Rocco, Verrillo, 
Novi, Viscosi, et al., 2013), whereas an extensive characterisation of the kernel proteome is 
still lacking. Only one recent paper has developed a highly specific competitive enzyme-linked 
immunosorbent assay to detect the addition of apricot kernels in almond products, based on 
specific proteins differential analysis (Zhang, Wang, Huang, Lai, Du, Liu, et al., 2016).  
The first objective of the present work was to get a comprehensive information on kernel 
proteome: the identification of minor proteins was improved by the use of spin columns packed 
with combinatorial peptide ligand libraries (CPLLs), a powerful non-depleting tool for 
discovering low-abundant proteins (Aiello, Fasoli, Boschin, Lammi, Zanoni, Citterio, et al., 
2016; Esteve, D'Amato, Marina, García, Citterio, & Righetti, 2012; Righetti, Fasoli, & 
Boschetti, 2011). The apricot kernel proteome was then elucidated by mass spectrometry (LC-
MS/MS) and searching in suitable databases. The second objective was the classification of the 
detected proteins based on physiological function and localisation using bioinformatic tools. 
Finally, the third objective was the identification of the potential bioactivities of peptides 
deriving from the digestion of the most abundant proteins through in silico enzymatic digestion 
and search in the BIOPEP database (Minkiewicz, Dziuba, Iwaniak, Dziuba, & Darewicz, 
2008).  
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9.2 Materials and Methods 
9.2.1 Chemicals 
All chemicals and reagents were analytical grade. Acetonitrile (ACN), acetic acid, acetone, 
formic acid (FA), methanol, sodium hydroxide, ammonium bicarbonate (NH4HCO3), 
trichloroacetic acid (TCA), β-mercaptoethanol, dithiothreitol (DTT), iodoacetamide (IAA), 
urea, sodium chloride (NaCl), trypsin, glycine, tris-(hydroxymethyl)-aminomethane were from 
Sigma-Aldrich Corporation (St Louis, MO, USA). ProteoMiner™ (CPLL), Laemmli buffer, 
Precision Plus Protein Standards, 40% acrylamide/bis solution, N,N,N′,N′-
tetramethylethylenediamine (TEMED), sodium dodecyl sulphate (SDS), and electrophoresis 
apparatus for one-dimensional electrophoresis were acquired at Bio-Rad (Hercules, CA, USA).  
 
9.2.2 Treatment of apricot kernels 
Apricot kernels were purchased in a local market (N'gaous, Batna, Algeria) in July 2015. The 
sample was extracted according to a literature method (Vita, Lucarotti, Alpi, Balestrini, Mello, 
Bachi, et al., 2013) with some modifications. Briefly, 0.5 g of kernels were ground to a fine 
powder using mortar and pestle cooling in ice. The powder was washed with hexane, then 
extracted with 12 mL of extraction buffer (1 M Urea, 50 mM Tris-HCl pH 8.0, 1% CHAPS, 
60 mM DTT) under stirring for 2 h at 4 °C. The homogenate was centrifuged for 30 min at 
8,400 g at 4 °C and extracted proteins (supernatant phase) were precipitated using 13% TCA 
solution containing 0.007% ß-mercaptoethanol in acetone (keeping at -20°C overnight and then 
at 4 °C for 2 h). The sample was centrifuged at 8,400 g at 4 °C for 30 min and the pellet was 
suspended into 5 mL of 50 mM Tris-HCl, pH 8.0, 50 mM NaCl. Part of the supernatant was 
collected as crude protein extract (Raw sample), whereas the other one was submitted to 
CPLLs incubation (Boschetti & Righetti, 2008). Before the enrichment process, the protein 
concentration was measured by the Bradford assay using bovine serum albumin as standard. 
The ProteoMiner enrichment was performed according to the manufacturer protocol. Briefly, 
the CPLLs spin column containing 50 µL of ProteoMiner beads, stored in a 20% ethanol and 
0.5% ACN solution, was conditioned through washing in 1 mL of water followed by 1 mL of 
phosphate buffered saline (150 mM NaCl, 10 mM NaH2PO4). Then, 1 mL of protein solution 
obtained from the previous extraction was incubated within the column for 2 h at room 
temperature under gently rocking. In order to remove any excess of non-adsorbed proteins, the 
CPLL column was washed with 1 mL of PBS buffer for 5 min and then centrifuged at 80 g, 
discarding the solution. To elute bound proteins, the ProteoMiner beads were incubated twice 
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with 100 µL of rehydrated elution reagent (5% acetic acid, 4 M urea, 1% CHAPS), for 15 min 
at room temperature and centrifuged for 2 min at 80 g. The eluted enriched proteins (EEP) 
were collected in a clean tube and stored at -20 °C. All EEP solutions were unified and 
precipitated using chloroform/methanol to remove the SDS excess. The resulting pellets were 
mixed with Laemmli buffer. Three independent experiments were performed as biological 
replicates.  
 
9.2.3 SDS-PAGE analysis 
For the SDS–PAGE analysis, 10 µL of EEP sample and Raw sample were loaded onto a SDS-
PAGE gel, composed by a 4% polyacrylamide stacking gel (125 mM Tris-HCl, pH 6.8, 0.1%, 
m/v, SDS) over a 12% resolving polyacrylamide gel (375 mM Tris-HCl, pH 8.8, 0.1%, m/v, 
SDS buffer). The cathodic and anodic compartments were filled with Tris-glycine buffer, pH 
8.3, containing SDS (0.1%, m/v). Electrophoresis was run at 100 V, until the dye front reached 
the bottom of the gel and at 150 V until separation end. After electrophoresis, gels were washed 
and stained/destained using colloidal Coomassie Blue and 7% (v/v) acetic acid in water, 
respectively. Images were acquired by the GS800 densitometer and analysed by software 
Quantity One (Bio-Rad). After this, the two gel lanes corresponding to EEP and Raw were cut 
into 11 segments along migration path. Each sample was rinsed with pure water and submitted 
to standard reduction and alkylation procedures. The reducing solution (150 µL of a 1 mg/mL 
DTT solution in 50 mM NH4HCO3) was added to gel pieces and incubated for 20 min at 56 
°C; after its removal, gel pieces were added twice to the washing solution [ACN/50 mM 
NH4HCO3 (1:1)]. The alkylating solution (150 µL, 20 mg/mL IAA solution in 50 mM 
NH4HCO3) was added to gel pieces and incubated in the dark for 45 min. After alkylating 
solution removal, gel pieces were covered by 50 mM NH4HCO3 adding 1 µg of trypsin solution 
in each sample cooling in ice. After overnight incubation at 37 °C, the resulting tryptic peptides 
were acidified by adding FA (pH < 3) and the solutions centrifuged at 10,000 rpm at 4 °C for 
10 min. The supernatants were then lyophilised using a Speed Vac (Martin Christ), suspended 
in 20 μL water/ACN (98:2), added with 0.1% FA, and submitted to nano-LC-MS/MS analysis.  
 
9.2.4 Nano LC-MS/MS analysis 
A SL ion trap mass spectrometer (Agilent Technologies, Palo Alto, CA, USA), interfaced to a 
Chip-nanospray ion source, was operated in data-dependent acquisition mode with the installed 
Data Analysis software. The reconstituted peptides (4 µL) were loaded onto an enrichment 
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column (Zorbax 300SB-C18, 5 µm pore size) at a flow rate of 4 µL/min for 2 min using 
isocratic 100% solvent phase (99% water, 1% ACN, and 0.1% FA). After clean-up, the chip 
valve was switched to separation, conducted in a 43 mm x 75 µm analytical column packed 
(Zorbax 300SB-C18, 5 µm pore size). The separated peptides were eluted into the mass 
spectrometer at the constant flow rate of 0.3 µL/min. The LC solvent A was 95% water, 5% 
ACN, 0.1% FA; solvent B was 5% water, 95% ACN, 0.1% FA. The nano-pump gradient 
program was as follows: 5% solvent B (0-1 min), 50 % solvent B (1-32 min), 95% solvent B 
(32-35 min) and back to 5% in 5 min to re-equilibrate the column. The nano-ESI source 
operated under the following conditions: drying gas temperature 300 °C, flow rate 3 L/min 
(nitrogen), capillary voltage 1950 V, with endplate offset -500V. Mass spectra were acquired 
in positive ionisation mode, in the mass range from m/z 300-2200, with target mass 700 m/z, 
average of 2 spectra, ICC target 30,000 and maximum accumulation time 150 msec. Cationic 
peptide ions detection was performed by data dependent acquisition AutoMS(n) mode with a 
dynamic exclusion set at 2 spectra and released after 0.1 min. Each sample was analysed twice. 
All MS/MS spectra of each duplicate were combined and submitted to database search.  
 
9.2.5 Protein identification from MS data 
Proteins were identified using Spectrum Mill MS Proteomics Workbench (Rev B.04.00, 
Agilent Technologies, Palo Alto, CA, USA) against the Uniprot-Plants-Viridiplantae database 
(3,579,823 sequences) obtained from the Uniprot database (version of January, 2016) 
(The UniProt Consortium, 2017). The parameters used were as follows: carbamidomethylation 
of cysteine (+57.02 Da) and oxidation of methionine (+15.99 Da) were set as a fixed and 
variable modification respectively; trypsin was specified as the proteolytic enzyme; 2 missed 
cleavages were allowed; peptide mass tolerance was set at 1 Da, fragment mass tolerance at 
0.7 Da, and peptide charge at +2 and +3. The thresholds used for peptide identification were 
peptide Local FDR ≤ 1%, Score Peak Intensity% ≥ 70%, difference of forward and reverse 
scores ≥ 2. Proteins were considered detected when identified by at least two peptides. 
Supplementary Table S1 reports a list of all identified proteins, MS/MS scores, sequence 
coverages, and all amino acid sequences of unique recognised peptides.  
 
9.2.6 Functional categorisation of identified proteins 
The identified proteins were categorised based on their cellular localisation, molecular 
functions or biological processes by using the open access software QuickGo (Binns, Dimmer, 
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Huntley, Barrell, O'Donovan, & Apweiler, 2009). The pathway mapping was performed using 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Kanehisa, Goto, 
Kawashima, & Nakaya, 2002). The STRING tool (Search Tool for the Retrieval of Interacting 
Genes) v.10 software (Szklarczyk, Franceschini, Wyder, Forslund, Heller, Huerta-Cepas, et al., 
2015), set on Arabidopsis thaliana as reference organism, was used to generate a protein-
protein interaction network (PPI). A functional analysis aimed at creating an interaction protein 
map was conducted subjecting the identified proteins (FASTA sequences IDs), detected in all 
analysed samples (Raw and EEP) in STRING. In the interactive network output, proteins are 
represented by nodes and interactions by connecting continuous and discontinuous lines for 
direct (physical) or indirect (functional) interactions, respectively. Each connection is 
supported by at least a literature reference or a canonical information stored in STRING dataset. 
The confidence value (score) was set to 0.7 (high confidence). The pathways classification was 
performed after the automatic functional enrichment in STRING, based on information 
provided by KEGG-Pathway Database. 
 
9.2.7 In silico simulated gastrointestinal digestion of major storage proteins 
and potential biological activities of generated peptides 
The investigation on bioactive peptides was conducted only on Prunin 1 and Prunin 2, the most 
abundant proteins in this kernel. A prediction of potential bioactive peptides encrypted in these 
proteins was obtained by combining different in-silico enzymatic digestions using the software 
tool PDMQ - Protein Digestion Multi Query (Haraszi, Tasi, Juhasz & Makai, 2015) in order to 
simulate gastrointestinal processes: pepsin (pH 1.3) was the first enzyme followed by trypsin 
and chymotrypsin. All generated peptides were then ranked using the tool PeptideRanker 
(Mooney, Haslam, Pollastri, & Shields, 2012) in order to evaluate the quality of these results. 
For ranking these peptides based on the probability of being bioactive, N-to-1 neural algorithm 
was used to produce a list of probability scores (Supplementary Table S2b). A score higher 
than 0.5 was considered as indicative for “bioactivity”. After such filtering, the peptide 
sequences were searched against the tool BIOPEP (Minkiewicz, Dziuba, Iwaniak, Dziuba, & 
Darewicz, 2008). 
 
9.2.8 Statistically Analysis 
The proteomic analyses were conducted on two independent samples, each injected twice. The 
statistical analysis of the mass spectrometry identification, carried out following a decoy 
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(reversed) database search, was performed using the MS/MS search option in Spectrum Mill 
to account for false positives. Peptide scores were compared to those of reversed peptide scores 
to obtain a delta forward-reverse score. Database Fwd-Rev Score ≥2 and Local False Discovery 
Rate ≤1% were used.  
 
9.3. Results and Discussion  
9.3.1 Characterisation of apricot kernel proteome 
In order to obtain an extensive identification of tiny kernel proteins, they were enriched by 
equalising the most abundant ones using spin columns packed with CPLLs (Aiello, et al., 
2016). The workflow adopted included proteome extraction using a strong reducing buffer, 
pre-fractionation via CPLLs technology, protein separations by SDS-PAGE, and 
characterisation by MS analysis. Figure 9.1A shows the SDS-PAGE profiles of the Raw and 
EEP samples. A comparison of these two profiles confirms that CPLLs were very efficient in 
increasing low-abundant protein detection. The Raw lane is characterised by three major 
protein bands, with molecular weights (MW) equal to 50–75 kDa, 50 kDa and  25kDa, which 
correspond to Prunin 1 (E3SH28, 63 kDa), Prunin 2 (E3SH29, 53 kDa) and two uncharacterised 
proteins (M5XS06 and M5XPY4, 25 kDa). Contrariwise, the EEP lane exhibits very intense 
and additional bands, particularly evident in the high MW region corresponding to 100-75 kDa. 
As revealed by EEP eluate profile, the combined use of CPLLs and strong reducing extraction 
buffer has contributed to increase capture mainly of membrane proteins, as demonstrated by 
the subsequently mass spectrometry analysis.  
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Figure 9.1 - A) SDS-PAGE profiles of Raw sample versus EEP sample; Mr = molecular mass ladder; 
staining with micellar Coomassie blue. B) Venn diagrams of all identified species in Raw and EEP 
samples against Uniprot_Viridiplantae database. In total, 44 proteins were identified exclusively in 
Raw, 73 only in EEP, and 58 in both samples. The squares indicate the numbers of IDs assigned to 
Prunus. 
 
Proteins from Raw and EEP samples were reduced, alkylated, digested, and analysed using 
nano-LC−MS/MS. It was possible identifying 175 unique gene products with at least two 
matched peptides. The Venn diagram (Figure 1B) reports the total IDs in terms of 
identifications obtained by matching MS/MS data against the Uniprot Viridiplantae database. 
Among identified proteins 44 (25.2 %) and 73 (41.7%) were specific to Raw and EEP samples, 
respectively, whereas 58 (33.1%) were identified in both samples (Table 9.1). Indeed, the 
CPLLs capture permitted the additional identification of 73 unique gene products that could 
not be detected via a conventional solubilisation protocol.  
Interestingly, 72% of total IDs was attributable to the Prunus genus, specifically three of them 
were assigned to almond (Prunus dulcis), whereas the remaining to peach (Prunus persica).  
Only a few proteins were identified by homology to other plant species, such as Oryza sativa, 
Setaria italica, Triticum aestivum, Vitis vinifera, and Arabidopsis thaliana. One of the most 
recent papers on Prunus seed proteome has considered plum and peach (Gonzalez-Garcia, 
Marina, Garcia, Righetti, & Fasoli, 2016): the analysis permitted to identify 141 unique gene 
products in plum and 97 in peach, however, only a small percentage of them belonged to the 
genus Prunus, whereas most belonged to Glycine max, Vitis vinifera, Zea mays, and Populus 
trichocarpa. 
The most abundant proteins in apricot kernel were Prunin 1 (E3SH28) and Prunin 2 (E3SH29), 
belonging to the cupin family and associated to 11S globulins. Prunin 1 has been identified as 
the major component in almond and has been recognised as a main almond allergen (Jin, 
Albillos, Guo, Howard, Fu, Kothary, et al., 2009). Beyond the nutrient reservoir function, the 
observed protein profile includes many GTPases involved in vesicle trafficking, cytoskeletal 
organisation and signal transduction as recently confirmed in peach by another paper (Falchi, 
Cipriani, Marrazzo, Nonis, Vizzotto, & Ruperti, 2010). We have identified also 
phosphatidylinositol binding protein, an important lipid binding proteins, playing roles in the 
stabilisation of membranes, cell wall organisation, seed development and germination (Liu, 
Zhang, Lu, Zeng, Li, Fu, et al., 2015). In addition, some methyltransferases were recognised. 
These proteins are connected to the biosynthesis of volatile phenolic derivatives in plants 
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(Lavid, Wang, Shalit, Guterman, Bar, Beuerle, et al., 2002), as well as involved in the 
enzymatic methylation of polyphenols, which results in antimicrobial properties.
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Table 9.1 Identified proteins in P. armeniaca kernels: comparison of EEP and Raw compositions a 
UniProt 
accession b 
Taxonomy Protein description c 
Summed 
MS/MS Search 
score 
% aa 
Protein 
MW (kDa) 
P 
unique 
EEP Raw 
Carbon Metabolism 
M5X7A6 PRUPE Starch synthase, chloroplastic/amyloplastic 11.51 5.4 715.99 2  x 
M5VX90 PRUPE Fructose catabolic process 12.09 10 375.69 2  x 
M5WKH0 PRUPE Tricarboxylic acid cycle 16.65 11.3 469.45 2  x 
Stress Related and Environmental Response Proteins 
M5XL25 PRUPE Small heat shock protein (HSP20) 27.50 15.5 173.81 2 x x 
O82011 SOLPE 17.7 kDa class I heat shock protein 20.20 16.8 176.85 2 x x 
M5X1C6 PRUPE Small heat shock protein (HSP20) 15.20 14.5 183.45 2 x x 
M5XPY4 PRUPE Response to stress 14.74 10 240.60 2 x x 
M5WG38 PRUPE Response to oxidative stress 12.40 9.7 384.07 2 x  
M5XKD9 PRUPE NB-ARC domain 14.26 4.9 109.79 2  x 
M5WH03 PRUPE Plant hormone signal transduction 15.68 6.3 767.31 2 x  
M5X2S0 PRUPE Plant-pathogen interaction 20.35 8 592.80 2 x x 
M5XA26 PRUPE Pectinesterase 16.68 3.4 640.13 2 x x 
M5W532 PRUPE Dirigent-like protein 13.43 34 20.78 2  x 
A5BMZ0 VITVI Putative uncharacterized protein 17.80 5.1 135.59 2 x x 
Oxidoreductive proteins 
D8SML7 SELML Cytochrome P450 21.63 9.1 538.96 2 x  
M5VT70 PRUPE Glutamine amidotransferases class-II 15.30 2.5 178.79 2 x  
M5WFA0 PRUPE Cytochrome P450 13.93 7.4 540.28 2  x 
M5VNJ0 PRUPE Alcohol dehydrogenase GroES-like domain 13.91 14.3 353.18 2  x 
M5WZ08 PRUPE Short chain dehydrogenase 12.65 13.9 375.32 2  x 
M5XNX5 PRUPE Cytochrome P450/ E-class, group I 12.08 11.1 590.05 2  x 
Nucleotide Binding 
M5VPJ6 PRUPE ABC transporter 12.79 7.6 692.18 2  x 
M5X1Y2 PRUPE Spliceosome 17.45 3.0 136.11 2  x 
A0A0K9QEM4 SPIOL Basic-leucine zipper domain 17.03 5.6 783.79 2  x 
B2XWN9 FAGEA DNA-directed RNA polymerase subunit beta 16.47 2.1 155.64 2 x  
M5XRM5 PRUPE Phosphoribulokinase 16.66 6.3 104.95 2 x x 
M5X306 PRUPE Triphosphate hydrolase activity 16.45 1.8 207.33 2 x  
M5VVC5 PRUPE mRNA surveillance pathway 16.19 1.1 425.57 2 x x 
M0TFM1 MUSAM Serine/threonine/dual specificity protein kinase 16.31 8.5 561.70 2  x 
A0A0D9Y5E4 ORYZ ATP binding. D-mannose binding lectin 16.55 3 193.23 2 x x 
A9RFQ7 PHYPA Myb-like DNA-binding domain 16.04 2.4 265.05 2 x  
M5X879 PRUPE NB-ARC domain/TIR domain/NACHT domain 17.09 2.3 116.47 2 x x 
M5Y288 PRUPE F-box domain 16.81 8.4 469.80 2 x x 
M5X7F6 PRUPE NB-ARC domain/Leucine Rich repeats/ATPase domain 16.71 2.8 166.99 2 x x 
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M5X3N3 PRUPE Phosphotransferase enzyme family 14.18 4.8 94.55 2 x x 
M5VXN8 PRUPE SET domain/Tesmin/TSO1-like CXC domain 14.17 5.2 100.69 2 x  
M5XPK4 PRUPE Cation transporting ATPase, 14.16 4.3 114.09 2 x x 
M5XIB1 PRUPE Snf2-ATP coupling, chromatin remodelling complex 16.02 1.3 326.26 2 x x 
M5X9G3 PRUPE Protein tyrosine kinase/PAN-like domain 15.82 6 832.15 2 x x 
M5WJX8 PRUPE Auxin response factor 15.78 5.2 80.07 2 x x 
M5WL01 PRUPE Phospholipid-translocating ATPase 15.69 6.8 81.86 2 x  
M5WQM8 PRUPE Phosphatidylinositol signaling system 15.09 2.5 204.24 2 x x 
M5WXM8 PRUPE NAC domain 13.69 4.7 967.98 2 x x 
M5X2H9 PRUPE tRNA synthetases class 15.46 4.3 91.41 2 x  
M5VX87 PRUPE Uncharacterized protein 12.51 7 66.15 2  x 
A0A078IK57 BRANA ATPase family 19.07 3.4 130.69 2 x x 
K3XUR4 SETIT Phosphatidylinositol-4-phosphate 5-Kinase 18.69 1.9 204.14 2 x x 
A8HM74 CHLRE Kinesin motor domain/K-box region 17.23 10.3 54.06 2 x  
M5X7V1 PRUPE Protein serine/threonine kinase activity 17.67 8.7 51.44 2  x 
V4V803 ROSI Protein kinase domain/Leucine Rich Repeat 17.13 5.6 100.34 2  x 
C1MUM4 MICPC Helicase conserved C-terminal domain 17.97 5.2 112.94 2 x  
Transcription factor activity 
A0A0E0EBP5 ORYZ Transcription factor TFIIB repeat 16.03 6.7 69.96 2 x  
F2DTK8 HORVD GRAS domain family 15.38 7.4 74.12 2 x  
M5VWQ0 PRUPE Anaphase-promoting complex subunit 4 WD40 domain 16.16 4.7 124.87 2 x  
M5VYG0 PRUPE Mediator complex subunit 13 C-terminal 11.04 2.8 206.67 2  x 
M5W6G9 PRUPE Mediator complex subunit MED14 15.85 2 188.73 2 x x 
A0A087SNJ1 AUXPR RNA-induced silencing complex 17.44 5.7 94.44 2  x 
F4IHS2 ARATH Chromatin structure-remodeling complex protein SYD 15.97 0.7 391.97 2  x 
M5XKW1 PRUPE PB1 domain 13.91 3.6 106.72 2 x x 
A0A087H600 ARAAL U3 ribonucleoprotein 18.83 7.1 59.37 2 x x 
Transferase activity 
M5VJV5 PRUPE Hexosyltransferase 16.42 11.1 43.36 2 x  
M5WDX6 PRUPE MT-A70 14.99 8.7 72.92 2 x x 
M5W9P4 PRUPE Glycosyltransferase family 14.70 7.3 59.077 2 x  
M5WEC8 PRUPE 
Putative S-adenosyl-L-methionine-dependent 
methyltransferase 
14.62 7.1 70.40 2 x x 
M5XEZ7 PRUPE Early transcription elongation factor of RNA pol II 13.88 1.9 161.24 2 x x 
M5VUM2 PRUPE 16S rRNA methyltransferase 12.61 11.7 43.57 2  x 
M5WAL1 PRUPE Glycosyltransferase family 29 11.26 7 49.68 2  x 
M5WMV1 PRUPE Ubiquitin ligase 19.31 7.1 60.91 2 x x 
Transporter activity 
M5X572 PRUPE ABC_membrane 31.46 8.1 137.73 4 x x 
M5XIX7 PRUPE Mito_carr 26.46 23.4 34.54 3  x 
R0HKY1 BRAS Substrate-specific transmembrane transporter activity 17.20 10.4 55.13 2  x 
M5WAE5 PRUPE Membrane insertase 14.08 8.1 60.05 2 x  
M5XM22 PRUPE RNA transport 13.03 14.7 19.06 2 x x 
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M5WUT7 PRUPE ABC2_membrane 19.58 4.3 110.56 2  x 
M5WRV7 PRUPE Voltage gated chloride channel 18.30 5 84.04 2  x 
A0A059AD39 EUCGR ABC transporter 17.45 4.9 136.39 2  x 
A0A078G4Y7 BRANA ABC transporter 15.68 4.6 137.29 2  x 
S8CX84 LAMI Nucleoporin autopeptidase 17.02 5.1 114.76 2  x 
M5VYB7 PRUPE Proton-dependent oligopeptide transporter family 17.33 8.7 63.98 2 x  
M5WDR1 PRUPE Uncharacterized protein 14.41 7.5 71.64 2 x  
M5X292 PRUPE Sugar transporter 14.27 6.1 55.94 2 x  
M5X4E2 PRUPE Endocytosis 15.03 10.9 44.71 2 x  
M5WPM9 PRUPE ABC transporter 13.64 2.1 165.79 2 x  
M5VMX6 PRUPE Major Facilitator Superfamily 13.48 13.5 48.16 2  x 
M5XKR7 PRUPE Cation transmembrane transporter activity 17.90 5.6 98.39 2  x 
A0A0D2NP98 CHLO Autophagy-related protein 3 20.15 14.1 39.30 2 x x 
Kinase activity 
M8BR74 AEGTA Casein kinase I isoform delta-like protein 15.85 3.6 145.93 2 x  
M5VG74 PRUPE Protein kinase domain 14.43 3.8 148.66 2  x 
M5WQP2 PRUPE Protein tyrosine kinase 14.91 4.9 114.65 2  x 
M5X8G0 PRUPE Protein kinase domain 13.55 9.4 67.11 2  x 
M5X2Q8 PRUPE Di-glucose binding within endoplasmic reticulum 13.52 6.1 98.79 2  x 
M5W5T2 PRUPE Phosphatidylinositol 3- and 4-kinase 11.66 2 280.37 2  x 
Hydrolase activity 
M5WI23 PRUPE Aspartic-type endopeptidase activity 31.00 8.8 47.59 2 x  
M5X2H5 PRUPE Alpha-1,2-Mannosidase 15.15 9.3 70.64 2 x x 
A0A0D2V8W9 GOSRA Dynamin GTPase effector domain 18.59 7.8 78.06 2 x  
M5XVK6 PRUPE Lipase/Hydrolase 17.99 8.2 69.94 2  x 
M5XBV0 PRUPE Protein serine/threonine phosphatase activity 15.03 9.7 47.49 2 x x 
M5WYB9 PRUPE Metal dependent phosphohydrolases 12.94 6.1 80.54 2 x x 
M5VWB9 PRUPE Exonuclease/phosphatase 13.86 13.1 57.98 2  x 
M5XKG8 PRUPE Hydroxyisourate hydrolase activity 14.68 15.4 36.92 2 x  
A0A0D2RN96 GOSRA Pectate lyase 15.99 16.6 42.62 2 x  
Binding activity 
A0A077S2P4 WHEAT IQ calmodulin-binding motif 20.01 1.5 259.90 2 x x 
V4KUD8 EUTSA Fatty-acyl-CoA binding 17.32 45 101.54 2 x x 
C1ECC7 MICSR Zinc ion binding 17.42 6.7 52.82 2 x x 
M5XLQ2 PRUPE BAH domain /Agenet domain 17.47 8.1 73.47 2  x 
M5VWP7 PRUPE DYW family of nucleic acid deaminases 17.33 5.1 86.51 2  x 
M5X7A2 PRUPE GTPase activity 17.27 4.3 72.88 2  x 
M5X8P0 PRUPE Phosphatidylinositol 3-phosphate binding 14.05 4.5 112.99 2 x x 
M5X715 PRUPE Glycosyltransferase 13.97 3 110.87 2 x x 
E3W0S0 ROSI DNA-directed RNA polymerase subunit beta 13.41 4.2 121.82 2  x 
M5VPV2 PRUPE Regulator of chromosome condensation 10.77 4.6 121.38 2  x 
M5WQZ5 PRUPE Chromatin binding 13.31 3 174.52 2 x x 
M5W7U6 PRUPE DYW family of nucleic acid deaminases 16.60 5.8 75.17 2  x 
 193 
 
M5X1G9 PRUPE Oleosin 21.23 12.8 15.61 2  x 
M5XB96 PRUPE Mitochondrial ribosomal protein subunit L20 17.82 5.8 83.16 2 x x 
M5VWL5 PRUPE Phosphatidylinositol binding 18.94 5.7 75.78 2  x 
M5X9Z6 PRUPE Proline-binding domain 15.44 3.2 180.67 2 x  
M5WNU7 PRUPE Plant-specific actin-binding protein 12.94 6.1 80.54 2 x x 
M5W984 PRUPE Mismatch repair 27.38 7.8 106.68 3 x x 
M5WS62 PRUPE Uridine kinase 19.15 7.9 53.94 2  x 
M5XRX7 PRUPE RNA binding activity 18.11 2.6 202.43 2  x 
M5XS06 PRUPE CTLH/CRA C-terminal to LisH motif domain 15.82 17.6 24.98 2 x x 
DNA metabolic process 
M5X0E1 PRUPE Nucleotide excision repair activity 23.58 6.6 117.19 3 x  
Q5NAA4 ORYSJ Helicase-like protein 21.38 2.4 188.53 2 x  
Storage Proteins 
E3SH28 PRUDU Prunin 1 132.8 25.7 63.39 9 x x 
E3SH29 PRUDU Prunin 2 96.65 12.5 57.23 6 x x 
M5Y3W2 PRUPE Nutrient reservoir protein 43.03 5.6 95.67 3 x x 
Cytoscheleton organization and multicellular component development 
M5XNW4 PRUPE Microtubule-associated protein 7 13.91 3.6 106.72 2 x x 
I6UTH7 SORBI Tan1 19.28 5.9 38.34 2 x x 
Translation activity 
M5WYZ2 PRUPE Translation initiation factor eIF3 15.77 3.5 185.56 2  x 
A0A022Q5F9 ERYGU Ribosomal protein S18 19.00 14.7 30.513 2 x  
M5Y4G5 PRUPE Zinc finger PHD-type 18.14 3.7 168.10 2 x x 
Other 
M5Y6F3 PRUPE Band_7 17.34 11.3 47.52 2  x 
M5VPQ9 PRUPE HAUS augmin-like complex subunit 3 15.19 6.4 70.02 2 x x 
A9YTJ2 PRUDU F-box associated interaction domain 14.22 16.6 31.78 2 x x 
M5VVG0 PRUPE Retrotransposon gag protein 12.45 6 71.06 2 x x 
M5XVF3 PRUPE Sieve element occlusion (SEO) protein 15.24 6.2 91.56 2  x 
a) Proteins with unknown function are listed in Supplementary Table S1 (data available on line as supporting materials) 
b) Protein ID, according to the Uniprot database. 
c) Protein description, according to the KEGG databas
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9.3.2 Protein functional data analysis 
The protein species identified were categorised into specific clusters, using the GO annotation 
tool, which allows automatic information retrieval from the website available databank. Figure 
9.2 shows the obtained clusters in which they are involved: biological processes (panel A), 
molecular functions (panel B), and cellular components (panel C). 
Focusing the attention on biological processes (Figure 9.2A), the largest clusters include 
proteins involved in biological process regulation (12.6%), cellular processes (10.2%), 
transport activities (8.8%), metabolic processes (8.4%), cellular component organisation 
(6.9%) and multicellular organisms development (6.4%). Fewer proteins are involved in 
cellular processes, such as growth factor, response to extracellular stimulus, and in cell-cell 
signalling. Regarding molecular functions (Figure 9.2B), 20.9% proteins are involved in 
nucleotide binding, 10.6% in hydrolase activities, 7.0% in kinase activities, 5.6% in catalytic 
activities, and only 2.6% in biosynthetic processes. As for subcellular localisation (Figure 
9.2C), most detected IDs are localised in membranes (48.4%), nucleus (10.1%), plastids 
(9.2%), cytoplasm (6.0%), and cell walls (1.4%).  
Figure 9.3 shows a comparison of the GO for molecular function annotation between EEP and 
Raw, based on the proteins uniquely identified in each sample. A 47% increment in the 
proteome discovery, attributed to minor proteins unrevealed without the CPLLs treatment, was 
observed for binding activity, whereas a 31% enhancement for catalytic activity.  
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Figure 9.2 - Gene Ontology (GO) analysis of identified gene products. Pie graphs of (A) biological 
processes, (B) molecular functions, and (C) cellular components show the percentage of proteins 
in each functional category. 
 
 
 
Figure 9.3 - Molecular Function GO Term Annotation Comparison obtained plotting the unique 
ID entries for Raw and EEP, respectively.  
 
9.3.3 Protein biology 
The protein classification based on their functional roles highlighted four main categories, 
transcription regulators, transmembrane transporters, stress-related proteins, and binding 
activities, providing a relevant contribution to kernel proteome knowledge during development 
and maturation. 
GRAS domain protein and TFIIB/Zinc finger transcription factor have been identified as 
transcriptional regulators. Involved in the yield and quality of storage compounds, transcription 
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factors are considered the main protagonists controlling early seed developments as well as 
genome-wide epigenetic events (Ikeda, 2012). Associated to well-established TFIIB, the 
mediator complex family, including MD13, has emerged as the most crucial cofactor in RNAP 
II-mediated transcriptional events due to its role either in growth or developmental processes 
or biotic and abiotic stress response (Samanta & Thakur, 2015).  
The ATP-binding cassette (ABC) transporter family, responsible of adenosine triphosphate 
(ATP) hydrolysis, one of the largest protein superfamilies in biology represented in all living 
organisms, is strictly correlated to active transport of a wide variety of substrates through the 
mitochondrial outer membranes and cytosol (Rea, 2007). The ABC transporter protein 
superfamily members share a hydrolytic ability useful in a wide array of functions, including 
DNA repair and RNA translocation.  
The voltage dependent anion channel (VDAC) assumes an important role in the regulation of 
energetic and metabolic functions (Shoshan-Barmatz & Ben-Hail, 2012). It is involved in Ca2+ 
transport across the mitochondrial outer membrane (Bathori, Csordas, Garcia-Perez, Davies, 
& Hajnoczky, 2006). The regulation of mitochondrial physiology needs an efficient metabolic 
exchange systems identified here into the Solute Carrier Protein Family, responsible of sugar-
phosphate/phosphate exchange.  
Pectinesterase (PME) was identified as the major protein involved in cell wall metabolism. The 
demethylation of cell wall pectins is mediated by pectin methylesterases, whose activity alters 
cell walls and mediates various physiological and biochemical processes in plants, including 
elongation growth, water uptake, and fruit ripening (Peaucelle, Braybrook, & Hofte, 2012). 
Several proteins related to stress-response, including 17.7 KDa class I heat shock proteins 
(HSPs) and NB-ARC domain protein, were also detected. Although HSPs were initially 
identified as being induced by heat stress, they are overrepresented under a variety of physical 
and chemical stimuli as well as during plant development and seeds growth (Koo, Park, Kim, 
Suh, Lee, Lee, et al., 2015; W. Wang, Vinocur, Shoseyov, & Altman, 2004). The possible 
important roles of HSPs in fruit development and ripening have been recently reported in 
tomato (Neta-Sharir, Isaacson, Lurie, & Weiss, 2005), apple (A. D. Wang, Tan, Tatsuki, Kasai, 
Li, Saito, et al., 2009), and apricot (Grimplet, Romieu, Audergon, Marty, Albagnac, Lambert, 
et al., 2005; Manganaris, Rasori, Bassi, Geuna, Ramina, Tonutti, et al., 2011).  
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9.3.4 PPI network of apricot kernel 
A proteome interactomic map was obtained using the STRING tool for obtaining cross-
correlation information. A. thaliana was selected as a reference organism, considering the lack 
of an extensive genome database for Prunus specie and the phylogenetic proximity of these 
species. Figure 9.4 shows the PPI network for apricot kernel (p value = 0.045) calculated by 
STRING (confidence score value > 0.7). By removing unconnected proteins, the PPI network 
contains 34 interactions. Proteins with the highest score values are characterised by the highest 
connectivity in the network. Supplementary Table 9.1S lists this latter information and all 
details, including phylogenetic co-occurrence, genetic neighbourhood and co-expression for 
each interaction. Among the overall interactions, 14 were endowed high confidence score value 
(upper to 0.9). The widest interactions involve proteins belonging to RNA-polymerase family 
protein as well as proteins with transcription regulation and nucleosome positioning activities, 
such as Chromatin structure-remodelling complex protein SYD.  
 
Figure 9.4 - Protein-Protein interaction network obtained by STRING software (p-value = 0.045). 
Different colored edges represent the existence of different types of evidence. A green line indicates 
neighborhood evidence; a blue line, gene-co-occurrence; a yellow line, text mining; a purple line, 
experimental evidence.  
 
9.3.5 Bioactivities of peptides from in silico digestion of prunins 
There is now a big interest for bioactive peptides from food sources (Arnoldi, Zanoni, Lammi, 
& Boschin, 2015) and some previous studies (Gonzalez-Garcia, Marina, & Garcia, 2014; 
Gonzalez-Garcia, Puchalska, Marina, & Garcia, 2015; Vasquez-Villanueva, Marina, & Garcia, 
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2015) had given indication that hydrolysates from total protein extracts from kernels of the 
Prunus genus provide antioxidant activities and angiotensin converting enzyme (ACE) 
inhibition. The final part of the work was, therefore, dedicated to investigate the possible 
physiological roles of peptides deriving from Prunin 1 (E3SH28) and Prunin 2 (E3SH29), the 
major storage proteins in apricot kernel. They were subjected to in silico digestion by sequential 
hydrolysis with pepsin, trypsin, and chymotrypsin. Although useful for obtaining a feasible 
prediction, this model does not exhaustively represent gastrointestinal digestion, because it 
does not consider several important aspects, such as peptidase activities, pH variations, and 
microbiota effects. Only peptides derived from 0 missed cleavage and containing at least 4 
amino acid residues were further evaluated, whereas smaller peptides (i.e. di- and tripeptides 
with MW < 400 Da) were not considered, since they cannot unambiguously belong to a single 
protein.  
To optimise the potential bioactive candidates selection, the predicted peptidome map was 
ranked by the tool PeptideRanker. A score value was assigned to each peptide using N-to-1 
neural network probability: peptides showing score values higher than 0.5 were considered to 
be potentially bioactive. In a probability range from 0 to 1, predicted values closest to 1 indicate 
a more confident prediction that the candidate resembles a bioactive peptide (Mooney, Haslam, 
Pollastri, & Shields, 2012). The total number of predicted peptides after in silico digestion was 
10 for Prunin 1 and 14 for Prunin 2 (Table 9.2). Out of these 24 peptides, 7 sequences had high 
probability to be bioactive, three deriving from Prunin 1 and four from Prunin 2. 
 
Table 9.2 – Predicted bioactive peptides generated from Prunin 1 (E3SH28) and Prunin 
2 (E3SH29) by in silico digestion. The best candidates (Peptide Ranker score values 
higher than 0.5) are labelled in bold.  
Protein Ids Peptide Score Potential bioactive 
sequence 
Activity 
E3SH28     
 GRPR 0.78 GRP, PR, RP, GR ACE inhibitor  
   RP DPP IV inhibitor 
 AGNQG 0.24 AG, GV, QG ACE inhibitor  
   AG, GV, IQ, NQ, QA, 
QG, QQ, VI 
DPP IV inhibitor 
 IVPQNH 0.15 VP, PQ,  ACE inhibitor  
   IV Glucose uptake stimulating peptide 
   VP, NH, PQ, QN DPP IV inhibitor 
 NLPIL 0.62 IL Glucose uptake stimulating peptide 
   LP, IL, NL,PI DPP IV inhibitor 
 GQNDNR 0.26 GQ  ACE inhibitor  
   GQ Neuropeptide inhibitor  
   GQ, DN, ND, NR, QN DPP IV inhibitor 
 QQGEQGRPGQH 0.21 PG,  Prolyl endopeptidase inhibitor  
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   GRP, RP, GR, GQ, GE, 
QG, PG 
ACE inhibitor  
   PG Antithrombotic 
   PG Peptide regulating the stomach 
mucosal membrane activity 
   GQ Neuropeptide inhibitor 
   GQ, RP, GE, PG, QG, 
QH, QQ 
DPP IV inhibitor 
 SPHW 0.91 PH ACE inhibitor  
   PHW Antioxidant 
   SP, HW, PH DPP IV inhibitor 
 SPQNQCQ 0.38 PQ ACE inhibitor  
   SP, NQ, PQ, QN DPP IV inhibitor 
 VSSDH 0.09 VS DPP IV inhibitor 
     
E3SH29     
 EPDNH 0.16 EP, DN, NH DPP IV inhibitor 
 IPQNH 0.26 IP, PQ ACE inhibitor  
   IP, NH, PQ, QN DPP IV inhibitor 
 QSEAGVT 0.1 AG, GV, EA ACE inhibitor  
   SE Stimulating vasoactive substance 
release 
   AG, ES, GV, IQ, QS,TE, 
VT 
ACE inhibitor  
 NPQGGR 0.57 GR, GG, QG, PQ ACE inhibitor  
   NP, GG, PQ, QG DPP IV inhibitor 
 NPQQQGR 0.31 GR, QG, PQ ACE inhibitor  
   NP, PQ, QG, QQ DPP IV inhibitor 
 NPSDPQF 0.76 PQ ACE inhibitor  
   NP, DP, PQ, PS, QF DPP IV inhibitor 
 GQDDNR 0.27 GQ ACE inhibitor  
   GQ Neuropeptide inhibitor  
   GQ, DN, NR, QD, QG DPP IV inhibitor 
 SATSPPR 0.55 PR, PP ACE inhibitor  
   PP, SP, AT, TS DPP IV inhibitor 
 TPHW 0.75 PH ACE inhibitor  
   PHW Antioxidant 
   TP, HW, PH DPP IV inhibitor 
 
 
The complete peptidome map (24 peptides) was then searched by using the BIOPEP database, 
including information about known bioactive peptides, in order to associate potential 
bioactivities to their sequences. This suggested numerous potential bioactivities, including 
dipeptidyl peptidase-IV (DPP-IV) and angiotensin converting enzyme I (ACE) inhibition, 
antioxidant properties, and glucose uptake stimulating activity. Most predicted peptides 
exhibited multifunctional activities, since they contain common structural requirements for 
each activity (Yea, Ebrahimpour, Hamid, Bakar, Muhammad, & Saari, 2014). Our discussion 
will be restricted to peptides with high PeptideRanker scores. 
All seven peptides were predicted as potential inhibitors of DPP-IV activity. This is a new 
molecular target correlated with type 2 diabetes development. This ubiquitous enzyme has been 
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shown to cleave and inactivate glucagon-like peptide-1 (GLP-1) and glucose dependent 
insulinotropic polypeptide (GIP) in the postprandial phase, leading to a loss in their 
insulinotropic activity (Juillerat-Jeanneret, 2014). In order to exert this activity, a peptide 
should have a hydrophobic character, a length varying from 2 to 8 amino acid residues, and 
contain a Pro residue located at the first, second, third, or fourth N-terminal position (Lammi, 
Zanoni, Arnoldi, & Vistoli, 2016). Based on these considerations, GRPR, NLPIL, NPQGGR, 
NPSDPQF, SATSPPR, and TPHW seem good candidates as DPP-IV inhibitors. DPP-IV 
inhibitory peptides have been found in hydrolysates from lupin and soybean protein (Lammi, 
et al, 2016). 
Six peptides were predicted as ACE-inhibitors, i.e. they are potentially hypotensive. The 
binding of a peptide to the ACE active site is strongly influenced by its C-terminal sequence 
(Hernandez-Ledesma, Contreras, & Recio, 2011).  Structure-activity studies have shown that 
a positively charged C-terminal residue, such as the ε-amino group of Lys and the guanidine 
group of Arg, is very important to exert this activity as well as a hydrophobic amino acid 
residue (aromatic or branched side chain) at least in one of the three C-terminal positions. These 
peptide motifs are present within peptides GRPR, NPQGGR, NPSDPQF, SATSPPR and 
TPHW.  
Two peptides, SPHW and TPHW, were predicted to be antioxidant for the presence of the 
fragment PHW, which provides this kind of activity. Only peptide NLPIL was predicted as 
glucose uptake stimulating, owing to the presence of the sequence IL. This peptide had been 
already identified in the sequence of plum kernel proteins (Prunus domestica L.) and shown to 
exert antioxidant capacity in vitro (Gonzalez-Garcia, Marina, Garcia, Righetti, & Fasoli, 2016).  
An open issue is the stability of these peptides toward hydrolysis by endoproteinases activities 
that was checked using the open access tool PROSPER (Song, Tan, Perry, Akutsu, Webb, 
Whisstock, et al., 2012). This process showed that out of these seven peptides only two are 
susceptible to partial hydrolysis by endoproteinases: the former, NLPIL, might be cleaved by 
elastase-2, matrix metalloprotease-9 and cathepsine-K, whereas the latter, NPQGGR, only by 
cathepsine-K. 
However, the intestinal phase of digestion is very difficult to model, since small intestinal brush 
border membrane contains many amino and carboxyl exopeptidases whose action here has not 
been considered. This is certainly a main limitation of this approach. 
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9.4. Conclusions 
In conclusion, taking advantage of high-throughput technologies, this work has provided 
innovative information on the proteome of apricot kernel. This represents a major improvement 
in the knowledge of this food material. Although in general this kernel finds a rare use in human 
nutrition owing to its bitterness, there are some specific recipes, such as Italian amaretti, in 
which this sensorial characteristic is looked for and carefully modulated precisely through a 
sapient addition of bitter apricot kernels. Moreover, kernels from sweet varieties may be used 
without any precaution as roasted salted kernels consumed as titbit or as a flour to be included 
in different food formulations. 
The presence of potentially bioactive peptides encrypted inside its proteins sequences suggests 
that apricot kernel proteins may offer useful health benefits, increasing even more the interest 
for this kernel. This fact would help maximising available resources and possibly providing 
new ingredients to exploit in innovative healthy foods. Finally, considering the challenges in 
correlating food protein sequences and health, we observe that, in order to facilitate proteome 
analysis in food chemistry, it would be very useful to develop specific bioinformatics tools 
including data processing, clustering, dynamics, and integration at various omics levels, and 
designed to take into account properties, such as taste, technological functions and health 
promoting features.  
 
Acknowledgments 
The authors are grateful to DGRSDT-MESRS (Algeria) for financial support.
 202 
 
 203 
 
 
References 
__________________________________________________________________________________ 
Aiello, G., Fasoli, E., Boschin, G., Lammi, C., Zanoni, C., Citterio, A., & Arnoldi, A. (2016). Proteomic 
characterization of hempseed (Cannabis sativa L.). Journal of Proteomics, 147, 187-196. 
Arnoldi, A., Zanoni, C., Lammi, C., & Boschin, G. (2015). The role of grain legumes in the prevention 
of hypercholesterolemia and hypertension. Critical Reviews in Plant Sciences, 34(1-3), 144-
168. 
Bathori, G., Csordas, G., Garcia-Perez, C., Davies, E., & Hajnoczky, G. (2006). Ca2+-dependent 
control of the permeability properties of the mitochondrial outer membrane and voltage-
dependent anion-selective channel (VDAC). Journal of Biological Chemistry, 281(25), 17347-
17358. 
Binns, D., Dimmer, E., Huntley, R., Barrell, D., O'Donovan, C., & Apweiler, R. (2009). QuickGO: a 
web-based tool for Gene Ontology searching. Bioinformatics, 25(22), 3045-3046. 
Boschetti, E., & Righetti, P. G. (2008). The ProteoMiner in the proteomic arena: a non-depleting tool 
for discovering low-abundance species. Journal of Proteomics, 71(3), 255-264. 
D'Ambrosio, C., Arena, S., Rocco, M., Verrillo, F., Novi, G., Viscosi, V., Marra, M., & Scaloni, A. 
(2013). Proteomic analysis of apricot fruit during ripening. Journal of Proteomics, 78, 39-57. 
Durmaz, G., & Alpaslan, M. (2007). Antioxidant properties of roasted apricot (Prunus armeniaca L.) 
kernel. Food Chemistry, 100(3), 1177-1181. 
Esteve, C., D'Amato, A., Marina, M. L., García, M. C., Citterio, A., & Righetti, P. G. (2012). 
Identification of olive (Olea europaea) seed and pulp proteins by nLC-MS/MS via 
combinatorial peptide ligand libraries. Journal of Proteomics, 75(8), 2396-2403. 
Falchi, R., Cipriani, G., Marrazzo, T., Nonis, A., Vizzotto, G., & Ruperti, B. (2010). Identification and 
differential expression dynamics of peach small GTPases encoding genes during fruit 
development and ripening. Journal of Experimental Botany, 61(10), 2829-2842. 
FAO (2012). www.fao.org (2012 data) 
Femenia, A., Rossello, C., Mulet, A., & Canellas, J. (1995). Chemical composition of bitter and sweet 
apricot kernels. Journal of Agricultural and Food Chemistry, 43(2), 356-361. 
Gonzalez-Garcia, E., Marina, M. L., & Garcia, M. (2014). Plum (Prunus Domestica L.) by-product as 
a new and cheap source of bioactive peptides: Extraction method and peptides characterization. 
Journal of Functional Foods, 11, 428-437. 
Gonzalez-Garcia, E., Marina, M. L., Garcia, M. C., Righetti, P. G., & Fasoli, E. (2016). Identification 
of plum and peach seed proteins by nLC-MS/MS via combinatorial peptide ligand libraries. 
Journal of Proteomics, 148, 105-112. 
Gonzalez-Garcia, E., Puchalska, P., Marina, M. L., & Garcia, M. C. (2015). Fractionation and 
identification of antioxidant and angiotensin-converting enzyme-inhibitory peptides obtained 
from plum (Prunus domestica L.) stones. Journal of Functional Foods, 19, 376-384. 
 204 
 
Grimplet, J., Romieu, C., Audergon, J. M., Marty, I., Albagnac, G., Lambert, P., Bouchet, J. P., & 
Terrier, N. (2005). Transcriptomic study of apricot fruit (Prunus armeniaca) ripening among 
13 006 expressed sequence tags. Physiologia Plantarum, 125(3), 281-292. 
Haraszi, R., Tasi, C., Juhasz, A., & Makai, S. (2015) PDMQ - Protein Digestion Multi Query software 
tool to perform in silico digestion of protein/peptide sequences. bioRxiv 014019, 
doi.org/10.1101/014019 
Hernandez-Ledesma, B., Contreras, M. D., & Recio, I. (2011). Antihypertensive peptides: Production, 
bioavailability and incorporation into foods. Advances in Colloid and Interface Science, 165(1), 
23-35. 
Ikeda, Y. (2012). Plant Imprinted Genes Identified by Genome-wide Approaches and Their Regulatory 
Mechanisms. Plant and Cell Physiology, 53(5), 809-816. 
Jin, T. C., Albillos, S. M., Guo, F., Howard, A., Fu, T. J., Kothary, M. H., & Zhang, Y. Z. (2009). 
Crystal Structure of Prunin-1, a Major Component of the Almond (Prunus dulcis) Allergen 
Amandin. Journal of Agricultural and Food Chemistry, 57(18), 8643-8651. 
Juillerat-Jeanneret, L. (2014). Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes 
and what else? Journal of Medicinal Chemistry, 57(6), 2197-2212. 
Kanehisa, M., Goto, S., Kawashima, S., & Nakaya, A. (2002). The KEGG databases at GenomeNet. 
Nucleic Acids Research, 30(1), 42-46. 
Karsavuran, N., Charehsaz, M., Celik, H., Asma, B. M., Yakinci, C., & Aydin, A. (2014). Amygdalin 
in bitter and sweet seeds of apricots. Toxicological and Environmental Chemistry, 96(10), 
1564-1570. 
Koo, H. J., Park, S. M., Kim, K. P., Suh, M. C., Lee, M. O., Lee, S. K., Xia, X. L., & Hong, C. B. 
(2015). Small Heat Shock Proteins Can Release Light Dependence of Tobacco Seed during 
Germination. Plant Physiology, 167(3), 1030-+. 
Kutlu, T., Durmaz, G., Ates, B., & Erdogan, A. (2009). Protective effect of dietary apricot kernel oil 
supplementation on cholesterol levels and antioxidant status of liver in hypercholesteremic rats. 
Journal of Food Agriculture & Environment, 7(3-4), 61-65. 
Lammi, C., Zanoni, C., Arnoldi, A., & Vistoli, G. (2016). Peptides Derived from Soy and Lupin Protein 
as Dipeptidyl-Peptidase IV Inhibitors: In Vitro Biochemical Screening and in Silico Molecular 
Modeling Study. Journal of Agricultural and Food Chemistry, 64(51), 9601-9606. 
Lavid, N., Wang, J., Shalit, M., Guterman, I., Bar, E., Beuerle, T., Menda, N., Shafir, S., Zamir, D., 
Adam, Z., Vainstein, A., Weiss, D., Pichersky, E., & Lewinsohn, E. (2002). O-
methyltransferases involved in the biosynthesis of volatile phenolic derivatives in rose petals. 
Plant Physiol, 129(4), 1899-1907. 
Lee, H.-h., Ahn, J.-H., Kwon, A.-R., Lee, E. S., Kwak, J.-H., & Min, Y.-H. (2014). Chemical 
Composition and Antimicrobial Activity of the Essential Oil of Apricot Seed. Phytotherapy 
Research, 28(12), 1867-1872. 
Liu, F., Zhang, X., Lu, C., Zeng, X., Li, Y., Fu, D., & Wu, G. (2015). Non-specific lipid transfer proteins 
in plants: presenting new advances and an integrated functional analysis. Journal of 
Experimental Botany, 66(19), 5663-5681. 
 205 
 
Lu, Y., Lu, Z., Gao, S., Lu, Y. M., Lu, Z. R., & Gao, S. Z. (1994). A study on the evolution relationship 
and classification of apricots via peroxidase isozyme zymogram analysis. Acta Agriculturae 
Boreali-Sinica, 9(4), 69-74. 
Manganaris, G. A., Rasori, A., Bassi, D., Geuna, F., Ramina, A., Tonutti, P., & Bonghi, C. (2011). 
Comparative transcript profiling of apricot (Prunus armeniaca L.) fruit development and on-
tree ripening. Tree Genetics & Genomes, 7(3), 609-616. 
Minkiewicz, P., Dziuba, J., Iwaniak, A., Dziuba, M., & Darewicz, M. (2008). BIOPEP database and 
other programs for processing bioactive peptide sequences. Journal of AOAC International, 
91(4), 965-980. 
Mooney, C., Haslam, N. J., Pollastri, G., & Shields, D. C. (2012). Towards the Improved Discovery 
and Design of Functional Peptides: Common Features of Diverse Classes Permit Generalized 
Prediction of Bioactivity. Plos One, 7(10). 
Neta-Sharir, I., Isaacson, T., Lurie, S., & Weiss, D. (2005). Dual role for tomato heat shock protein 21: 
protecting photosystem II from oxidative stress and promoting color changes during fruit 
maturation. Plant Cell, 17(6), 1829-1838. 
Ozboy-Ozbas, O., Seker, I. T., & Gokbulut, I. (2010). Effects of resistant starch, apricot kernel flour, 
and fiber-rich fruit powders on low-fat cookie quality. Food Science and Biotechnology, 19(4), 
979-986. 
Ozcan, M. (2000). Composition of some apricot (Prunus armeniaca L.) kernels grown in Turkey. Acta 
Alimentaria, 29(3), 289-293. 
Peaucelle, A., Braybrook, S., & Hofte, H. (2012). Cell wall mechanics and growth control in plants: the 
role of pectins revisited. Frontiers in Plant Science, 3. 
Rea, P. A. (2007). Plant ATP-Binding cassette transporters. Annual Review of Plant Biology, 58, 347-
375. 
Righetti, P. G., Fasoli, E., & Boschetti, E. (2011). Combinatorial peptide ligand libraries: The conquest 
of the 'hidden proteome' advances at great strides. Electrophoresis, 32(9), 960-966. 
Samanta, S., & Thakur, J. K. (2015). Importance of Mediator complex in the regulation and integration 
of diverse signaling pathways in plants. Frontiers in Plant Science, 6. 
Seker, I. T., Ozboy-Ozbas, O., Gokbulut, I., Ozturk, S., & Koksel, H. (2009). Effects of fiber-rich apple 
and apricot powders on cookie quality. Food Science and Biotechnology, 18(4), 948-953. 
Seker, I. T., Ozboy-Ozbas, O., Gokbulut, I., Ozturk, S., & Koksel, H. (2010). Utilization of apricot 
kernel flour as fat replacer in cookies. Journal of Food Processing and Preservation, 34(1), 15-
26. 
Shoshan-Barmatz, V., & Ben-Hail, D. (2012). VDAC, a multi-functional mitochondrial protein as a 
pharmacological target. Mitochondrion, 12(1), 24-34. 
Song, J., Tan, H., Perry, A. J., Akutsu, T., Webb, G. I., Whisstock, J. C., & Pike, R. N. (2012). 
PROSPER: an integrated feature-based tool for predicting protease substrate cleavage sites. 
PLoS One, 7(11), e50300. 
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., 
Roth, A., Santos, A., Tsafou, K. P., Kuhn, M., Bork, P., Jensen, L. J., & von Mering, C. (2015). 
 206 
 
STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic 
Acids Research, 43(Database issue), D447-452. 
The UniProt Consortium. (2017). UniProt: the universal protein knowledgebase. Nucleic Acids 
Research, 45(D1), D158-D169. 
Turan, S., Topcu, A., Karabulut, I., Vural, H., & Hayaloglu, A. A. (2007). Fatty acid, triacylglycerol, 
phytosterol, and tocopherol variations in kernel oil of Malatya apricots from Turkey. Journal 
of Agricultural and Food Chemistry, 55(26), 10787-10794. 
Varsha, R., Akash, J., Jasmine, C., Raj, V., Jain, A., & Chaudhary, J. (2012). Prunus armeniaca 
(Apricot): an overview. Journal of Pharmacy Research, 5(8), 3964-3966. 
Vasquez-Villanueva, R., Marina, M. L., & Garcia, M. C. (2015). Revalorization of a peach (Prunus 
persica (L.) Batsch) byproduct: Extraction and characterization of ACE-inhibitory peptides 
from peach stones. Journal of Functional Foods, 18, 137-146. 
Vita, F., Lucarotti, V., Alpi, E., Balestrini, R., Mello, A., Bachi, A., Alessio, M., & Alpi, A. (2013). 
Proteins from Tuber magnatum Pico fruiting bodies naturally grown in different areas of Italy. 
Proteome Science, 11. 
Wang, A. D., Tan, D. M., Tatsuki, M., Kasai, A., Li, T. Z., Saito, H., & Harada, T. (2009). Molecular 
mechanism of distinct ripening profiles in 'Fuji' apple fruit and its early maturing sports. 
Postharvest Biology and Technology, 52(1), 38-43. 
Wang, W., Vinocur, B., Shoseyov, O., & Altman, A. (2004). Role of plant heat-shock proteins and 
molecular chaperones in the abiotic stress response. Trends in Plant Science, 9(5), 244-252. 
Yea, C. S., Ebrahimpour, A., Hamid, A. A., Bakar, J., Muhammad, K., & Saari, N. (2014). Winged 
bean [Psophorcarpus tetragonolobus (L.) DC] seeds as an underutilised plant source of 
bifunctional proteolysate and biopeptides. Food & Function, 5(5), 1007-1016. 
Yildirim, F. A., & Askin, M. A. (2010). Variability of amygdalin content in seeds of sweet and bitter 
apricot cultivars in Turkey. African Journal of Biotechnology, 9(39), 6522-6524. 
Yildirim, F. A., Yildirim, A. N., Askin, M. A., & Kankaya, A. (2010). Total oil, fatty acid composition 
and tocopherol content in kernels of several bitter and sweet apricot (Prunus armeniaca Batsch) 
cultivars from Turkey. Journal of Food Agriculture & Environment, 8(3-4), 196-201. 
Zhang, S., Wang, S., Huang, J., Lai, X., Du, Y., Liu, X., Li, B., Feng, R., & Yang, G. (2016). High-
specificity quantification method for almond-by-products, based on differential proteomic 
analysis. Food Chemistry, 194, 522-528. 
 
  
 207 
 
 
 
 
 
 
Part III. 
Concluding Remarks 
 
 
 208 
 
GENERAL CONCLUSIONS AND PERSPECTIVES 
 
The present thesis offers new insights into the nutritional peptidomics, providing data on the 
discovery, quantification, and functional analysis of plant protein derived peptides, specifically 
on lupin and hempseed protein hydrolysates, soy derived peptides, and apricot kernel ones. In 
the meantime, it provides also an extensive study of the proteomes of hemp and apricot seed 
either by a functional or a descriptive point of view.  
The key achievement of this PhD project was the development of a multidisciplinary strategy 
aimed at elucidating the composition of plant protein hydrolysates by providing both functional 
and structural information. The adopted strategy supports and improves the conventional 
approach currently used for biopeptides discovery by introducing as a specific feature in vitro 
absorption experiments using differentiated cell line such as Caco-2. This was done in order to 
overcome the expensive and quite long fractionation steps used in the classical downstream 
approach. In fact, the absorption experiments permits on one side to obtain a rough evaluation 
of the bioavailability and on the other greatly reduce the sample complexity, since the number 
of peptides detected after absorption is generally not very high. The following experiments are 
thus focused on a relatively small list of bioavailable peptides.  
Moreover, the high complexity of protein hydrolysates usually makes very difficult the 
identification of single bioactive peptides. To reach the goal, our approach has adopted 
bioinformatics tools, such as molecular modelling to investigate the quantitative structure–
activity relationship (QSAR) and in silico digestion.  
As part of the research study, the in vitro absorption experiments performed on the monolayer 
of Caco-2 were optimized to assess cell-penetrating peptides providing the first report on the 
absorbability of lupin hydrolysates. Biochemical analysis have revealed that the absorption 
does not impair the HMGCoAR activity, but on the contrary, enriches the concentration of the 
most active peptides, since the absorbed mixtures are more active than the starting 
hydrolysates. Among the absorbable peptic peptides, P5 (LILPKHSDAD) deriving from the 
β-conglutin precursor, was suggested as the best inhibitor of the protein-protein interaction 
(PPI) between PCSK9 and the LDLR by the molecular modelling study. This was confirmed 
experimentally, since the IC50 value was equal to 1.6±0.33 μM. Quantitative data by the 
optimization of LC-MRM methods pointed out that P5 represents the 11.5% of the absorbed 
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solution. These qualitative and quantitative findings are useful to explain the beneficial effects 
provided by lupin protein consumption observed in vivo in animal and human studies.  
With the aim to clarify better the fate of peptides during the gastrointestinal absorption, a study 
on soy glycinin-derived peptides (IAVPGEVA, IAVPTGVA and LPYP) revealed the 
existence of an in situ competition between the absorption and the metabolic degradation in 
part due to the action of brush border peptidases, such as DPP-IV expressed at the Caco-2 cell 
surface, which impair the absorption. However, the degradation products, AVPGEVA, 
AVPTGVA and as well as the shortest one, IAVPT and IAVP were also absorbed. These 
results open new perspectives aimed at the exploration of mechanism of transports by which 
these bioactive peptides are internalized. The future verification of the activities provided by 
the shortest fragments will be of remarkable interest in order to sort out any synergistic effects, 
which could increase or reduce the beneficial effect.  
The proteomics investigations performed on C. sativa and P. armeniaca seeds contributed not 
only to mapping the seed proteome composition, but also to set-up an analytical approach 
useful in the quality control of food processing. The innovative approach of using the Peptide 
Ligand Library (CPLL) technology, integrated to the state of art techniques for sample 
preparation, could be applied to the further exploration of other plant species and products. The 
peptidomics maps of C. sativa, obtained through the screening and optimization of different 
hydrolytic conditions, revealed the possibility to obtain diverse hydrolyses with diversified 
activities, through the selection of the best proteolytic enzyme. In particular, our findings 
suggest that using pepsin it is possible to produce peptides able to mediate a 
hypocholesterolemic effect through a statin-like mechanism.  
In conclusion, a growing body of reports on novel peptide sequences and function-structure 
relationships contributed to the improvement of plant protein and peptide database-platforms. 
Information obtained from characterizing structural components of plant hydrolysates offers 
useful technological and functional implications for food ingredient formulation or 
pharmacological use.  
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Appendix  
 
ETH-Institute of Molecular Systems Biology 
 
The latest scientific contribution to this thesis comes from the activities carried out at Institute 
of Molecular Systems Biology in the Aebersold group, where I spent 7 months within my PhD 
course. The topic of research to which I took part, was quite far from the main researches in 
line to my project based on food-peptidomics. However, the interest toward the new and high-
throughput mass spectrometric techniques, has led me to widen my background focusing my 
attention on the current analytical aspects for peptide identification and quantitation in complex 
samples. The use of novel unbiased mass spectrometric techniques, although mainly applied to 
human proteome researches, has the potential to be adapted also to food component 
characterization, paying particular attention to both peptides identification and quantification 
when complex mixtures are handled.  
 
- Recent Advances in Mass Spectrometry -  
The most proteomic studies are currently geared toward the discovery or validation of 
differential protein regulation on a large scale in response to biological perturbations. Mass 
spectrometry is the method of choice to answer these biological questions. The abilities of MS 
technologies to identify and quantify thousands of proteins in a single shot already have a broad 
impact on biology and personalized medicine.1 The different MS acquisition strategies and the 
type of information that can be generated through this high-throughput-based approach are 
actually increased and an implementation of the classical data acquisition modes has been 
observed in the years.  
 
Untargeted proteomics - shotgun proteomics -  
In the past decade, most of the MS based proteomic studies were carried out using shotgun 
proteomics or discovery based which employs data dependent acquisition (DDA). Though 
widely used, DDA has a number of limitations including instrumental scanning speed, 
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stochastic selection of ions for fragmentation and poor repeatability 2, a relatively narrow 
dynamic range  and the issues of chimericy (cofragmentation of two or more ions) 3,4 etc. 
Furthermore, the number of peptides presented in a biological digest may be many times larger 
than the number of ions that can be sequenced in an experiment despite the recent advances in 
instrumentation. Due to the bias nature of DDA for the most abundant species, low abundance 
peptides are unlikely being sequenced in a complex biological sample. Similarly, closely eluted 
isobaric species, may not be sequenced completely owing to the typical dynamic exclusion 
setting used in DDA. 
 
Targeted proteomics - SRM - 
In contrast to untargeted proteomics, recently, the targeted proteomics using SRM method has 
experienced a renaissance. Basically this approach is used to monitor a number of selected 
precursors and fragment transitions of targeted peptides over the LC retention time, yielding a 
set of chromatographic traces with the retention time and signal intensity for a distinct 
transition. The selection of the SRM transitions is normally calculated on the basis of the data 
acquired previously by product ion scanning, repository data in the public databases or based 
on a series of empirical rules predicting the enzymatic cleavage sites.5  
Despite the advantages, targeted proteomics has not been the preferred method by many 
proteomic researchers. Given that it is a targeted approach, a prior knowledge of the targeted 
proteins in the sample is a requisite. Arguably, up to 6000 transitions can be monitored by an 
SRM experiment using triggered or intelligent selected reaction monitoring (iSRM) on the 
latest triple quadrupole mass spectrometer.6 However, only a relatively small number of 
proteins (up to 100) are monitored by a typical SRM experiment in practice. The method also 
requires lengthy and labor intensive development and optimization process.7 Furthermore, in 
SRM, the detection of a chromatographic peak, even with all the predicted SRM transitions 
detected, does not confirm the identity of the peptide. This is because the mass of interfering 
ions could fall within the tolerance of both quadrupoles and leads to a false positive 
identification and the data generated will have to be validated with relatively expensive 
reference or isotopically labeled peptide standards.8  
To overcome these limitation, while achieving comparable specificity, another targeted 
approach was recently developed: SWATH-MS.9 
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Data Independent Acquisition (DIA) via SWATH-MS 
DIA methods 10 combine certain aspects of both DDA and SRM methods. As with the targeted 
acquisition mode, the instrument performs continuous time-resolved acquisition of MS/MS 
signals for each precursor mass region. In contrast to DDA and SRM methods, however, the 
aim of the DIA mode is to exhaustively acquire MS/MS spectra for any possible precursor 
mass. Because the current instrumentation is too slow to cover the complete tryptic peptide m/z 
range (typically 300–1,200) with a small precursor isolation window in the time frame of a 
typical LC separation, the compromise of the DIA method is to use a much wider precursor 
isolation mass windows for precursor fragmentation as compared with the 1–3 Da used in SRM 
or DDA. Thus, a mixture of several precursor (peptide) ions are deliberately isolated and 
fragmented, creating multiplexed MS/MS spectra consisting of fragment ion signals from 
different peptides. Given sufficient acquisition speed of the instrument and appropriate window 
sizes, it has become possible to cover the entire informative m/z range of a peptide mixture and 
to generate exhaustive maps of all observable peptide fragments with continuous MS/MS 
acquisition and sufficient time resolution of the data points.11  Despite this huge amount of data 
acquired with this strategy, SWATH-MS (Sequential Window Acquisition of all 
Theoretical Mass Spectra) strategy maintains its roots in the idea of targeted data analysis, 
whereby extracted ion chromatograms (XIC) of the most intense transitions of a targeted 
peptide are generated from all corresponding MS2 spectra, producing chromatographic data 
that is similar to SRM traces. This approach reduces the complexity of the data significantly, 
facilitating data analysis while retaining the complete fragment ion information of all 
precursors. 
 
Figure i) reports schematically the different acquisition modes and the resulted data structures 
obtained by DDA, SRM and DIA approaches.  
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Figure i) - Data structure of the LC-MS and LC-MS/MS signals acquired in the three main 
bottom-up proteomic acquisition strategies: (a) data-dependent acquisition (DDA), (b) targeted 
selected reaction monitoring (SRM), and (c) data-independent acquisition (DIA).  
In DDA, or shotgun (panel a) the instrument is operated in iterative acquisition cycles of intact 
precursor-level spectra (MS, or MS1) and fragment ion spectra (MS/MS, or MS2). Decisions about 
which precursors to select for fragmentation are made in real time by the instrument software, according 
to predefined criteria such as intensity threshold. Typical instrument configurations for DDA workflows 
include different Orbitrap hybrids or quadrupole time-of-flight (TOF). Peptide identity is derived from 
the combined information of the precursor mass and the corresponding fragment ion masses (MS/MS), 
usually following untargeted, spectrum-centric searching strategies.12 For SRM (panel b) 
predetermined fragment ion signals is repeatedly recorded for each predefined peptide over time. The 
lists of transitions is a prior required. The technique is best applied for consistently quantifying or 
validating the presence of targeted peptides, rather than discovering new peptides/proteins. Both 
qualitative and quantitative information is directly derived from the resulting fragment ion 
chromatographic signals of individual transitions. In DIA (panel c, left), the complete precursor mass 
range is selected for fragmentation in consecutive and contiguous steps (e.g., of 25 Da as shown here 
for region 500–525 m/z and adjacent regions), repeatedly during the LC separation, regardless of the 
detection or presumed presence of peptides in that mass-and-time space. For DIA, the time-and-mass-
continuous MS/MS recordings can be displayed side-by-side across the LC separation (time), resulting 
in a three-dimensional MS2 map of the LC-MS/MS data. 11 
 
 
 
In the current thesis these methodology, were used to investigate the pathways of glucose 
metabolism alterations and tumorigenesis by comprehensively exploration of proteome. In 
details, SWATH-MS and targeted SRM analysis were used for the evaluation of metabolic and 
systematic protein profile alteration upon drug perturbation on human colon cancer cell model. 
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Project 
 
Evaluation of metabolic and systematic drug perturbation on 
human colon cancer cell model by targeted SRM and SWATH-
MS analysis 
 
State of art  
Cancer cells differ from their normal counterparts in several aspects including deregulated 
control of cell proliferation, ability to evade apoptotic cell regulatory signals, and modification 
of numerous metabolic pathways.13 Accumulating evidence suggests that malignant 
transformation is associated with changes that affect several branches of metabolism in 
particular those associated with bioenergetics.14   
In fact, according to the Hallmarks of Cancer proposed by Hanahan and Weinberg 15, 
reprogramming of energy metabolic pathways, such as glycolysis and associated anabolic 
pathways, is a central feature of tumorigenesis. Cancer-associated metabolic changes including 
(1) deregulated uptake of glucose and amino acids, (2) use of opportunistic modes of nutrient 
acquisition, (3) use of glycolysis/TCA cycle intermediates and (4) metabolic interactions with 
the microenvironment, are crucial to carcinogenesis. In particular, enhanced glycolytic flux 
leads to an increased synthesis of intermediates for sustaining anabolic pathways, critical for 
cancer cell growth and survival. In addition, the activation of an alternative pathway for glucose 
metabolism – the Polyol pathway – is frequently observed in colon cancer cells.16 Possible 
mechanisms by which this metabolic alteration may evolve during cancer development have 
been proposed. The mechanisms include (1) mitochondrial defects, (2) adaptation to hypoxic 
environment in cancer tissues, (3) oncogenic signals, and (4) abnormal expression of certain 
metabolic enzymes. In this scenario, the increased dependence of cancer cells on direct 
glycolytic pathway and/or on its associated pathways provides a biochemical basis for the 
design of therapeutic strategies using pharmacological inhibition of glycolysis and anti-cancer 
drugs in order to identify the principal activated routes during tumorigenesis and cancer 
progression.  
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Aim of the study 
In this study, targeted SRM and SWATH/DIA mass spectrometric approaches were used to 
investigate the modulation of the polyol pathway and/or glycolysis induced by 1) carbon 
source-environment perturbations, and 2) therapeutic metabolic inhibitors on the human colon 
cancer cell line, HT29.  
In details, the cellular proteome was probe for: 
(1) The effect of glycolytic inhibitors on cellular metabolism in wild-type colon cancer cells.  
(2) The effect of different growth conditions: nutrient availability from carbon sources, such 
high sugar environment (glucose, sorbitol, fructose), could differentially affect the utilization 
of the polyol pathway in colon cancer cells. 
Model-based statistical analysis was employed to identify significantly dysregulated proteins 
and networks upon metabolic and systematic drug perturbation.  
 
The overall workflow applied is reported in Figure ii. 
 
 
 
Figure ii) - Methodological approaches adopted.  
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Methodologies 
SRM assay development and time-scheduled SRM analysis. Biologically relevant target 
proteins involved both in the glycolysis and in the pathways which may be triggered by the 
inhibition of glycolysis or polyol pathway, were selected. SRM assays were design to quantify 
48 proteins covering glycolysis, polyol pathway, tricarboxylic acid cycle, pentose phosphate 
pathway, hexose metabolism and gluconeogenesis. Moreover, proteins of the different 
branches of the glycolysis, such as those involved in amino-acid biosynthesis and degradation, 
in isoprenoid biosynthesis and in the fermentation of pyruvate to lactate were also included in 
the final set of targeted proteins. 
Development and validation of SRM assays to measure abundances of proteins was guided by 
a “human” spectral library previously generated in-house through a LC-MS/MS analysis. SRM 
assays were developed following the general high-throughput strategy previously reported.17 
Initially, 4–6 unique peptides ranging from 6 to 20 amino acids in length, containing tryptic 
ends and no missed cleavages, were chosen for each of the selected proteins. All peptides 
containing amino acids prone to undergo unspecific reactions (e.g., Met, Trp, Asn and Gln) 
were generally avoided and only selected when no other options were available. Proteotypic 
peptides matching to the spectral library were ranked by intensity using Skyline and the most 
intense transitions consisting of doubly or triply charged precursor ions and singly or doubly 
charged fragment ions of the y- and b- ion series, with the restrictions listed above, were 
experimentally tested in SRM mode to select the most suitable transitions for quantification 
experiments. Time-scheduled SRM methods was used to monitor the target proteins. In time 
scheduled SRM mode, the full cycle time is used to detect and quantify peptides expected to 
elute within a given retention-time window. This restricts the acquisition of defined transitions 
to a window around the elution time of the corresponding peptide. Retention time scheduling 
for all transitions was selected based on Skyline scheduling predictions. A window of ± 2.5 
min was used to schedule all transitions. Overall, 635 transitions were selected to monitor the 
selected proteins.  
 
Measurements and data analysis. SRM analysis was conducted on TSQ Vantage instrument 
equipped with a nano-electrospray ionization source and coupled to a Nano-LC Ultra 2D HPLC 
system. Q1 and Q3 operated at unit resolution (0.7 m/z half-maximum peak width) with a cycle 
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time <2 s. Chromatographic separation of peptides was performed on a frit column (150 mm x 
75 μm) made in-house and coupled to a fused silica emitter (100 mm x 75 μm). The columns 
were packed with reverse-phase C18 material. The peptides were eluted using a linear gradient 
of acetonitrile/water containing 0.1% formic acid at a flow rate of 300 nL/min. An elution 
gradient of 5% to 35% acetonitrile over 60 min was used.   
Statistical analysis of data from proteome profiling. SRM data was statistically analyzed to 
detect differences between the different concentrations of inhibitors or sugars tested. The input 
files for this analysis contained values for Condition, Bioreplicate, and Run, as pre-assigned in 
Skyline according to the experimental design. All input files were elaborated through MSstats, 
R-package in R statistical software. All transition intensities were transformed into log2 values.  
MSstat  
The MSstat analysis has provided the following steps as reported in Figure iii.  
 
 
 
Figure iii) - MSstats pipelines 
 
In details, Data processing and Quality control analysis included the Intensity 
Normalization, the Quality Control plotting, Features selection and Removing Interferences. 
The last steps concerned the plotting profile in order to visualize the potential source of 
variation such as Run, Transition, and Conditions. At least, Group comparison allowed us to 
test proteins for differential abundance. Log2 fold change was used to provide an estimation 
of the differences between two conditions. Fold change cut-off of 1.5 was here used. The results 
are constrained with an adjusted p-value cut-off of 0.05. The results are then visualised 
through Volcano Plots and Heat maps.  
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SWATH-MS analysis workflow 
 Automated analysis of SWATH-MS data 
In parallel, all digested peptides were measured on the 5600+ TripleToF from Sciex in DIA 
mode and analysed by OpenSWATH-workflow, an open-source-cross-platform, which allows 
targeted analysis in an automated mode.  
The steps performed by the OpenSWATH software during SWATH data analysis are reported 
in Figure iv. 
 
Figure iv) - Steps performed by the OpenSWATH software during SWATH data analysis. The 
graphic illustrates a peptide precursor with three fragment ion transitions, which are shown in red, green 
and blue. The graph on the left side shows the three transitions in a mass to charge ratio versus retention 
time graph. Over the whole retention time a specific mass is extracted. This is a so called transition. 
The four graphs on the right side illustrate the OpenSWATH analysis step. On the upper part the inputs 
and the formats of the input files are listed, which are necessary for the OpenSWATH pipeline. For the 
analysis, the raw data were converted to the mzXML data format. The OpenSWATH analysis required 
a SWATH assay library. This library was generated in advance from DDA analysis. In the first step the 
acquired MS data were aligned according to the retention times of the iRT-peptides. In the second step, 
the transitions for the fragment ions were extracted by making use of the assay library. Afterwards, the 
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extracted peak-groups were scored by several algorithms. The scores considered among other attributes 
how well the transitions aligned in terms of retention time, the peak shapes and peak intensities. The 
PyProphet algorithm weighted the different scores and calculated a single score for each assay. As the 
library also consisted of decoy peptide sequences further filtering by an FDR was conducted by the 
OpenSWATH pipeline.  
 
 
However, in order to conduct a targeted quantitative analysis of SWATH-MS data, a spectral 
assay library, containing all peptides acquired in a sample, was required. The spectral library 
used as input for peptide queries in the OpenSWATH analysis was a previously published as 
proteome library containing mass spectrometric coordinates for 10,000+ human proteins built 
by combining several hundred DDA analyses of various human cells and tissues types. iRT 
standard peptides (Biognosys) were included in the library for automatic retention time 
calibration of each different sample set with the ion library retention times. Basically, the 
complete set of coordinates present in the library describes (i) which peptides of a protein are 
most representative, i.e. unique and well detectable, (ii) the elution time of these peptides from 
the LC, (iii) their pre-dominant charge state, (iv) the most abundant fragment ions formed 
during fragmentation and (v) their relative intensity.   
The OpenSWATH pipeline consists of the OpenSWATH software 18, for identifying and 
extracting quantitative data from targeted peptides within the fragment ion maps and for 
assessing a statistical assessment of the correct identification of these targeted peptides using 
the mProphet algorithm.  
The algorithm used by OpenSWATH platform were basically summarized in the following 
steps: 
 
 
1) Assay libraries importing. 2) Data conversion. 3) Retention-time alignment. 4) 
Chromatogram extraction and identification of the peak groups. 5) Peak-group scoring. 6) 
Statistical analysis.  
 
 
Data Conversion. The acquired SWATH-MS data together with the assay library comprise 
the input data were converted to suitable open file formats (mzML and TraML). 
 
Retention-time alignment. Each run was aligned against a previously determined normalized 
retention-time space using reference peptides whose mappings to the normalized space was 
known (for example, spiked-in peptides). Outlier detection is subsequently applied to remove 
wrongly assigned reference peptides and to evaluate the quality of the alignment. 
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Chromatogram extraction. Using the m/z and retention time information from the assay 
library, the workflow extracts ion chromatograms from the corresponding MS2 map, producing 
integrated fragment ion count vs. retention time data.  
 
Peak-group scoring. For the chromatogram extraction scoring, PyProphet 19,  an improved 
version of the mProphet 20 algorithm, was used.  
The core algorithm identifies 'peak groups' (that is, positions in the chromatograms where 
individual fragment traces coelute) and scores them using multiple, orthogonal scores. These 
scores are based on the elution profiles of the fragment ions, the correspondence of the peak 
group with the expected retention time and fragment-ion intensity from the assay library, as 
well as the properties of the full MS/MS spectrum.  
PyProphet considered extrinsic scores (e.g. Retention time deviation of the peak-groups 
compared to the expected retention time of the spiked-in iRT-peptides. Intensity correlation 
with the intensity of the peak-group in the spectral library) and intrinsic scores (e.g. Co-elution 
score for precursor and transitions, peak shape score for precursor and fragments, intensity of 
the precursor and transitions).  
 
Statistical analysis: SWATH2stats and MapDIA. For downstream statistical and 
quantitative analysis, MapDIA (Model-based Analysis of Quantitative Mass Spectrometry 
Data in Data Independent Acquisition Mode) tool was applied by the use of SWATH2stats R-
package  
SWATH2stats package allowed further visualization of the FDR thresholds and to transform 
the data to a format which was suitable for the mapDIA analysis.21 The latter provides 
hierarchical model-based statistical significance analysis for multi-group comparisons under 
representative experimental designs, providing reliable classification of differentially 
expressed proteins with accurate control of the false discovery rates. 
In details, the mapDIA workflow consists of three major steps: intensity normalization, 
peptide/ fragment selection, and statistical analysis. First, the fragment-level intensities by total 
intensity sums as well as by local intensity sums in retention time space were normalized. 
Second, the outliers were removed and peptides/ fragments that preserved the major 
quantitative patterns across all samples for each protein were selected. Last, using the selected 
fragments and peptides, mapDIA performed model-based statistical significance analysis of 
protein-level differential expression between specified groups of samples. 
 
Based on the methodologies illustrated, the proteome changes upon cellular perturbation either 
induced by glycolytic inhibitors or by sugar environment alterations, were investigated, 
however, the institute holds the intellectual property rights, since the results are not jet 
disclosed.  
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